WO1997019098A9

WO1997019098A9 - Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics

Info

Publication number: WO1997019098A9
Application number: PCT/US1996/018542
Authority: WO
Filing date: 1996-11-15
Publication date: 1997-11-06
Anticipated expiration: 1998-05-17

Abstract

Recombinant or substantially pure preparations of H. pylori polypeptides are described. The nucleic acids encoding the polypeptides also are described. The H. pylori polypeptides are useful in vaccine compositions.

Description

NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER

PYLORI FOR DIAGNOSTICS AND THERAPEUTICS

Background of the Invention He licobacter pylori is a gram-negative, S-shaped, microacrophilic bacterium that was discovered and cultured from a human gastric biopsy specimen. (Warren. J.R. and B. Marshall, (1983) Lancet I : 1273-1275; and Marshall et al., (1984) Microbios Lett. 25: 83- 88). H. pylori has been strongly linked to chronic gastritis and duodenal ulcer disease. (Rathbone et. al., (1986) Gut 27: 635-641 ). Moreover, evidence is accumulating for an etiologic role of H. pylori in nonulcer dyspepsia, gastric ulcer disease, and gastric adenocarcinoma. (Blaser M. J., (1993) Trends Microbiol. Y. 255-260). Transmission of the bacteria occurs via the oral route, and the risk of infection increases with age. (Taylor, D.N. and M. J. Blaser, (1991) Epidemiol. Rev 13: 42-50). H. pylori colonizes the human gastric mucosa, establishing an infection that usually persists for decades. Infection by H. pylori is prevalent worldwide. Developed countries have infection rates over 50% of the adult population, while developing countries have infection rates reaching 90% of the adults over the age of 20. (Hopkins R. J. and J. G. Morris (1994) Am. J. Med. 97: 265-277).

The bacterial factors necessary for colonization of the gastric environment, and for virulence of this pathogen, are poorly understood. Examples of the putative virulence factors include the following: urease, an enzyme that may play a role in neutralizing gastric acid pH (Eaton et al., (1991 ) Infect. Immunol. 59: 2470-2475; Ferrero, R.L. and A. Lee

(1991) Microb. Ecol. Hlth. Dis. 4: 121-134; Labigne et al., (1991) J Bacteriol. 173: 1920- 1931); the bacterial flagellar proteins responsible for motility across the mucous layer. (Hazell et al., (1986) J. Inf. Dis. 1_53: 658-663; Leying et al., (1992) Mol. Microbiol. 6: 2863-2874; and Haas et al., (1993) Mol. Microbiol. 8: 753-760); Vac A, a bacterial toxin that induces the formation of intracellular vacuoles in epithelial cells (Schmitt. W. and R. Haas, (1994) Molecular Microbiol. 12(2): 307-319); and several gastric tissue-specific adhesins. (Boren et al., (1993) Science 262: 1892-1895; Evans et al., (1993) J. Bacteriol. 175: 674-683; and Falk et al., (1993) Proc. Natl. Acad. Sci. USA 90: 2035-203).

Numerous therapeutic agents are currently available that eradicate H. pylori infections in vitro. (Huesca et. al., (1993) Zhl. Bakt. 280: 244-252; Hopkins, R. j. and J. G. Morris, supra). However, many of these treatments are suboptimally effective in vivo because of bacterial resistance, altered drug distribution, patient non-compliance or poor drug availabilty. (Hopkins, R. J. and J. G. Morris, supra). Treatment with antibiotics combined with bismuth are part of the standard regime used to treat H. pylori infection. (Malfertheiner, P. and J. E. Dominguez-Munoz (1993) Clinical Therapeutics 15_. Supp. B: 37-48). Recently, combinations of proton pump inhibitors and a single antibiotic have been shown to ameliorate duodenal ulcer disease. (Malfertheiner, P. and J. E. Dominguez- Munoz supra). However, methods employing antibiotic agents can have the problem of the emergence of bacterial strains which are resistant to these agents. (Hopkins, R. J. and J. G. Morris, supra). These limitations demonstrate that new more effective methods are needed to combat H. pylori infections in vivo. In particular, the design of new vaccines that may prevent infection by this bacterium is highly desirable.

Summary of the Invention

This invention relates to novel genes, e.g., genes encoding bacterial surface proteins, from the organism Helicobacter pylori, and other related genes, their products, and uses thereof. The nucleic acids and peptides of the present invention have utility for diagnostic and therapeutics for H. pylori and other Helicobacter species. They can also be used to detect the presence of// pylori and other Helicobacter species in a sample; and for use in screening compounds for the ability to interfere with the H. pylori life cycle or to inhibit //. pylori infection. More specifically, this invention features compositions of nucleic acids corresponding to entire coding sequences of H. pylori surface proteins or parts thereof, nucleic acids capable of binding mRNA from H. pylori surface proteins to block protein translation, and methods for producing H. pylori surface proteins or parts thereof using peptide synthesis and recombinant DNA techniques. This invention also includes antibodies and nucleic acids sequences useful as probes to detect H pylori infection. In addition, vaccine compositions and methods for the protection against infection by H. pylori are described.

Brief Description of the Drawings Figure 1 is a table which contains information from homology searches performed on the sequences of this invention using the BLAST algorithm contained in the Wisconsin Sequence Analysis Package. Figure 2 is a bar graph that depicts the antibody titer in serum of mice following immunization with specific H. pylori antigens.

Figure 3 is a bar graph that depicts the antibody titer in mucous of mice following immunization with specific H. pylori antigens.

Figure 4 is a bar graph that depicts therapeutic immunization of// pylori infected mice with specific antigens dissolved in HEPES buffer.

Figure 5 is a bar graph that depicts therapeutic immunization of H. pylori infected mice with specific antigens dissolved in buffer containing DOC.

Detailed Description of the Invention In one aspect, the invention features a substantially pure nucleic acid encoding an

H. pylori polypeptide having an amino acid sequence of SEQ ID NO:l 15, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 1. In another aspect, the invention features a substantially pure nucleic acid encoding an //. pylori polypeptide having an amino acid sequence of SEQ ID NO:l 16, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:2.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 1 17, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:3.

In another aspect, the invention features a substantially pure nucleic acid encoding an //. pylori polypeptide having an amino acid sequence of SEQ ID NO: 1 18, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:4.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 1 19, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:5.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 120, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:6. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 121, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:7.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 122, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:8.

In another aspect, the invention features a substantially pure nucleic acid encoding an //. pylori polypeptide having an amino acid sequence of SEQ ID NO: 123, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:9.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 124, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 10.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 125, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 1 1. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 126, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 12.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 127. such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 13. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 128, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 14.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 129, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 15.

In another aspect, the invention features a substantially pure nucleic acid encoding an H pylori polypeptide having an amino acid sequence of SEQ ID NO: 130, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 16.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 131, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 17.

In another aspect, the invention features a substantially pure nucleic acid encoding an H pylori polypeptide having an amino acid sequence of SEQ ID NO: 132, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 18. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 133, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 19.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 134, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:20.

In another aspect, the invention features a substantially pure nucleic acid encoding an H pylori polypeptide having an amino acid sequence of SEQ ID NO: 135, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:21.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 136, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:22.

In another aspect, the invention features a substantially pure nucleic acid encoding an //. pylori polypeptide having an amino acid sequence of SEQ ID NO: 137, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:23. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 138, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:24.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 139, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:25. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 140, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:26.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 141, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:27.

In another aspect, the invention features a substantially pure nucleic acid encoding an H pylori polypeptide having an amino acid sequence of SEQ ID NO: 142, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:28.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 143, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:29.

In another aspect, the invention features a substantially pure nucleic acid encoding an H pylori polypeptide having an amino acid sequence of SEQ ID NO: 144, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:30. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 145, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:31.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 146, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:32.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 147, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:33.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 148, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:34.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 149, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:35. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 150, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:36.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 151 , such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:37. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 152, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:38.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 153, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:39.

In another aspect, the invention features a substantially pure nucleic acid encoding an //. pylori polypeptide having an amino acid sequence of SEQ ID NO: 154, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:40.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 155, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:41.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 156, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:42. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 157, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:43.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 158, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 44.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 159, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:45.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 160, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:46.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 161. such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:47. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 162, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:48.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 163, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:49. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 164, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:50.

In another aspect the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 165, such as a nucleic ac id comprising a nucleotide sequence of SEQ ID NO:51.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 166, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:52.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 167, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:53.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 168, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:54. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 169, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:55.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 170, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 56.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 171 , such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:57.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 172, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:58.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 173, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:59. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 174, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:60.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 175, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:61. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 176. such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:62.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 177, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:63.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 178, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:64.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 179, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:65.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 180, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:66. In another aspect, the invention features a substantially pure nucleic acid encoding an //. pylori polypeptide having an amino acid sequence of SEQ ID NO: 181 , such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:67.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 182, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:68.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 183, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:69.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 184, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:70.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 185, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:71. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 186, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:72.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 187, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:73. In another aspect, the invention features a substantially pure nucleic acid encoding an //. pylori polypeptide having an amino acid sequence of SEQ ID NO: 188, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:74.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 189, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:75.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 190, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:76.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 191 , such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:77.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 192, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:78. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 193, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:79.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 194, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:80.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 195, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:81.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 196, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:82.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 197, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:83. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 198, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:84.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 199, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:85. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:200, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:86.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:201 , such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:87.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:202, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:88.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:203, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:89.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:204, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:90. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:205, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:91.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:206, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:92.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:207, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:93.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:208, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:94.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:209, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:95. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:210, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:96.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:21 1, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:97. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:212, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:98.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:213, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:99.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:214, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 100.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:215, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 101.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:216, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 102. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:217, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 103.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:218, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 104.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:219, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 105.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:220, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 106.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:221, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 107. In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:222, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 108.

In another aspect, the invention features a substantially pure nucleic acid encoding an H pylori polypeptide having an amino acid sequence of SEQ ID NO:223, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 109. In another aspect, the invention features a substantially pure nucleic acid encoding an //. pylori polypeptide having an amino acid sequence of SEQ ID NO:224, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: l 10.

In another aspect, the invention features a substantially pure nucleic acid encoding an H pylori polypeptide having an amino acid sequence of SEQ ID NO:225, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 111.

In another aspect, the invention features a substantially pure nucleic acid encoding an H pylori polypeptide having an amino acid sequence of SEQ ID NO:226, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:l 12.

In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO:227, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:l 13.

In another aspect, the invention features a substantially pure nucleic acid encoding an H pylori polypeptide having an amino acid sequence of SEQ ID NO:228. such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO:l 14. In another aspect, the invention comprises nucleic acids capable of binding mRNA of H. pylori. Such nucleic acid is capable of acting as anti-sense nucleic acid to control the translation of mRNA of H pylori. A further aspect features a nucleic acid which is capable of binding specifically to an H. pylori nucleic acid. Such nucleic acid has utility as probes and as capture reagents. In another aspect, the invention features an expression system comprising an open reading frame corresponding to H. pylori nucleic acid. The nucleic acid further comprises a control sequence compatible with an intended host. The expression system is useful for making polypeptides corresponding to H. pylori nucleic acid.

In another aspect, the invention features a cell transformed with the expression system to make H. pylori polypeptides.

In another aspect, the invention features a method of generating antibodies against H pylori proteins which are capable of binding specifically to H. pylori proteins. Such antibody has utility as reagents for immunoassays to evaluate the abundance and distribution of H. pylori-specific antigens. In another aspect, the invention features a method of generating vaccines for immunizing an individual against H pylori. The method includes: immunizing a subject with an H. pylori protein, e.g., a surface protein, or portion thereof, and a pharmaceutically acceptable carrier. Such vaccines have therapeutic and prophylactic utilities.

In another aspect, the invention provides a method for generating a vaccine comprising a modified immunogenic H. pylori protein, e.g., a surface protein, or portion thereof, and a pharmacologically acceptable carrier. In another aspect, the invention features a method of evaluating a compound, e.g. a polypeptide, e.g., a fragment of a host cell polypeptide. for the ability to bind an H. pylori polypeptide. The method includes: contacting the candidate compound with an H. pylori polypeptides and determining if the compound binds or otherwise interacts with an //. pylori polypeptide. Compounds which bind H pylori are candidates as activators or inhibitors of the bacterial life cycle. These assays can be performed in vitro or in vivo.

In another aspect, the invention features a method of evaluating a compound, e.g. a polypeptide, e.g., a fragment of a host cell polypeptide, for the ability to bind an H. pylori nucleic acid, e.g., DNA or RNA. The method includes: contacting the candidate compound with an H. pylori nucleic acid and determining if the compound binds or otherwise interacts with an H. pylori polypeptide. Compounds which bind H. pylori axe candidates as activators or inhibitors of the bacterial life cycle. These assays can be performed in vitro or in vivo.

The invention features, H. pylori polypeptides, preferably a substantially pure preparation of an H. pylori polypeptide, or a recombinant H. pylori polypeptide. In preferred embodiments: the polypeptide has biological activity; the polypeptide has an amino acid sequence at least 60%, 80%, 90%, 95%, 98%, or 99% homologous to an amino acid sequence contained in SEQ ID NOs:l 15-228; the polypeptide has an amino acid sequence essentially the same as an amino acid sequence in SEQ ID NOs: 115-228; the polypeptide is at least 5, 10, 20, 50, 100, or 150 amino acids in length; the polypeptide includes at least 5, preferably at least 10, more preferably at least 20, more preferably at least 50, 100, or 150 contiguous amino acids contained in SEQ ID NOs: 1 15-228.

In preferred embodiments: the H pylori polypeptide is encoded by a nucleic acid in SEQ ID NOs: 1-114, or by a nucleic acid having at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% homology with a nucleic acid of SEQ ID NOs: 1-114. In a preferred embodiment, the subject H. pylori polypeptide differs in amino acid sequence at 1, 2, 3, 5, 10 or more residues from a sequence in SEQ ID NOs:l 15-228. The differences, however, are such that: the H. pylori polypeptide exhibits an //. pylori biological activity, e.g., the H. pylori polypeptide retains a biological activity of a naturally occurring H. pylori enzyme. In preferred embodiments, the polypeptide includes all or a fragment of an amino acid sequence contained in SEQ ID NOs: 1 15-228; fused, in reading frame, to additional amino acid residues, preferably to residues encoded by genomic DNA 5' to the genomic DNA which encodes a sequence contained in SEQ ID NOs: 115-228.

In yet other preferred embodiments, the H. pylori polypeptide is a recombinant fusion protein having a first H. pylori polypeptide portion and a second polypeptide portion, e.g., a second polypeptide portion having an amino acid sequence unrelated to H. pylori. The second polypeptide portion can be, e.g., any of glutathione-S-transferase, a DNA binding domain, or a polymerase activating domain. In preferred embodiment the fusion protein can be used in a two-hybrid assay.

Polypeptides of the invention include those which arise as a result of alternative transcription events, alternative RNA splicing events, and alternative translational and postranslational events. The invention includes an immunogen which includes an H. pylori polypeptide in an immunogenic preparation, the immunogen being capable of eliciting an immune response specific for said H. pylori polypeptide, e.g., a humoral response, an antibody response, or a cellular response. In preferred embodiments, the immunogen comprises an antigenic determinant from a protein contained in SEQ ID NOs:l 15-228. In another aspect, the invention provides a substantially pure nucleic acid having a nucleotide sequence which encodes an H. pylori polypeptide. In preferred embodiments: the encoded polypeptide has biological activity the encoded polypeptide has an amino acid sequence at least 60%, 80%, 90%o, 95%, 98%, or 99% homologous to an amino acid sequence contained in SEQ ID NOs: 1 15-228; the encoded polypeptide has an amino acid sequence essentially the same as an amino acid sequence in SEQ ID NOs: 1 15-228; the encoded polypeptide is at least 5, 10, 20, 50, 100, or 150 amino acids in length; the encoded polypeptide comprises at least 5, preferably at least 10, more preferably at least 20, more preferably at least 50, 100, or 150 contiguous amino acids contained in SEQ ID NOs: 1 15- 228. In preferred embodiments: the nucleic acid is that of SEQ ID NOs: 1 - 1 14; the nucleic acid is at least 60%, 70%, 80%), 90%, 95%, 98%, or 99% homologous with a nucleic acid sequence contained in SEQ ID NOs: 1-1 14.

In a preferred embodiment, the encoded H. pylori polypeptide differs in amino acid sequence at 1, 2, 3, 5, 10 or more residues, from a sequence in SEQ ID NOs: 1 15-228. The differences, however, are such that: the H. pylori encoded polypeptide exhibits a //. pylori biological activity, e.g., the encoded H. pylori enzyme retains a biological activity of a naturally occurring H. pylori.

In preferred embodiments, the encoded polypeptide includes all or a fragment of an amino acid sequence contained in SEQ ID NOs:l 15-228; fused, in reading frame, to additional amino acid residues, preferably to residues encoded by genomic DNA 5' to the genomic DNA which encodes a sequence contained in SEQ ID NOs: 115-228.

In preferred embodiments, the subject H. pylori nucleic acid will include a transcriptional regulatory sequence, e.g. at least one of a transcriptional promoter or transcriptional enhancer sequence, operably linked to the H. pylori gene sequence, e.g., to render the H. pylori gene sequence suitable for expression in a recombinant host cell.

In yet a further preferred embodiment, the nucleic acid which encodes an H. pylori polypeptide of the invention, hybridizes under stringent conditions to a nucleic acid probe corresponding to at least 12 consecutive nucleotides contained in SEQ ID NOs: 1-1 14; more preferably to at least 20 consecutive nucleotides contained in SEQ ID NOs: 1-1 14; more preferably to at least 40 consecutive nucleotides contained in SEQ ID NOs: 1-1 14.

In a preferred embodiment, the nucleic acid encodes a peptide which differs by at least one amino acid residue from the sequences shown in SEQ ID NOs.l 15-228. In a preferred embodiment, the nucleic acid differs by at least one nucleotide from a nucleotide sequence shown in SEQ ID NOs: 1-1 14 which encodes amino acids shown in SEQ ID NOs: 115-228.

In another aspect, the invention includes: a vector including a nucleic acid which encodes an H. pylori-like polypeptide, e.g., an H. pylori polypeptide; a host cell transfected with the vector; and a method of producing a recombinant H pylori-like polypeptide, e.g., an H. pylori polypeptide; including culturing the cell, e.g., in a cell culture medium, and isolating the H. pylori-like polypeptide, e.g., an H. pylori polypeptide, e.g., from the cell or from the cell culture medium.

In another aspect, the invention features, a purified recombinant nucleic acid having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% homology with a sequence contained in SEQ ID NOs: 1-114.

The invention also provides a probe or primer which includes a substantially purified oligonucleotide. The oligonucleotide includes a region of nucleotide sequence which hybridizes under stringent conditions to at least 10 consecutive nucleotides of sense or antisense sequence contained in SEQ ID NOs: 1-1 14, or naturally occurring mutants thereof. In preferred embodiments, the probe or primer further includes a label group attached thereto. The label group can be, e.g., a radioisotope, a fluorescent compound, an enzyme, and/or an enzyme co-factor. Preferably the oligonucleotide is at least 10 and less than 20, 30, 50, 100, or 150 nucleotides in length. The invention involves nucleic acids, e.g., RNA or DNA, encoding a polypeptide of the invention. This includes double stranded nucleic acids as well as coding and antisense single strands.

The H. pylori strain, from which genomic sequences have been sequenced, has been deposited in the American Type Culture Collection(ATCC # 55679) as strain ΗP-J99. The nucleic acid sequences of this invention may be obtained directly from the

DNA of the above referenced H. pylori strain by using the polymerase chain reaction (PCR). See "PCR, A Practical Approach" (McPherson, Quirke, and Taylor, eds., IRL Press, Oxford, UK, 1991) for details about the PCR. High fidelity PCR can be used to ensure a faithful DNA copy prior to expression. In addition, amplified products can be checked by conventional sequencing methods. Clones carrying the desired sequences described in this invention may be obtained by screening the libraries by means of the PCR or by hybridization of synthetic oligonucleotide probes to filter lifts of the library colonies or plaques as known in the art (see, eg, Sambrook et al., Molecular Cloning, A Laboratory Manual 2nd edition, 1989, Cold Spring Harbor Press, NY).

Nucleic acids isolated or synthesized in accordance with features of the present invention are useful, by way of example, without limitation, as probes, primers, capture ligands, antisense genes and for developing expression systems for the synthesis of proteins and peptides corresponding to such sequences.

As probes, primers, capture ligands and antisense agents, the nucleic acid will normally comprise approximately twenty or more nucleotides for specificity as well as the ability to form stable hybridization products.

Putative functions have been determined for several of the H. pylori polypeptides of the invention, as shown in Figure 1.

Accordingly, uses of the claimed H. pylori polypeptides in these identified functions are also within the scope of the invention.

In addition, the present invention encompasses //. pylori polypeptides characterized as shown in Table 1 below, including: H. pylori outer membrane proteins, H. pylori periplasmic/secreted proteins, and other H. pylori surface proteins. Members of these groups were identified by BLAST homology searches. The H. pylori polypeptides identified in Table 1 are representative members of the groups identified above and are in no way limiting. Additional members of the groups can be identified within the //. pylori polypeptides disclosed herein by the methods known to those skilled in the art.

TABLE 1

SEQ ID NO Blast Gene Description identifier Symbol/Name

Outer Membrane Proteins

71 16626 (SEQ ID NO:223) P26093 e (P4) e (P4) lipoprotein attached by lipid in H. influenza

29479681 (SEQ ID NO: 179) P13036 fecA Receptor in Iron (III) dicitrate transport E. coli

36126938 (SEQ ID NO: 199) LI 2346 copB Major out. memb. prot. in M. catarrhalis

Periplasmic/Secreted Proteins

30100332 (SEQ ID NO: 181 ) P23847 dppA Periplasmic dipeptide binding protein in E. coli

Other Surface Proteins

4821082 (SEQ ID NO:212) P08089 M protein M protein of group A. Streptococci

978477 (SEQ ID NO:228) L28919 FBP54 Surface Ag of grp A. Streptococci binds fibronectin

Definitions

A purified preparation or a substantially pure preparation of a polypeptide, as used herein, means a polypeptide that has been separated from other proteins, lipids. and nucleic acids with which it naturally occurs. Preferably, the polypeptide is also separated from substances, e.g., antibodies or gel matrix, e.g., polyacrylamide, which are used to purify it. Preferably, the polypeptide constitutes at least 10, 20, 50 70, 80 or 95% dry weight of the purified preparation. Preferably, the preparation contains: sufficient polypeptide to allow protein sequencing; at least 1, 10, or 100 μg of the polypeptide; at least 1 , 10. or 100 mg of the polypeptide.

A purified preparation of cells refers to, in the case of plant or animal cells, an in vitro preparation of cells and not an entire intact plant or animal. In the case of cultured cells or microbial cells, it consists of a preparation of at least 10% and more preferably 50% of the subject cells. The metabolism of a substance, as used herein, means any aspect of the, expression, function, action, or regulation of the substance. The metabolism of a substance includes modifications, e.g., covalent or non covalent modifications of the substance. The metabolism of a substance includes modifications, e.g., covalent or non covalent modification, the substance induces in other substances. The metabolism of a substance also includes changes in the distribution of the substance. The metabolism of a substance includes changes the substance induces in the distribution of other substances.

A substantially pure nucleic acid, e.g., a substantially pure DNA, is a nucleic acid which is one or both of: not immediately contiguous with both of the coding sequences with which it is immediately contiguous (i.e., one at the 5' end and one at the 3' end) in the naturally-occurring genome of the organism from which the nucleic acid is derived; or which is substantially free of a nucleic acid sequence with which it occurs in the organism from which the nucleic acid is derived. The term includes, for example, a recombinant DNA which is incorporated into a vector, e.g., into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other DNA sequences. Substantially pure DNA also includes a recombinant DNA which is part of a hybrid gene encoding additional H. pylori DNA sequence.

Homologous refers to the sequence similarity or sequence identity between two polypeptide molecules or between two nucleic acid molecules. When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared x 100. For example, if 6 of 10, of the positions in two sequences are matched or homologous then the two sequences are 60% homologous. By way of example, the DNA sequences ATTGCC and TATGGC share 50% homology. Generally, a comparison is made when two sequences are aligned to give maximum homology.

The terms peptides, proteins, and polypeptides are used interchangeably herein. As used herein, the term "surface protein" refers to all surface accessible proteins, e.g. inner and outer membrane proteins, proteins adhering to the cell wall, and secreted proteins.

As used herein, the term "transgene" means a nucleic acid sequence (encoding, e.g., one or more polypeptides), which is partly or entirely heterologous, i.e., foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an endogenous gene of the transgenic animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the cell's genome in such a way as to alter the genome of the cell into which it is inserted (e.g., it is inserted at a location which differs from that of the natural gene or its insertion results in a knockout). A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid, such as introns, that may be necessary for optimal expression of the selected nucleic acid, all operably linked to the selected nucleic acid, and may include an enhancer sequence.

As used herein, the term "transgenic cell" refers to a cell containing a transgene. As used herein, a "transgenic animal" is any animal in which one or more, and preferably essentially all, of the cells of the animal includes a transgene. The transgene can be introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA.

As used herein, the term "cell-specific promoter" means a DNA sequence that serves as a promoter, i.e., regulates expression of a selected DNA sequence operably linked to the promoter, and which effects expression of the selected DNA sequence in specific cells of a tissue. The term also covers so-called "leaky" promoters, which regulate expression of a selected DNA primarily in one tissue, but cause expression in other tissues as well.

A polypeptide has H. pylori biological activity if it has one, two, three, and preferably more of the following properties: (1) if when expressed in the course of an H. pylori infection, it can promote, or mediate the attachment of H. pylori to a cell (2) it has an enzymatic activity characteristic of an H pylori protein (3) or the gene which encodes it can rescue a lethal mutation in an H. pylori gene. A polypeptide has biological activity if it is an antagonist, agonist, or super-agonist of a polypeptide having one of the above-listed properties.

Misexpression, as used herein, refers to a non-wild type pattern of gene expression. It includes: expression at non-wild type levels, i.e., over or under expression; a pattern of expression that differs from wild type in terms of the time or stage at which the gene is expressed, e.g., increased or decreased expression (as compared with wild type) at a predetermined developmental period or stage; a pattern of expression that differs from wild type in terms of decreased expression (as compared with wild type) in a predetermined cell type or tissue type; a pattern of expression that differs from wild type in terms of the splicing size, amino acid sequence, post-transitional modification, or biological activity of the expressed polypeptide; a pattern of expression that differs from wild type in terms of the effect of an environmental stimulus or extracellular stimulus on expression of the gene, e.g., a pattern of increased or decreased expression (as compared with wild type) in the presence of an increase or decrease in the strength of the stimulus. As used herein, "host cells" and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refers to cells which can become or have been used as recipients for a recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transfected. It is understood by individuals skilled in the art that the progeny of a single parental cell may not necessarily be completely identical in genomic or total DNA compliment to the original parent, due to accident or deliberate mutation.

As used herein, the term "control sequence" refers to a nucleic acid having a base sequence which is recognized by the host organism to effect the expression of encoded sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include a promoter, ribosomal binding site and terminators; in eukaryotes, generally such control sequences include promoters, terminators and in some instances, enhancers. The term control sequence is intended to include at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences.

As used herein, the term "operably linked" refers to sequences joined or ligated to function in their intended manner. For example, a control sequence is operably linked to coding sequence by ligation in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequence and host cell. An "open reading frame", also referred to herein as ORF, is a region of nucleic acid which encodes a peptide. This region may represent a portion of a coding sequence or a total sequence.

As used herein, a "coding sequence" is a nucleic acid sequence which is transcribed into messenger RNA and/or translated into a peptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the five prime terminus and a translation stop code at the three prime terminus. A coding sequence can include but is not limited to messenger RNA, synthetic DNA, or recombinant nucleic acid sequences.

A "gene product" is a protein or structural RNA which is specifically encoded for by a gene.

As used herein, the term "probe" refers to a nucleic acid, peptide or other chemical entity which specifically binds to a molecule of interest. Probes are often associated with or capable of associating with a label. A label is a chemical moiety capable of detection. Typical labels comprise dyes, radioisotopes, luminescent and chemiluminescent moieties, fluorophores, enzymes, precipitating agents, amplification sequences, and the like. Similarly, a nucleic acid, peptide or other chemical entity which specifically binds to a molecule of interest and immobilizes such molecule is referred herein as a "capture ligand". Capture ligands are typically associated with or capable of associating with a support such as nitro-cellulose, glass, nylon membranes, beads, particles and the like. The specificity of hybridization is dependent on conditions such as the base pair composition of the nucleotides, and the temperature and salt concentration of the reaction. These conditions are readily discernable to one of ordinary skill in the art using routine experimentation.

The experimental manipulation of such conditions has been well described in the literature including such books as Molecular Cloning: A Laboratory Manual, Sambrook, J., Fritsch, E.F., Maniatis, T., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2nd ed. (1989). The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Sambrook, Fritsch, and Maniatis, Molecular Cloning; Laboratory Manual 2nd ed. (1989); DNA Cloning, Volumes I and II (D.N Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed, 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); the series, Methods in Enzymoloqy (Academic Press, Inc.), particularly Vol. 154 and Vol. 155 (Wu and Grossman, eds.) and PCR-A Practical Approach (McPherson, Quirke, and Taylor, eds., 1991).

Probes

A nucleic acid isolated or synthesized in accordance with SEQ ID NOs: 1-1 14 can be used as a probe to specifically detect //. pylori. With the sequence information set forth in the present application, sequences of twenty or more nucleotides are identified which provide the desired inclusivity and exclusivity with respect to H. pylori, and extraneous nucleic acid sequences likely to be encountered during hybridization conditions. More preferably, the sequence will comprise at least twenty to thirty nucleotides to convey stability to the hybridization product formed between the probe and the intended target molecules.

Sequences larger than 1000 nucleotides in length are difficult to synthesize but can be generated by recombinant DNA techniques. Individuals skilled in the art will readily recognize that the nucleic acid sequences, for use as probes, can be provided with a label to facilitate detection of a hybridization product.

Nucleic acid isolated and synthesized in accordance with SEQ ID NOs: 1 -1 14 may also be useful as probes to detect homologous regions (especially homologous genes) of other Helicobacter species using relaxed stringency hybridization conditions, as will be obvious to anybody skilled in the art.

Capture Ligand

For use as a capture ligand, the nucleic acid selected in the manner described above with respect to probes, can be readily associated with a support. The manner in which nucleic acid is associated with supports is well known. Nucleic acid having twenty or more nucleotides in a sequence contained in SEQ ID NOs: 1-1 14 have utility to separate H. pylori nucleic acid from the nucleic acid of each other and other organisms. Nucleic acid having twenty or more nucleotides in a sequence shown in SEQ ID NOs: 1-114 may also have utility to separate other Helicobacter species from each other and from other organisms. Preferably, the sequence will comprise at least twenty nucleotides to convey stability to the hybridization product formed between the probe and the intended target molecules. Sequences larger than 1000 nucleotides in length are difficult to synthesize but can be generated by recombinant DNA techniques.

Primers Nucleic acid isolated or synthesized in accordance with the sequences described herein have utility as primers for the amplification of H. pylori nucleic acid. These nucleic acids may also have utility as primers for the amplification of nucleic acid sequences in other Helicobacter species. With respect to polymerase chain reaction (PCR) techniques, nucleic acid sequences of > 10-15 nucleotides contained in SEQ ID NOs: 1-1 14 have utility in conjunction with suitable enzymes and reagents to create copies of//, pylori nucleic acid. More preferably, the sequence will comprise twenty or more nucleotides to convey stability to the hybridization product formed between the primer and the intended target molecules. Binding conditions of primers greater than 100 nucleotides are more difficult to control to obtain specificity. High fidelity PCR can be used to ensure a faithful DNA copy prior to expression. In addition, amplified products can be checked by conventional sequencing methods. The copies can be used in diagnostic assays to detect specific sequences, including genes from H. pylori and/or other Helicobacter species. The copies can also be incorporated into cloning and expression vectors to generate polypeptides corresponding to the nucleic acid synthesized by PCR, as will be described in greater detail below.

Antisense

Nucleic acid or nucleic acid-hybridizing derivatives isolated or synthesized in accordance with the sequences described herein have utility as antisense agents to prevent the expression of// pylori genes. These sequences may also have utility as antisense agents to prevent expression of genes of other Helicobacter species. Nucleic acid or derivatives corresponding to H. pylori nucleic acid sequences is loaded into a suitable carrier such as a liposome or bacteriophage for introduction into bacterial cells. For example, a nucleic acid having twenty or more nucleotides is capable of binding to bacteria nucleic acid or bacteria messenger RNA. Preferably, the antisense nucleic acid is comprised of 20 or more nucleotides to provide necessary stability of a hybridization product of non-naturally occurring nucleic acid and bacterial nucleic acid and/or bacterial messenger RNA. Nucleic acid having a sequence greater than 1000 nucleotides in length is difficult to synthesize but can be generated by recombinant DNA techniques. Methods for loading antisense nucleic acid in liposomes is known in the art as exemplified by U.S. Patent 4,241,046 issued December 23, 1980 to Papahadjopoulos et al.

Expressing H. pylori Genes

The function of a specific gene or operon can be ascertained by expression in a bacterial strain under conditions where the activity of the gene product(s) specified by the gene or operon in question can be specifically measured. Alternatively, a gene product may be produced in large quantities in an expressing strain for use as an antigen, an industrial reagent, for structural studies, etc. This expression could be accomplished in a mutant strain which lacks the activity of the gene to be tested, or in a strain that does not produce the same gene product(s). This includes, but is not limited to other Helicobacter strains, and other bacterial strains such as E. coli, Norcardia, Corynebacterium, and Streptomyces species. In some cases the expression host will utilize the natural Helicobacter promoter whereas in others, it will be necessary to drive the gene with a promoter sequence derived from the expressing organism (e.g., an E. coli beta-galactosidase promoter for expression in E. coli).

To express a gene product using the natural H. pylori promoter, a procedure such as the following is used. A restriction fragment containing the gene of interest, together with its associated natural promoter element and regulatory sequences (identified using the DNA sequence data) is cloned into an appropriate recombinant plasmid containing the following components: an origin of replication that functions in the host organism, and an appropriate selectable marker. This can be accomplished by a number of procedures known to those skilled in the art. It is most preferably done by cutting the plasmid and the fragment to be cloned with the same restriction enzyme to produce compatible ends that can be ligated to join the two pieces together. The recombinant plasmid is introduced into the host organism by electroporation and cells containing the recombinant plasmid are identified by selection for the marker on the plasmid. Expression of the desired gene product is detected using an assay specific for that gene product.

In the case of a gene that requires a different promoter, the body of the gene (coding sequence) is specifically excised and cloned into an appropriate expression plasmid. This subcloning can be done by several methods, but is most easily accomplished by PCR amplification of a specific fragment and ligation into an expression plasmid after treating the PCR product with a restriction enzyme or exonuclease to create suitable ends for cloning.

Expressed Genes in Therapeutics

Nucleic acid isolated or synthesized in accordance with the sequences described herein have utility to generate proteins and peptides. The nucleic acid exemplified in SEQ ID NOs: 1-1 14 or fragments of said nucleic acid sequences encoding immunogenic portions of H. pylori proteins (SEQ ID NO: 115-228) can be cloned into suitable vectors or used to isolate nucleic acid. The isolated nucleic acid is combined with suitable DNA linkers and cloned into a suitable vector.

The host cell may be any procaryotic or eucaryotic cell. For example, an H. pylori peptide may be expressed in bacterial cells such as E. coli, insect cells (baculovirus), yeast, or mammalian cells such as Chinese hamster ovary cell (CHO). Other suitable host cells are known to those skilled in the art.

Expression in eucaryotic cells such as mammalian, yeast, or insect cells can lead to partial or complete glycosylation and/or formation of relevant inter- or intra-chain disulfide bonds of a recombinant peptide product. Examples of vectors for expression in yeast S. cerivisae include pYepSecl (Baldari. et al., (1987) Embo J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54: 1 13- 123), and pYES2 (Invitrogen Coφoration, San Diego, CA). Baculovirus vectors available for expression of proteins in cultured insect cells (SF 9 cells) include the pAc series (Smith et al., (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow, V.A., and Summers, M.D., (1989) Virology 170:31-39). Generally, COS cells (Gluzman, Y., (1981) Cell 23 : 175- 182) are used in conjunction with such vectors as pCDM 8 (Aruffo, A. and Seed, B., (1987) Proc. Natl. Acad. Sci. USA 84:8573-8577) for transient amplification/expression in mammalian cells, while CHO (dhfr Chinese Hamster Ovary) cells are used with vectors such as pMT2PC (Kaufman et al. ( 1987), EMBO J. 6: 187- 195) for stable amplification/expression in mammalian cells. Vector DNA can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, or electroporation. Suitable methods for transforming host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual. 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.

Expression in procaryotes is most often carried out in E. coli with either fusion or non-fusion inducible expression vectors. Fusion vectors usually add a number of NH2 terminal amino acids to the expressed target gene. These NH2 terminal amino acids often are referred to as a reporter group. Such reporter groups usually serve two purposes: 1) to increase the solubility of the target recombinant protein; and 2) to aid in the purification of the target recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the reporter group and the target recombinant protein to enable separation of the target recombinant protein from the reporter group subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRJT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase, maltose E binding protein, or protein A, respectively, to the target recombinant protein. A preferred reporter group is poly(His), which may be fused to the amino or carboxy terminus of the protein and which renders the recombinant fusion protein easily purifiable by metal chelate chromatography.

Inducible non-fusion expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pETl Id (Studier et al., Gene Expression Technology: Methods in Enzymology 185. Academic Press, San Diego, California (1990) 60-89). While target gene expression relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc, expression of target genes inserted into pETl Id relies on transcription from the T7 gnlO-lac 0 fusion promoter mediated by coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gnl under the transcriptional control of the lacUV 5 promoter.

For example, a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding an //. pylori peptide can be cultured under appropriate conditions to allow expression of the peptide to occur. The peptide may be secreted and isolated from a mixture of cells and medium containing the peptide. Alternatively, the peptide may be retained cytoplasmically and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. Peptides of the invention can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for such peptides. Additionally, in many situations, peptides can be produced by chemical cleavage of a native protein (e.g., tryptic digestion) and the cleavage products can then be purified by standard techniques.

In the case of membrane bound proteins, these can be isolated from a host cell by contacting a membrane-associated protein fraction with a detergent forming a solubilized complex, where the membrane-associated protein is no longer entirely embedded in the membrane fraction and is solubilized at least to an extent which allows it to be chromatographically isolated from the membrane fraction. Several different criteria are used for choosing a detergent suitable for solubilizing these complex. For example, one property considered is the ability of the detergent to solubilize the H. pylori protein within the membrane fraction at minimal denaturation of the membrane-associated protein allowing for the activity or functionality of the membrane-associated protein to return upon reconstitution of the protein. Another property considered when selecting the detergent is the critical micells concentration (CMC) of the detergent in that the detergent of choice preferably has a high CMC value allowing for ease of removal after reconstitution. A third property considered when selecting a detergent is the hydrophobicity of the detergent. Typically, membrane-associated proteins are very hydrophobic and therefore detergents which are also hydrophobic, e.g. the triton series, would be useful for solubilizing the hydrophobic proteins. Another property important to a detergent can be the capability of the detergent to remove the H. pylori protein with minimal protein-protein interaction facilitating further purification. A fifth property of the detergent which should be considered is the charge of the detergent. For example, if it is desired to use ion exchange resins in the purification process then preferably detergent should be an uncharged detergent. Chromatographic techniques which can be used in the final purification step are known in the art and include hydrophobic interaction, lectin affinity, ion exchange, dye affinity and immunoaffinity. One strategy to maximize recombinant H. pylori peptide expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 1 19-128). Another strategy would be to alter the nucleic acid encoding H. pylori peptide to be inserted into an expression vector so that the individual codons for each amino acid would be those preferentially utilized in highly expressed E. coli proteins (Wada et al., (1992) Nuc. Acids Res_^ 20:21 1 1 -2118). Such alteration of nucleic acids of the invention can be carried out by standard DNA synthesis techniques.

The nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which. like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See, e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et al. U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos. 4,401 ,796 and 4,373,071 , incorporated by reference herein).

Drug Screening Assays By making available purified and recombinant H. pylori polypeptides, the present invention provides assays which can be used to screen for drugs which are either agonists or antagonists of the normal cellular function, in this case, of the subject H. pylori polypeptides, or of their role in intracellular signaling. Such inhibitors or potentiators may be useful as new therapeutic agents to combat H pylori infections in humans. A variety of assay formats will suffice and, in light of the present inventions, will be comprehended by the skilled artisan.

In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect of the drug on the molecular target as may be manifest in an alteration of binding affinity with other proteins or change in enzymatic properties of the molecular target. Accordingly, in an exemplary screening assay of the present invention, the compound of interest is contacted with an isolated and purified H. pylori polypeptide. Screening assays may be constructed in vitro with a purified H. pylori enzyme such that the action of the enzyme produces an easily detectable reaction product. The efficacy of the compound can be assessed by generating dose response curves from data obtained using various concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. Suitable products include those with distinctive absoφtion, fluorescence, or chemi-luminescence properties, for example, because detection may be easily automated. A variety of synthetic or naturally occurring compounds may be tested in the assay to identify those which inhibit or potentiate the activity of the H. pylori enzyme. Some of these active compounds may directly, or with chemical alterations to promote membrane permeability or solubility, also inhibit or potentiate the same enzymatic activity in whole, live H. pylori cells.

Antibodies

The invention also includes antibodies specifically reactive with the subject H. pylori-like polypeptide. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (See, for example, Antibodies: A Laboratory Manual ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the peptide. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of the subject H pylori polypeptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies. In a preferred embodiment, the subject antibodies are immunospecific for antigenic determinants of the H. pylori polypeptides of the invention, e.g. antigenic determinants of a polypeptide shown in SEQ ID NOs: 1 15-228 or a closely related human or non-human mammalian homolog (e.g. 90% percent homologous, more preferably at least 95 percent homologous). In yet a further preferred embodiment of the present invention, the anti-H. pylori antibodies do not substantially cross react (i.e. react specifically) with a protein which is: e.g., less than 80% percent homologous to a sequence shown in SEQ ID NOs: 115-228. By "not substantially cross react", it is meant that the antibody has a binding affinity for a non-homologous protein which is less than 10 percent, more preferably less than 5 percent, and even more preferably less than 1 percent, of the binding affinity for a protein contained in SEQ ID NOs: 1 15-228. In a most preferred embodiment, there is no crossreactivity between bacterial and mammalian antigens.

The term antibody as used herein is intended to include fragments thereof which are also specifically reactive with H. pylori polypeptides. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab')2 fragments can be generated by treating antibody with pepsin. The resulting F(ab')2 fragment can be treated to reduce disulfide bridges to produce Fab' fragments. The antibody of the present invention is further intended to include bispecific and chimeric molecules having an anti-H. pylori portion.

Both monoclonal and polyclonal antibodies (Ab) directed against H. pylori polypeptides or H. pylori polypeptide variants, and antibody fragments such as Fab' and F(ab^')2, can be used to block the action of H. pylori polypeptide and allow the study of the role of a particular H. pylori polypeptide of the present invention in aberrant or unwanted intracellular signaling, as well as the normal cellular function of the H. pylori and by microinjection of anti-H. pylori polypeptide antibodies of the present invention. Antibodies which specifically bind H. pylori epitopes can also be used in immunohistochemical staining of tissue samples in order to evaluate the abundance and pattern of expression of H. pylori antigens. Anti-H. pylori polypeptide antibodies can be used diagnostically in immuno-precipitation and immuno-blotting to detect and evaluate H pylori levels in tissue or bodily fluid as part of a clinical testing procedure. Likewise, the ability to monitor H. pylori polypeptide levels in an individual can allow determination of the efficacy of a given treatment regimen for an individual afflicted with such a disorder. The level of an H pylori polypeptide can be measured in cells found in bodily fluid, such as in urine samples or can be measured in tissue, such as produced by gastric biopsy.

Diagnostic assays using anti-H. pylori antibodies can include, for example, immunoassays designed to aid in early diagnosis of H pylori infections. The present invention can also be used as a method of detecting antibodies contained in samples from individuals infected by this bacterium using specific H. pylori antigens. Another application of anti-H. pylori polypeptide antibodies of the present invention is in the immunological screening of cDNA libraries constructed in expression vectors such as λgtl 1 , λgtl 8-23, λZAP, and λORF8. Messenger libraries of this type, having coding sequences inserted in the correct reading frame and orientation, can produce fusion proteins. For instance, λgtl 1 will produce fusion proteins whose amino termini consist of β-galactosidase amino acid sequences and whose carboxy termini consist of a foreign polypeptide. Antigenic epitopes of a subject H pylori polypeptide can then be detected with antibodies, as, for example, reacting nitrocellulose filters lifted from infected plates with anti-H. pylori polypeptide antibodies. Phage, scored by this assay, can then be isolated from the infected plate. Thus, the presence of// pylori gene homologs can be detected and cloned from other species, and alternate isoforms (including splicing variants) can be detected and cloned.

Vaccines

The present invention also includes vaccine compositions for protection against infection by H. pylori or for treatment of H pylori infection, a gram-negative spiral microaerophilic bacterium. In one embodiment, the vaccine compositions contain immunogenic surface proteins from H. pylori, or portion thereof, and a pharmaceutically acceptable carrier. Nucleic acids within the scope of the invention are exemplified by the nucleic acids shown in SEQ ID NOs: 1-1 14 and which encode H. pylori surface proteins shown in SEQ ID NOs: 115-228. However, any nucleic acid encoding an immunogenic H. pylori protein, or portion thereof, which is capable of expression in a cell, can be used in the present invention. These vaccines can have therapeutic and prophylactic utilities. Another aspect of the present invention provides vaccine compositions for protection against infection by H. pylori or for treatment of H. pylori infection, which contain a modified immunogenic H pylori protein or portion thereof, and a pharmaceutically acceptable carrier. It is possible to modify the structure of a H pylori protein or peptide for such puφoses as increasing solubility, enhancing stability (e.g., shelf life ex vivo and resistance to proteolytic degradation in vivo). A modified H pylori protein or peptide can be produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion, or addition.

Another example of modification of an H pylori peptide is substitution of cysteine residues preferably with alanine, serine, threonine. leucine or glutamic acid residues to minimize dimerization via disulfide linkages. In addition, amino acid side chains of fragments of the protein of the invention can be chemically modified. Another modification is cyclization of the peptide.

In order to enhance stability and/or reactivity, an H pylori protein or peptide can be modified to incoφorate one or more polymoφhisms in the amino acid sequence of the protein resulting from any natural allelic variation. Additionally, D-amino acids, non- natural amino acids, or non-amino acid analogs can be substituted or added to produce a modified protein within the scope of this invention. Furthermore, an H.pylori protein can be modified using polyethylene glycol (PEG) according to the method of A. Sehon and co- workers (Wie et al., supra) to produce a protein conjugated with PEG. In addition, PEG can be added during chemical synthesis of the protein. Other modifications of H pylori proteins include reduction/alkylation (Tarr, Methods of Protein Microcharacterization, J. E. Silver ed., Humana Press, Clifton NJ 155-194 (1986)); acylation (Tarr, supra); chemical coupling to an appropriate carrier (Mishell and Shiigi, eds, Selected Methods in Cellular Immunology, WH Freeman, San Francisco, CA (1980), U.S. Patent 4,939,239; or mild formalin treatment (Marsh, (1971) Int. Arch, of Allergy and Appl. Immunol., 4 199 - 215). To facilitate purification and potentially increase solubility of an H. pylori protein or peptide, it is possible to add an amino acid fusion moiety to the peptide backbone. For example, hexa-histidine can be added to the protein for purification by immobilized metal ion affinity chromatography (Hochuli, E. et al., (1988) Bio/Technology, 6: 1321 - 1325). In addition, to facilitate isolation of peptides free of irrelevant sequences, specific endoprotease cleavage sites can be introduced between the sequences of the fusion moiety and the peptide.

To potentially aid proper antigen processing of T cell epitopes within an H. pylori protein of the invention, canonical protease sensitive sites can be engineered between regions, each comprising at least one T cell epitope via recombinant or synthetic methods. For example, charged amino acid pairs, such as KK or RR, can be introduced between regions within a protein or fragment during recombinant construction thereof. The resulting peptide can be rendered sensitive to cleavage by cathepsin and/or other trypsin- like enzymes which would generate portions of the protein containing one or more T cell epitopes. In addition, such charged amino acid residues can result in an increase in the solubility of the peptide.

Site-directed mutagenesis of a nucleic acid encoding an H. pylori protein can be used to modify the structure of the peptide by methods known in the art. Such methods may, among others, include polymerase chain reaction (PCR) with oligonucleotide primers bearing one or more mutations (Ηo et al., (1989) Gene, 77: 51 - 59) or total synthesis of mutated genes (Ηostomsky, Z. et al., (1989) Biochem. Biophys. Res. Comm, JJ3L 1056 - 1063). To enhance recombinant protein expression, the aforementioned methods can be applied to change the codons present in the cDNA sequence of the invention to those preferentially utilized by the host cell in which the recombinant protein is being expressed (Wada et al., supra). An extensive discussion of mutagenesis protocols is provided in the "Production of Fragments and Analogs" section herein.

Another aspect of the invention provides a vaccine composition for protection against infection by H pylori which contains an immunogenic fragment of an H. pylori protein or portion thereof, and a pharmaceutically acceptable carrier. Preferred fragments include peptides of at least about 10 amino acid residues in length, preferably about 10-20 amino acid residues in length, and more preferably about 12-16 amino acid residues in length. Immunogenic peptides of the invention can be obtained, for example, by screening peptides recombinantly produced from the corresponding fragment of the nucleic acid encoding the full-length H pylori protein. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, an H. pylori protein may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or preferably divided into overlapping fragments of a desired length. The fragments can be produced (recombinantly or by chemical synthesis) and tested to identify those peptides having the ability to induce a T cell response, such as stimulation (proliferation, cytokine secretion). An extensive discussion of peptide analogs and fragments is provided in the "Production of Fragments and Analogs" section herein.

In one embodiment, immunogenic H pylori fragments can be identified by the ability of the peptide to stimulate T cells. Peptides which stimulate T cells, as determined by, for example, T cell proliferation or cytokine secretion are defined herein as comprising at least one T cell epitope. T cell epitopes are believed to be involved in initiation and peφetuation of the immune response to the protein allergen which is responsible for the clinical symptoms of allergy. These T cell epitopes are thought to trigger early events at the level of the T helper cell by binding to an appropriate ΗLA molecule on the surface of an antigen presenting cell, thereby stimulating the T cell subpopulation with the relevant T cell receptor for the epitope. These events lead to T cell proliferation, lymphokine secretion, local inflammatory reactions, recruitment of additional immune cells to the site of antigen/T cell interaction, and activation of the B cell cascade, leading to the production of antibodies. One isotype of these antibodies, IgE, is fundamentally important to the development of allergic symptoms and its production is influenced early in the cascade of events at the level of the T helper cell, by the nature of the lymphokines secreted. A T cell epitope is the basic element, or smallest unit of recognition by a T cell receptor, where the epitope comprises amino acids essential to receptor recognition. Amino acid sequences which mimic those of the T cell epitopes and which modify the allergic response to protein allergens are within the scope of this invention.

In another embodiment, immunogenic components of the invention are identified through genomic vaccination. The basic protocol is based on the idea that expression libraries consisting of all or parts of a pathogen genome, e.g., an H. pylori genome, can confer protection when used to genetically immunize a host. This expression library immunization (ELI) is analogous to expression cloning and involves reducing a genomic expression library of a pathogen, e.g., H pylori, into plasmids that can act as genetic vaccines. The plasmids can also be designed to encode genetic adjuvants which can dramatically stimulate the humoral response. These genetic adjuvants can be introduced at remote sites and act as well extracelluraly as intracellularly. This is a new approach to vaccine production that has many of the advantages of live/attenuated pathogens but no risk of infection. An expression library of pathogen DNA is used to immunize a host thereby producing the effects of antigen presentation of a live vaccine without the risk. For example, in the present invention, random fragments from the H. pylori genome or from cosmid or plasmid clones, as well as PCR products from genes identified by genomic sequencing, can be used to immunize a host. The feasibility of this approach has been demonstrated with Mycoplasma pulmonis (Barry et al., Nature 377:632- 635, 1995), where even partial expression libraries of Mycoplasma pulmonis, a natural pathogen in rodents, provided protection against challenge from the pathogen.

ELI is a technique that allows for production of a non-infectious multipartite vaccine, even when little is known about pathogen's biology, because ELI uses the immune system to screen candidate genes. Once isolated, these genes can be used as genetic vaccines or for development of recombinant protein vaccines. Thus, ELI allows for production of vaccines in a systematic, largely mechanized fashion.

Screening peptides for those which are immunogenic can be accomplished using one or more of several different assays. For example, in vitro, peptide T cell stimulatory activity is assayed by contacting a peptide known or suspected of being immunogenic with an antigen presenting cell which presents appropriate MΗC molecules in a T cell culture. Presentation of an immunogenic H. pylori peptide in association with appropriate MHC molecules, to T cells, in conjunction with the necessary costimulation, has the effect of transmitting a signal to the T cell that induces the production of increased levels of cytokines, particularly of interleukin-2 and interleukin-4. The culture supernatant can be obtained and assayed for interleukin-2 or other known cytokines. For example, any one of several conventional assays for interleukin-2 can be employed, such as the assay described in Proc. Natl. Acad. Sci USA, 86: 1333 (1989) the pertinent portions of which are incoφorated herein by reference. A kit for an assay for the production of interferon is also available from Genzyme Coφoration (Cambridge, MA).

Alternatively, a common assay for T cell proliferation entails measuring tritiated thymidine incoφoration. The proliferation of T cells can be measured in vitro by determining the amount of ^H-labeled thymidine incoφorated into the replicating DNA of cultured cells. Therefore, the rate of DNA synthesis and, in turn, the rate of cell division can be quantified.

To produce modified proteins or immunogenic fragments by recombinant DNA techniques, an expression vector containing a nucleic acid encoding all or a portion of a H. pylori protein, operably linked to at least one regulatory sequence can be used. Operably linked is intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allows expression of the nucleotide sequence. Regulatory sequences are art-recognized and include promoters, enhancers and other expression control elements. Such regulatory sequences are described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. In one embodiment of the present invention, the expression vector includes nucleic acid, preferably a DNA, encoding a modified H. pylori protein or immunogenic fragment having all or a portion of the amino acid sequence . Such expression vectors can be used to transfect cells to thereby produce proteins or peptides, including fusion proteins or peptides encoded by nucleic acids as described herein.

Host cells suitable for transfection and recombinant production of H. pylori proteins of the invention include any procaryotic or eucaryotic cell. For example, an H. pylori protein or peptide may be expressed in bacterial cells such as E. coli, insect cells (baculovirus), yeast, or mammalian cells such as Chinese hamster ovary cells (CHO). Other suitable host cells can be found in Goeddel, (1990) supra or known to those skilled in the art. H. pylori proteins and fragments of the invention can also be chemically synthesized, using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. The nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (see e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et_aL, U.S. Patent No. 4,458,066; and Itakura, U.S. Patent Nos. 4,401,796 and 4,373,071, incoφorated by reference herein). Vaccine compositions of the present invention containing DNA encoding immunogenic protein from H pylori, or containing modified protein or fragments, contain both the DNA or protein and a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier that does not cause an allergic reaction or other untoward effect in patients to whom it is administered. Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody. For vaccines of the invention containing modified H pylori protein or immunogenic protein fragments, the protein or peptide must be coadministered with a suitable adjuvant.

It will be apparent to those of skill in the art that the therapeutically effective amount of DNA or protein of this invention will depend, inter alia, upon the administration schedule, the unit dose of antibody administered, whether the protein or DNA is administered in combination with other therapeutic agents, the immune status and health of the patient, and the therapeutic activity of the particular protein or DNA.

Vaccine compositions are conventionally administered parenterally, e.g., by injection, either subcutaneously or intramuscularly. Methods for intramuscular immunization are described by Wolff et al. (1990) Science 247: 1465-1468 and by Sedegah et al. (1994) Immunology 9J_: 9866-9870. Other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Oral immunization is preferred over parenteral methods for inducing protection against infection by H. pylori. Czinn et. al. (1993) Vaccine 1 1 : 637-642. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.

The vaccine compositions of the invention can include an adjuvant, including, but not limited to aluminum hydroxide; N-acetyl-muramyl~L-threonyI-D-isoglutamine (thr- MDP); N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 1 1637, referred to as nor- MDP); N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-( 1 '-2'-dipalmitoy 1-sn- gIycero-3-hydroxyphos-phoryloxy)-ethylamine (CGP 19835 A, referred to a MTP-PE); RIBI, which contains three components from bacteria; monophosphoryl lipid A; trehalose dimycoloate; cell wall skeleton (MPL + TDM + CWS) in a 2% squalene/Tween 80 emulsion; and cholera toxin. Others which may be used are non-toxic derivatives of cholera toxin, including its B subunit, and/or conjugates or genetically engineered fusions of the H pylori polypeptide with cholera toxin or its B subunit, procholeragenoid, fungal polysaccharides, including schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of E. coli, non-H pylori bacterial lysates. block polymers or saponins.

Other suitable delivery methods include biodegradable microcapsules or immuno- stimulating complexes (ISCOMs), cochleates, or liposomes, genetically engineered attenuated live vectors such as viruses or bacteria, and recombinant (chimeric) virus-like particles, e.g., bluetongue. The amount of adjuvant employed will depend on the type of adjuvant used. For example, when the mucosal adjuvant is cholera toxin, it is suitably used in an amount of 5 μg to 50 μg, for example 10 μg to 35 μg. When used in the form of microcapsules, the amount used will depend on the amount employed in the matrix of the microcapsule to achieve the desired dosage. The determination of this amount is within the skill of a person of ordinary skill in the art. Carrier systems in humans may include enteric release capsules protecting the antigen from the acidic environment of the stomach, and including H pylori polypeptide in an insoluble form as fusion proteins. Suitable carriers for the vaccines of the invention are enteric coated capsules and polylactide-glycolide microspheres. Suitable diluents are 0.2 N NaΗC03 and/or saline. Vaccines of the invention can be administered as a primary prophylactic agent in adults or in children, as a secondary prevention, after successful eradication of H. pylori in an infected host, or as a therapeutic agent with the aim to induce an immune response in a susceptible host to prevent infection by H. pylori. The vaccines of the invention are administered in amounts readily determined by persons of ordinary skill in the art. Thus, for adults a suitable dosage will be in the range of 10 μg to 10 g, preferably 10 μg to 100 mg, for example 50 μg to 50 mg. A suitable dosage for adults will also be in the range of 5 μg to 500 mg. Similar dosage ranges will be applicable for children. Those skilled in the art will recognize that the optimal dose may be more or less dependant upon the patient's body weight, disease, the route of administration, and other factors. Those skilled in the art will also recognize that appropriate dosage levels can be obtained based on results with known oral vaccines such as, for example, a vaccine based on an E. coli lysate (6 mg dose daily up to total of 540 mg) and with an enterotoxi genie E. coli purified antigen (4 doses of 1 mg) (Schulman et al., J. Urol. 150:917-921 (1993); Boedecker et al., American Gastroenterological Assoc. 999:A-222 (1993)). The number of doses will depend upon the disease, the formulation, and efficacy data from clinical trials. Without intending any limitation as to the course of treatment, the treatment can be administered over 3 to 8 doses for a primary immunization schedule over 1 month (Boedeker, American Gastroenterological Assoc. 888:A-222 (1993)).

In a preferred embodiment, a vaccine composition of the invention can be based on a killed whole E. coli preparation with an immunogenic fragment of an H. pylori protein of the invention expressed on its surface or it can be based on an E. coli lysate, wherein the killed E. coli acts as a carrier or an adjuvant.

It will be apparent to those skilled in the art that some of the vaccine compositions of the invention are useful only for preventing H. pylori infection, some are useful only for treating H pylori infection, and some are useful for both preventing and treating H pylori infection. In a preferred embodiment, the vaccine composition of the invention provides protection against H pylori infection by stimulating humoral and/or cell-mediated immunity against H pylori. It should be understood that amelioration of any of the symptoms of H pylori infection is a desirable clinical goal, including a lessening of the dosage of medication used to treat H #y/or/-caused disease, or an increase in the production of antibodies in the serum or mucous of patients.

Determination of candidate protein antigens for antibody and vaccine development

The selection of candidate protein antigens for vaccine development were derived from the nucleotide sequence. First, all possible open reading frames (ORF's) greater than 50 nucleotides in all six reading frames were identified and translated into amino acid sequences. Second, the identified ORF's were analyzed for homology to other known exported or membrane proteins and the ORF's were also analyzed using the discriminant analysis described by Klein, et al. (Klein, P., Kanehsia, M., and DeLisi, C. (1985) Biochimica et Biophysica Acta 815, 468-476) for predicting exported and membrane proteins. Homology searches were performed using the BLAST algorithm contained in the

Wisconsin Sequence Analysis Package (Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) to compare each predicted ORF amino acid sequence with all sequences found in the current GenBank, SWTSS-PROT and PIR databases. BLAST searches for local alignments between the ORF and the databank sequences and reports a probability score which indicates the probability of finding this sequence by chance in the database. ORF's with significant homology (e.g. probabilities better than 1x10 (ee-6)) to membrane or exported proteins represent likely protein antigens for vaccine development. Possible functions are provided to some of the H. pylori genes as indicated in Figure 560 based on sequence homology to genes cloned in other organisms. Discriminant analysis (Klein, et al. supra) was used to examine the ORF amino acid sequences using our own software. This algorithm uses the intrinsic information contained in the ORF amino acid sequence and compares it to information derived from the properties of known membrane and exported proteins. This comparison predicts which proteins will be exported, membrane associated or cytopiasmic. ORF amino acid sequences identified as exported or membrane associated by this algorithm are likely protein antigens for vaccine development.

Infrequently it is not possible to distinguish between multiple possible nucleotides at a given position in the nucleic acid sequence. In those cases the ambiguities are denoted by an extended alphabet as follows:

These are the official IUPAC-IUB single-letter base codes

Code Base Description

G Guanine

A Adenine

T Thymine

C Cytosine

R Purine (A or G)

Y Pyrimidine (C or T or U)

M Amino (A or C)

K Ketone (G or T)

S Strong interaction (C or G) w Weak interaction (A or T)

H Not-G (A or C or T)

B Not-A (C or G or T)

V Not-T (not-U) (A or C or G)

D Not-C (A or G or T)

N Any (A or C or G or T)

The amino acid translations of this invention account for the ambiguity in the nucleic acid sequence by translating the ambiguous codon as the letter "X". In all cases, the permissible amino acid residues at a position are clear from an examination of the nucleic acid sequence based on the standard genetic code.

Production of Fragments and Analogs

The inventor has discovered novel gene products, e.g. bacterial surface gene products, from the organism H. pylori. Once an example of this core structure has been provided one skilled in the art can alter the disclosed structure (of H. pylori genes), e.g., by producing fragments or analogs, and test the newly produced structures for activity.

Examples of prior art methods which allow the production and testing of fragments and analogs are discussed below. These, or analogous methods can be used to make and screen libraries of polypeptides, e.g., libraries of random peptides or libraries of fragments or analogues of cellular proteins for the ability to bind H. pylori polypeptides. Such screens are useful for discovery of inhibitors of H. pylori. Generation of Fragments

Fragments of a protein can be produced in several ways, e.g., recombinantly, by proteolytic digestion, or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end (for a terminal fragment) or both ends (for an internal fragment) of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments. Digestion with "end-nibbling" endonucleases can thus generate DNA's which encode an array of fragments. DNA's which encode fragments of a protein can also be generated by random shearing, restriction digestion or a combination of the above-discussed methods. Fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, peptides of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.

Production of Altered DNA and Peptide Sequences: Random Methods Amino acid sequence variants of a protein can be prepared by random mutagenesis of DNA which encodes a protein or a particular domain or region of a protein. Useful methods include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences. (Methods for screening proteins in a library of variants are elsewhere herein).

PCR Mutagenesis

In PCR mutagenesis, reduced Taq polymerase fidelity is used to introduce random mutations into a cloned fragment of DNA (Leung et al., 1989, Technique 1 :1 1-15). This is a very powerful and relatively rapid method of introducing random mutations. The DNA region to be mutagenized is amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase. e.g., by using a dGTP/dATP ratio of five and adding Mn²⁺ to the PCR reaction. The pool of amplified DNA fragments are inserted into appropriate cloning vectors to provide random mutant libraries.

Saturation Mutagenesis

Saturation mutagenesis allows for the rapid introduction of a large number of single base substitutions into cloned DNA fragments (Mayers et al., 1985, Science 229:242). This technique includes generation of mutations, e.g., by chemical treatment or irradiation of single-stranded DNA in vitro, and synthesis of a complimentary DNA strand. The mutation frequency can be modulated by modulating the severity of the treatment, and essentially all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for mutant fragments both neutral substitutions, as well as those that alter function, are obtained. The distribution of point mutations is not biased toward conserved sequence elements.

Degenerate Oligonucleotides

A library of homologs can also be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of a degenerate sequences can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The synthesis of degenerate oligonucleotides is known in the art (see for example, Narang, SA (1983) Tetrahedron 39:3; Itakura et al. (1981) Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al. (1984) WJ«. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198: 1056; Ike et al. (1983) Nucleic Acid Res. 1 1 :477. Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) Science 249:386-390; Roberts et al. (1992) PNAS 89:2429-2433; Devlin et al. (1990) Science 249: 404-406; Cwirla et al. (1990) PNAS 87: 6378-6382; as well as U.S. Patents Nos. 5.223,409, 5,198,346, and 5,096,815).

Production of Altered DNA and Peptide Sequences: Methods for Directed Mutagenesis Non-random or directed, mutagenesis techniques can be used to provide specific sequences or mutations in specific regions. These techniques can be used to create variants which include, e.g., deletions, insertions, or substitutions, of residues of the known amino acid sequence of a protein. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conserved amino acids and then with more radical choices depending upon results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

Alanine Scanning Mutagenesis

Alanine scanning mutagenesis is a useful method for identification of certain residues or regions of the desired protein that are preferred locations or domains for mutagenesis, Cunningham and Wells (Science 244:1081-1085, 1989). In alanine scanning, a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine). Replacement of an amino acid can affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions are then refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis may be conducted at the target codon or region and the expressed desired protein subunit variants are screened for the optimal combination of desired activity.

Oligonucleotide-Mediated Mutagenesis

Oligonucleotide-mediated mutagenesis is a useful method for preparing substitution, deletion, and insertion variants of DNA, see, e.g., Adelman et al., (DNA 2:183, 1983). Briefly, the desired DNA is altered by hybridizing an oligonucleotide encoding a mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the desired protein. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incoφorate the oligonucleotide primer, and will code for the selected alteration in the desired protein DNA. Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al. (Proc. Natl. Acad. Sci. USA, 75: 5765 [1978]).

Cassette Mutagenesis

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al. (Gene, 34:315[1985]). The starting material is a plasmid (or other vector) which includes the protein subunit DNA to be mutated. The codon(s) in the protein subunit DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide- mediated mutagenesis method to introduce them at appropriate locations in the desired protein subunit DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated desired protein subunit DNA sequence. Combinatorial Mutagenesis

Combinatorial mutagenesis can also be used to generate mutants (Ladner et al., WO 88/06630). In this method, the amino acid sequences for a group of homologs or other related proteins are aligned, preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences. The variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential sequences are expressible as individual peptides, or alternatively, as a set of larger fusion proteins containing the set of degenerate sequences.

Primary Fligh-Through-Put Methods for Screening Libraries of Peptide Fragments or Homologs

Various techniques are known in the art for screening generated mutant gene products. Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, e.g., in this case, binding to H. pylori polypeptide or an interacting protein, facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the techniques described below is amenable to high through-put analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.

Two Hybrid Systems

Two hybrid assays such as the system described above (as with the other screening methods described herein), can be used to identify polypeptides, e.g., fragments or analogs of a naturally-occurring H. pylori polypeptide, e.g., of cellular proteins, or of randomly generated polypeptides which bind to an H. pylori protein. (The H. pylori domain is used as the bait protein and the library of variants are expressed as fish fusion proteins.) In an analogous fashion, a two hybrid assay (as with the other screening methods described herein), can be used to find polypeptides which bind a H. pylori polypeptide.

Display Libraries

In one approach to screening assays, the candidate peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind an appropriate receptor protein via the displayed product is detected in a "panning assay". For example, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) Bio/Technology 9:1370-1371; and Goward et al. (1992) TIBS 18:136-140). In a similar fashion, a detectably labeled ligand can be used to score for potentially functional peptide homologs. Fluorescently labeled ligands, e.g., receptors, can be used to detect homologs which retain ligand-binding activity. The use of fluorescently labeled ligands, allows cells to be visually inspected and separated under a fluorescence microscope, or, where the moφhology of the cell permits, to be separated by a fluorescence-activated cell sorter.

A gene library can be expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at concentrations well over 10^ phage per milliliter, a large number of phage can be screened at one time. Second, since each infectious phage displays a gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical E. coli filamentous phages Ml 3, fd., and fl are most often used in phage display libraries. Either of the phage gill or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle. Foreign epitopes can be expressed at the NH2-terminal end of pill and phage bearing such epitopes recovered from a large excess of phage lacking this epitope (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267:16007-16010; Griffiths et al. (1993) EMBO J 12:725-734; Clackson et al. (1991) Nature 352:624-628; and Barbas et al. (1992) PNAS 89:4457-4461). A common approach uses the maltose receptor of E. coli (the outer membrane protein, LamB) as a peptide fusion partner (Charbit et al. (1986) EMBO 5, 3029-3037). Oligonucleotides have been inserted into plasmids encoding the LamB gene to produce peptides fused into one of the extracellular loops of the protein. These peptides are available for binding to ligands, e.g., to antibodies, and can elicit an immune response when the cells are administered to animals. Other cell surface proteins, e.g., OmpA (Schorr et al. (1991) Vaccines 91, pp. 387-392), PhoE (Agterberg, et al. (1990) Gene 88, 37-45), and PAL (Fuchs et al. (1991) Bio/Tech 9, 1369-1372), as well as large bacterial surface structures have served as vehicles for peptide display. Peptides can be fused to pilin, a protein which polymerizes to form the pilus-a conduit for interbacterial exchange of genetic information (Thiry et al. ( 9%9) Appl. Environ. Microbiol. 55, 984-993). Because of its role in interacting with other cells, the pilus provides a useful support for the presentation of peptides to the extracellular environment. Another large surface structure used for peptide display is the bacterial motile organ, the flagellum. Fusion of peptides to the subunit protein flagellin offers a dense array of many peptide copies on the host cells (Kuwajima et al. (1988) Bio/Tech. 6, 1080-1083). Surface proteins of other bacterial species have also served as peptide fusion partners. Examples include the Staphylococcus protein A and the outer membrane protease IgA of Neisseria (Hansson et al. (1992) J. Bacteriol. 174, 4239-4245 and Klauser et al. (1990) EMBOJ. 9, 1991-1999).

In the filamentous phage systems and the LamB system described above, the physical link between the peptide and its encoding DNA occurs by the containment of the DNA within a particle (cell or phage) that carries the peptide on its surface. Capturing the peptide captures the particle and the DNA within. An alternative scheme uses the DNA- binding protein Lad to form a link between peptide and DNA (Cull et al. (1992) PNAS USA 89:1865-1869). This system uses a plasmid containing the Lad gene with an oligonucleotide cloning site at its 3'-end. Under the controlled induction by arabinose, a Lacl-peptide fusion protein is produced. This fusion retains the natural ability of Lad to bind to a short DNA sequence known as LacO operator (LacO). By installing two copies of LacO on the expression plasmid, the Lacl-peptide fusion binds tightly to the plasmid that encoded it. Because the plasmids in each cell contain only a single oligonucleotide sequence and each cell expresses only a single peptide sequence, the peptides become specifically and stably associated with the DNA sequence that directed its synthesis. The cells of the library are gently lysed and the peptide-DNA complexes are exposed to a matrix of immobilized receptor to recover the complexes containing active peptides. The associated plasmid DNA is then reintroduced into cells for amplification and DNA sequencing to determine the identity of the peptide ligands. As a demonstration of the practical utility of the method, a large random library of dodecapeptides was made and selected on a monoclonal antibody raised against the opioid peptide dynoφhin B. A cohort of peptides was recovered, all related by a consensus sequence corresponding to a six- residue portion of dynoφhin B. (Cull et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89-1869)

This scheme, sometimes referred to as peptides-on-plasmids, differs in two important ways from the phage display methods. First, the peptides are attached to the C- terminus of the fusion protein, resulting in the display of the library members as peptides having free carboxy termini. Both of the filamentous phage coat proteins, pill and pVIII, are anchored to the phage through their C-termini, and the guest peptides are placed into the outward-extending N-terminal domains. In some designs, the phage-displayed peptides are presented right at the amino terminus of the fusion protein. (Cwirla, et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 6378-6382) A second difference is the set of biological biases affecting the population of peptides actually present in the libraries. The Lad fusion molecules are confined to the cytoplasm of the host cells. The phage coat fusions are exposed briefly to the cytoplasm during translation but are rapidly secreted through the inner membrane into the periplasmic compartment, remaining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, containing the peptides, protruding into the periplasm while awaiting assembly into phage particles. The peptides in the Lacl and phage libraries may differ significantly as a result of their exposure to different proteolytic activities. The phage coat proteins require transport across the inner membrane and signal peptidase processing as a prelude to incoφoration into phage. Certain peptides exert a deleterious effect on these processes and are underrepresented in the libraries (Gallop et al. (1994) J Med. Chem. 37(9): 1233-1251). These particular biases are not a factor in the Lad display system. The number of small peptides available in recombinant random libraries is enormous. Libraries of 10^-10^ independent clones are routinely prepared. Libraries as large as 10^ recombinants have been created, but this size approaches the practical limit for clone libraries. This limitation in library size occurs at the step of transforming the DNA containing randomized segments into the host bacterial cells. To circumvent this limitation, an in vitro system based on the display of nascent peptides in polysome complexes has recently been developed. This display library method has the potential of producing libraries 3-6 orders of magnitude larger than the currently available phage/phagemid or plasmid libraries. Furthermore, the construction of the libraries, expression of the peptides, and screening, is done in an entirely cell-free format. In one application of this method (Gallop et al. (1994) J Med. Chem. 37(9):1233-

1251), a molecular DNA library encoding 10^ decapeptides was constructed and the library expressed in an E. coli S30 in vitro coupled transcription/translation system. Conditions were chosen to stall the ribosomes on the mRNA, causing the accumulation of a substantial proportion of the RNA in polysomes and yielding complexes containing nascent peptides still linked to their encoding RNA. The polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened. RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening. The polysome display method can be coupled to the phage display system. Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector. This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing vector for peptide identification. By expressing the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) Anal. Biochem 204,357-364). To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.

Secondary Screens

The high through-put assays described above can be followed by secondary screens in order to identify further biological activities which will, e.g., allow one skilled in the art to differentiate agonists from antagonists. The type of a secondary screen used will depend on the desired activity that needs to be tested. For example, an assay can be developed in which the ability to inhibit an interaction between a protein of interest and its respective ligand can be used to identify antagonists from a group of peptide fragments isolated though one of the primary screens described above. Therefore, methods for generating fragments and analogs and testing them for activity are known in the art. Once the core sequence of interest is identified, it is routine to perform for one skilled in the art to obtain analogs and fragments.

Peptide Mimetics The invention also provides for reduction of the protein binding domains of the subject H pylori-like family polypeptides, e.g., an H pylori polypeptide, to generate mimetics, e.g. peptide or non-peptide agents. The peptide mimetics are able to disrupt binding of a H pylori to its counter ligand, e.g., in the case of an H pylori polypeptide binding to a naturally occurring ligand. The critical residues of a subject H pylori polypeptide which are involved in molecular recognition of a polypeptide can be determined and used to generate H. /7y/øπ^'-derived peptidomimetics which competitively or noncompetatively inhibit binding of the H pylori polypeptide with an interacting polypeptide (see, for example, "Peptide inhibitors of human papillomavirus protein binding to retinoblastoma gene protein" European patent applications EP-412,762A and EP- B31 ,080A). For example, scanning mutagenesis can be used to map the amino acid residues of a particular H pylori polypeptide involved in binding an interacting polypeptide, peptidomimetic compounds (e.g. diazepine or isoquinoline derivatives) can be generated which mimic those residues in binding to an interacting polypeptide. and which therefore can inhibit binding of an H. pylori polypeptide to an interacting polypeptide and thereby interfere with the function of H pylori polypeptide. For instance, non- hydrolyzable peptide analogs of such residues can be generated using benzodiazepine (e.g., see Freidinger et al. in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gama lactam rings (Garvey et al. in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) J Med Chem 29:295; and Ewenson et al. in Peptides: Structure and Function (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), β-turn dipeptide cores (Nagai et al. (1985) Tetrahedron Lett 26:647; and Sato et al. (1986) J Chem Soc Perkin Trans 1 :1231), and β- aminoalcohols (Gordon et al. (1985) Biochem Biophys Res Communl26:4\9; and Dann et al. (1986) Biochem Biophys Res Commun 134:71). Kjts

The nucleic acid, peptides and antibodies of the present invention can be combined with other reagents and articles to form kits. Kits for diagnostic puφoses typically comprise the nucleic acid, peptides or antibodies in vials or other suitable vessels. Kits typically comprise other reagents for performing hybridization reactions, polymerase chain reactions (PCR), or for reconstitution of lyophilized components, such as aqueous media, salts, buffers, and the like. Kits may also comprise reagents for sample processing such as detergents, chaotropic salts and the like. Kits may also comprise immobilization means such as particles, supports, wells, dipsticks and the like. Kits may also comprise labeling means such as dyes, developing reagents, radioisotopes, fluorescent agents, luminescent or chemiluminescent agents, enzymes, intercalating agents and the like. With the nucleic acid and amino acid sequence information provided herein, individuals skilled in art can readily assemble kits to serve their particular puφose.

Exemplification I. Cloning and Sequencing of H. pylori DNA

H. pylori chromosomal DNA was isolated according to a basic DNA protocol outlined in Schleif R.F. and Wensink P.C, Practical Methods in Molecular Biology, p.98, Springer-Verlag, NY., 1981, with minor modifications. Briefly, cells were pelleted, resuspended in TE (10 mM Tris, 1 mM EDTA, pΗ 7.6) and GES lysis buffer (5.1 M guanidium thiocyanate, 0.1 M EDTA, pΗ 8.0, 0.5% N-laurylsarcosine) was added.

Suspension was chilled and ammonium acetate (NΗ4AC) was added to final concentration of 2.0 M. DNA was extracted, first with chloroform, then with phenol-chloroform, and reextracted with chloroform. DNA was precipitated with isopropanol, washed twice with 70% EtOH, dried and resuspended in TE. Following isolation whole genomic H. pylori DNA was nebulized (Bodenteich et al., Automated DNA Sequencing and Analysis (J.C. Venter, ed.), Academic Press, 1994) to a median size of 2000 bp. After nebulization, the DNA was concentrated and separated on a standard 1% agarose gel. Several fractions, corresponding to approximate sizes 900-1300 bp, 1300-1700 bp, 1700-2200 bp, 2200-2700 bp, were excised from the gel and purified by the GeneClean procedure (Bio 101 , Inc.).

The purified DNA fragments were then blunt-ended using T4 DNA polymerase. The healed DNA was then ligated to unique BstXI-linker adapters in 100-1000 fold molar excess. These linkers are complimentary to the BstXI-cut pMPX vectors, while the overhang is not self-complimentary. Therefore, the linkers will not concatemerize nor will the cut-vector religate itself easily. The linker-adopted inserts were separated from the unincoφorated linkers on a 1% agarose gel and purified using GeneClean. The linker- adapted inserts were then ligated to each of the 20 pMPX vectors to construct a series of "shotgun" subclone libraries. The vectors contain an oul-of-frame lacZ gene at the cloning site which becomes in- frame in the event that an adapter-dimer is cloned, allowing these to be avoided by their blue-color.

All subsequent steps were based on the multiplex DNA sequencing protocols outlined in Church G.M. and Kieffer-Higgins S., Science 240:185-188, 1988. Only major modifications to the protocols are highlighted. Briefly, each of the 20 vectors was then transformed into DH5 competent cells (Gibco/BRL, DH5α transformation protocol). The libraries were assessed by plating onto antibiotic plates containing ampicillin, methicillin and IPTG/Xgal. The plates were incubated overnight at 37°C. Successful transformants were then used for plating of clones and pooling into the multiplex pools. The clones were picked and pooled into 40 ml growth medium cultures. The cultures were grown overnight at 37°C. DNA was purified using the Qiagen Midi-prep kits and Tip-100 columns (Qiagen, Inc.). In this manner, 100 μg of DNA was obtained per pool. 15 96-well plates of DNA were generated to obtain a 5-10 fold sequence redundancy with 250-300 base average read-lengths. These purified DNA samples were then sequenced using the multiplex DNA sequencing based on chemical degradation methods (Church G.M. and Kieffer-Higgins S., Science 240:185-188, 1988) or by Sequithrem (Epicenter Technologies) dideoxy sequencing protocols. The sequencing reactions were electrophoresed and transferred onto nylon membranes by direct transfer electrophoresis from 40 cm gels (Richterich P. and Church G.M., Methods in Enzemology 218: 187-222, 1993) or by electroblotting (Church, supra). 24 samples were run per gel. 45 successful membranes were produced by chemical sequencing and 8 were produced by dideoxy sequencing. The DNA was covalently bound to the membranes by exposure to ultraviolet light, and hybridized with labeled oligonucleotides complimentary to tag sequences on the vectors (Church, supra). The membranes were washed to rinse off non-specifically bound probe, and exposed to X-ray film to visualize individual sequence ladders. After autoradiography, the hybridized probe was removed by incubation at 65°C, and the hybridization cycle repeated with another tag sequence until the membrane has been probed 38 times for chemical sequencing membranes and 10 times for the dideoxy sequencing membranes. Thus, each gel produced a large number of films, each containing new sequencing information. Whenever a new blot was processed, it was initially probed for an internal standard sequence added to each of the pools.

Digital images of the films were generated using a laser-scanning densitometer (Molecular Dynamics, Sunnyvale, CA). The digitized images were processed on computer workstations (VaxStation 4000's) using the program REPLICA™ (Church et al.,

Automated DNA Sequenicng and Analysis (J.C. Venter, ed.). Academic Press. 1994). Image processing included lane straightening, contrast adjustment to smooth out intensity differences, and resolution enhancement by iterative gaussian deconvolution. The sequences were then automatically picked in REPLICA™ and displayed for interactive proofreading before being stored in a project database. The proofreading was accomplished by a quick visual scan of the film image followed by mouse clicks on the bands of the displayed image to modify the base calls. For typical sequences derived by chemical sequencing, the error rate of the REPLICA™ base calling software was 2-5% with most errors occurring near the end of a sequence read. Many of the sequence errors could be detected and corrected because multiple sequence reads covering the same portion of the genomic DNA provide adequate sequence redundancy for editing. Each sequence automatically received a number correspond to (microtiter plate and probe information) and lane set number (corresponding to microtiter plate columns). This number serves as a permanent identifier of the sequence so it is always possible to identify the original of any particular sequence without recourse to a specialized database.

Routine assembly of//, pylori sequences was done using the program FALCON (Church, Church et al., Automated DNA Sequenicng and Analysis (J.C. Venter, ed.), Academic Press, 1994). This program has proven to be fast and reliable for most sequences. The assembled contigs were displayed using a modified version of GelAssemble, developed by the Genetics Computer Group (GCG) (Devereux et al., Nucleic- Acid Res. 12:387-95, 1984) that interacts with REPLICA™. This provided for an integrated editor that allows multiple sequence gel images to be instantaneously called up from the REPLICA™ database and displayed to allow rapid scanning of contigs and proofreading of gel traces where discrepancies occurred between different sequence reads in the assembly.

II. Identification, cloning and expression of recombinant H. pylori DNA sequences

To facilitate the cloning, expression and purification of membrane and secreted proteins from H. pylori a powerful gene expression system, the pET System (Novagen), for cloning and expression of recombinant proteins in E. coli, was selected. Also, a DNA sequence encoding a peptide tag, the Ηis-Tag, was fused to the 3' end of DNA sequences of interest in order to facilitate purification of the recombinant protein products. The 3' end was selected for fusion in order to avoid alteration of any 5' terminal signal sequence. The exception to the above was ppiB, a gene cloned for use as a control in the expression studies. In this study, the sequence for H. pylori ppiB contains a DNA sequence encoding a Ηis-Tag fused to the 5' end of the full length gene, because the protein product of this gene does not contain a signal sequence and is expressed as a cytosolic protein. PCR Amplification and cloning of DNA sequences containing ORF 's for membrane and secreted proteins from the J99 Strain of Helicobacter pylori.

Sequences chosen (from the list of the DNA sequences of the invention) for cloning from the J99 strain of H. pylori were prepared for amplification cloning by polymerase chain reaction (PCR). Synthetic oligonucleotide primers (Table 2) specific for the 5' and 3' ends of open reading frames (ORFs) were designed and purchased (GibcoBRL Life

Technologies, Gaithersburg, MD, USA). All forward primers (specific for the 5' end of the sequence) were designed to include an Ncol cloning site at the extreme 5' terminus, except for H pylori sequence 4821082 (SEQ ID NO: 212) where Ndel was used. These primers were designed to permit initiation of protein translation at a methionine residue followed by a valine residue and the coding sequence for the remainder of the native H. pylori DNA sequence. An exception is H pylori sequence 4821082 (SEQ ID NO: 212) where the initiator methionine is immediately followed by the remainder of the native H pylori DNA sequence. All reverse primers (specific for the 3' end of any H. pylori ORF) included a EcoRI site at the extreme 5' terminus to permit cloning of each H pylori sequence into the reading frame of the pET-28b. The pET-28b vector provides sequence encoding an additional 20 carboxy-terminal amino acids including six histidine residues (at the extreme C-terminus), which comprise the Flis-Tag. An exception to the above, as noted earlier, is the vector construction for the ppiB gene. A synthetic oligonucleotide primer specific for the 5' end of ppiB gene encoded a BamΗI site at its extreme 5' terminus and the primer for the 3' end of the ppiB gene encoded a Xhol site at its extreme 5' terminus.

TABLE 2

Oligonucleotide primers used for PCR amplification of H. pylori DNA sequences

Outer membrane Proteins Forward primer 5' to 3' Reverse Primer 5' to 3'

71 16626 (SEQ ID NO: 223) 5'-ATATCCATGGTGAGT 5'-ATGAATTCAATTTTT TTGATGA-3' (SEQ ID TATTTTGCCA-3' (SEQ ID NO:229) NO:230)

29479681 (SEQ ID NO: 179) 5'-AATTCCATGGTGGGG 5'-ATGAATTCTCGATAG GCTATG-3' (SEQ ID CCAAAATC-3' (SEQ ID NO:231) NO:232)

Periplasmic/ Secreted Proteins

30100332 (SEQ ID NO: 181) 5-.ATTTCCATGGTCATG 5'-ATGAATTCCATCTTT TCTCATATT-3* (SEQ ID TATTCCAC-3' (SEQ ID NO:233) NO:234)

4721061 (SEQ ID NO: 21 1 ) 5'-AACCATGGTGATTT 5'-AAGAATTCCACTCA

TAAGCATTGAAAG-3' AAATTTTTTAACAG-3'

(SEQ ID NO:235) (SEQ ID NO:236) Other Surface Proteins

4821082 (SEQ ID NO: 212) 5'-GATCATCCATATGTT 5'-TGAATTCAACCATTT ATCTTCTAAT-3' (SEQ ID TAACCCTG-3' (SEQ ID

NO:237) NO:238)

978477 (SEQ ID NO: 228) 5'-TATACCATGGTGAA S'-AGAATTCAATTGCG ATTTTTTCTTTTA-3' (SEQ TC TTGTAAAAG-3' (SEQ ID ID NO:239) NO:240)

Cytopiasmic Protein ppiB 5'-TTATGGATCCAAAC 5'-TATCTCGAGTTATA CAATTAAAACT-3' (SEQ ID GAGAAGGGC-3' (SEQ ID NO:241 ) NO:242)

Genomic DNA prepared from the J99 strain of H. pylori (ATCC #55679) was used as the source of template DNA for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). To amplify a DNA sequence containing an H pylori ORF, genomic DNA (50 nanograms) was introduced into a reaction vial containing 2 mM MgCl2, 1 micromolar synthetic oligonucleotide primers (forward and reverse primers) complementary to and flanking a defined H pylori ORF, 0.2 mM of each deoxynucleotide triphosphate; dATP, dGTP, dCTP, dTTP and 2.5 units of heat stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA) in a final volume of 100 microliters. The following thermal cycling conditions were used to obtain amplified DNA products for each ORF using a Perkin Elmer Cetus/ GeneAmp PCR System 9600 thermal cycler:

Sequences 7116626 (SEQ ID NO: 223), 29479681 (SEQ ID NO: 179), 30100332 (SEQ ID NO: 181), 4821082 (SEQ ID NO: 212) and 978477 (SEQ ID NO: 228);

Denaturation at 94°C for 2 min,

2 cycles at 94°C for 15 sec, 30°C for 15 sec and 72°C for 1.5 min 23 cycles at 94°C for 15 sec, 55°C for 15 sec and 72°C for 1.5 min Reactions were concluded at 72°C for 6 minutes.

Sequence 4721061 (SEQ ID NO: 211);

Denaturation at 94°C for 2 min,

2 cycles at 94°C for 15 sec, 36°C for 15 sec and 72°C for 1.5 min 23 cycles at 94°C for 15 sec, 60°C for 15 sec and 72°C for 1.5 min Reactions were concluded at 72°C for 6 minutes.

Conditions for amplification oϊH. pylori ppiB;

Denaturation at 94°C for 2 min,

2 cycles at 94°C for 15 sec, 32°C for 15 sec and 72°C for 1.5 min 25 cycles at 94°C for 15 sec, 56°C for 15 sec and 72°C for 1.5 min Reactions were concluded at 72°C for 6 minutes Upon completion of thermal cycling reactions, each sample of amplified DNA was washed and purified using the Qiaquick Spin PCR purification kit (Qiagen. Gaithersburg, MD, USA). All amplified DNA samples were subjected to digestion with the restriction endonucleases, Ncol and EcoRI (New England BioLabs, Beverly, MA, USA), or in the case of H pylori sequence 4821082 (SEQ ID NO: 212), with Ndel and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). DNA samples were then subjected to electrophoresis on 1.0 % NuSeive (FMC BioProducts, Rockland, ME USA) agarose gels. DNA was visualized by exposure to ethidium bromide and long wave uv irradiation. DNA contained in slices isolated from the agarose gel was purified using the Bio 101 GeneClean Kit protocol (Bio 101 Vista, CA, USA).

Cloning ofH. pylori DNA sequences into the pET-28b prokaryotic expression vector.

The pET-28b vector was prepared for cloning by digestion with Ncol and EcoRI, or in the case of H pylori sequence 4821082 (SEQ ID NO: 212) with Ndel and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). In the case of cloning ppiB, the pET-28a vector, which encodes a Ηis-Tag that can be fused to the 5' end of an inserted gene, was used and the cloning site prepared for cloning with the ppiB gene by digestion with BamΗI and Xhol restriction endonucleases. Following digestion, DNA inserts were cloned (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994) into the previously digested pET-28b expression vector, except for the amplified insert for ppiB, which was cloned into the pET-28a expression vector. Products of the ligation reaction were then used to transform the BL21 strain of E. coli (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994) as described below.

Transformation of competent bacteria with recombinant plasmids

Competent bacteria, E coli strain BL21 or E. coli strain BL21(DE3), were transformed with recombinant pET expression plasmids carrying the cloned H pylori sequences according to standard methods (Current Protocols in Molecular, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). Briefly, 1 microliter of ligation reaction was mixed with 50 microliters of electrocompetent cells and subjected to a high voltage pulse, after which, samples were incubated in 0.45 milliliters SOC medium (0.5% yeast extract, 2.0 % tryptone, 10 mM NaCl, 2.5 mM KCl, 10 M MgC12, 10 mM MgS04 and 20, mM glucose) at 37°C with shaking for 1 hour. Samples were then spread on LB agar plates containing 25 microgram/ml kanamycin sulfate for growth overnight. Transformed colonies of BL21 were then picked and analyzed to evaluate cloned inserts as described below. Identification of recombinant pET expression plasmids carrying H. pylori sequences

Individual BL21 clones transformed with recombinant pET-28b-H. pylori ORFs were analyzed by PCR amplification of the cloned inserts using the same forward and reverse primers, specific for each H pylori sequence, that were used in the original PCR amplification cloning reactions. Successful amplification verified the integration of the H. pylori sequences in the expression vector (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994).

Isolation and Preparation of plasmid DNA from BL2I transformants

Individual clones of recombinant pET-28b vectors carrying properly cloned H. pylori ORFs were picked and incubated in 5 mis of LB broth plus 25 microgram/ml kanamycin sulfate overnight. The following day plasmid DNA was isolated and purified using the Qiagen plasmid purification protocol (Qiagen Inc., Chatsworth, CA. USA).

Expression of recombinant H pylori sequences in E. coli The pET vector can be propagated in any E. coli K- 12 strain e.g. HMS 174, HB 101 ,

JM109, DH5, etc. for the puφose of cloning or plasmid preparation. Hosts for expression include E. coli strains containing a chromosomal copy of the gene for T7 RNA polymerase. These hosts are lysogens of bacteriophage DE3, a lambda derivative that carries the lad gene, the lacUV5 promoter and the gene for T7 RNA polymerase. T7 RNA polymerase is induced by addition of isopropyl-B-D-thiogalactoside (IPTG), and the T7 RNA polymerase transcribes any target plasmid, such as pET-28b, carrying a T7 promoter and a gene of interest. Strains used include: BL21(DE3) (Studier, F.W., Rosenberg, A.H., Dunn, J.J., and Dubendorff, J.W. (1990) Meth. Enzymol. 185, 60-89).

To express recombinant H. pylori sequences, 50 nanograms of plasmid DNA isolated as described above was used to transform competent BL21(DE3) bacteria as described above (provided by Novagen as part of the pET expression system kit). The lacZ gene (beta-galactosidase) was expressed in the pET-System as described for the H. pylori recombinant constructions. Transformed cells were cultured in SOC medium for 1 hour, and the culture was then plated on LB plates containing 25 micrograms/ml kanamycin sulfate. The following day, bacterial colonies were pooled and grown in LB medium containing kanamycin sulfate (25 micrograms/ml) to an optical density at 600 nM of 0.5 to 1.0 O.D. units, at which point, 1 millimolar IPTG was added to the culture for 3 hours to induce gene expression of the H pylori recombinant DNA constructions .

After induction of gene expression with IPTG, bacteria were pelleted by centrifugation in a Sorvall RC-3B centrifuge at 3500 x g for 15 minutes at 4°C. Pellets were resuspended in 50 milliliters of cold 10 mM Tris-HCl, pH 8.0, 0.1 M NaCl and 0.1 mM EDTA (STE buffer). Cells were then centrifuged at 2000 x g for 20 min at 4°C. Wet pellets were weighed and frozen at -80°C until ready for protein purification.

III. Purification of recombinant proteins from E. coli Analytical Methods The concentrations of purified protein preparations were quantified spectrophotometrically using absorbance coefficients calculated from amino acid content (Perkins, S.J. 1986 Eur. J. Biochem. 157, 169-180). Protein concentrations were also measured by the method of Bradford, M.M. (1976) Anal. Biochem. 72, 248-254, and Lowry, O.H., Rosebrough, N., Farr, A.L. & Randall, R.J. (1951) J. Biol. Chem. 193, pages 265-275, using bovine serum albumin as a standard.

SDS-polyacrylamide gels (12% or 4.0 to 25 % acrylamide gradient gels) were purchased from BioRad (Hercules, CA, USA), and stained with Coomassie blue. Molecular weight markers included rabbit skeletal muscle myosin (200 kDa), E. coli (- galactosidase (1 16 kDa), rabbit muscle phosphorylase B (97.4 kDa), bovine serum albumin (66.2 kDa), ovalbumin (45 kDa), bovine carbonic anhydrase (31 kDa), soybean trypsin inhibitor (21.5 kDa), egg white lysozyme (14.4 kDa) and bovine aprotinin (6.5 kDa).

/. Purification of soluble proteins

All steps were carried out at 4°C. Frozen cells were thawed, resuspended in 5 volumes of lysis buffer (20 mM Tris, pH 7.9, 0.5 M NaCl, 5 mM imidazole with 10% glycerol, 0.1 % 2-mercaptoethanol, 200 μg/ ml lysozyme, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 10 ug/ml each of leupeptin, aprotinin, pepstatin, L-l-chloro-3-[4- tosylamido]-7-amino-2-heptanone (TLCK), L-l-chloro-3-[4-tosylamido]-4-phenyl-2- butanone (TPCK), and soybean trypsin inhibitor, and ruptured by several passages through a small volume microfluidizer (Model M-l 1 OS, Microfluidics International Coφoration, Newton, MA). The resultant homogenate was made 0.1 % Brij 35, and centrifuged at 100,000 x g for 1 hour to yield a clear supernatant (crude extract).

Following filtration through a 0.8 μm Supor filter (Gelman Sciences, FRG) the crude extract was loaded directly onto a Ni^^+" nitrilotriacetate-agarose (NTA) with a 5 milliliter bed volume (Hochuli, E., Dbeli, H., and Schacheer, A. (1987) J. Chromatography 41 1, 177-184) pre-equilibrated in lysis buffer containing 10 % glycerol, 0.1 % Brij 35 and 1 mM PMSF. The column was washed with 250 ml (50 bed volumes) of lysis buffer containing 10 % glycerol, 0.1 % Brij 35, and was eluted with sequential steps of lysis buffer containing 10 % glycerol, 0.05 % Brij 35, 1 mM PMSF, and 20, 100, 200, and 500 mM imidazole in succession. Fractions were monitored by absorbance at OU2go ⁿm, an peak fractions were analyzed by SDS-PAGE. Fractions containing the recombinant protein eluted at 100 mM imidazole. Recombinant beta-galactosidase (lacZ) and pept idyl -prolyl cis-trans isomerase (ppiB)

Fractions containing the recombinant proteins from the Ni2⁺-NTA-agarose columns were pooled and then concentrated to approximately 5 ml by centrifugal filtration (Ccntriprep-10, Amicon, MA), and loaded directly onto a 180-ml column (1.6 X 91 cm) of Scphacryl S-100 HR gel filtration medium equilibrated in Buffer A (10 mM Hepes, pH 7.5, 150 mM NaCl, 0.1 mM EGTA) and run in Buffer A at 18 ml/h. Fractions containing the recombinant protein were identified by absorbance at 280 nm and analyzed by SDS-PAGE. Fractions were pooled and concentrated by centrifugal filtration.

Recombinant protein 7116626 (SEQ ID NO: 223) Fractions containing the recombinant protein from the Ni^⁺ -NTA-agarose column were pooled and dialyzed overnight against 1 liter of dialysis buffer (10 mM MOPS, pH 6.5, 50 mM NaCl, 0.1 mM EGTA, 0.02% Brij 35 and 1 mM PMSF). In the morning, a fine white precipitate was removed by centrifugation and the resulting supernatant was loaded onto an 8 ml (8 x 75 mm) MonoS high performance liquid chromatography column (Pharmacia Biotechnology, Inc., Piscataway, NJ, USA) equilibrated in buffer B (10 mM

MOPS, pH 6.5, 0.1 mM EGTA) containing 50 mM NaCl. The column was washed with 10 bed volumes of buffer B containing 50 mM NaCl, and developed with a 50-ml linear gradient of increasing NaCl (50 to 500 mM). Recombinant protein 71 16626 (SEQ ID NO: 223) eluted as a shaφ peak at 300 mM NaCl.

2. Purification of insoluble proteins from inclusion bodies

The following steps were carried out at 4°C. Cell pellets were resuspended in lysis buffer with 10% glycerol 200 μg/ ml lysozyme, 5 mM EDTA, ImM PMSF and 0.1 % - mercaptoethanol. After passage through the cell disrupter, the resulting homogenate was made 0.2 % deoxycholate, stirred 10 minutes, then centrifuged at 20,000 x g, for 30 min. The pellets were washed with lysis buffer containing 10 % glycerol, 10 mM EDTA, 1% Triton X-100, 1 mM PMSF and 0.1% -mercaptoethanol, followed by several washes with lysis buffer containing 1 M urea, 1 mM PMSF and 0.1 % 2-mercaptoethanol. The resulting white pellet was composed primarily of inclusion bodies, free of unbroken cells and membranous materials..

Recombinant proteins 30100332 (SEQ ID NO: 181), 4721061 (SEQ ID NO: 211)

The following steps were carried out at room temperature. Purified inclusion bodies were dissolved in 20 ml 8.0 M urea in lysis buffer with 1 mM PMSF and 0.1 % 2- mercaptoethanol, and incubated at room temperature for 1 hour. Materials that did not dissolve were removed by centrifugation. The clear supernatant was filtered, then loaded onto a Ni2+ -NTA agarose column pre-equilibrated in 8.0 M urea in Lysis Buffer. The column was washed with 250 ml (50 bed volumes) of lysis buffer containing 8 M urea, 1.0 mM PMSF and 0.1 % 2-mercaptoethanol, and developed with sequential steps of lysis buffer containing 8M urea, 1 mM PMSF, 0.1 % 2-mercaptoethanol and 20, 100, 200, and 500 mM imidazole in succession. Fractions were monitored by absorbance at OD280 nm, and peak fractions were analyzed by SDS-PAGE. Fractions containing the recombinant protein eluted at 100 mM imidazole.

Recombinant proteins 29479681 (SEQ ID NO: 179), 978477 (SEQ ID NO: 228)

The pellet containing the inclusion bodies was solubilized in buffer B containing 8 M urea, 1 mM PMSF and 0.1 % 2-mercaptoethanol, and incubated for 1 hour at room temperature. Insoluble materials were removed by centrifugation at 20,000 x g for 30 min, and the cleared supernatant was loaded onto a 15 ml ( 1.6 x 7.5 cm ) SP-Sepharose column pre-equilibrated in buffer B, 6 M urea, 1 mM PMSF, 0.1 % 2-mercaptoethanol. After washing the column with 10 bed volumes, the column was developed with a linear gradient from 0 to 500 mM NaCl.

Dialysis and concentration of protein samples

Urea was removed slowly from the protein samples by dialysis against Tris- buffered saline (TBS; 10 mM Tris pH 8.0, 150 mM NaCl) containing 0.5 % deoxycholate (DOC) with sequential reduction in urea concentration as follows; 6M, 4M, 3M, 2M, IM, 0.5 M and finally TBS without any urea. Each dialysis step was conducted for a minimum of 4 hours at room temperature.

After dialysis, samples were concentrated by pressure filtration using Amicon stirred-cells. Protein concentrations were measured using the methods of Perkins (1986 Eur. J. Biochem. 157, 169-180), Bradford ((1976) Anal. Biochem. 72, 248-254) and Lowry ((1951) J. Biol. Chem. 193, pages 265-275).

The recombinant proteins purified by the methods described above are summarized in Table 3 below.

TABLE 3

J99 Homolog Gene Baccterial Method of Relative Final Con¬ Composition Sequence identified symbol of fraction purification MW on centration of buffer Identifier by Blast Homolog used to SDS-PAGE of purified purify gel protein recombinant proteins

Outer Membrane Proteins

71 16626 P26093 e(P4) Soluble His-Tag 29 kDa 0.8 mg/ml A (SEQ ID fraction

NO: 223)

1.85 mg/ml C

29479681 P13036 fee A Inclusions SP- 23 kDa 2.36 mg ml B (SEQ ID bodies Sepharose NO: 179) 0.5 mg ml B as dry pellet gel filtration S 100 HR

Periplasmic/Secreted Protein

3010032 P23847 dppA Inclusion His-Tag 1 1 kDa 2.88 mg/ml B (SEQ ID bodies NO: 181)

4721061 P36175 GCP Inclusion His-Tag 38 kDa 2.8 mg ml B (SEQ ID bodies NO: 21 1 )

Other Surface Proteins

4821082 P08089 M protein Inclusion His-Tag 20 kDa 1.16 mg ml B (SEQ ID bodies NO:212)

978477 L28919 FBP54 Inclusion SP- 44 kDa 2.56 mg/ml B (SEQ ID bodies Sepharose NO: 228)

0.3 mg/ml B

Control Proteins with His-Tag

P00722 lacZ Soluble His-Tag 1 16 kDa 10 mg ml A fraction gel filtration S200 HR ppiB Soluble His-Tag 21 kDa 4.4 mg/ml A fraction gel filtration S 100 HR

Buffer compositions:

A=10 mM Hepes pH 7.5, 150 mM NaCl, 0.1 M EGTA B= 10 mM Tris pH 8.0, 150 mM NaCl, 0.5 % DOC C= 10 M MOPS pH 6.5, 300 M NaCl, 0.1 EGTA

IV. Analysis of H. pylori proteins as Vaccine candidates

To investigate the immunomodulatory effect of//, pylori proteins, a mouse///. pylori model was used. This model mimics the human //. pylori infection in many respects. The focus is on the effect of oral immunization in H. pylori infected animals in order to test the concept of therapeutic oral immunotherapy.

Animals

Female SPF BALB/c mice were purchased from Bomholt Breeding center (Denmark). They were kept in ordinary makrolon cages with free supply of water and food. The animals were 4-6 weeks old at arrival.

Infection

After a minimum of one week of acclimatization, the animals were infected with a type 2 strain (VacA negative) of H. pylori (strain AH244, originally isolated from an ulcer patient). In our hands, this strain has earlier proven to be a good colonizer of the mouse stomach. The bacteria were grown overnight in Brucella broth supplemented with 10 % fetal calf serum, at 37°C in a microaerophilic atmosphere (10% C0₂, 5%0₂). The animals were given an oral dose of omeprazole (400 μmol/kg) and 3-5 h after this an oral inoculation of /, pylori in broth (approximately 10 cfu animal). Positive take of the infection was checked in some animals 2-3 weeks after the inoculation.

Antigens Recombinant //. pylori antigens were chosen based on their association with externally exposed H. pylori cell membrane. These antigens were selected from the following groups: (1.) Outer Membrane Proteins; (2.) Periplastic/Secreted proteins; (3.) Outer Surface proteins; and (4.) Inner Membrane proteins. All recombinant proteins were constructed with a hexa-ΗIS tag for purification reasons and the non-Helicobacter pylori control protein (β-galactosidase from E. coli; LacZ), was constructed in the same way.

All antigens were given in a soluble form, i.e. dissolved in either a ΗEPES buffer or in a buffer containing 0.5% Deoxycholate (DOC). The antigens are listed in Table 4 below.

Table 4

Helicobacter pylori proteins

Outer membrane Proteins

SEQ ID NO: 179 SEQ ID NO:223

Periplastic/Secreted proteins

SEQ ID NO:181 SEQ ID NO:211

Other cell envelope proteins

SEQ ID NO:212 SEQ ID NO:228

Control proteins β-galactosidase (LacZ)

Immunizations

Ten animals in each group were immunized 4 times over a 34 day period (day 1 , 15, 25 and 35). Purified antigens in solution or suspension were given at a dose of 100 μg/mouse. As an adjuvant, the animals were also given 10 μg/mouse of Cholera toxin (CT) with each immunization. Omeprazole (400 μmol/kg) was given orally to the animals 3-5 h prior to immunization as a way of protecting the antigens from acid degradation. Infected control animals received ΗEPES buffer + CT or DOC buffer + CT. Animals were sacrificed 2-4 weeks after final immunization. A general outline of the study is shown in Table 5 below. Table 5

Study outline, therapeutic immunization:

Mice were all infected with H. pylori strain AH244 at day 30. Proteins are listed by their Seq ID #'s.

Substance Mouse strain Dose/mouse Dates for n≡lO dosing

1. Controls, PBS Balb/c 0.3 ml 0, 14, 24, 34

2. Cholera toxin, 10 μg Balb/c 0.3 ml 0, 14, 24, 34

3. Protein 179, 100 μg + CT 10 μg Balb/c 0.3 ml 0, 14, 24, 34 4. Protein 181 , 100 μg + CT 10 μg Balb/c 0.3 ml 0, 14, 24, 34

5. Protein 211, 100 μg + CT 10 μg Balb/c 0.3 ml 0, 14, 24, 34

6. Protein 212, 100 μg + CT 10 μg Balb/c 0.3 ml 0, 14, 24, 34

7. Protein 228, 100 μg + CT 10 μg Balb/c 0.3 ml 0, 14, 24, 34

8. Protein 223, 100 μg + CT 10 μg Balb/c 0.3 ml 0, 14, 24, 34

Analysis of infection

Mucosal infection: The mice were sacrificed by C0₂ and cervical dislocation. The abdomen was opened and the stomach removed. After cutting the stomach along the greater curvature, it was rinsed in saline. The mucosa from the antrum and coφus of an area of 25mm was scraped separately with a surgical scalpel. The mucosa scraping was suspended in Brucella broth and plated onto Blood Skirrow selective plates. The plates were incubated under microaerophilic conditions for 3-5 days and the number of colonies was counted. The identity of H. pylori was ascertained by urease and catalase test and by direct microscopy or Gram staining. The urease test was performed essentially as follows. The reagent, Urea Agar Base

Concentrate, was purchased from DIFCO Laboratories, Detroit, MI (Catalog # 0284-61-3). Urea agar base concentrate was diluted 1 :10 with water. 1 ml of the diluted concentrate was mixed with 100-200 μl of actively growing H. pylori cells. Color change to magenta indicated that cells were urease positive. The catalase test was performed essentially as follows. The reagent, N,N,N',N'-

Tetramethyl-p-Phenylenediamine, was purchased from Sigma, St. Louis, MO (Catalog # T3134). A solution of the reagent (1% w/v in water) was prepared. H. pylori cells were swabbed onto Whatman filter paper and overlaid with the 1% solution. Color change to dark blue indicated that the cells were catalase positive. Serum antibodies: From all mice serum was prepared from blood drawn by heart puncture. Serum antibodies were identified by regular ELISA techniques, where the specific antigens of Helicobacter pylori were plated.

Mucosal antibodies: Gentle scrapings of a defined part of the coφus and of 4 cm of duodenum were performed in 50% of the mice in order to detect the presence of antibodies in the mucous. The antibody titers were determined by regular ELISA technique as for serum antibodies.

Statistical analysis: Wilcoxon-Mann- Whitney sign rank test was used for determination of significant effects of the antigens on Helicobacter pylori colonization. P<0.05 was considered significant. Because the antrum is the major colonization site for Helicobacter most emphasis was put upon changes in the antral colonization.

Results

Antibodies in sera: All antigens tested given together with CT gave rise to a measurable specific titer in serum. The highest responses were seen with SEQ ID NOs:223, 21 1, and 212 (see Figure 2).

Antibodies in mucus: In the mucus scrapings, specific antibodies against all antigens tested were seen. By far the strongest response was seen with SEQ ID NOs: 181 , followed by 223 (see Figure 3).

Therapeutic immunization effects: All control animals (BALB/c mice) were well colonized with H. pylori (strain

AΗ244) in both antrum and coφus of the stomach. Of the antigens tested 2 proteins (SEQ ID NOs: 21 1 and 212) gave a good and significant reduction and/or eradication of the H pylori infection. The degree of colonization of the antrum was lower following immunization with SEQ ID NOs: 228 and 223 compared to control. The effect of SEQ ID NOs: 179, and 181 did not differ from control. The control protein lacZ, i.e. the non-H. pylori protein, had no eradication effect and in fact had higher Helicobacter colonization compared to the ΗEPES + CT control. All data are shown in Figures 4 and 5 for proteins dissolved in ΗEPES and DOC respectively. Data is shown as geometric mean values. n=8- 10 Wilcoxon-Mann- Whitney sign rank test * = p<0.05; x/10 = number of mice showing eradication of H. pylori over the total number of mice examined.

The data presented indicate that all of the H. pylori associated proteins included in this study, when used as oral immunogens in conjunction with the oral adjuvant CT, resulted in stimulation of an immune response as measured by specific serum and mucosal antibodies. A majority of the proteins led to a reduction, and in some cases complete clearance of the colonization of H pylori in this animal model. It should be noted that the reduction or clearance was due to heterologous protection rather than homologous protection (the polypeptides were based on the H pylori J99 strain sequence and used in the therapeutic immunization studies against a different (AΗ244) challenge strain), indicating the vaccine potential against a wide variety of H. pylori strains. The highest colonization in the antrum was seen in animals treated with the non-

Helicobacter protein LacZ, indicating that the effects seen with the Helicobacter pylori antigens were specific. Taken together these data strongly support the use of these H. pylori proteins in a pharmaceutical formulation for the use in humans to treat and/or prevent H. pylori infections.

V. Sequence Variance Analysis of genes in Helicobacter pylori strains Three genes were cloned and sequenced from several strains of H pylori to compare the DNA and deduced amino acid sequences. This information was used to determine the sequence variation between the H pylori strain, J99, and other H. pylori strains isolated from human patients.

Preparation of Chromosomal DNA.

Cultures of H pylori strains (as listed in Table 8) were grown in BLBB (1% Tryptone, 1% Peptamin 0.1% Glucose, 0.2% Yeast Extract 0.5% Sodium Chloride, 5% Fetal Bovine Serum) to an OD₆₀₀ of 0.2. Cells were centrifuged in a Sorvall RC-3B at 3500 x g at 4°C for 15 minutes and the pellet resuspended in 0.95 mis of 10 mM Tris-ΗCl, 0.1 mM EDTA (TE). Lysozyme was added to a final concentration of 1 mg/ml along with SDS to 1% and RNAse A + TI to 0.5mg/ml and 5 units/ml respectively, and incubated at 37°C for one hour. Proteinase K was then added to a final concentration of 0.4mg/ml and the sample was incubated at 55°C for more than one hour. NaCl was added to the sample to a concentration of 0.65 M, mixed carefully, and 0.15 ml of 10% CTAB in 0.7M NaCL (final is 1 % CTAB/70mM NaCL) was added followed by incubation at 65°C for 20 minutes. At this point, the samples were extracted with chloroform :isoamyl alcohol, extracted with phenol, and extracted again with chloroform:isoamyl alcohol. DNA was precipitated with either EtOΗ (1.5 x volumes) or isopropanol (0.6 x volumes) at -70°C for 10 minutes, washed in 70% EtOΗ and resuspended in TE.

PCR Amplification and cloning.

Genomic DNA prepared from twelve strains oi Helicobacter pylori was used as the source of template DNA for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). To amplify a DNA sequence containing an H pylori ORF, genomic DNA (10 nanograms) was introduced into a reaction vial containing 2 mM MgCl₂, 1 micromolar synthetic oligonucleotide primers (forward and reverse primers, see Table 6) complementary to and flanking a defined H. pylori ORF, 0.2 mM of each deoxynucleotide triphosphate; dATP, dGTP, dCTP, dTTP and 0.5 units of heat stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA) in a final volume of 20 microliters in duplicate reactions. Table 6 Oligonucleotide primers used for PCR amplification of H pylori DNA sequences.

Outer membrane Forward primer 5' to 3' Reverse Primer 5' to 3' Proteins

SEQ ID NO:223 5'-ATATCCATGGTGAGTTTGA 5'-ATGAATTCAATTTTTTATTTT TGA-3' (SEQ ID NO:243) GCCA-3' (SEQ ID O:244)

SEQ ID NO:179 5'-AATTCCATGGCTATCCAAAT 5'-ATGAATTCGCCAAAATCGTA CCG-3' (SEQ ID NO:245) GTATT-3' (SEQ ID NO:246)

SEQ ID NO: 199 5'-GATACCATGGAATTTATGAA 5'-TGAATTCGAAAAAGTGTAGT AAAG-3' (SEQ ID NO:247) TATAC-3' (SEQ ID NO:248)

The following thermal cycling conditions were used to obtain amplified DNA products for each ORF using a Perkin Elmer Cetus/ GeneAmp PCR System 9600 thermal cycler:

Sequences (by SEQ ID NO:) 223 and 199; Denaturation at 94°C for 2 min,

2 cycles at 94°C for 15 sec, 30°C for 15 sec and 72^ϋC for 1.5 min 23 cycles at 94°C for 15 sec, 55°C for 15 sec and 72°C for 1.5 min Reactions were concluded at 72°C for 6 minutes.

Sequences (by SEQ ID NO:) 179; Denaturation at 94°C for 2 min, 2 cycles at 94°C for 15 sec, 30°C for 20 sec and 72°C for 2 min 25 cycles at 94°C for 15 sec, 55°C for 20 sec and 72°C for 2 min Reactions were concluded at 72°C for 8 minutes.

Upon completion of thermal cycling reactions, each pair of samples were combined and used directly for cloning into the pCR cloning vector as described below.

Cloning ofH pylori DNA sequences into the pCR TA cloning vector.

All amplified inserts were cloned into the pCR 2.1 (pCRII in the case of H pylori sequence 223) vector by the method described in the Original TA cloning kit (Invitrogen, San Diego, CA). Products of the ligation reaction were then used to transform the TOPI OF' (INVaF' in the case of H pylori sequence 223) strain of E. coli as described below.

Transformation of competent bacteria with recombinant plasmids Competent bacteria, E coli strain TOPI OF' or E. coli strain INVaF' were transformed with recombinant pCR expression plasmids carrying the cloned H. pylori sequences according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). Briefly, 2 microliters of 0.5 micromolar BME was added to each vial of 50 microliters of competent cells. Subsequently, 2 microliters of ligation reaction was mixed with the competent cells and incubated on ice for 30 minutes. The cells and ligation mixture were then subjected to a "heat shock" at 42°C for 30 seconds, and were subsequently placed on ice for an additional 2 minutes, after which, samples were incubated in 0.45 milliliters SOC medium (0.5% yeast extract, 2.0 % tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgC12, 10 mM MgS04 and 20, mM glucose) at 37"C with shaking for 1 hour. Samples were then spread on LB agar plates containing 25 microgram/ml kanamycin sulfate or 100 micrograms/ml ampicillan for growth overnight. Transformed colonies of TOP10F' or INVaF' were then picked and analyzed to evaluate cloned inserts as described below.

Identification of recombinant PCR plasmids carrying H. pylori sequences

Individual TOPI OF' or INVaF' clones transformed with recombinant pCR-H.pylori ORFs were analyzed by PCR amplification of the cloned inserts using the same forward and reverse primers, specific for each H. pylori sequence, that were used in the original PCR amplification cloning reactions. Successful amplification verified the integration of the H. pylori sequences in the cloning vector (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994).

Individual clones of recombinant pCR vectors carrying properly cloned H pylori ORFs were picked for sequence analysis. Sequence analysis was performed on ABI Sequencers using standard protocols (Perkin Elmer) using vector-specific primers (as found in PCRII or pCR2.1, Invitrogen, San Diego, CA) and sequencing primers specific to the ORF as listed in Table 7 below.

Table 7

Oligonucleotide primers used for sequencing of H pylori DNA sequences.

Outer Forward primers 5' to 3' Reverse Primers 5' to 3' membrane

Proteins

SEQ ID NO:223 5'-TTGAACACTTTTGATTATGCGG-3' 5'-GTCTTTAGCAAAAATGGCGTC- (SEQ ID NO:249) 3' (SEQ ID NO:251 )

5'-GGATTATGCGATTGTTTTACAAG- 5'-AATGAGCGTAAGAGAGCCTTC- 3' (SEQ ID NO:250) 3' (SEQ ID NO:252)

SEQ ID NO:179 5 -CTTATGGGGGTATTGTCA-3' (SEQ ID 5'-AGGTTGTTGCCTAAAGACT-3' NO.-253) (SEQ ID NO:255)

5'-AGCATGTGGGTATCCAGC-3' (SEQ 5'-CTGCCTCCACCTTTGATC-3' ID NO:254) (SEQ ID NO:256)

SEQ ID NO: 199 5'-ACCAATATCΛATTGGCACT-3' (SEQ 5'-CTTGCTTGTCATATCTAGC-3' ID NO:257) (SEQ ID NO:259)

5 -ACTTGGAAAAGCTCTGCA-3' (SEQ 5'-GTTGAAGTGTTGGTGCTA-3' ID NO:258) (SEQ ID NO:260) 5'-CAAGCAAGTGGTTTGGTTTTAG-3' 5'-GCCCATAATCAAAAAGCCCAT- (SEQ ID NO:261 ) 3' (SEQ ID NO:263)

5'-TGGAAAGAGCAAATCATTGAAG-3' 5'-CTAAAACCAAACCACTTGCT (SEQ ID O:262) TGTC-3' (SEQ ID NO:264)

Vector Primers 5'-GTAAAACGACGGCCAG-3' (SEQ ID 5'-CAGGAAACAGCTATGAC-3' NO:265) (SEQ ID O:266)

Results

The PCR error rate for the experiments described herein was determined to be 2 base changes out of 4485 bases, which is equivalent to an estimated error rate of less than or equal to 0.04%. DNA sequence analysis was performed on four different open reading frames identified as genes and amplified by PCR methods from a dozen different strains of the bacterium Helicobacter pylori. The deduced amino acid sequences of three of the four open reading frames that were selected for this study showed statistically significant BLAST homology to defined proteins present in other bacterial species. Those ORFs included: SEQ ID NO:223, homologous to lipoprotein e (P4) present in the outer membrane of H. influenzae; SEQ ID NO: 179, homologous to fecA, an outer membrane receptor in iron (III) dicitrate transport in E. coli. SEQ ID NO: 199 was identified as an unknown open reading frame, because it showed low homology with sequences in the public databases. To assess the extent of conservation or variance in the ORFs across various strains of H. pylori, changes in DNA sequence and the deduced protein sequence were compared to the DNA and deduced protein sequences found in the J99 strain of H. pylori (see Table 8 below). Results are presented as percent identity to the J99 strain of H. pylori sequenced by random shotgun cloning. To control for any variations in the J99 sequence each of the four open reading frames were cloned and sequenced again from the J99 bacterial strain and that sequence information was compared to the sequence information that had been collected from inserts cloned by random shotgun sequencing of the J99 strain.

Table 8

Multiple Strain DNA Sequence analysis of II pylon Vaccine Candidates

J99 Seα ID # 223 223 179 179 199 199

Length of Region 232 a a 696 nt 182 a a 548 nt 273 a a 819 nt

Sequenced

Strain Tested

AA Nuc AA Nuc AA identity Nuc identity identity identity identity Identity

J99 100 00% 100 00% 100 00% 100 00% 99 63% 99 88%

AH244 n d n d 99 09% 96 71% 98 90% 96 45%

AH4 97 84% 95 83% n d n d 97 80% 95 73%

AH5 98 28% 96 12% 98 91% 96 90% 98 53% 95 73%

AH15 9741% 95 98% 99 82% 97 99% 99 63% 96 09%

AH61 97 84% 95 98% 99 27% 97 44% n d n d

5155 n d n d 9945% 97 08% 98 53% 95 60%

5294 98 28% 95 40% 99 64% 97 26% 97 07% 9548%

7958 97 84% 95 40% n d n d 99 63% 9646%

5640 97 41% 9569% 9909% 9763% 98 53% 9548%

AH18 98 71% 95 69% 99 64% 97 44% 100 00% 95 97%

AH24 97 84% 95 40% 99 27% 96 71% 100 00% 96 46% n d = not done

VI. Experimental Knock-Out Protocol for the Determination of Essential H pylori Genes as Potential Therapeutic Targets Therapeutic targets are chosen from genes whose protein products appear to play key roles in essential cell pathways such as cell envelope synthesis, DNA synthesis, transcription, translation, regulation and colonization/virulence.

The protocol for the deletion of portions of H pylori genes/ORFs and the insertional mutagenesis of a kanamycin-resistance cassette in order to identify genes which are essential to the cell is modified from previously published methods (Labigne-Roussel et al., 1988, J. Bacteriology 170, pp. 1704-1708; Cover et al.,1994, J. Biological Chemistry 269, pp. 10566-10573; Reyrat et al., 1995, Proc. Natl. Acad. Sci. 92, pp 8768-8772) The result is a gene "knock-out."

Identification and Cloning ofH. pylori Gene Sequences

The sequences of the genes or ORFs (open reading frames) selected as knock-out targets are identified from the H. pylori genomic sequence and used to design primers to specifically amplify the genes/ORFs. All synthetic oligonucleotide primers are designed with the aid of the OLIGO program (National Biosciences, Inc., Plymouth, MN 55447, USA), and can be purchased from Gibco/BRL Life Technologies (Gaithersburg, MD, USA). If the ORF is smaller than 800 to 1000 base pairs, flanking primers are chosen outside of the open reading frame. Genomic DNA prepared from the Helicobacter pylori HP-J99 strain (ATCC 55679) is used as the source of template DNA for amplification of the ORFs by PCR (polymerase chain reaction) (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). For the preparation of genomic DNA from //. pylori, see Example I. PCR amplification is carried out by introducing 10 nanograms of genomic HP- J99 DNA into a reaction vial containing 10 mM Tris pH 8.3, 50 mM KCl, 2 mM MgCl₂, 2 microMolar synthetic oligonucleotide primers (forward=Fl and reverse=Rl), 0.2 mM of each deoxynucleotide triphosphate (dATP,dGTP, dCTP, dTTP), and 1.25 units of heat stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA) in a final volume of 40 microliters. The PCR is carried out with Perkin Elmer Cctus/GeneAmp PCR System 9600 thermal cyclers.

Upon completion of thermal cycling reactions, each sample of amplified DNA is visualized on a 2% TAE agarose gel stained with Ethidium Bromide (Current Protocols in Molecular Biology, John Wiley a d Sons, Inc., F. Ausubel et al., editors, 1994) to determine that a single product f the expected size had resulted from the reaction. Amplified DNA is then washed and purified using the Qiaquick Spin PCR purification kit (Qiagen, Gaithersburg, MD, USA).

PCR products are cloned into the pT7Blue T-Vector (catalog#69820-l, Novagen, Inc., Madison, WI, USA) using the TA cloning strategy (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). The ligation of the PCR product into the vector is accomplished by mixing a 6 fold molar excess of the PCR product, 10 ng of pT7Blue-T vector (Novagen), 1 microliter of T4 DNA Ligase Buffer (New England Biolabs, Beverly, MA, USA), and 200 units of T4 DNA Ligase (New England Biolabs) into a final reaction volume of 10 microliters. Ligation is allowed to proceed for 16 hours at 16°C. Ligation products are electroporated (Current Protocols in Molecular Biology, John

Wiley and Sons, Inc., F. Ausubel et al., editors, 1994) into electroporation-competent XL-1 Blue or DH5-α E.coli cells (Clontech Lab., Inc. Palo Alto, CA, USA). Briefly, 1 microliter of ligation reaction is mixed with 40 microliters of electrocompetent cells and subjected to a high voltage pulse (25 microFarads, 2.5 kV, 200 ohms) after which the samples are incubated in 0.45 ml SOC medium (0.5% yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgS0₄ and 20 mM glucose) at 37°C with shaking for 1 hour. Samples are then spread onto LB (10 g/1 bacto tryptone, 5 g/1 bacto yeast extract, 10 g/1 sodium chloride) plates containing 100 microgram/ml of Ampicillin, 0.3% X-gal, and 100 microgram/ml IPTG. These plates are incubated overnight at 37°C. Ampicillin-resistant colonies with white color are selected, grown in 5 ml of liquid LB containing 100 microgram/ml of Ampicillin, and plasmid DNA is isolated using the Qiagen miniprep protocol (Qiagen. Gaithersburg, MD, USA). To verify that the correct H.pylori DNA inserts had been cloned, these pT7Blue plasmid DNAs are used as templates for PCR amplification of the cloned inserts, using the same forward and reverse primers used for the initial amplification of the J99 H.pylori sequence. Recognition of the primers and a PCR product of the correct size as visualized on a 2% TAE, ethidium bromide stained agarose gel are confirmation that the correct inserts had been cloned. Two to six such verified clones are obtained for each knock-out target, and frozen at -70°C for storage. To minimize errors due to PCR, plasmid DNA from these verified clones are pooled, and used in subsequent cloning steps.

The sequences of the genes/ORFs are again used to design a second pair of primers which flank the region of H pylori DNA to be either interrupted or deleted (up to 250 basepairs) within the ORFs but are oriented away from each other. The pool of circular plasmid DNAs of the previously isolated clones are used as templates for this round of PCR. Since the orientation of amplification of this pair of deletion primers is away from each other, the portion of the ORF between the primers is not included in the resultant PCR product. The PCR product is a linear piece of DNA with H pylori DNA at each end and the pT7Blue vector backbone between them which, in essence, results in the deletion of a portion of the ORFs. The PCR product is visualized on a 1% TAE, ethidium bromide stained agarose gel to confirm that only a single product of the correct size has been amplified.

A Kanamycin-resistance cassette (Labigne-Roussel et al., 1988 J. Bacteriology 170, 1704- 1708) is ligated to this PCR product by the TA cloning method used previously (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). The Kanamycin cassette containing a Campylobacter kanamycin resistance gene is obtained by carrying out an EcoRI digestion of the recombinant plasmid pCTm an (Cover et al.,1994, J. Biological Chemistry 269, pp. 10566-10573). The proper fragment (1.4 kb) is isolated on a 1% TAE gel, and isolated using the QIAquick gel extraction kit (Qiagen, Gaithersburg, MD, USA). The fragment is end repaired using the Klenow fill-in protocol, which involved mixing 4ug of the DNA fragment, 1 microliter of dATP,dGTP, dCTP, dTTP at 0.5 mM.2 microliter of Klenow Buffer (New England Biolabs) and 5 units of Klenow DNA Polymerase I Large (Klenow) Fragment (New England Biolabs) into a 20 microliter reaction, incubating at 30°C for 15 min, and inactivating the enzyme by heating to 75°C for 10 minutes. This blunt-ended Kanamycin cassette is then purified through a Qiaquick column (Qiagen, Gaithersburg, MD, USA) to eliminate nucleotides. The "T" overhang is then generated by mixing 5 micrograms of the blunt-ended kanamycin cassette, 10 mM Tris pΗ 8.3, 50 mM KCl, 2 mM MgCl₂, 5 units of DNA Polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA), 20 microliters of 5 mM dTTP, in a 100 microliter reaction and incubating the reaction for 2 hours at 37°C. The "Kan-T" cassette is purified using a QIAquick column (Qiagen, Gaithersburg, MD, USA). The PCR product of the deletion primers (F2 and R2) is ligated to the Kan-T cassette by mixing 10 to 25 ng of deletion primer PCR product, 50 - 75 ng Kan-T cassette DNA, 1 microliter lOx T4 DNA Ligase reaction mixture, 0.5 microliter T4 DNA Ligase (New England Biolabs, Beverly, MA, USA) in a 10 microliter reaction and incubating for 16 hours at 16°C. The ligation products are transformed into XL-1 Blue or DH5-α E.coli cells by electroporation as described previously. After recovery in SOC, cells arc plated onto LB plates containing 100 microgram/ml Ampicillin and grown overnight at 37°C. These plates are then replica plated onto plates containing 25 microgram ml Kanamycin and allowed to grow overnight. Resultant colonies have both the Ampicillin resistance gene present in the pT7Blue vector, and the newly introduced Kanamycin resistance gene. Colonies are picked into LB containing 25 microgram/ml Kanamycin and plasmid DNA is isolated from the cultured cells using the Qiagen miniprep protocol (Qiagen, Gaithersburg, MD, USA).

Several tests by PCR amplification are conducted on these plasmids to verify that the Kanamycin is inserted in the H. pylori gene/ORF, and to determine the orientation of the insertion of the Kanamycin-resistance gene relative to the H. pylori gene/ORF. To verify that the Kanamycin cassette is inserted into the H. pylori sequence, the plasmid DNAs are used as templates for PCR amplification with the set of primers originally used to clone the //. pylori gene/ORFs. The correct PCR product is the size of the deleted gene/ORF but increased in size by the addition of a 1.4 kilobase Kanamycin cassette. To avoid potential polar effects of the kanamycin resistance cassette on H. pylori gene expression, the orientation of the Kanamycin resistance gene with respect to the knock-out gene/ORF is determined and both orientations are eventually used in //. pylori transformations (see below). To determine the orientation of insertion of the kanamycin resistance gene, primers are designed from the ends of the kanamycin resistance gene ("Kan-1" 5'-ATCTTACCTATCACCTCAAAT-3' (SEQ ID NO:267), and "Kan-2" 5^*- AGACAGCAACATCTTTGTGAA-3' (SEQ ID NO:268)). By using each of the cloning primers in conjunction with each of the Kan primers (4 combinations of primers), the orientation of the Kanamycin cassette relative to the H.pylori sequence is determined. Positive clones are classified as either in the "A" orientation (the same direction of transcription is present for both the H. pylori gene and the Kanamycin resistance gene), or in the "B" orientation (the direction of transcription for the H.pylori gene is opposite to that of the Kanamycin resistance gene). Clones which share the same orientation (A or B) are pooled for subsequent experiments and independently transformed into H. pylori.

Transformation of Plasmid DNA into H. pylori cells

Two strains of H. pylori are used for transformation: HP-J99 (ATCC 55679), the clinical isolate which provided the DNA from which the //. pylori sequence database is obtained, and AH244, an isolate which had been passaged in, and has the ability to colonize the mouse stomach. Cells for transformation are grown at 37°C, 10% C0₂, 100% humidity, either on Sheep-Blood agar plates or in Brucella Broth liquid. Cells are grown to exponential phase, and examined microscopically to determine that the cells are "healthy" (actively moving cells) and not contaminated. If grown on plates, cells are harvested by scraping cells from the plate with a sterile loop, suspended in 1 ml of Brucella Broth, spun down (1 minute, top speed in eppendorf micro fuge) and resuspended in 200 microliters Brucella Broth. If grown in Brucella Broth liquid, cells are centrifuged (15 minutes at 3000 φm in a Beckman TJ6 centrifuge) and the cell pellet resuspended in 200 microliters of Brucella broth. An aliquot of cells is taken to determine the optical density at 600 nm, in order to calculate the concentration of cells. An aliquot (1 to 5 OD₆₀₀ units/25 microliter) of the resuspended cells is placed onto a prewarmed Sheep-Blood agar plate, and the plate is further incubated at 37°C, 6% C0₂, 100%) humidity for 4 hours. After this incubation, 10 microliters of plasmid DNA (100 micrograms per microliter) is spotted onto these cells. A positive control (plasmid DNA with the ribonuclease H gene disrupted by kanamycin resistance gene) and a negative control (no plasmid DNA) are done in parallel. The plates are returned to 37°C, 6% C0₂ for an additional 4 hours of incubation. Cells are then spread onto that plate using a swab wetted in Brucella broth, and grown for 20 hours at 37°C, 6% C0 . Cells are then transferred to a Sheep-Blood agar plate containing 25 micrograms/ml Kanamycin, and allowed to grow for 3 to 5 days at 37°C, 6% C0₂, 100% humidity. If colonies appear, they are picked and regrown as patches on a fresh Sheep- Blood agar plate containing 25 micrograms/ml Kanamycin.

Three sets of PCR tests are done to verify that the colonies of transformants have arisen from homologous recombination at the proper chromosomal location. The template for PCR (DNA from the colony) is obtained by a rapid boiling DNA preparation method as follows. An aliquot of the colony (stab of the colony with a toothpick) is introduced into 100 microliters of 1% Triton X-100, 20 mM Tris, pH 8.5, and boiled for 6 minutes. An equal volume of phenol : chloroform (1 :1) is added and vortexed. The mixture is microfuged for 5 minutes and the supernatant is used as DNA template for PCR with combinations of the following primers to verify homologous recombination at the proper chromosomal location.

TEST 1. PCR with cloning primers originally used to amplify the gene/ORF. A positive result of homologous recombination at the correct chromosomal location should show a single PCR product whose size is expected to be the size of the deleted gene/ORF but increased in size by the addition of a 1.4 kilobase Kanamycin cassette. A PCR product of just the size of the gene/ORF is proof that the gene had not been knocked out and that the transformant is not the result of homologous recombination at the correct chromosome location. TEST 2. PCR with F3 (primer designed from sequences upstream of the gene/ORF and not present on the plasmid), and either primer Kan-1 or Kan-2 (primers designed from the ends of the kanamycin resistance gene), depending on whether the plasmid DNA used was of "A" or "B" orientation. Homologous recombination at the correct chromosomal location will result in a single PCR product of the expected size (i.e., from the location of F3 to the insertion site of kanamycin resistance gene). No PCR product or PCR product(s) of incorrect size(s) will prove that the plasmid had not integrated at the correct site and that the gene had not been knocked out.

TEST 3. PCR with R3 (primer designed from sequences downstream of the gene/ORF and not present on the plasmid) and either primer Kan-1 or Kan-2, depending on whether the plasmid DNA used was of "A" or "B" orientation. Homologous recombination at the correct chromosomal location will result in a single PCR product of the expected size (i.e., from the insertion site of kanamycin resistance gene to the downstream location of R3). Again, no PCR product or PCR product(s) of incorrect size(s) will prove that the plasmid had not integrated at the correct site and that the gene had not been knocked out. Transformants showing positive results for all three tests above indicate that the gene is not essential for survival in vitro.

A negative result in any of the three above tests for each transformant indicates that the gene had not been disrupted, and that the gene is essential for survival in vitro.

In the event that no colonies result from two independent transformations while the positive control with the disrupted ribonuclease H plasmid DNA produces transformants, the plasmid DNA is further analyzed by PCR on DNA from transformant populations prior to plating for colony formation. This will verify that the plasmid can enter the cells and undergo homologous recombination at the correct site. Briefly, plasmid DNA is incubated according to the transformation protocol described above. DNA is extracted from the H. pylori cells immediately after incubation with the plasmid DNAs and the DNA is used as template for the above TEST 2 and TEST 3. Positive results in TEST 2 and TEST 3 would verify that the plasmid DNA could enter the cells and undergo homologous recombination at the correct chromosomal location. If TEST 2 and TEST 3 are positive, then failure to obtain viable transformants indicates that the gene is essential, and cells suffering a disruption in that gene are incapable of colony formation

VII. High-throughput drug screen assay Cloning, expression and protein purification

Cloning, transformation, expression and purification of the H. pylori target gene and its protein product,e.g., an H. pylori enzyme, to be used in a high-throughput drug screen assay, is carried out essentially as described in Examples II and III above. Development and application of a screening assay for a particular H. pylori gene product, peptidyl-propyl cis-trans isomerase, is described below as a specific example. Enzymatic Assay

The assay is essentially as described by Fisher (Fischer, G., et.al. (1984) Biomed, Biochim. Acta 43: 1 101-1 1 1 1). The assay measures the cis-trans isomerization of the Ala- Pro bond in the test peptide N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma # S-7388, lot # 84H5805). The assay is coupled with α-chymotrypsin, where the ability of the protease to cleave the test peptide occurs only when the Ala-Pro bond is in trans. The conversion of the test peptide to the trans isomer in the assay is followed at 390 nm on a Beckman Model DU-650 spectophotometer. The data are collected every second with an average scanning of time of 0.5 second. Assays are carried out in 35 mM Hepes, pH 8.0, in a final volume of 400 ul, with 10 μM α-chymotrypsin (type 1-5 from bovine Pancreas, Sigma # C-7762, lot 23H7020) and 10 nM PPIase. To initiate the reaction, 10 μl of the substrate ( 2 mM N-Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide in DMSO) is added to 390 μl of reaction mixture at room temperature.

Enzymatic assay in crude bacterial extract.

A 50 ml culture of Helicobacter pylori (strain J99) in Brucella broth is harvested at mid-log phase (OD ₆₀o _nm ~ ^and resuspended in lysis buffer with the following protease inhibitors: 1 mM PMSF, and 10 μg/ml of each of aprotinin, leupeptin, pepstatine, TLCK, TPCK, and soybean trypsin inhibitor. The suspension is subjected to 3 cycles of freeze- thaw (15 minutes at -70 C, then 30 minutes at room temperature), followed by sonication (three 20 second bursts). The lysate is centrifuged (12,000 g x 30 minutes) and the supernatant is assayed for enzymatic activity as described above.

Many H. pylori enzymes can be expressed at high levels and in an active form in E. coli. Such high yields of purified proteins provide for the design of various high throughput drug screening assays.

Other Embodiments Included in the invention are: allelic variations; natural mutants; induced mutants; proteins encoded by DNA that hybridizes under high or low stringency conditions to a nucleic acid which encodes a polypeptide as shown in SEQ ID NOs: 1-1 14 (for definitions of high and low stringency see Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989, 6.3.1 - 6.3.6, hereby incoφorated by reference); and, polypeptides specifically bound by antisera to H. pylori polypeptides, especially by antisera to an active site or binding domain of H. pylori polypeptide The invention also includes fragments, preferably biologically active fragments, or analogs of H. pylori polypeptides A biologically active fragment or analog is one having any in vivo or in vitro activity which is characteristic of the //. pylori polypeptides shown in SEQ ID NOs: 115-228, or of other naturally occurring H. pylori polypeptides, e.g., one or more of the biological activities described above. Especially preferred are fragments which exist in vivo, e.g., fragments which arise from post transcriptional processing or which arise from translation of alternatively spliced RNA's. Fragments include those expressed in native or endogenous cells as well as those made in expression systems, e.g., in CΗO cells. Because peptides such as H. pylori polypeptides often exhibit a range of physiological properties and because such properties may be attributable to different portions of the molecule, a useful H pylori fragment or H. pylori analog is one which exhibits a biological activity in any biological assay for H. pylori activity. Most preferably the fragment or analog possesses 10%), preferably 40%, or at least 90% of the activity of H pylori, in any in vivo or in vitro assay.

Analogs can differ from naturally occurring H. pylori polypeptides in amino acid sequence or in ways that do not involve sequence, or both. Non-sequence modifications include changes in acetylation, methylation, phosphorylation, carboxylation, or glycosylation. Preferred analogs include H. pylori polypeptides (or biologically active fragments thereof) whose sequences differ from the wild-type sequence by one or more conservative amino acid substitutions or by one or more non-conservative amino acid substitutions, deletions, or insertions which do not abolish the biological activity of the H pylori polypeptide. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, e.g., substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Other conservative substitutions can be taken from the table below.

TABLE 9 CONSERVATIVE AMINO ACID REPLACEMENTS

For Amino Acid Code Replace with any of

Alanine A D-Ala, Gly, beta-Ala, L-Cys, D-Cys

Arginine R D-Arg, Lys, D-Lys, homo- Arg, D-homo-Arg, Met, lie, D- Met, D-Ile,Orn, D-Orn

Asparagine N D-Asn, Asp, D-Asp, Glu, D-Glu, Gin, D-Gln

Aspartic Acid D D-Asp, D-Asn, Asn, Glu, D-Glu, Gin, D-Gln

Cysteine C D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr

Glutamine Q D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp

Glutamic Acid E D-Glu, D-Asp, Asp, Asn, D-Asn, Gin, D-Gln

Glycine G Ala, D-Ala, Pro, D-Pro, β-Ala Acp

Isoleucine I D-Ile. Val, D-Val, Leu, D-Leu, Met, D-Met

Leucine L D-Leu, Val, D-Val, Leu, D-Leu, Met, D-Met

Lysine K D-Lys, Arg, D-Arg, homo- Arg, D-homo-Arg, Met, D-Met, Ile, D-lle, Orn, D-Orn

J Methionine M D-Met. S-Me-Cys, Ile, D-Ile, Leu. D-Leu, Val. D-Val Phenylalanine F D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp. D-Trp, Trans-3,4, or 5-phenylproline, cis-3,4, or 5-phenylproline

Proline P D-Pro, L-l-thioazolidine-4-carboxylic acid, D-or L-l - oxazolidine-4-carboxylic acid

Serine S D-Ser, Thr, D-Thr, allo-Thr, Met,D-Met, Met(O), D- Met(O), L-Cys, D-Cys

Threonine T D-Thr, Ser, D-Ser. allo-Thr. Met,D-Met, Met(O), D- Met(O), Val, D-Val

Tyrosine Y D-Tyr, Phe, D-Phe, L-Dopa, His, D-His

Valine V D-Val, Leu, D-Leu, Ile, D-Ile, Met,D-Met

Other analogs within the invention are those with modifications which increase peptide stability; such analogs may contain, for example, one or more non-peptide bonds (which replace the peptide bonds) in the peptide sequence. Also included are: analogs that include residues other than naturally occurring L-amino acids, e.g., D-amino acids or non- naturally occurring or synthetic amino acids, e.g., β or γ amino acids; and cyclic analogs.

As used herein, the term "fragment", as applied to a H. pylori analog, will ordinarily be at least about 20 residues, more typically at least about 40 residues, preferably at least about 60 residues in length. Fragments of H. pylori polypeptides can be generated by methods known to those skilled in the art. The ability of a candidate fragment to exhibit a biological activity of H. pylori polypeptide can be assessed by methods known to those skilled in the art as described herein. Also included are H. pylori polypeptides containing residues that are not required for biological activity of the peptide or that result from alternative mRNA splicing or alternative protein processing events.

In order to obtain an H. pylori polypeptide, H. pylori polypeptide-encoding DNA can be introduced into an expression vector, the vector introduced into a cell suitable for expression of the desired protein, and the peptide recovered and purified, by prior art methods. Antibodies to the peptides an proteins can be made by immunizing an animal, e.g., a rabbit or mouse, and recovering anti-H pylori polypeptide antibodies by prior art methods. The nucleic acids and corresponding polypeptides of the invention were disclosed previously in the corresponding US application, U.S.S.N. 08/561 ,469, filed November 17, 1995 (Attorney Docket No.: GTN-001CP). The correlation between sequence identification numbers in the above-identified parent applications and sequence identification numbers provided herein is outlined in Table 10 below. TABLE 10

Parent Relation New Parent Parent Relation¬ New Nucleic -ship Nucleic Λmino amino acid ship Amino Acid SEQ Acid SEQ Acid SEQ HPP# Acid SEQ IDNO: IDNO: IDNO: IDNO:

881 a 1 385 2 a 115

882 a 2 390 9 a 116

883 a 3 401 20 a 117

884 a 4 407 26 a 118

885 a 5 409 28 a 119

886 a 6 410 29 a 120

887 a 7 413 34 a 121

888 a 8 431 55 a 122

889 a 9 435 60 a 123

890 a 10 442 68 a 124

891 a 11 445 71 a 125

892 a 12 449 75 a 126

893 a 13 463 89 a 127

894 a 14 464 90 a 128

895 a 15 467 94 a 129

896 a 16 470 97 a 130

897 a 17 474 101 a 131

898 a 18 476 103 a 132

899 a 19 477 104 a 133

900 a 20 480 107 a 134

901 a 21 485 114 a 135

902 a 22 487 116 a 136

903 a 23 502 133 a 137

904 a 24 507 139 a 138

905 a 25 508 140 a 139

906 a 26 511 144 a 140

907 a 27 515 148 a 141

908 a 28 517 150 a 142

909 a 29 521 154 a 143

910 a 30 526 161 a 144

911 a 31 534 170 a 145

912 a 32 538 175 a 146

913 a 33 541 178 a 147

914 a 34 545 183 a 148

915 a 35 549 187 a 149

916 a 36 551 189 a 150

917 a 37 552 190 a 151

918 a 38 557 195 a 152

919 a 39 559 197 a 153

920 a 40 561 199 a 154

921 a 41 569 209 a 155

922 a 42 571 211 a 156

923 a 43 580 220 a 157

924 a 44 584 224 a 158 925 a 45 594 234 a 159

926 a 46 595 235 a 160

927 a 47 615 256 a 161

928 a 48 616 257 a 162

929 a 49 624 265 a 163

930 a 50 626 267 a 164

931 a 51 628 269 a 165

932 a 52 632 273 a 166

933 a 53 634 275 a 167

934 a 54 637 279 a 168

935 a 55 641 283 a 169

936 a 56 644 287 a 170

937 a 57 645 288 a 171

938 a 58 646 289 a 172

939 a 59 648 291 a 173

940 a 60 652 296 a 174

941 a 61 662 307 a 175

942 a 62 671 316 a 176

943 a 63 672 317 a 177

944 a 64 675 320 a 178

945 a 65 677 322 a 179

946 a 66 684 331 a 180

947 a 67 685 332 a 181

948 a 68 686 333 a 182

949 a 69 693 343 a 183

950 a 70 703 356 a 184

951 a 71 704 357 a 185

952 a 72 709 363 a 186

953 a 73 710 364 a 187

954 a 74 711 366 a 188

955 a 75 715 371 a 189

956 a 76 723 380 a 190

957 a 77 724 381 a 191

958 a 78 731 388 a 192

959 a 79 734 391 a 193

960 a 80 745 406 a 194

961 a 81 753 415 a 195

962 a 82 754 416 a 196

963 a 83 758 420 a 197

964 a 84 760 422 a 198

965 a 85 764 426 a 199

966 a 86 765 427 a 200

967 a 87 766 428 a 201

968 a 88 774 437 a 202

969 a 89 776 439 a 203

970 a 90 778 441 a 204

971 a 91 785 448 a 205

972 a 92 788 452 a 206

973 a 93 793 457 a 207

974 a 94 795 459 a 208 975 a 95 797 461 a 209

976 a 96 806 471 a 210

977 a 97 812 477 a 211

978 a 98 820 486 a 212

979 a 99 823 489 a 213

980 a 100 827 493 a 214

981 a 101 833 499 a 215

982 a 102 834 500 a 216

983 a 103 842 509 a 217

984 a 104 852 521 a 218

985 a 105 854 523 a 219

986 a 106 858 529 a 220

987 a 107 863 536 a 221

988 a 108 864 539 a 222

989 a 109 865 540 a 223

990 a 110 867 542 a 224

991 a 111 872 548 a 225

992 a 112 877 553 a 226

993 a 113 878 554 a 227

994 a 114 880 556 a 228 a=sequences from USSN 08/561,469, filed November 17, 1995 (Attorney Docket No.: GTN 001CP).

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims.

Other embodiments are within the following claims.

7

SEQUENCE LISTING

(1) GENERAL INFORMATION

(l) APPLICANT

(A) NAME Astra Aktiebolag

(B) STREET S-151 85

(C) CITY Sodertalje

(D) STATE

(E) COUNTRY Sweden

(F) POSTAL CODE (ZIP)

(il) TITLE OF INVENTION NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER PYLORI FOR DIAGNOSTICS AND THERAPEUTICS

(in) NUMBER OF SEQUENCES 268

(iv) COMPUTER READABLE FORM

(A) MEDIUM TYPE CD/ROM ISO9660

(B) COMPUTER

(C) OPERATING SYSTEM

(D) SOFTWARE

(v) CURRENT APPLICATION DATA

(A) APPLICATION NUMBER

(B) FILING DATE

(vi) PRIOR APPLICATION DATA

(A) APPLICATION NUMBER US 08/561,469

(B) FILING DATE 17-NOV-1995

(vii) CORRESPONDENCE ADDRESS

(A) ADDRESEE LAHIVE & COCKFIELD

(B) STREET 60 State Street, Suite 510

(C) CITY Boston

(D) STATE Massachusetts

(E) COUNTRY USA

(F) ZIP 02109-1875

(viii) ATTORNEY/AGENT INFORMATION

(A) NAME Mandragouras, Amy E

(B) REGISTRATION NUMBER 36,207

(C) REFERENCE/DOCKET NUMBER GTN-001CPPC

(x) TELECOMMUNICATION INFORMATION

(A) TELEPHONE (617)227-7400

(B) TELEFAX (617)227-5941 (2) INFORMATION FOR SEQ ID NO: 1

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH: 519 base pairs

(B) TYPE nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: ιsc_feature

(B) LOCATION 1...519

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1

ATGAAAGGYC CYATCCTATG GCCGGCGTTT TCTCAATTTA GCGATCAAGA TTTGAGCGAT 60

ATTGTGGCGT ATCTCACTTC TATTTTGCCT AAAAATTTGA GCGATAAGGA AGTGTTCGCG 120

CAAAGTTGTC AAAGGTGCCA TAGCCTGGAT TATGCTAAAG ATAAGGCCTT TAGCGATCCT 180

AAAGATTTAG CCAATTATTT AGGCTCTCAT GCGCCTGATT TGTCCATGAT GATTAGGGCT 240

AAGGGCGAAC ATGGCTTGAA TGTTTTCATC AACGATCCGC AAAAGCTTTT GCCTGGCACA 300

GCC TGCCTA GAGTGGGATT GAATGAAAAA GCTCAAAAAC AAGTCATTTC TTATTTGGAA 360

AAAGCGGGCG ATAGGAAAAA GCATGAAAGG AATACTTTAG GGATTAAGAT CATGATTTTC 420

TTTGCGGTGC TGTCGTTCTT GGCTTACGCT GGAAAAGAAA AGTTTGGAGC GAAGTGCATT 480

AAATTTAAAA AAGGGGGGAC ATGGTTTTAT GATTTTTAA 519

(2) INFORMATION FOR SEQ ID NO:2 :

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 186 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE. DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(VI) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...186

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2

ATGCAAGAAT TCAGTTTGTG GTGCGATTTT ATAGAAAGGG ATTTTTTAGA AAACGATTTT 60

TTAAAGCTCA TCAATAAGGG GGCTATTTGC GGGRCGACGA GTAACCCTAG TTTGTTTTGC 120

GAAGCGATCA CAAAAAGCGC GTTTTATCAA GATGAAATCG CTAAAMCTCA AAGGCAAAAA 180

AGCTAA 186

(2) INFORMATION FOR SEQ ID NO:3 :

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 861 base pairs

(B) TYPE, nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular (n) MOLECULE TYPE: DNA (genomic)

( n) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...861

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3

TTGAASCCGA TGAAAGTGAT TCAAGTTTTT TTATTTTCCA ACCCTTTTTG CGCGATTGTG 60

CCTAACACGG AGCCAGAACA TTTGGAGCAT TATGACCACG ATTTAGAACG CTTTTTCTTC 120

GCTTATAAAT ATTTTTTAGA CCATGCTCAA AAAAGAGTGA TCTATAAAGA AGATCCTTTT 180

TTAAAAAACT ATTCTAAAGA CGCCATTGTT TTAGAAAAAA AAGACATTTA TAATATCCAA 240

TACATTTTAA AAGACGGAGA GCCTTACACT TCGTTTGAAT TGAAAAATTT GGGGGCTTTT 300

TTGGTGTGGG GGTTAGGCGA ACATAACGCC ACGAATGCGA GTTTGGCGAT TTTAAGCGCT 360

TTAGATGAAT TAAATTTAGA AGAAATTAGA AATAATTYAT TGAATTTTAA AGGCATTAAA 420

AAACGCTTTG ATATTTTGCA AAAAAACAAT CTCATTCTCA TTGATGATTA CGCCCACCAC 480

CCTACTGAAA TTGGCRCCAC TTTAAAAAGC GCTAGGATTT ATGCCAATTT ATTGAATACG 540

CAAGAAAAAA TTATAGTGAT CTGGCAAGCG CACAAA ACT CTCGCTTAAT GGACAATTTA 600

GAAGAATTTA AAAAATGTTT TTTAGAGCAT TGCGACAGGT TGATCATTTT ACCCGTTTAT 660

AGCGCGAGTG AAGTTAAAAG AGACATTGAT TTGAAAGCCC ATTTTAAGCA TTATAACCCC 720

ACCTTTATAG ACAGGGTGCG TAAAAAGGGG GATTTTTTAG AGCTGTTAGT CAATGATAAT 780

GTGGTAGAAA CGATTGAAAA AGGCTTTGTG ATAGGCTTTG GAGCGGGGGA TATTACCTAT 840

CAGTTGAGAG GCGAAATGTA A 861

(2) INFORMATION FOR SEQ ID NO:4 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 186 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(IV) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...186

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4

TTGTTGCTTT TCTTTCTTTT GAARGGCGTC GTTTTTTCTT TGGGCTTTTT TTCCTTTTTT 60

GAAGAAGTCT CTGGCTCTTT TGRAGCTGTT TCTTTGARCG TGTTAGCGTT AGTCATGGGG 120

TCTAGTYCTG GGTTAGAAGA ATTCTGTGTC TTAGAAGAGC TTATAAATTC AGGGCTATCA 180

GTATAG 186

(2) INFORMATION FOR SEQ ID NO:5 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 369 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL. NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...369

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5

ATGGGTTTTT TAAAAGTTTT AAAACATGAC GCTTTAGGGC AAGTAGGGAA TATTGTTATA 60

GGGAATTTCT TAATAACGCT CACTGTTTTA GCGGTTTGTT TTTCCTCTCA AAGCGCTGAA 120

GAAACGACCA TGCTCACCCT AAGCTACACG CTCTTTTTTA TTTTAGGGGC GTTTTTATTA 180

GTCGCAATCA GCGTGGGAGC GATCAAAAAC CTCAACGCGC TTTTTTCTAA AAGAGGGGTT 240

TTAAGCTTTT CCTTACCCAT TAGTTTGGAA TCTTTATTGC TCCCTAAAAT CTTGCTCCCC 300

AKGGTGTTTT TTTATCTTCA GTTTGTTCTG GTTTGTGGCG AGCGTGCGTT TGGGCTATTA 360

CCTTTTTAA 369

(2) INFORMATION FOR SEQ ID NO: 6 :

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 564 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...564

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:6

ATGTTAAAAA CCCACTTAAG CAGCGCTAGG GGCGTTGTGG TGTTGTCTAA GATTTTACCG 60

GTGAACGTGG TGTTAATGGT GAGCGTGCGC TTGTTTGAAA AGGAATTAAA ACGCAAACCT 120

TACTACATCA TTGCGAGCGC ACACAGCGAT GAAGGTTTAG AAAAATTAAA AAAATTWGGG 180

GYTGATATGG TGGKTTYCCC TACAAAACTY ATGGCGCAGA GAGTGAGCGC GAATKGMTGG 240

TGYKTCCTGG ATATGGAAAA TATCTTAGAG CGTTTTATCA ACAAAAAAGA CACGCTTTTA 300

GACTTAGAGG AAGTGATTGT CCCCAAAACC AGCTGGCTTG TGTTAAGGAA ATTAAAAGAA 360

GCCCATTTTA GAGAGATCGC TAAAGCCTTT GTGATTGGTA TCACTCAAAA AGATGGCAAA 420

TACATCCCCA TGCCTGACGG GGAAACGATT ATTGCAAGCG AATCCAAGCT ATTGATGGTT 480

GGCACTTCAG AAGGCGTTGC GACCTGTAAG CAACTCATTA CTAGCCACCA AAAACCAAAA 540

GAAGTGGATT ACATTTCATT GTGA 564

(2) INFORMATION FOR SEQ ID NO:7 :

( ) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 582 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(i ) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi ) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...582

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 7

GTGGGGAGCT TTTTATTCGT GGGGCCTAGT GGGGTAGGGA AAACAGAATT GGCTAAAGAA 60

TTGGCCTTGA ATTTGMATTT GCATTTTGAA CGCTTTGACA TGAGCGAATA CAAAGAAGCC 120

CATAGCGTGG CAAAGCTCAT CGGAAGTCCT AGCGGTTATG TGGGGTTTGA GCAAGGGGGG 180

TTATTGGTGA ATGCGATTAA AAAGCACCCG CATTGTTTGC TGCTTTTAGA TGAGATAGAA 240

AAGGCCCACC CTAATGTGTA TGATTTGTTG TTGCAGGTGA TGGAKAACGC CACTTTGAGC 300

GATAATTTAG GCAACAAGGC GAGTTTTAAG CATGTGATAC TGATTATGAC KKCAARTGTG 360

GGGAGTAAGG ATAAGGACAC GCTAGGGTTT TTTAGCACTA AAAACGCCAA GTATGATAGA 420

GCCGTTAAAG AGCTTTTAAC CCCTGAATTG CGATCCAGAA TTGATGCGAT CGTGCCGTTT 480

AACGCGCTCA GTTTGGAGGA TTTTGAAACG CATTGTTTCT GTGGAATTGG ACGGGTTAAA 540

AGCCCTAGCA CTAGAGCAAG GCGTGATCTT AAAATTCCAT AA 582

(2) INFORMATION FOR SEQ ID NO: 8 :

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 909 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...909

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8

ATGGCTTTTC AGGTCAATAC AAATATCAAT GCGATGAATG CGCATGTGCA ATCCGCACTC 60

ACTCAAAACG CACTTAAAAC TTCATTGGAG CGATTGAGTT CAGGTTTAAG GATCAATAAA 120

GCGGCTGATG ACGCATCAGG CATGACGGTG GCGGATTCTT TGCGTTCGCA AGCGAGCAGT 180

TTGGGTCAAG CGATTGCCAA CACGAATGAC GGCATGGGGA TTATCCAGGT TGCGGATAAG 240

GCTATGGATG AGCAATTAAA AATCTTAGAC ACCGTTAAGG TTAAAGCGAC TCAAGCGGCT 300

CAAGATGGGC AAACTACGGA ATCTCGTAAA GCGATTCAAT CTGACATCGT TCGTTTGATT 360

CAAGGTTTGG ATAATATCGG TAACACAACG ACTTATAACG GGCAAGCGTT ATTGTCTGGT 420

CAATTCACTA ACAAAGAATT CCAAGTAGGG GCTTATTCTA ACCAAAGCAT TAAGGCTTCT 480

ATCGGCTCTA CCACTTCCGA TAAAATCGGT CAGGTTCGTA TCGCTACAGG CGCGTTAATC 540

ACGGCTTCTG GGGATATTAG CTTGACTTTT AAACAAGTGG ATGGCGTGAA TGATGTAACT 600

TTAGAGAGCG TAAAAGTTTC TAGTTCAGCA GGCACAGGGA TCGGCGTGTT AGCAGAAGTG 660

ATCAATAAAA ACTCTAACCG AACAGGGGTT AAAGCTTATG CGAGCGTTAT CACCACGAGC 720

GATGTGGCGG TCCAGTCAGG AAGTTTGAGT AATTTAACCT TAAATGGGAT TCATTTGGGT 780

AATATCGCAG ATATTAAGMR AAACGACTCA GACGGAAGGT TAGTCACAGC RATCAATGCG 840

GTCACTTCAG AAACCGGTGT GGWAGCTTAT ACGGATCAAA AAGGACGCTT GAATTTGCGC 900

AGTATAGGT 909

(2) INFORMATION FOR SEQ ID NO: 9 :

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 486 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

( v) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...486

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9

ATGTTTTTTA AAACTTATCA AAAATTACTG GGCGCGAGCT GTTTGGCGCT GTATTTAGTG 60

GGCTGTGGGA ATGGTGGTGG CGGTGAATCG CCGGTTGAGA TGATTRCAAA TAGCGAGGGT 120

ACGTTTCAAA TCGACTCCAA AGCAGATAGC ATTACTATTC AAGGCGTGAA GCTTAATAGA 180

GGTAATTGTG CTGTCAATTT TGTTCCAGTA AGTGAGACGT TTCAAATGGG TGTTTTAAGT 240

CAAGTTACTC CAATCTCTAT ACAGGATTTT AAAGATATGG CAAGCACTTA TAAGATATTT 300

GATCAAAAGA AAGGGTTGGC AAACATAGCA AATAAAATTT CTCAATTAGA GCAAAAGGGT 360

GTGATGATGA AACCTCMAAC CCTTAATTTT GGAGAAAGTT TAAAAGGCAT TTCTCAAGGG 420

TGCAATATTA TAGAGGCAGA AATACAAACC GACAAAGGCG CTTGGACTTT TAACTTTGAT 480

AAATAA 486

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 276 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...276

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:10

GTGTGTTTAG GGCTAGCTGA TGTGATGGTG GTTTTAAGCT TGCACCTCAA CCTAAACCCC 60

ACCAACCCTA AATGGCTCAA TAGGGACAGG TTGGTTTTTA GCGGAGGGCA TGCGAGCGCG 120

TTAGTGTATA GTTTGTTGCA TTTGTGGGGC TTTGATTTGA GTTTAGACGA TTTAAAGCGT 180

TTCAGGCAAT TACACTCTAA AACCCCAGGA CACCCTGAAT TACACCACAC CGAAGGCATT 240

GAAATCACCA CASCCTTTAG GGCAAGGTTT TGCTAA 276

(2) INFORMATION FOR SEQ ID NO: 11:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 561 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

( il) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE: (A) ORGANISM- Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...561

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11

ATGACAACAC CGATGATTAT TATTTCCCTA GAAATGGGGT TATCTTTAGT TCCTATGCGA 60

CAATGTCTGG TTTGCCAAGC TCTGGCACGC TCAATTTCTT GGAACGGGTT AGGCGGGAAT 120

GTCCGTAACA CCAAAGTTTA TGGTAAATTC GCCGCTTACC ACCATTTGCA AAAATATTTA 180

TTGATAGATT TGATCGCTCG TTTTAAAACG CAAGGGGGCT ATATCTTTAG GTATAACACC 240

GATGATTACT TGCCCTTAAA CTCCACTTTC TACATGGGGG GSGTAACCAC GGTGAGAGGC 300

TTTAGGAACG GCTCAATCAC ACCTAAAGAT GAGTTTGGCT TGTGGCTTGG AGGCGATGGG 360

ATTTTTACCR CTTCTACTGA ATTGAGCTAT GGGGTGTTAA AAGCGGCTAA AATGCGTTTA 420

GCGTGGTTTT TTGACTTTGG TTTCTTAACC TTTAAMACCC CAACTAGGGG GAGTTTCTTC 480

TATAACGCTY CCACCACGAC GGCGAATTTT AAAGATTATG RCGTTGTAGG GRCTGRGTTT 540

GARRGGGCGA CTTGGAGGGC T 561

(2) INFORMATION FOR SEQ ID NO:12:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH- 315 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY, circular

(11) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL. NO

(iv) ANTI-SENSE: NO

( i) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...315

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12

ATGCAAGCGT TAAAATCATT GCTTGAAGTG ATTACAAAAC TCCAGAATCT AGGCGGCTAT 60

TTGATGCATA TAGCTATTTT CATCATTTTT ATTTGGATTG GAGGRCTTAA GTTTGTGCCT 120

TACGAAGCTG AAGGGATCGC CCCTTTTGTG RCCAACTCCC CTTTCTTTTC TTTCATGTAT 180

AAATTTGAAA AACCTGCATA CAAACAACAC AAAATGTCTG AATCCCAATC CATGCAAGAA 240

GAAATGCAAG ATAACCCTAA AATCGTTGAA AACAAAKAAT GGCATAAAGA AAACCGCACT 300

TCATTTAGTG GCTGA 315

(2) INFORMATION FOR SEQ ID NO:13:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH- 549 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE-

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...549 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:13

ATGCAGTTTG AAGAAATGAA AGAATTAGCC CATCAAATTG GCGTGTTTTA CCATGTTGGC 60

GTTGATGGCA TCGCGCTCTT TTTGTTGCTC TTAAACGCTA TCGTGGTGTT ATTGTCCGTG 120

GTTTATGTCA AAGAGCGTCG TAAAGACTTT GTGATTTGTC TTTTATTGTT AGAMGGGATC 180

TTAATGGGCG TGTTTTCTTC TCTTAATGTG ATCTTTTTCT ACGCTTTTTG GGAAATCTCG 240

CTCTTGCCGG TTTTATACCT CATCGGTCGT TTTGGCCGTA ATAACAAAAT CTATTCTGGC 300

ATGAAGTTTT TCCTCTACAC CTTTTTAGCG TCGTTGTGCA TGCTTTTAGG CATTTTATAC 360

ATCGGGTATG ACTACGCCAA TAATTACGGC ATGATGAGTT TTGATATTTT AGACTGGTAT 420

CAGTTGAATT TTTCTAGCGG GATTAAAACC TGGCTCTTTG TAGCTTTCTT AATAGGGATT 480

GCGGTTAAAA TCCCGCTCTT TCCCTTCACA CATGGCTGCC TTATGCGTAT TCTAACGCCC 540

CCACTCTAG 549

(2) INFORMATION FOR SEQ ID NO: 14:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 351 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY- circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(IV) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14

GTGAAAAAAT ACGCTGAAGA TTTTATCACC AAAGATGAAG TGAAATCCCT TTTAGAGCGC 60

TTGGCTAAAG ACTATCCTAC GATTGTAGAA GAGAGTAAAA AAATCCCCAC CGGTGCGATC 120

CGCTCAGTCT TGCAAGCCTT GTTGCATGAA AAAATCCCCA TTAAGGACAT GCTCACTATT 180

TTGGAAACGA TTACTGATAT TGCTCCATTG GTTCAAAACG ATGTGAATAT CTTAACCGAA 240

CAAGTGAGGG CGAGGCTTTC YAGGGTGATC ACCAACGCTT TTAAATCTGA AGACGGGCGT 300

TTGAAATTTT TAACCTTTTC TACCGATRGC GAACAATTTT TKGCTCAATA A 351

(2) INFORMATION FOR SEQ ID NO: 15:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 720 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

( x) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...720

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15

ATGATGAAAA ACAAACGCTC TCAAAATAGC CCTTATGTAA CGCCTGACAA CCCTTATCTA 60 ACGCTAGAAA AAGCTTTAGG GTATTCTTTT AAAGACAAGC GTTTATTGGA GCAAGCCTTA 120 ACGCATAAAT CATGTAAGCT CGCTTTAAAC AATGAGCGCT TGGAATTTTT GGGCGATGCG 180

GTGTTGGGCT TGGTGATAGG GGAGCTGCTA TACCATAAAT TCTRTCAWTR CGATGGGGGC 240

AAACTCTCTA AATTAAGGGC TTCTATTGTG AGCGCGCATG GTTTCACTAA ATTAGCGAAA 300

GCGATTGCTT TACAAGATTA TTTGCGCGTT TCTTCTTCTG AAGAAATTTC TAAGGGGAGG 360

GAAAAACCCT CTATTCTRTC AAGCGCTTTT GAGGCTTTAA TGGCTGGGGT GTATTTAGAA 420

GCAGGGTTAG CTAAGGTGCG TAAAATCATA CAAAATTTAC TCAATCGTGC TTACAAGCGT 480

TTGGATTTGG AGCATTTGTT TATGGATTAT AAAACCGCTT TGCAGGAATT GACCCAAKCK 540

CAGTTTTGCG TGATCCCCAC TTACCAATTA CTCCAAGAAA AAGGCCCCGA TCACCATAAA 600

GAATTTGAAA TGGCTCTATA CATTCAAGAT AAAATGTATG CGACCGCTAA AGGCAAGAGT 660

AAAAAAGAAG CCGAACAGCA ATGCGCTTAT CAAGCGCTTC AAAACTTAAG GAAGCCAAAT 720

(2) INFORMATION FOR SEQ ID NO: 16:

(l) SEQUENCE CHARACTERISTICS-

(A) LENGTH: 687 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

( ix) FEATURE :

( A) NAME/ KEY : rtu sc_f ea ture

( B ) LOCATION 1 . . . 687

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16

TTGCTGGTCT TACTCAATCT AAAGAWTACG CCGAATTTGA TGTGGCCTTT AGATATTATT 60

GTGGTTGTGG CATGGGTGTT ATGGGGGGTT AATATGTTTG GGAGCATGAG CGTTAGAAGA 120

GAGAATACTA TTTATGTGTC TTTGTGGTAT TACATCGCTA CTTATGTGGG TATAGCGGTG 180

ATGTATATCT TCAATAACCT TTCTATCCCC ACCTATTTTG TCGCTGATAT GGGGAGCGTT 240

TGGCATTMTA TTTCTATGTA TTCAGGCAGT AATGATGCGC TCATTCAATG GTGGTGGGGG 300

CATAATGCGG TCGCTTTTGT CTTTACGAGT GGGGTGATTG GCACAATTTA TTATTTCTTG 360

CCTAAAGAGA GCGGCCAGCC TATCTTTTCT TACAAACTCA CTTTGTTTTC TTTTTGGAGT 420

TTGATGTTTG TTTATATTTG GGCGGGCGGG CACCATTTGA TCTATTCCAC CGTGSCTGAT 480

KGRGTACAAA CCCTTTCTAG CGYGTTTTCA GTGGTGTTGA TCTTGCCTTC GYGGGGGACA 540

GCGATTAACA TGCTTTTAMC GATGAGAGGC CAATGGCACC AGYTCAAAGA AAGCCCTTTG 600

ATCAAGTTTT TAGTTTTAGC CTCAACTTTC TACATGCTTT CCACGCTAGA AGGCTCCATT 660

CAAGCCATTA AAAGCGTGAA CGCTTAG 687

(2) INFORMATION FOR SEQ ID NO: 17:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 489 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...489

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17 ATGAAAGCAC CCTCCCAAYA GGATTTAAAA AAAATCTTAG GGATTGAAGA AGTCATAATS 60 STATCCACAA GCCCCATGGA ATTACGATTG GCCAATCAAA AGCTAGGCAA TCGTTTCATT 120 AAAACCTTAC AAGCCATGAA CGAATTAGAC ATGGGTGCAT TTTTTAACGC TTACGCTCAA 180 ACAACCAAAG ATCCCACCCA TGCCACTAGC TATGGCGTTT TTGCGGCGAG TTTGAATATG 240 GAATTGAAAA AGGCTTTAAG GCATTATCTT TATGCGCAAA CTTCTAACAT GGTGATCAAC 300 TGCGTTAAAA GCGTCCCCTT ATCCCAAAAC GACGGGCAAA AAATCTTATT GAGCTTGCAA 360 AGCCCTTTTA ACCAGCTCAT AGAAAAAACC CTAGAACTAG ACGAAAGCCA CTTGTGCGCA 420 GCAAGCGTTC AAAACGACAT TAAGGCGATG CAGCATGAGA GTTTATACTC GCGCCTTTAT 480 ATGTCTTGA 489

(2) INFORMATION FOR SEQ ID NO: 18.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 180 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE- NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...180

(xi) SEQUENCE DESCRIPTION- SEQ ID NO: 18

ATGGCGTTTA TTCTAACCAC AAACCTATTT ATCAAGAGTT TTACGAACTC AATTCGCATA 60 ACGGGTTGTA TTATCAGCCC TAATGTGTTT TTTGCTTATG AATTTTGCGC GTTAGGGTTT 120 AGAAAAGGGG GGTTAATTTT GGATAATTTT TCTAAATTCG TGAGCCACAG GTTGCAATAA 180

(2) INFORMATION FOR SEQ ID NO: 19:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH. 747 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE. DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE-

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY- mιsc_feature

(B) LOCATION 1.. 747

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 19

GTGCGTTTTT TCATTTTTTT AATTCTCATT TGCCCTTTAA TATGCCCCTT AATGAGCGCG 60 GATAGCGCTT TACCTAGCGT CAATCTCTCT TTAAACGCTC CTAGTGATCC TAAACAACTC 120 GTAACCACCC TTAATGTCAT CGCCTTACTC ACGCTTTTGG TTTTAGCCCC ATCGTTGATT 180 TTAGTGATGA CGAGTTTCAC CCGTTTGATC GTGGTGTTTT CTTTTTTAAG GACCGCTTTA 240 GGCACGCAAC AAACCCCACC CACTCAAATT CTAGTCTCGC TCTCTTTGAT ATTGACTTTT 300 TTTATCATGG AACCTAGCTT GAAAAAGGCT TATGATACAG GGATTAAGCC TTATATGGAT 360 AAAAAGATTT CTTACACCGA AGCGTTTGAA AAAAGCACTC TGCCTTTCAA GGAATTCATG 420 CTTAAAAACA CACGAGAAAA AGATCTAGCC CTTTTTTTTA GGATTAGGAA TTTGCCTAAC 480 CCTAAAACCC CTGATGATGT GAGCTTGAGC GTTTTAATCC CGGCATTTAT GATAAGCGAG 540

TTGAAAACAG CGTTTCAAAT CGGCTTTTTA CTCTACTTGC CTTTTTTGGT GATTGATATG 600

GTTATCAGCT CTATTTTAAT GGCGATGGGT ATGATGATGC TCCCGCCTGT AATGATTTCT 660

CTGCCTTTTA AAATTTTGGT GTTTATTCTG GTGGATGGGT TTAATTTATT GACCGAAAAT 720

TTAGTGGCGA GTTTTAAAAT GGTTTAA 747

(2) INFORMATION FOR SEQ ID NO: 20:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 501 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi ) ORIGINAL SOURCE :

(A) ORGANISM : Hel icobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...501

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20

TTGTTGGTTA CTTTTTTGAA TGGGTTTGAC CCAAAAATCG CTAATTTAAG GAAAGCGTGC 60

AATGTTTATA GYGTGGGGGT GATTTATATT GTAACCACCA ACACGCTCAA TATTTTAAGT 120

TGTGAGAGTT TTGAAATTTT AGAAAAAAGA GAGCTGGATA CAAGCGGCGT TACTAAAACT 180

TCCACGCCGT TTTTTTCTAG GGTTGAGGGC ATTGATGCAG GCACGCTAGG GAAACTTTTT 240

TCAGGCAGTC AATCTAAAAA TTACTTCGCT TACTATGACG CTTTAGTGAA AAAAGAAAAA 300

CGAAAAGAAG TAAGGATTGA AAAGAAAGAA GAAAGGATTG ATGCTAGAGA AAATAAACGA 360

GAAATCAAGC AAGAAGCCAT TAAAGAGCCT AAAAAAGCCA ATCAAGGCAC AGAAAACGCT 420

CCCACTTTAG AAGAGAAAAS CTACCAAAAR GCAGAGCGAA AATTTGACGC TAAAGRAGRA 480

AGGMGATCGT TCAAGRGATG A 501

(2) INFORMATION FOR SEQ ID NO:21:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 381 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(IV) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...381

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21

ATGGAAAACA GCACACTTTA TATTGTTATT GCCGGCTTAT GGCTTGCTGT AGGCTTTGGA 60

ATCTTTTTAA AGAAATTAGA CATGCCCGTT ATCATTGGCT ACATTTGCAC AGGAACGGTC 120

TTAGCGGCTT TTTTTAAAAT TAATGATTTT AATTTGTTGT CTGATATTGG TGAATTTGGT 180

ATCGTCTTTT TAATGTTTAT GATAGGCATT GAGTTTAATT TTGACAAGCT CAAGTCCATC 240

AAACAAGAAG TGCTCGTTTT TGGGCTTTTA CAGGTTGTTT TATGCGCTTT AATCGCTTTT 300

TTATTGGGGT ATTTTGTTCT GGGTCTTTCG CCCATTTTTT CCCTTGTTTT AGGCATGGGG 360

CTTTCACTCT CTTCAACCGC C 381 (2) INFORMATION FOR SEQ ID NO:22.

(l) SEQUENCE CHARACTERISTICS-

(A) LENGTH: 51 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(lli) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...51

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22 TTGTTACTCA TGCTTAATAA GCCAAAGCCT TTATTTTTGM CTCTTGGTTA A 51

(2) INFORMATION FOR SEQ ID NO: 23:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1053 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: m sc_feature

(B) LOCATION 1...1053

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23

ATGGCATTAA GGGTATTATT ATTCTTTTGT TTTTTGTTTT TGCAAGCAGA AGATAAGAGC 60

CAAGAAT AT CATCTATACA AAAACAAATG GCTTTGGTGG ATAAAAAACT CGCCAAAGAC 120

GATAACGTGT GGTTGAAAAA ATTTGAAAAC TATAAAATTT ACAACCAAAT TTATACTGAA 180

AAAGAGAGCG TGAGGCAGGA ATTAAGGCGC TTAAAAAACA AAAAAAGCAA GGATTTATTA 240

AAGATTAGCA CCTTAGAGCA TACCTTAAAG GCTTTAGAGT CCCAGCAAAA AATGTTTGAA 300

AGCTATGGGG TCAATCCTTT TAAGGACTTG ATAGAGCGCC CCAATATCCC CAATATCCCT 360

AATATCGCTA ACCCTATTGC GATCATTGAT GGCATTTCTT TCATCAAGAG CATGCGTTTA 420

AAGCATGAAA ATCTTAAAAA TAACCAGACT TCTTTAGGAG AAGTTTTAAA GCTTTTAGAT 480

CAAAAACACC AGCTTTTAAA TCAGTGGCAC GCTTTGGATA AAAGCGCGAA ATTAAGCGAT 540

GAGATTTATC AAACTCAAGC CAAACGCTTA GAATTGCAAG GGGCTCAAAA CATTCTAAAA 600

ACCACRATCG GGATTTTCCA AAAAGACAGC GATGAAGCTA TAAGCATTGT CAAATCTCAA 660

GTTAAAAACC AGCTTTTTAA ATTGGTTTAT GTGTTTTTAG CGGCCCTTTT GAGCGTGGTG 720

TTTGCGTGGA TTTTAAAAAT CATTTCCAGT AAATACATTG AAAATAATGA GCGCGTCTAT 780

ACCGTGAATA AAGCCATTAA CTTCGTGAAT GTGAGCGTGA TCGKTKKAAT CTTKCTTTTT 840

TCTTATTTAG AAAACGTTAC TTACTTGGTA ACGGTTTTAG GCTTTGCGAG CGCGGGCTTA 900

GCGATTKCGA TGAAGGATTT ATTCATGAGC TTGCTCGGGT GGTTTATCAT TTTGATTGGG 960

GGGAGCGTGC ATGTGGGCGA TAGGGTGCGT ATCGCTAAGG GGACGGATAT TTTTATTGGC 1020

GATGTGTTGG ATACTTCTAA TGTTGTACAT TAA 1053

(2) INFORMATION FOR SEQ ID NO:24: (.) SEQUENCE CHARACTERISTICS

(A) LENGTH. 300 base pairs

(B) TYPE- nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY circular

(__) MOLECULE TYPE DNA (genomic)

(ill) HYPOTHETICAL. NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE-

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 ..300

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24

ATGAAAGAAC AAGAATGGGA TTTAAGCGCT TTATTTGAAA ATAAAGAAAG CGCAGAAGAA 60

TTTTTAAAAA CCTTACAAAC AGAAGTGCAA GAATTTGAGA ACGCTTATCA AAATAACCTT 120

AAGAATTTAG ACGCTGCAAA ATTTGCCAAC ACTCTTAAAC ATTACGAAAA TTTGTCAGAA 180

AAGATCTCTA GAGCGATGGC TTACGCCAAT TACTTTTTGC CAAGAACACT AAAGAAGCGA 240

AGTTTTATTC GCAATGCAAA TGGCTTGTGC AAATATCCAA CAACACCTTT TATTCTTTGA 300

(2) INFORMATION FOR SEQ ID NO:25:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 237 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY- mιsc_f ature

(B) LOCATION 1...237

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:25

TTGCGCGTGG GCATGTATGA AGTGTGTAAC CATAAAGACG GCACCGCTTA TCATTCCACA 60

AGAGGTTCTA AGGTTACCTT AGCGTGTAAA ACCGGCACCG CGCAAGTCGT AGAAATCGCT 120

CAAAACATCG TCAATCGCAT GAAAGAAAAG GATATGGAAT ATTTCCATCS MTCCCATRCG 180

TGGATTACGR CATATCTTTR CCCTATGAAA AACCCAAATA CGCTATCACT ATTTTAG 237

(2) INFORMATION FOR SEQ ID NO: 26:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 159 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: NO ( v) ANTI-SENSE: NO (vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1...159

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26

TTGGGTTTGG TGWRCGGRAT TTCTCTCTTG CATTTGAGTT TGGAGCAAAA AATCAGCGTG 60 TTTCTTGGRC YCAATTTAAT GCTTTAYCCG GTCAYAGAGG TGCTTTTTAG TATCCTTAGG 120 CGCAAAATAA AACGCCAGAA AGCCACCCAT GCCGGATAA 159

(2) INFORMATION FOR SEQ ID NO: 27.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1134 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(lil) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...1134

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:27

TTGGCTCAAC CGGTTCAGGT AAGAACAGTG TTTATGTCCA TGACTCTAAA CGCTATGGGG 60

CAATTTGCCT A AATTTTCC TGCTAATATC AGCAAAGACA AGCAAAAGCT CACTATGGTT 120

TATATGGATA AAGATTATGG CGCTTATGGG AATATTGTTG CAATGGGTGG GGAGTATGTC 180

AAGATTGAGC TAGGGACAGA TACAGGATTA AATCCTTTTG CTTGGGCAGC TTGTGTGCAA 240

AAAACAAATG CAACAATGGA GCAAAAACAA ACAGCTATTT CTGTTGTCAA AGAGCTTGTG 300

AAAAACTTAG CAACTAAAAG CGATGAAAAA GATGAAAATG GCAACAGCAT CTCTTTTAGC 360

CTAGCAGATT CTAATACGCT TGCAGCGGCA GTAACCAACC TTATCACAGG AGATATGAAC 420

CTAGATTATC CTATCACTCA ACTTATTAAT GCTTTCGGGA AAGACCACAA TGATCCTAAT 480

GGGCTTGTCG CGCGATTAGC GCCTTTTTGC AAATCAACCA ATGGTGAATT TCAATGGCTT 540

TTTGACAATA AAGCAACAGA TCGCTTAGAT TTTTCAAAAA CGATTATTGG CGTTGATGGG 600

TCAAGTTTCT TAGACAATAA TGACGTTTCG CCTTTTATTT GTTTTTACCT TTTCGCTCGT 660

ATCCAAGAAG CAATGGATGG GCGTAGATTT GTCTTAGATA TTGATGAAGC GTGGAAATAT 720

TTAGGCGATC CAAAGGTCGC TTATTTTGTG AGAGACATGC TAAAAACTGC AAGGAAAAGA 780

AACGCTATTG TTAGACTTGC GACTCAAAGC ATCACTGATC TTTTGGCTTG CCCTATTGCT 840

GATACGATTA GAGAACAATG CCCTACAAAG ATTTTTTTGA GAAACGATGG GGGTAATCTT 900

TCTGATTACC AAAGATTAGC CAATGTTACA GAAAAAGAAT TTGAAATCAT CACTAAGGGG 960

CTGGATAGGA AAATCCTCTA CAAACAGGAT GGAAGCCCTA GCGTTATCGC TAGTTTTAAT 1020

TTGAGAGGCA TTCCTAAAGA ATATTTGAAA ATTTTATCCA CAGATACTGT ATTTGTCAAA 1080

GAAATTGACA AGATTATCCA AAACCATAGT ATCATAGATA AATATCAGCC TTGA 1134

(2) INFORMATION FOR SEQ ID NO: 28:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY, circular

(n) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: NO ( iv) ANTI - SENSE : NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...465

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28

ATGAAATTGG TGAGTCTTAT TGTAGCGTTA GTTTTTTGTT GTTTTTTAGG GGCTGTAGAG 60

TTGCCTGGAG TTTATCAAAC TCAAGAATTT TTATACATGA AAAGCTCTTT TGTGGAGTTT 120

TTTGAGCATA ACGGGAAGTT CTATGCCTAT GGTATTTCTG ATGTGRATGR CTCTAAAGCC 180

AAAAAAGACA AACTCAATCC TAACCCAAAG CTAAGGAATC GCAGCGATAA AGGCGTGGTG 240

TTTTTAAGCG ATTTGATTAA GGTTGGGGAA CAATCTTATA AAGGCGGTAA GGCGTRTAAT 300

TTTTRTGACG GCAAGACCTM CCATGTGAGA GTCACTCAAA RTTCAAACGG GGATTTGRAA 360

TTCACTTCAA GCTATGRCAA ATGGGGGTAT GTGGGCAAAA CCTTCACCTG GAAACGCCTG 420

AGCGATGAAG AAATCAAAAA TCTAAAGCTC AAGCGTTTTA ACTGA 465

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29 TTGGAGACCC TATTCTTGGT ATAG 24

(2) INFORMATION FOR SEQ ID NO:30:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 345 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...345

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30 ATGSACACAC ACGACAGGCG CAAGTTAAGA ATTARCCTTA CACAAACGAC GACTTTAGTG 60 GCCACTATTG GCTCAAACGC CCCTTATATC GGTCTTTTAG GGACGGTTAT GGGGATCATG 120

CTCACCTTTA TGGATTTAGG CTCAGCTTCT GGCATTGACA CTAAGGCGAT CATGACTAAT 180

TTAGCCCTTG CTTTAAAAGC GACCGGCATG GGGTTATTGG TAGCGATCCC TGCGATTGTG 240

ATTTATAACT TGTTAGTGAG AAAAAGCGAG ATTTTAGTTA CCAAATGGGA TATTTTCCAC 300

CATCCGGTTG ATACGCAATC CCATGAGGTT TATAGCAAAG CCTAA 345

(2) INFORMATION FOR SEQ ID NO: 31.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 204 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

( i) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...204

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31

ATGCAGGATT TAGACAATAA CATGTCCTTA GACACCGCTC ACAACACGCT GAGTTCTAAC 60

GGGAAAAACA TCACCATTGC CGGGGTGGTA AAAGCCTTAC AAAAAATTGG CGTGAGCGCT 120

AAGGGGATGG TTTCAATCTT GCAAGCCCTA AAAAAAAGCG GCGCGATTAG CGCGAAATGG 180

AGATACTATG ATAAACAACA ATAA 204

(2) INFORMATION FOR SEQ ID NO: 32:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 267 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY, circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...267

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32

TTGCACCCTT TAGCGGATGT CTTTGTGGTG AATGACAAAC GGYCCGTTTT AGCGATGGTA 60

RCGATGTTGA TTGRCTCGTT AGCGAATATC TTTTTCAATT ACTTGTTTAT TTTTGKGTTG 120

GAAGTGGGGG TTCAAGGCAG MGCGATAGTC ACCGTGATAG GGCATGCGAT AGGGGGTTTA 180

GTCTTAATGC AGCATTTTTG GCGCAAAAAA GGGGAGTTGT ATTTTATCAA ACTGATTTTC 240

TTTATCTTCA GTCATTTCTT CAGCTAA 267

(2) INFORMATION FOR SEQ ID NO: 33:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 831 base pairs

(B) TYPE- nucleic acid

(C) STRANDEDNESS: double (D) TOPOLOGY circular

(11) MOLECULE TYPE DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE. NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY- mιsc_ eature

(B) LOCATION 1 ..831

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.33

ATGTTAAGGA AAAACATTTT AGCTTACTAT GGGGCGAATT TTCTCTTAAT CATCGCTCAA 60 AGCTTGCCCC ATGCGATTTT AACCCCCTTG TTGCTTTCTA AAGGGCTTAG TTTGAGTGAA 120 ATCTTGCTCG TGCAAACCTT TTTTAGTTTT TGCGTGCTGG TGGCTGAATA CCCAAGCGGC 180 GTTTTAGCGG ATTTGATGAG CCGGAAGAAT TTATTCCTGG TTTCTAATGT GTTTTTAATC 240 GCTAGTTTTT CGTTGGTGCT GTTTTTTGAT AGTTTTATCC TCATGCTTTT AGCGTGGGGG 300 TTGTATGGTT TGTATAGCGC ATGCTCTAGC GGCACGATTG AAGCTTCACT CATCACAGAC 360 ATTAAGGAAA ACAAAAAAGA TTTATCCAAG TTTTTAGCCA AAAACAATCA AATTACTTAT 420 TTGGGCATGA TTATAGGGAG TTCTTTGGGA TCGTTTTTGT ATCTCAAAGT CCATGCGATG 480 CTGTATGTCG TGGGGATTTT TTTAATCATG CTCTGTGCGC TAACAATCAT CATTTATTTT 540 AAAGAAAAAG AAGGGGATTT TAAAAGCCAA AAAAATTTGA AACTCCTTAA AGAGCAAGTC 600 AAAGGCAGTC TTAAAGAGCT TAAAGATAAC CCCAAGCTTA AAATTTTGTT AGTGGGGCAT 660 TTGATTACGC CTGTCTTTTT TATGAGCCAT TTCCAAATGT GGCAAGCGTA TTTTTTAAAA 720 CAAGGCGTTA AAGAGCAATA CCTTTTTGTG TTCTATATCG CTTTTCAAGT GATTTCCATC 780 CCTCATTCAT TTTTTAAAAG CCAAAAATTA KCAGCCAAAA AATCGCCCTG A 831

(2) INFORMATION FOR SEQ ID NO:34:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 282 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL. NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...282

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34

TTGTATCCGC CGGGATCTGT GGTTAAAATG GGCGTGGGGT TAAGCTTTTT AGAAAACCTT 60 CATATCACAG AAAACACCAC TATCCCCACA CCGCCTTTTA TTGAAGTGGG CAAGCGCAAA 120 TTCAGGGACT GGAAAAAAAC AGGGCATGGC AATTCTAATT TGTATAAAGC CATTAGGGAG 180 TCCGTGGATG TGTATTTTTA TAAGTTTGGG CTTGAAATCT CTATAGAAAA MCTCTCTAAA 240 MCCTTTAAGG RAAGTGGRCT TTGGGGAAAA AACGGRCGTT GA 282

(2) INFORMATION FOR SEQ ID NO:35:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH- 183 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS- double

(D) TOPOLOGY: circular (ii) MOLECULE TYPE. DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE.

(A) ORGANISM Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1...183

(xi) SEQUENCE DESCRIPTION. SEQ ID NO: 35

ATGGCACACC ATKAAGAACA ACACGGCGGG CACCACCACC AYCACCACCA CACACACCAC 60

CACCATTATC ATGGCGGCGA ACACCACCAT CACCACCACA GYTCTCATCA TGAAGAAGGT 120

TGTTGCAGCA CTAGCGATAG TCATCATCAA GAAGAAGGTT GTTGYCACGG GYAYCACGAG 180

TAA 183

(2) INFORMATION FOR SEQ ID NO: 36:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 894 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(i ) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE- NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...894

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36

TTGGTTAAAA TAAGGTTATT TGATTTTACT ATAAGGTTGT TTAAACCTGA ATTTCACATT 60

TTTGATTTTT TAAAAGGGAT TAGAGTTCTT ATGATTGAAT GGATGCAAAA TCATAGAAAG 120

TATTTAGTGG TTACGATATG GATAAGCACG ATCGCTTTTA TTGCCGCCGG AATGATAGGT 180

TGGGGGCAAT ACAGCTTTTC TTTAGATAGC GATAGCGCTG CCAAAGTGGG ACAGATTAAG 240

ATTTCTCAAG AAGAATTAGC CCAAGAATAC CGCCGCCTTA AAGACGCCTA TGCTGAGTCT 300

ATCCCTGATT TTAAAGAACT CACCGAAGAT CAAATCAAAG CCATGCATTT AGAAAAAAGC 360

GCGCTAGATT CGCTCATCAA TCAAGCTTTA TTGAGGAATT TCGCTTTAGA TTTAGGGCTT 420

GGTGCTACCA AGCAAGAAGT GGCCAAAGAG ATCAGAAAAA CGAACGTTTT TCAAAAAGAT 480

GGCGTTTTTG ATGAAGAATT GTATAAAAAT ATCTTAAAAC AAAGCCATTA CCGCCCCAAG 540

CATTTTGAAG AAAGCGTTGA AAGGCTTTTA ATCCTTCAAA AAATCAGCGC TCTATTCCCC 600

AAAACCACCA CCCCTTTGGA GCAATCCAGT CTATCGCTTT GGGCAAAATT GCAAGACAAA 660

TTAGACATTC TTATCCTAAA TCCTAATGAT GTTAAAATCT CTCTCAATGA AGAAGAGATG 720

AAAAAATATT ATGAAAACCA TAGAAAGGAT TTTAAAAAGC CCACAAGCTT TAAAACACGC 780

TCTTTATATT TTGACGCTAG TTTAGAAAAA ACTGATTTGA AAGAGTTGGA GGAATACTAC 840

CATAAAAACA AGGTGTCTTA TTTGGACAAM AGMGGGGAAA TTACAGGATT TTAA 894

(2) INFORMATION FOR SEQ ID NO:37.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 273 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE. DNA (genomic) (ill) HYPOTHETICAL- NO

(iv) ANTI-SENSE: NO

(v ) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc__feature

(B) LOCATION 1...273

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37

ATGGTTAAAC ACTATCTTTT CATGGCGGTT TCGCAGGTCT TTTTCTCCTT CTTTTTAGTG 60

CTGTTTTTTA TCTCTTCCAT TGTGTTATTA ATCAGTATTG CAAGCGTAAC GCTCGTGATT 120

AAAGTGAGCT TTTTGGATCT GGTGCAACTC TTTTTGTATT CCTTGCCWGG AACCATTTTT 180

TTTATTTTGC CGATYACTTT TTTTGCGGCT TKGCGYTTGG GGSTTTCAAG GCTTAGCTAT 240

GACCATGAAT TGTTAGTGTT TTTTCTCYTT TAG 273

(2) INFORMATION FOR SEQ ID NO: 38:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 261 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...261

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38

ATGAGTAAAA GAGCGATCCG TTTCCCTAAC AAGCTTTTTT CATACCCTAA ACCCAAAATA 60

AAAGCGACAA ACACAAGCCA CACCGTTTTA TTCGCATACC CGCTCAAACC CCACGAAATG 120

GCCTTATTAG CGCTCGCTAC CTCACTGCTC GCTCCAATTT TTAACGCTAT ACACAGCACT 180

AACGCGCTCA ACGCTATCAA ACCTGATGGC ACCGGCTCTA AAATTAACCC TATAATCATG 240

CCCATGAAAA TACAAAAATA A 261

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 426 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(IV) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...426 (x ) SEQUENCE DESCRIPTION: SEQ ID NO:39

GTGTATAGCC GTTTTTTTGC CAACCAGCAT GAATTTGACT TTGAAGCTCA AGGGGCGCTA 60

GGGAGCGATC AATCAAGCTT GAATTTCAAA AGTACTCTAT TACAAGATTT GAATCAAAGC 120

TATAATTACT TAGCCTATAG CGCCACAGCA AGAGCGAGTT ATGGTTATGA CTTCGCGTTT 180

TTTAGGAACG CTTTAGTGTT AAAACCAAGC GTGGGCGTGA GCTATAACCA TTTAGGTTCA 240

ACCAACTTTA AAAGCAATAG CCAATCACAA GTGGCTTTAA AAAATGGCGC GAGCAGTCAG 300

CATTTATTCA ACGCTAACGC AACGTGGAAG CGCGTTATTA TTATGGGGAC ACTTCATACT 360

TTTATTTGCA TGTGGGAGTT TTACAAGAGT TCGCTCACTT TGGATCGAAT GATGTGGCGT 420

CTTTAA 426

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 558 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...558

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40

ATGYATGAAA ATGGTAGGGG TGTACCTAAA GATTACAAGA AAGCGGTTGA ATATTTCCAA 60

AAAGCTGTTG ATAACGATAT ACCTAGAGGG TA AACAATT TGGGCGTGAT GTATAAAGAG 120

GGTAAGGGAG TTCCTAAAGA TGAAAAGAAA GCGGTGGAAT ATTTTAGAAT AGCTACAGAG 180

AAAGGTTATA CTAACGCTTA TATCAACTTA GGCATCATGT ATATGGAGGG CAGGGGAGTT 240

CCAAGTAACT ATGCGAAAGC GACAGAATGT TTTAGAAAAG CGATGCATAA GGGCAATGTG 300

RAAGCTTATA TTCTCCTAGG GGATATTTAT TATAGCGGAA TGATCAATTG GGTATTGAGC 360

CGGACAAAGA TAAGGCTGGT CCATTATAAA ATGGCGGCCG ATGTRAGTTC TTCYAGAGCY 420

TATRAAGGGT TGTCAGAGTC YTATCSGTAT GGGYTAGGCG TGGAAAAAGA KWAAAAAAAG 480

GCYGAAGAAT ACATGCAAAA AGCATGCGAT TTTGACATTG ATAAAAATTG TAAGAAAAAG 540

AACACTTCAA GCCGATAA 558

(2) INFORMATION FOR SEQ ID NO: 41:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 420 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

( vi ) ORIGINAL SOURCE :

( A ) ORGANISM : Hel icobac ter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...420

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41 TTGCTCAACA TGTGGGATGA AGCCAAGAAA GAAGGGATCA ACATCAATAC AGAAAAGCTC 60 TCTCAAGAAT TGGGGGTTGT GTGCGTGCCA ACAAGCGCGA GATYCAAAGA AGATCGCTTG 120

AACACAGAGC TTTTATTAGA CGAAATTGTC AGGCTTTATT CTCAAAACAC TACAAACAAC 180

GAAAACATCA AAGTCCCATC TCAAAGTTTT AAAGAGTCTT TAAAATACAG CCAGAGCGCC 240

CAAAGAATCG CTAAATCAGT GATCAGTGAA AACAAACAAA ATGCGAGTTT TGAACACACT 300

TATAAGATTG ATAAGATTTT TAATGCACCA GCGTTATGGG ATTTTCATTT TTTTDGGGTT 360

TATGTTTATC ATCTTTTCTT TGAGCTTTTT AATAGGAGGG GGAGTGCRAA AAGCCCTTGA 420

(2) INFORMATION FOR SEQ ID NO: 42:

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH 582 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY- circular

( i l ) MOLECULE TYPE . DNA ( genomic )

( i n ) HYPOTHETICAL : NO

( iv ) ANTI - SENSE NO

(vi ) ORIGINAL SOURCE :

( A) ORGANISM Hel icobac ter pylor i

(ix) FEATURE-

(A) NAME/KEY- mιsc_feature

(B) LOCATION 1...582

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42

ATGCAAGAAG CGTTGTTGCG TTTTCAAGAG GGCTTTAAGG AGTGGGGTTA TCTTATTTTA 60

TTTTTGTATT CTTTGGGGGG TGGGTATGTA GGGATTGTCA TCGCTTCCAT TTTGAGCGCT 120

ACCACGCACG CTTTGGATAT AAAAATAACC ATTCTTGTCG CTTTTTTAGG GAATTTAATA 180

GGGAGTGGGG CTCTTGTAAT CTTTGCCCGC TATCAAAAAA GAGAGTTTTT AAAGTATTTC 240

CAAAAGCATA GAAGAAAGCT TGCTTTGGCG AGTTTGTGGG TGAAACGCTA CGCCTTGCTC 300

ATGATTTTTG TCAATAAATA TCTCTATGGG ATTAAAAGCG TTGTGCCTTT GGCAATTGGT 360

TTTAGCAAAT ACCCTTTAAA AAAGTTTTTA TGGCTTAATG TTTTTTCCAG TTTTTTGTGG 420

GCGTTAATCG TGGGGAGCGT TTCTTTTCAA GCGAGCGATT GGGTGAAAAC GCTGTATGAA 480

AGGCTTTCTC ATTACACTTC GTTTTTTGTC ATAAGTTTTG TTCTTATAGC GCTTTTAATA 540

TGGTTTTTAT TGAAACGATA TTCGCGCAAA ATGGGKTTTT AA 582

(2) INFORMATION FOR SEQ ID NO: 43:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH 390 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM. Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...390

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43

ATGCGAAAGG GGCGTGTGAT GTTATGCGTG TTTGATATAG AAACCATTCC TAATATAAGC 60

TTGTGTAAAG AGCATTTTCA ATTAAAAGAA GACGATGCGC TAAAAATCTG TGAATGGAGT 120

TTTGAAAAGC AAAAAGAAAA AAGCGGGAGC GAGTTTTTGC CCCTTTATTT GCATGAAATC 180

ATCTCTATTG CAGCMGTCAT TGGCGATGAT TACGGGCAAT TTATCAAAGT AGGGAATTTT 240

GGTCAAAAAC ACGAGAATAA AGAGGATTTT GCGAGCGAAA AAGAGCTTTT AGAGGACTTT 300 TTCAAATACT TTAACGAAAA GCAACCGCGC CTAATAAGCT TTAAWGGCAG GGGTTTTGGA 360 TATTCCCCTA CTCACGCTCA AAGCCCTTAA 390

(2) INFORMATION FOR SEQ ID NO: 44.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 924 base pairs

(B) TYPE: nucleic ac d

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...924

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44

ATGGCTAAAA AGAAAATTGC GATCAGCTGT GGGGATATTC AAGGCGTAGG CTTAGAATTG 60

ATCTTAAAAA GCCATAAGGA AGTGAGTGCA CTTTGTGAGC CGTTGTATCT CGTTCATAGC 120

GAACTTCTAG AACGAGCCAA TCAATTGCTT GATAACGCTT ATGAAACTAA AACGCTTAAT 180

GCGATCGCTA TTGATGCCCC TTTACCCTTA TTAAACTCTA GCACGATAGG CAAAGTCAGC 240

ACTCAAAGCG GGGCGTATAG CTTTGAGAGT TTTAAAAAGG CTTGCGAGTT GGCGGATAGT 300

AAAGAAGTGG ATGGCATTTG CACTTTGCCT ATCAACAAAC TCGCATGGCA ACAAGCTCAA 360

ATCCCTTTTG TGGGGCATAC CGATTTTTTG AAACAACGCT ACAAAGATCA TCAAATTATT 420

ATGATGCTTG GGTGTTCAAA ACTCTTTGTG GGGCTATTTA GCGACCATGT GCCTTTAAGC 480

GCGGTTTCTC AACTCATTCA AGTGAAAGCG TTAGTTAAGT TTTTATTAGC GTTTCAAAAA 540

AGCACTCAAG CCAAAATCGT TCAAGTGTGT GGTTTCAACC CCCATGCGGG CGAAGAGGGA 600

TTGTTTGGGG AAGAAGATGA AAAGATTTTA AAAGCCATTC AAGAGAGCAA CCAAACGCTA 660

GGTTTTGAAT GCTTTTTGGG GCCACTGCCC GCTGATAGCG CTTTTGCCCC CAATAAACGC 720

AAAATAACCC CCTTTTATGT GAGCATGAGC CATGATGTAG GGCTAGCCCC TTTAAAAGCG 780

CTCTATTTTG ATGAAAGCAT CAATGTGAGT TTGAACGCTC CCATTTTACG CGCTTCCACT 840

GACCACGGCA CGGCGTTTGA TATTGCTTAT CAAAATAAGG CGAACCATAA AAGCTATTTG 900

AACGCGATCA AATACTTGGC TTAA 924

(2) INFORMATION FOR SEQ ID NO: 45:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 440 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(11) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...440

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45

ATGAGCAGCG GGTTAATTTA CATTTCRTTA GAAGTCTTGG TARCGTGTTT GATCACCGCT 60 CTAATCATGT ATTATGTGAT GAAAAAGATC TATTACGCTA GAGGGCAAGC CATTTTAAAA 120 GGCGCTTCAG CCAAAGCTAA ATTAATGGAA TTTCAAGCGA AATCTTTCGT GGAAGCTGAA 180 GAAATGCGCA TGAAAAGCCA AGAATGCAAG TTGCAACAGC AATATGAAAA TAAGAATTTG 240

CAACTCCAAA CCCATTTTGA TAAAAAAGAA GCGCATTTGA AGCATTTAGA AGCGCAGCAC 300

AAAGAATTTG TAAGAGATGA AAAACGCTAT TTGGAAAAGG AAAAAAAAGA GCTTGAAAAA 360

GAACGCCAAA TTTTAGAAMM AGAGAGGGAA AATTTTRRRR RSCAGCGCGC CTTTGTRRRG 420

RRGSCTCRRG CCAAAGCGCT 440

(2) INFORMATION FOR SEQ ID NO:46

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH 384 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1.. 384

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:46

ATGAATATCA AAATTTTAAA AATATTAGTT GGAGGGTTAT TTTTTTTGAG CTTGAACGCC 60

CATTTATGGG GGAAACAAGA CAATAGCTTT TTAGGGATTG GTGAAAGAGC CTATAAAAGC 120

GGGAATTATT CTAAAGCGGC GTCTTATTTT AAAAAAGCAT GCAACGATGG GGTGAGTGAA 180

GGCTGCACGC AATTAGGAAT CATTTATGAA AACGGGCAAG GCACTAGAAT AGATTATAAA 240

AAAGCCCTAG AATATTATAA AACCGCATGC CAGGCTGATG ATAGGGAAGG GTGTTTTGGC 300

TTAGGGGGGC TTTATGATGA GGGTTTAGGC ACGGCTCAAA ATTATCAAGA AGCCMTTGAC 360

GCTTACGCAA GGCATGCGTT TTAA 384

(2) INFORMATION FOR SEQ ID NO:47:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 351 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY, circular

(ll) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...351

( i) SEQUENCE DESCRIPTION: SEQ ID NO:47

ATGGCGATAG CCATTAAGGA TTTATTGAGC GCTTATAAAG TCGTTTTACC TTTGGATAAA 60

ATCAGCATGC CATCTAGCGC GGATTTGAAG CTCACTTTGC AATTCTTAAA AAACACCGCC 120

CCCTTATTTA GCGTTCAAGG CAGCGTTAAT TTGCAAGAAG GCACTTTCTC GCTCTATAAT 180

ATCCCCCTTT ACACGCAAAG CGCTCAAATC AATTTGGACA TCGCCCAAGA ATACCAATAC 240

ATCTACATAG ACACGATCCA CACGCGCTAT GCAAACATGC KGGATTTAGA CGCTAAAATC 300

GCTTTAGATT TAGGTCAAAA AAACCTYTCY YKGGAKKCYY TAGGKCCATA A 351

(2) INFORMATION FOR SEQ ID NO: 48. (l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 249 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY, circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE. NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1. .249

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:48

ATGCCGGATA AYTTGCATTT GCACACCCTT TTATYTAAAT TCTTGCAACA ACGCTCTTTC 60

AATTACCCTA ACCCTTTATG CGCGTTTATC CTTATTCTAT GCAACCTGCC TTTTATTTTA 120

ATAAGCGTTT TGTTTCGCTT GGACGCTTAT GCGCTCATTG TGATTAGCCT AGTCTTTATC 180

RCATGCTATT TAATAGGCTM TGCTTATTTG AATAGGCAAG TTTGCGCTTT AGAAAAGCGG 240

GCGTTTTAA 249

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 351 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49

TTGAAAGTAA CRAATCCGCA TTTGTTGGTG GTAATCCAAG ATTTAAACGC TCGCATCGCT 60

TTAATGAAAC TCTTATTCCA AAACGTTAAG AGCGCGAACA AAGAATTGGT TTTTTGCAAT 120

AAAGAAAAAC GCTTGATAAG GTCTTTTGAT GCACAAAAAG AATACGGCAT CACGCCTGTA 180

GAAAATATTT TAAGCGTTTT AGACACCGCT ATGAATCCTA ACAGCGCGCT TGTGATAGAC 240

AATCTCAACG AAGCGAAAGA ATTGCACGAC AAAGTAGGGG CGGAAAAGTT AAAATCGTTT 300

TTAGAAAAAG CCCMTAGACA ACGAGCAGTA TTGCGTCATT TTTGCGCATG A 351

(2) INFORMATION FOR SEQ ID NO: 50:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 597 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: NO (iv) ANTI-SENSE. NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...597

(xi) SEQUENCE DESCRIPTION. SEQ ID NO: 50

ATGAAAGAAT CTTTTTACAT AGAGGGAATG ACTTGCACGG CGTGTTCTAG CGGGATTGAA 60

CGCTCTTTAG GACGTAAAAG TTTTGTGAAA AAAATAGAAG TGAGCCTTTT AAATAAGAGC 120

GCTAACATTG AATTTAACGA AAATGAAACC AATTTAGACG AAATTTTTAA ACTCATTGAA 180

AAACTGGGTT ATAGCCCTAA AAAAACTCTA GCAGAAGAAA AAAAAGAATT TTTTAGCCCT 240

AATGTTAAAT TAGCGTTGGC GGTTATTTTC ACGCTTTTTG TGGTGTATCT TTCTATGGGG 300

GCGATGCTTA GCCCTAGCCT TTTACCTGAA AGCTTGCTTA CGATTAACCA TCATAGTAAT 360

TTTTTAAACG CTTGCTTACA GCTTATAGGC GCGCTCATTG TCATGCATTT GGGGAGGGAT 420

TTTTACATTC AAGGGTTTAA AGCCTTATGG CACAGACAAC CCAACATGAG CAGCCTTATC 480

GCCATAGGCA CAAGTGCTGC CTTAATTTCA GCCTGTGGCA ATTGTATTTG GTTTATACCA 540

ATCATTATAC CGATCAGTGG TCTTATGGGC ATTATTATTT TGAAAGCGTG TGCGTGA 597

(2) INFORMATION FOR SEQ ID NO: 51:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 258 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(IV) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...258

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51

GTGGGGATTG TGCCGGATAA TTTGTGGAAG CTCAAACGCT TCAATCAAGA CTGGCGCGTT 60

GGGGACACGC TCATTACTGC TATTGGGCAA GGCTCTTTTT TAGCCACGCC TTTGCAGGTG 120

TTAGCCTACA CAGGACTCAT TGCGACAGGC AAACTGGCAA CGCCTCATTT TGCTATCCAT 180

AACCAACAAC CGCTCAAAGA CCCCCTGAAT AGGTTTTCAA AAAAAGAAGC TCCAAGCCTT 240

GCGCGTGGGC ATGTATGA 258

(2) INFORMATION FOR SEQ ID NO: 52:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1032 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE- NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM- Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY: mιsc_feature

(B) LOCATION 1...1032

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52

ATGCAAAACT TATTGATACA AGCAGAAAAT GCAATCGCTC TACTTTTTTT GTTAAATGAC 60

AAAAACCTAA AAGGAAAAAT AGATTTGATA TATATTGACC CTCCATTTGC TACAAACAAT 120

CATTTTACTA TCACAAATGG TAGAGCAACC ACAATTAGCA ATTCTAAGAA TGGCGATATT 180

GCTTATAGTG ATAAAGTAGT GGGTATGGAT TTTATGGAAT TTTTAAAACA ACGCCTGGTA 240

TTGCTTAAAG AATTGCTTTC AGAACAAGGC TCTATCTATG TGCATACAGA TTACAAGATA 300

GGGCATTATG TCAAGGTAAT GTTAGATGAA ATATTTGGCA TACAAAATTT TAGAAATGAA 360

ATCACACGCA TAAAGTGCAA TCCTAAAAAT TTTAAAAGGA TAGGCTATGG TAACATAAAA 420

GATATGATTT TATTTTACTC TAAAGGAAAA AATCCCATTT TTAACGAACC TAAGATCCCT 480

TATACGCCAC AAGATTTAGA AAAACGATTC CCTAAAATTG ACAAAGATAA AAGGCGTTAC 540

ACTACCGTTC CAATACATGC TCCAGGAGAA GTGGAAAGTG GCGAATGTTC TAAAGCATTT 600

AAAGGTATGC TACCTCCAAA AGGGCGGCAT TGGCGCACTG ATATTGCCAC ACTTGAGCGT 660

TGGGATAAAG AAGGTTTGAT TGAGTATTCT AACAATAATA ACCCTAGAAA AAAAATTTAT 720

GCCTTAGAAC AAGTTGGCAA AAGAGTCCAA GACATCTGGG AATTTAAAGA CCCACAATAT 780

CCAAGCTACC CTACAGAAAA AAACGCTCAA TTATTAGACT TAATCATTAA AACCTCTTCT 840

AATAAAGATA GTATTGTTTT AGATTGTTTT TGTGGTTCTG GAACAACCTT AAAATCTGCG 900

TTTTTATTGC AACGAAAATT TATAGGCATT GATAATTCCG ATTTGGCTAT CCAAGCTTGC 960

AAAAACAAGC TTGAAACAAT AACAAAAGAC TTGTTTGTTT CTCAAAATTT TTATGATTTC 1020

CTTGTTTTTT AA 1032

(2) INFORMATION FOR SEQ ID NO: 53:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 531 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

( vi ) ORIGINAL SOURCE :

( A ) ORGANISM : Hel icobacter pylor i

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...531

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53

ATGACAAGCG TTGTCATCAA GCCCCATGCC TATGGCGAGC AAGTCCAAGA AATAGAAGAA 60 GAGTCAGATA GCGATTATGA AAAGAATAAC GACCAGGAAG CGATCAATTT TGGTATCGCC 120 TTGCATAAGG GATTGGAATA CCAATACGCT TACAACATTC CTAAACAAAG CGTTTTAGAA 180 TATTTAAACT ACCACTATGG TTTTTATGGT TTGGATTACC AAGCGTTAGA AGAAAGTTTA 240 GAGCTTTTTG AAAACGATGC AGGGATACAA GCCCTTTTTA AAAATCATGC CTTAAAGGGT 300 GAAGCGGCTT TTTTATTCCA AGGGGTTGTG TCTAGGATTG ATGTTTTATT GTGGGATAGA 360 GGGCAAAATT TGTATGTTTT AGATTATAAA AGCTCTCAAA ATTACCAGCA AAGCCATAAA 420 GCGCAAGTGT CTCATTACGC TGAGTTTTTG CGAACTCAAG SCCCCCATTT TAAGATACAA 480 GCGGGCATTA TTTACGCTCA TAAAAGACTG CTTGAAAAAT YATGGGKTTG A 531

(2) INFORMATION FOR SEQ ID NO: 54:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 783 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO ( iv ) ANTI - SENSE : NO

(vi) ORIGINAL SOURCE-

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...783

(xi) SEQUENCE DESCRIPTION. SEQ ID NO: 54

ATGTCTGAGG ATTTGCCTTT TGCGAGCGAT TCGCAATTCA CTTACAATGG GGTGAGCATC 60

ACGCGCCCCA CTAATGAGGT CAATGATGTG ATCAGCGGGG TTAATATCAC TTTAGAGCAA 120

ACCACAGAGC CTAATAAGCC TGCCATTATC AGCGTGAGCA GAGACAATCA AGCCATTATA 180

GACAGCCTTA AAGAATTTGT CAAAGCCTAT AATGAGCTTA TCCCTAAACT AGACGAAGAC 240

ACGCGCTATG ACGCTGACAC TAAAATCGCC GGGATTTTTA ACGGCGTGGG CGATATTCGT 300

GCCATTAGAT CCTCTCTTAA TAATGTGTTT TCTTATAGCG TGCATACGGA TAATGGGGTA 360

GAAAGCTTGA TGAAATACGG GCTTAGTTTA GACGATAAGG GCGTGATGAG TTTGGATGAA 420

GCTAAAT AT CAAGTGCATT AAATTCTAAC CCTAAAGCGA CTCAAGATTT TTTCTATGGG 480

AGCGATAGCA AGGATATGGG GGGCAGAGAA ATCCACCAAG AGGGCATTTT TTCTAAATTC 540

AATCAAGTCA TCGCTAACCT CATAGATGGA GGGAACGCTA AATTAAAGAT TTATGAAGAT 600

TCCCTAGACA GAGACGCTAA AAGCCTGACC AAAGACAAAG AAAACGCTCA AGAGCTTTTA 660

AAAACCCGCT ATAACATCAT GGCGGAGCGC TTTGCCGCTT ATGATAGTCA AATCTCTAAA 720

GCCAATCAAA AATTCAATTC CGTGCAAATG ATGATCGATC AAGCAGCGGC TAAAAAGAAT 780

TAA 783

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 438 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(11) MOLECULE TYPE: DNA (genomic)

(lli) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...438

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55

ATGCGCATCG TATTTATGGG AACGCCTAGT TTTGCTGAAG TGATCTTAAG GGCGTTGGTT 60

GAAAATGAAG ATAAAAAGAT AGAAGTGGTG GGGCTATTCA CTCAAAGGGA CAAACCTTTT 120

GGGCGCAAAA AAGAATTGAA AGCCCCAGAG ACTAAAACAT ACATTTTAGA AAATCATTTA 180

AATATTCCCA TTTTCCAGCC GCAAAGTTTG AAAGAGCCTG AAGTTCAAAT CTTAAAAGGT 240

TTGAAGCCTG ATTTTATCGT GGTGGTGGCT TATGGTAAGA TTTTGCCTAA AGAGGTTTTA 300

ACCATCGCTC CTTGCATTAA TTTGCATGCG TCGTTATTGC CCAAATACAG GGGGGCTTCG 360

CCCATTCATG AGATGATACT CAATGACGAT AGGATTTATG GCATAAGCAC CATGCTTATG 420

GAKTTTGGAA TTGGATAG 438

(2) INFORMATION FOR SEQ ID NO: 56:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 747 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: NO ( iv ) ANTI - SENSE NO

(Vl) ORIGINAL SOURCE

(A) ORGANISM Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY mιsc_teature

(B) LOCATION 1 747

(Xl) SEQUENCE DESCRIPTION SEQ ID NO 56

ATGCGTTTTT ATTTTAAATT CCTTTGGCTT TTAGGGATTT TTCTTATTTT TTATTTTTTA 60 GACATTAAAG GCAGCTCTTC TTATATCAGC GACCGGGTTA AAAGCGCCTT GATGAGCGCG 120 AAAAACAGCT TACTAGACAA CGTTCAAGCG TATTTTTTTC AAGCCCAAAA CATTAAGGAA 180 TTTCAAAAAG AACGCTTGAT TTTAGAAGCT TTAAAACTAG AAAACGCTGA TTTGAAAGAG 240 CGTTTGAATA GTATTTATCC TTTAGAAAAT CCAAAAATGA CTTATACCCC TACTTTCATG 300 ACTTCATTCA TCAATTTAGA AGACACACAC AGCGTTTCTC TCAACCCTAT TGTGAATTTA 360 GAAGAAAACA AGATTTATGG CCTTGTCTCT CACAACCAAG CCATAGGCAT TGCCGTGCTA 420 GAAAAAGGGC GCTTGAACGG GTTTTTGAAC GCCCACAAGC GGTGTGCTTA TAGCGTGATG 480 ATAGGCCAAA ATCAAGTCTT AGGCTTTATA GGGACTAATT TCAAGCAAGA ATTAGTCGTG 540 GATTTCATTG TCCCAAGCGC TGAAATCAAC ATAGGCGATC AAGTGCTAAC GAGCGGGCTA 600 GATGGGATTT TTGGAGCGGG GGTGTTTGTG GGTGAAGTTT CAAGCGTTGA AGATCATTAC 660 ACTTATAAAA GCGCGGTGTT GAAAAACGCT TTTTTAAGCG AAGCCAAACT TTTAAGGCAT 720 GTGTTTTTAA GCGGTGTGAA AAACTAG 747

(2) INFORMATION FOR SEQ ID NO 57

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH 360 base pairs

(B) TYPE nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY circular

(ii) MOLECULE TYPE DNA (genomic)

(ill) HYPOTHETICAL NO

(iv) ANTI-SENSE NO

(Vi) ORIGINAL SOURCE

(A) ORGANISM Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY mιsc_feature

(B) LOCATION 1 360

(xi) SEQUENCE DESCRIPTION SEQ ID NO 57

TTGGCTTTAA GATTGCCTTT TTTGATCGCT CACGTCATCA ACATGTTTTT ATTCTACCTC 60 ATAGGGCGAA AGATTTTAAA AAAGCCTAAA GACGCTCTTT ATGTGGTATT GACTTACGCT 120 TTATTGCCTG GGGTGAATCT CTTTGCGATT TTACTGGCTA AAAGCGTGCT GGTGTTAAGC 180 CTTGGGCTTT TGATTAGCTA TTTGTATATT AAAACCCAAA AAATCCCTTA TTTAACCCTT 240 AGCGCTTGCG CGTTTTTAGA CGGTGCGTTC ATCCCGCTTT TACTAGGGGT TTTTGCCTAC 300 GCTTTAAGGA AAACGGCTAT TTTAAGAGCG CGATCTTTGC TTTGGTGGTT TTAMTTGTGA 360

(2) INFORMATION FOR SEQ ID NO 58

(1) SEQUENCE CHARACTERISTICS

(A) LENGTH 327 base pairs

(B) TYPE nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY circular

(n) MOLECULE TYPE DNA (genomic) (ill) HYPOTHETICAL NO (iv) ANTI-SENSE NO ( vi ) ORIGINAL SOURCE :

( A ) ORGANI SM : Helicobac ter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...327

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58

GTGAATTTAA TGGACTATTT TTCTAAAAGT TTGTTTTTAA ATTCATTGAA CACGCAGCGA 60

TTGATCGTCT CCAACAAATT AGCGATTGAC GTGCAATACG GCATGCTCCA AAGTGTCCGC 120

AAAAATTACC CTGATGTGGT GGATGGGGGT GTTAGGGAGG GGCCTTTTTG GGTGTTAGCC 180

GGGGCYTTAA TGCCTTCAAT TTTAATAGAA ATTGGTTATA ATTCCCATGC GATAGAATCT 240

AAACGCATCC AAAGCAAACC GTATCAAAAA ATCTTGGCTA AGGGCATTGC TGATGGCATT 300

GATAGTTTCT TCAGCAAGAA TGATTAG 327

(2) INFORMATION FOR SEQ ID NO:59:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 474 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...474

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59

TTGGCGTCTC GCTATTCTGT GGCTGTTGGG AATTTATTTT CAGAGCATTT GTATGATTTA 60

AGAAATGAAA CCATGACCAA TCTCATTGGT TTTTTACTGG TGTTGGCGTC CATTTGGGTG 120

TTTTTTTTAG CTCTTGGAGT GTTGCTAGGC AAGATGTTAG TCTTTAGCGG TCTAGGCATT 180

ATAGACAAGG CGTTAGGGTT TATTTTTTCA TGTTTGAAGA CTTTTTTAGT GCTTTCTTTC 240

ATCCTTTATG CGCTCTCTAA AATGGATTTA ATGAAAGACG CTAACGCCTA TTTGCAAGAA 300

AAGAMCRCTA TTTTCCCCAC CATRAAAARC RTCRCTAGTA AGATCATGCG CCTTGATGGC 360

GTCAAACATG TGGAGAAAAA CCTTAAAGAC AACCTTGAAG AAATGAGCGA TGAAGTTAAA 420

AA AAAGGAT CTATTGATAA CGCCAAAGAA TCTTTTAATA AGGGCTACGG ATAA 474

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 246 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...246 (xi) SEQUENCE DESCRIPTION: SEQ ID NO.60

TTGAGCAAGC AAAGCGCGGA CATTGTGATC ACTAATGACT CCTTAAGCTC TTTAGTCAAA 60

GTTTTAGCGA TCGCTAAAAA AACTAAAAGC ATTACTTGGC AAAATATCTT GTTCGCTTTG 120

GGGATTAAGG CGGTTTTTAT CGTGCTAGGG CTTATGGGGG TAGCGAGCTT GTGGGAAGCG 180

GTCTTTGGCG ATGTGGGGGT TACGCTTTTA GCYTTAGCCA ATTCCATKCG CACGATGAGG 240

GCTTAA 246

(2) INFORMATION FOR SEQ ID NO: 61:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 240 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL. NO

(iv) ANTI-SENSE: NO

(v ) ORIGINAL SOURCE:

(A) ORGANISM- Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...240

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 61

ATGAAAAATT TAAGGCATTT TAGAAAGCTT ATCGCCTTTT TAGGTTTTTC ACCTCTTTTA 60

TTACAAGCGG ATATGACTAC CTTTTTTAAT TCCATTGAAC AACAGCTCAC TAGCCCTACG 120

GCTAAAGGCA TTTTAATGGT TATTTTTTTA GGACTTGCTA TTTTTATATG GAAAAACTTA 180

GATAGATGGA AAGAAATTTT AATGACCGTG CTTGCTTTAA AAGRAGTCCC CATGCAATMW 240

(2) INFORMATION FOR SEQ ID NO: 62:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 978 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

( ix ) FEATURE :

( A ) NAME/ KEY : rτusc_f eature

( B ) LOCATION 1 . . . 978

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62

TTGGCGGGTT TGCYAGTGGG GTGTATRCGG ATGAAACAAA CATTTTGGGR ACTTAGTTGG 60

GGGGAAAAAA GCCAAAAGGT ATGCGTGCAT CGTCCATGGT ATGCTATATG GAGTTGCGAT 120

AAATGGGAGG AAAAAACACA ACAATTTACA GGAAACCAAC TCATCACAAA AACTTGGGCA 180

GGGGGTAATG CGGCTAACTA CTACCACTCT CAAAACAACC AAGACATCAC AGCCAATTTA 240

AAAAATGATA ACGGCACTTA TTTTTTAAGC GGTCTGTATA ACTACACCGG AGGGGAATAT 300

AATGGGGGGA ATTTAGACAT TGAATTAGGC AGTAACGCTA CTTTTAATCT AGGTGCGAGT 360

AGTGGGAATA GCTTCACTTC TTGGTATCCT AATGGGCATA CTGATGTTAC TTTTAGCGCT 420

GGGACTATCA ATGTGAATAA CAGCGTAGAA GTGGGCAATC GTGTGGGATC GGGAGCTGGC 480

ACGCACACCG GCACAGCCAC TTTAAACTTG AACGCTAATA AGGTTACTAT CAATTCCAAT 540 ATCAGCGCGT ATAAAACT C GCAAGTGAAT GTAGGCAATG CTAACAGCGT TATTACCATT 600

AATTCGGTTT CTTTAAATGG GGAAACTTGC AGKTCTTTAG CTAGGGTGGG CGTAGGGGCT 660

AATTGCTCCA CTTCTGGGCC TAGCTATTCT TTTAAAGGGA CSACTAACGC TACTAACACS 720

ACTTTTAGCA AWTCAAGCGG SAGTTTCACT TTTGAAGARA ACGCCACTTT TAGCGGGGCG 780

AAATTAAATG GGGGGGCATT CACTTTCAAT AAAAAGTTTA ACGCTACCAA TAATACCGCT 840

TTTAATAGCG GTAGTTTTAC TTTTAAAGGC ACAAGCTCTT TTAATGGTGC GAATTTTAGT 900

AACGCTTCCT ATACTTTTAA TAATCAAGCC ACTTTCCAAA ACAGCTCCTT TAATGGGGGG 960

ACTTTTACTT TTAATTGA 978

(2) INFORMATION FOR SEQ ID NO:63:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 816 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

( vi ) ORIGINAL SOURCE :

( A) ORGANISM : Hel icobac ter pylor i

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...816

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:63

TTGTTAAGTT TAGTTAAAGG GAAAACCATG CTCCGCTCTC TCTATAGTGC CACTTCAGGG 60

ATGCTCGCCC AACAAACGCA CATTGACACC ACTTCAAACA ACATCGCCAA TGTCAATACC 120

ACCGGGTTTA AAAAATCTCG CGCGGATTTT AACGACTTGT TTTACCAAGC GATGCAATAC 180

GCCGGCACCA ACACAAGCAA CACGACTTTA TCGCCAGATG GCATGGAAGT GGGCCTTGGC 240

GTACGCCCTA GTGCGATTAC CAAAATGTTT TCGCAAGGCA GCCCTAAAGA AACGGAGAAT 300

AATTTAGATA TTGCTATTAC AGGTAAAGGC TTTTTTCAAG TCCAGCTTCC TGATGGCACT 360

ACCGCTTACA CAAGGAGCGG GAATTTCAAG CTAGACGAGC AGGGCAATCT TGTAACAAGC 420

GAGGGCTATC TCCTCATCCC TCAAATCACT TTACCCGAAG ACACCACGCA AGTGAATATC 480

GGTGTGGATG GCACGGTGAG CGTGACTCAA GGCTTGCAAA CGACTTCTAA CGTGATCGGG 540

CAAATCACTT TGGCTAATTT TGTCAATCCG GCGGGGCTTC ATTCTATGGG GGATAATTTG 600

TTTTCCATCA CCAACGCTAG CGGCGATGCG ATTGTGGGCA ACCCGGATTC TCAAGGCTTA 660

GGCAAGTTAA GGCAAGGCTT TTTGGAGCTT AGTAACGTGA GATTGGTAGA AGAAATGACA 720

GATCTAATCA CCGCTCAAAG GGCTTATGAA GCCAATTCTA AAAGCATTCA AACCGCTGAT 780

GCCATGCTCC AAACAGTCAA TTCCCTCAAA CGCTAA 816

(2) INFORMATION FOR SEQ ID NO:64:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 273 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

( vi ) ORIGINAL SOURCE :

(A ) ORGANISM : Hel icobacter pylori

( ix ) FEATURE :

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...273

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64 ATGCAAAATG GGTATTATGC GGCCACAGGG GCAATGGCTA CACAATTTAA CCGCTTGGAT 60 TTAACCTCTA ACAATTTAGC CAACCTAAAC ACCAACGGCT TTAAAAGAGA CGATGCGATT 120 ACAGGCGATT TTTTAAGGCT TTACCAAGAA TACCGAGAGC AACTGCCCTT AGAAGATCAA 180 ACCAAAGCGA GCGCGAAGTA TCTCAACCGC AMCCTCAATC GTGTGCCTAT TCTATCARAA 240 ATCTATACKK ATAGGRAGCT TGGCYGCGTT TGA 273

(2) INFORMATION FOR SEQ ID NO: 65-

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH: 585 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY circular

(il) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...585

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65

GTGGGGGCTA TGCCTACTAT CCAAATCCGT GRCTTTGGAG CGGGGGGTTC AGGGCATAGC 60

GATGCGACGC TCATGTTAGT TAATGGTATT CCTGTTTATA TGGCCCCTTA CGCTCACATT 120

GAGCTAGACA TTTTCCCTGT TACCTTTCAA GCCATTGATC GCATTGATGT GATCAAAGGT 180

GGAGGCAGCG TGCAATATGG GCCTAACACT TATGGGGGTA TTGTCAATAT CATCACTAAA 240

CCTATCCCTA ATCAATGGGA AAACCAAGCG GCTGAAAGGA YCACTTATTG GGCTAAGGCT 300

AGAAACGCTG GGTTTGCCGC TCCCCYTGAT AAAACCGGCG ATCCTTCTTT CATCAAGTCT 360

TTAGGCAACA ACCTCCTCTA TAACACTTAT GTGAGGAGCG GAGGGATGAT CAATAAGCAT 420

GTGGGTATCC AGCGCAAGCT AACTGGGTTA GAGGCCAAGG CTTTAGGGAC AATAGCCCCT 480

CTAGTATTTC AAACTATTGG CTGGATGGGG TCTATGACAT CAATGAAAGC AATGGGATTA 540

AAGCCTATTA CCAATACTAC GATTTTGGCT ATCGSCCAAC CGGGA 585

(2) INFORMATION FOR SEQ ID NO: 66:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 255 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM. Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...255

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66

ATGAGAWAGG AGAAAATAAT GACGAATTTT GAAAAGRTTA TCGCGCAAAA CAGGCTCAAA 60 ACGAACGCGG TTTTAACCAC TTACTGCGCG ATTTTTGCTT TTATTGGGTT GTTGGTGGAT 120 GCTATTAGAA TCAACGCTAA TGATTTAGGT ATAGCCCTTT TTAAACTCAT GACTTTTCAA 180 ATTTTTCCTA CGRTTACTAT TGTCATGTTT GTGGTGGCTT TTGTCATTAK KCKKAGTTTG 240 TATCCAAAAT TTTAG 255 (2) INFORMATION FOR SEQ ID NO: 67-

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 231 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(in, HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...231

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67

ATGGRCATGT CTCATATTAT TAAGAGCATT GAAGCTTTAG ATGACTATAC CATTAGATTC 60

ACGCTTAATG GGCCAGAAGC CCCGTTTTTA GCGAATTTGG GCATGGACTT TTTAAGCATT 120

TTGAGTAAGG ATTACGCTGA TTACTTGGCT CAAAATAATA AAAAAGACGA GTTGGCTAAA 180

AAMCCTGTTG GGACAGGGCC TTTCAAATTC TTTTTGTGGA ATAAAAGATG A 231

(2) INFORMATION FOR SEQ ID NO: 68:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 591 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

( n) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

( vi ) ORIGINAL SOURCE :

(A) ORGANISM : Hel icobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...591

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68

TTGATGAGGA AAATTTTTTC TTATATTTCT AAGGTTCTAT TATTTATTGG GGTGGTTTAT 60

GCAGAGCCTG ATTCTAAAGT GGAAGCCTTA GAAGGGAGGA AGCAAGAGTC TTCTTTGGAT 120

AAAAAAATCC GCCAAGAATT GAAGAGTAAG GAATTGAAGA ATAAGGAATT AAAGAACAAG 180

GATTTGAAAA ATAAAGAAGA AAAGAAAGAA ACAAAAGCCA AGAGAAAACC CAGAGCAGAA 240

GTCCATCATG GGGACGCCAA AAATCCCACT CCAAAGATCA CGCCTCCTAA AATCAAAGGG 300

AGTAGTAAGG GCGTTCAAAA TCAAGGCGTT CAAAACAACG CGCCAAAACC TGAAGAAAAA 360

GATACAACCC CTCAAGCTAC TGAAAAAAAT AAGGAAACAA GCCCTAGCTC TCAATTCAAT 420

TCCATTTTTG GTAATCCTAA TAACGCTACC AACAACACCC TTGAAGATAA GGTCGTAGGG 480

GGCATTTCAT TGCTTGTTAA TGGTTCGCCT ATCACGCTGT ATCAAATCCA AGAAGAGCAA 540

GAAAAATCTA AAGTGAGYAA SGCTCRAGCT AGGGATCGTT TGAKTCKCTG A 591

(2) INFORMATION FOR SEQ ID NO: 69:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 540 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...540

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69

ATGAAGAGAT CTTCTGTATT TAGTTTCTTG GTAGCTTTTT TATTGGTAGT TGGCTGTAGT 60

CATAAAATGG ATAATAAGAC TGTGGCTGGC GATGTGAGCA CTAAAGCGGT TCAGACTGCG 120

CCTGTTACTA CAGAACCAGC TCCAGAGAAA GAAGAGCCTA AACAAGAGCC AGCTCCAGTG 180

GTTGAAGAAA AGCCGGCTAT TGAAAGCGGG ACTATCATCG CTTCTATTTA TTTTGATTTT 240

GACAAGTATG AGATCAAAGA ATCCGATCAA GAGACTTTAG ATGAGATCGT GCAAAAAGCT 300

AAAGAAAACC ACATGCAAGT GCTTTTGGAA GGCAATACCG ATGAATTTGG CTCTAGCGAA 360

TACAACCAAG CGCTTGGCGT TAAAAGGACT TTGAGCGTGA AAAACGCTTT AGTCATTAAA 420

GGGGTAGAAA AAGATATGAT CAAAACCATC AGTTTTGGCG AAAGCAAACC CAAATGCGTC 480

CAAAAAACTA GAGAATGTTA CAGAGAAAAC AGAAGAGTGG ATGTCAAATT AGTGAAGTAA 540

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 861 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...861

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:70

ATGGGAACGC TCATTGAAAA ATGGTTTGGC TTCTCTCAAA TCAGAGAAGA ATTAGAAGCT 60

CGCATCAGTG AGTTAGAAGA CGAAAACACC GAATTGTTAA GAGAAAGAGA ATACTTAGCT 120

GCAGAAACTA GCGAGTTAAA AGACGCTAAC GATCAATTAC GGCAAAAAAA CGACAAGTTA 180

TTCATAACAA AAGACAAGCT AACCAAAGAA AACACCGAGT TATTCGCAGA AAACGAAAGC 240

TTATCTGTAA AAATCAGCGG GTTAGAACAC TCTAACGATC AATTATGGCA AAACAATAAC 300

AAGCTCACTA AAGAAAAAGC AGAACTGAAA ACGGAAAAAG ACATTTTAGC TAAAGAAAAC 360

ACACGCTTAT TAGCAGCCAG AGATCGGCTG ACTGAAGAAA AAAGAGAATT GACAACAGAA 420

AAAGAAAGGC TAAAAAGAGA AAACACCGAG CTAACCCATA AAATCACCGA GCTGACTAAA 480

GAAAATAAAG CACTAACCAC CGAAAACGAC AAGCTCAACC ACCAAGTTAC CGCGCTCACT 540

AATGAGCGAG ATAGTCTCGA ACAAGAGCGA GCGCGATTGC AAGATGCGCA TGGGTTTCTA 600

GAAAAACGAT GCACCAATTT AGAGAAAGAA AACCAACGCC TAACTGACAA GCTCAAACAA 660

TTAGAAAGCG CTCAAAAAAG CTTGGAAAAC ACTAACAATC AATTACGGCA AGCTTTAGAA 720

AACTCTAATG TCCAATTAGC ACAAGCTAAA GARARAATWG CCATAGAGRA AAGCGAGCTG 780

GMGCGAAGAA ATCGCACGCT TGAAGAGCTT AGAGGGTATG GAAGCCAAAA GSCGATCTGG 840

ACTTACACAW CAGGCGTTTA G 861

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH 333 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...333

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71

GTGTTGCGCA AGCTTTTGGG TAAAAATTGC ATAGAAACGC ATAAGGGGGT GGGCTATCGC 60

TTAACCCACT ATGAAAAAAA ATCCCTCAAA CTCTTTTTAG GGACTTATTT AGGCTCTTCG 120

TTTGTGTTAA TGCTAGTGAT TAGCGTTTTA GCGTTTAACT ATGAAAAAAA CGAAAAAATC 180

AAARTGATAC GCATGGACAT GGACAAAATG GCTTCTAAGA TCGCTAGTGA AATTATCCAA 240

TTGCACATGC AAACGCATGC GGATTATCAC AACGCTTTAA ACGCCCTGAT TTCACGTTAT 300

AAAGACGTTT CCATAGYCCT YTYYGAYACG TAA 333

(2) INFORMATION FOR SEQ ID NO:72:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 375 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY, circular

(ii) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL. NO

(iv) ANTI-SENSE: NO

(Vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_£eature

(B) LOCATION 1...375

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72

TTGATGACCA AAAGCTTAAA ACTCATTCAA AAAGGGGTTA AAAACCTCTA TGAAACCCTT 60

AAAAATAGGG CTTTAGAGCA TCAAGACACG CTAATGGTGG GCAGAAGCCA TGGGGTGTTT 120

GGCGAACCCA TCACCTTTGG TTTAGTTTTA GCTCTTTTTG CTGATGAAAT CAAACGGCAT 180

TTAAAAGCCC TGGATTTAAC GATGGAATTT ATCRGCGTWG GGGCGATCAG TGGGGCTATG 240

GGGAATTTCG CGCACGCCCC TTTAGAATTA GAAGAATTAG CGTGCGGATT TTTAGGCTTA 300

AAAACCGCTA ATATCAGCAA TCAAGTCATT CAAAGAGACC GCTACGCAGG CTTGCATGCG 360

ATCTGGCTCT TTTAG 375

(2) INFORMATION FOR SEQ ID NO:73

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 288 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY, circular

(n) MOLECULE TYPE: DNA (genomic) ( ll) HYPOTHETICAL NO (iv) ANTI-SENSE- NO

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY- mιsc_feature

(B) LOCATION 1...288

(Xl) SEQUENCE DESCRIPTION. SEQ ID NO.73

TTGTCAGACG CTTCAAAAAG ATCCCTTAAT CCAACCTTAA TGATGAATAA TAATAATACC 60

CTACCCAAAC CCCTAGAAGA AAGCCTAGAT TTAAAAGAGT TTATCGCTCT TTTTAAAACC 120

TTTTTCGCAA AAGAAAGAGG TTCTATTGCT TTAGAAAACG ATCTCAAACA GGCTTTCACT 180

TATTTAAATG AAGTGGATGC GATCGGTTTG CCTGCCCCCM AAAAGCGTGA AAGAAAGCGA 240

TCTTATTGTT GTCAAACTCA CCAAATTAGG GACGCTCCAT TTAGATGA 288

(2) INFORMATION FOR SEQ ID NO: 74:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 243 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

( i) MOLECULE TYPE: DNA (genomic)

( ll) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...243

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:74

TTGCCTATTA TTTTAYCTGT AATCGTGATG ATGTTTTTTT CCAAAATCGT TGGCGATTTT 60

ATTGAAAAGC ATTATCGCGT CAAAACTTTA GCCTTTGTGT TTTTGCTCGT TGTGGGCGTG 120

TTTTTGTTTT TAGAAGGCTT GCATTTACAC ATCAATAAAA ACTATTTGTA TGCGGGTATT 180

GGTTTTGCCT TGCTCATAGA ATGCTTGRAT ATTTTCATAG AAAAGAAAAT GAAAAAAAGT 240

TAA 243

(2) INFORMATION FOR SEQ ID NO:75.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 798 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1. .798

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75 1 1

ATGATAAAAG CGCGGTTTAA AAAACGCCTT TTAGGATCTA GGGGCGCGTT TGATTTGAAT 60 ATAGACTTAG AAATTAAAGA AGCAGAAGTT GTCGCTTTAT TAGGAGAATC GGGAGCGGGT 120 AAAAGCACGA TCTTACGCAT TTTAGCAGGG CTTGAAGCGG TGAGTAGCGG CTATATTGAA 180 GCCAATCATT CAGTATGGTT AGACACTCAA AAAAAGATTT TTTTAAAACC ACAACAGCGA 240 AAAATCGGCT TTGTGTTTCA AGATTACGCC CTATTCCCTC ATTTAAACGT GTATCAAAAC 300 ATCGCCTTTG CTCACCCTAA AGATAAAAAT AAAATCCACG AAGTGTTACG CTTAATGCGT 360 TTAGAAAACC TAAGCCAGCA AAAAATTCCC AAACTCTCTG GCGGGCAAGC CCAACGAGTC 420 GCTTTAGCAA GAGCTTTAAT CGCAGCCAAA AATCTATTGC TTTTAGATGA GCCTTTAAAC 480 GCCCTAGATA ACGCCTTAAA AAACGAGGTG CAACAAGGTT TGCTTGATTT TATCAAGCGT 540 GAAAATTTAA GCGTGTTATT GGTAAGTCAT GATCCAAACG AAATAACCAA ACTCGCGCGA 600 ACTTTCCTCT TTTTAAACAA TGGCGTTATT GATCCTAATC AAGAAAATCG GCTTTTTTCA 660 AACCGCTTAT TGGTAAAACC TCTCTTTGAA GATGAAAATT ATTGCCATTA TGAGGTCATT 720 CCTCAAACGA TCAGTTTGCC CAAAGATTGT CTGAACCCAA CTTTTAAGCT TGATTTCATT 780 CAAAACAAAA AATTTTAG 798

(2) INFORMATION FOR SEQ ID NO:76:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 195 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...195

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76

GTGAAATTCA GCGTTTTAAC CCTTTTCCCG CAACTCATCT TGCCTTATTT TGAAGATTCT 60

ATTTTAAAAA GAGCGTTAGA AAAAAACCTT TTTGAATTGG AAGTGTTAAA CCTTAGAGAT 120

TTTAGCGCTA ACAAATATCA AAAAGCGGAK TCACACGCTC ATTGGTGGGG GTGCGGGGCA 180

AATTTTAGAC CCTGA 195

(2) INFORMATION FOR SEQ ID NO: 77:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 414 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ni) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...414

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:77

TTGTGGCGCA CACCGAAGAC RCCCTTAGTC ATTAAACCCT ATTTGAAAAG CATGAGCGAT 60 TCAGAGATYT TTGCGGYCAY GTGCGTGGGY ATGGCYAGCG TTRCGGGGCC TGTGTTAGCC 120 GGGTATGCGA GCATGGGCAT TCCTTTACCT TATTTAATCG CCGCATCGTT TATGTCCGCT 180 CCTGGGGGGT TGCTGTTCGC TAAAACCATT TACCCGCAAA ACGAAACCAT TTCTAGCCAT 240 GCAGATGTTT CTGCAGAAGA GCATGTCAAT ATTATAGAAG CTAYCGCWMA TGGGGCAAGC 300 ACAGGGGYTC ATTTAGCCTT GCATGTGGGG GCGATGCTTT TAGCCTTTGT GGGGATGGTC 360 GCGCTCGTTA ACGGGCTTTT AGGGGTTGTA GGGGGATTTT TAGGCATGGA GCAT 414

(2) INFORMATION FOR SEQ ID NO:78:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH- 348 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

( ix ) FEATURE :

(A) NAME/KEY : raιsc_f eature

( B ) LOCATION 1 . . . 348

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78

GTGATGAACT TTTTTGTGGG CGGACTTTCC ATTGTTTGTA ATGTGGTGGT CATCACTTAC 60

TCCGCGCTCC ACCCTACAGC CCCTGTAGAA GGTGCAGAAG ATATTGTTCA AGTATCGCAC 120

CATTTGACCA GTTTCTATGG GCCAGCGACT GGGTTATTGT TTGGKTTTAC CTACTTGTAT 180

GCCGCTATCA ACCACACTTT TGGTTTGGAT TGGAGACCCT ATTCTTGGTA TAGCTTATTC 240

GTAGCGATCA ACACTGTTCC TGCTGCGATT TTATCCCACT ATAGCGATAT GCTTGATGAC 300

CACAAAGTGT TAGGCATCAC TGAAGGCGAT TGGTGGGCAA TCATATKG 348

(2) INFORMATION FOR SEQ ID NO:79:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 684 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...684

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79

GTGCTTTTGG GCAAGCATAG TGGGGCGGGG TTGTTGAGCG CTTTAWGCGC GTTAAGTTTT 60

GGATCTGGGG TGGTGAGTAT CCAAGCGTTA GAGTGCGAGA TAACTTCTAA TAACAAGCCT 120

TTAGAATTGG TTTTTTGTGA AAATTTCCCT AAAAAGCTCA GCGCGTTCGC TCTTGGCATG 180

GGGTTAGAAA ATATTCCAAA GGATTTTAAG AAGTGGCTTG AATTAGCCCC ATGCGTTTTA 240

GATGCGGGCG TTTTTTATCA TAAAGAAGTG TTACAAGCCT TAGAAAAAGA AGTGATCTTA 300

ACCCCTCACC CTAAAGAGTT TTTATCGTTA TTGAAATCAG TGGGGATCAA TATAAGCATG 360

CTAGAATTAC TAGACAATAA ACTAGAAATC GCAAGGGATT TTTCTCAAAA ATACCCCAAG 420

GTGGTTTTGC TTTTAAAGGG GGCTAATACC CTAATCGCTC ATCAAGGGCG GGTTTTTATC 480

AACAATTTAG GGAGCGTGGC TTTRGCCAAA GCAGGCAGTG GCGATGTGTT AGCGGGGCTG 540

ATTGTAAGCC TACTTTCTCA AAACTACACG CCTTTAGRCG CCGCSATTAA CGCAAGTTTG 600 1 13

GCGCACGCCC TAGCGGGTTT ARAATTTAAG AATMATTAMG CTTTAACGCC CSTAGATTTG 660 ATAGAAAAGR TCAAACGACT ATAA 684

(2) INFORMATION FOR SEQ ID NO: 80-

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH. 328 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY circular

(n) MOLECULE TYPE. DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE. NO

(vi) ORIGINAL SOURCE-

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...328

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80

GTGCYTTTAT ACCTAGCACT AACCTTGAGT TTAGGCATTG CTATGCTTTT AGTGGAAATG 60

CTGATTGGAA ATTTGGGTAA AAAAGACGTT GTTTCCAATT ATCAAATCTT AGATCCTAAA 120

AGGAAAAAAT ATTACCCTTT CACTTCTTTT TTTATTTTAG GCGGCCCTCT CATTCTATCT 180

TTTTATGCGG TGGTGTTAGG CTGGGTGCTT TACTATCTTT TTGTAGTAAC TTTTGATTTG 240

CCTAAAGATT TAGMGCAGGC TAAAATGCAR TTCMGMATGC TTCAAAATGG CAGTTTGATC 300

TGGCCTGTTA TTGACTTTAG CGCATGCT 328

(2) INFORMATION FOR SEQ ID NO: 81:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH 294 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY, circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL. NO

(IV) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...294

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:81

TTGACAACAA AAGCGTGTTG GTTGCTTCGG GTTTGTTGTT ATAGAAGTCT AAATATTACA 60

ATCAAGGATA GAACGATGAA AACCAATGGT CATTTTAAGG ATTTTGCATG GAAAAAATGC 120

TTTTTAGGCG CGAGCGTGGT GGCTTTATTA GTGGGGTGTA GCCCGCATAT TATTGAAACC 180

AATGAAGTTG CTTTGAAATT GAATTACCAT CCAGCTAGCG AGAAAGTTCA AGCGTTAGAT 240

GAAAAGATTT TACTTTTAAG GCCAGCTTTC CAATACAGCG AKAATATTTG CTAA 294

(2) INFORMATION FOR SEQ ID NO: 82 :

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH. 438 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS- double

(D) TOPOLOGY- circular 14

(11) MOLECULE TYPE: DNA (genomic) lm) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE-

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...438

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82

TTGAGTGAGT GGCAAACATT TTGTTTAAAA GATTTAGGGA AAATAGTCGG CGGCGCTACC 60 CCACCTACCA ATAACCCCAA AAATTATGGC AATAAAATTG CTTGGATTAC CCCTAAAGAT 120 TTATCCACTT TACAAGGGCG CTACATTAAA AAAGGCAGCC GCAGCATTTC ACGATTAGGG 180 TTTAAATCAT GCTCTTGTGT GTTGCTCCCA AAGCATGCCA TTTTATTTTC TTCAAGAGCT 240 CCCATAGGTT ATGTGGCAAT TGCTGAAAAA AGGCTATGCA CCAATCAAGG TTTTAAAAGT 300 ATTATCCCTA ACAAAAAAAT TTATTTTGAA TTTTTATATT ACTTATTAAA ATACTATAAG 360 GATAACATTT CCAACATAGG GGGCGGAACT ACTTTTAAAG AAGTTTCAGG GGCTACTTTA 420 GGKTCTATTC CAAGTTAA 438

(2) INFORMATION FOR SEQ ID NO: 83-

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 822 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_ eature

(B) LOCATION 1...822

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83

ATGGAATTTA TGAAAAAGTT TGTAGCTTTA GGGCTTCTAT CCGCGGTTTT AAGCTCTTCG 60

TTGTTAGCCG AAGGTGATGG TGTTTATATA GGGACTAATT ATCAGCTTGG ACAAGCCCGT 120

TTGAATAGCA ATATTTATAA TACAGGGGAT TGCACAGGGA GTGTTGTAGG TTGCCCCCCA 180

GGTCTTACCG CTAATAAGCA TAATCCAGGA GGCACCAATA TCAATTGGCA CTCCAAATAC 240

GCTAATGGGG CTTTGAATGG TTTTGGGTTG AATGTGGGTT ATAAGAAATT CTTCCAATTC 300

AAGTCGCTAG ATATGACAAG CAAGTGGTTT GGTTTTAGAG TGTATGGGCT TTTTGATTAC 360

GGGCATGCCG ATTTAGGTAA ACAAGTTTAT GCACCTAATA AAATCCAGTT GGATATGGTC 420

TCTTGGGGTG TGGGGAGCGA TTTGTTAGCT GATATTATTG ATAAAGACAA CGCTTCTTTT 480

GGTATTTTTG GTGGGGTCGC TATCGGCGGT AACACTTGGA AAAGCTCTGC AGCAAACTAT 540

TGGAAAGAGC AAATCATTGA AGCCAAAGGT CCTGATGTTT GTACCCCTAC TTATTGTAAC 600

CCTAATGCCC CTTATAGCAC CAACACTTCA ACCGTCGCTT TTCAAGTGTG GTTGAATTTT 660

GGGGTGAGAG CCAATATCTA CAAGCATAAT GGCGTGGAAT TTGGCGTGAG AGTGCCGCTA 720

CTCATCAATA AATTTTTGAG CGCGGGTCCT AACGCTACTA ACCTTTATTA CCATTTGAAA 780

CGGGATTATT CGCTTTATTT GGGGTATAAC TACACTTTTT AA 822

(2) INFORMATION FOR SEQ ID NO: 84:

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH: 447 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS double (D) TOPOLOGY circular

(ll) MOLECULE TYPE. DNA (genomic)

(in) HYPOTHETICAL- NO

(iv) ANTI-SENSE- NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM. Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1...447

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84

TTGGTCCAAA TCGTAGTCGT GTTTTATGGT TTGCCCGCCC TTGGGGTCTA TATGGATCCA 60

ATCCCGGCAG GCATTATTGC GTTTTCTTTT AATGTGGGGG CATACGCTTC AGAGACTTTG 120

AGGGCGAGCT TTCTTTCTGT CCCTAAAGAT CAATGGGATT CAAGCTTGAG TTTGGGCTTG 180

AATTACTTGC AAACCTTTTG GCATGTCATC TTTTTTCAAG CGCTCAAAGT CGCCACGCCA 240

AGCCTAAGTA ACACTTTCAT CAGCCTTTTT AAAGAAACTT CTTTAGCGTC TGTGGTCACT 300

ATCGCAGAGG KTTTTAGAAT CGCACAGCAA AAAGYGAACG TCAGCTATGA CTTTYYGCCT 360

ATTTATTTGG AAGKCGCTTT GATTTACTGG CTTTTTTGCT TGGTTTTAGA AGTGATTCAA 420

AAGCGCGTGG AAAAAATCTT AAATTAA 447

(2) INFORMATION FOR SEQ ID NO: 85:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH. 405 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...405

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85

GTGGTGGCTG ATGAAGTTAG GAATTTAGCT GGGCGCACTC AAAAGTCTTT AGCCGAAATC 60

AATTCCACTA TCATGGTGAT TGTCCAAGAA ATCAATGATG TGAGTTCGCA AATGAATCTC 120

AATTCGCAAA AAATGGAGCG CTTGAGCGAT ATGAGTAAAA GCGTGCAAGA AACTTACGAA 180

AAAATGAGTT CTAATTTAAG CTCAGTCGTT TTAGACAGCA ATCAAAGCAT GGACGATTAC 240

GCTAAATCCG GACACCAAAT TGAAGCTATG GTAAGCGATT TTGCAGAAGT GGAAAAAGTG 300

GCTTCTAAGA CTTTGGCTGA TTCTTCAGAT ATTTTAAACA TCGCTACGCA TGTGAGTGGA 360

ACGACCATGA ATTTAKACAA ACAAGTGAAT TTGTTTAAAA CTTAA 405

(2) INFORMATION FOR SEQ ID NO: 86:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 402 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: NO ( iv ) ANTI - SENSE : NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...402

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86

ATGAATTACG ATAACTATTG GGATGAGGAC AAACCAGAAC TCAATATCAC GCCTTTAGTG 60

GATGTGATGC TTGTTTTATT GGCTATTCTT ATGGTAACGA CGCCCACTCT CACCTATAAA 120

GAAGAGATTG CCTTGCCTTC TGGTTCAAAA ACTGCTAGAG CCACTCAAGA TAAAGTGATA 180

GAGATACGCA TGGATAAAGA CGCAAAAATC TATATAGATA GTCAAACCTA TGAATACAMC 240

TCTTTCCCGG ACACTTTCAA TTTGCTTTCT AAAAAATACG ATAAAGATAC TAGGGTGAGT 300

ATCCGTGCGG ACAAGCGATT GACCTATGAC AAAGTGATTT ATTTGTTAAA AACGATTAAA 360

GAAGCGGGGT TTTTGAAAGT TTCTTTAATC ACAAGTCCTT AA 402

(2) INFORMATION FOR SEQ ID NO: 87 :

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 216 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...216

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 87

ATGCCACCCA CACSCCCCCA AGCGAGTATT TTAAGGCTAA CCCTAAAAAA CCCTTTGMGC 60

MTGCTATCTC GTTATTCGCT CTGTCTGTTG AAAAAAACGC GCTTGCAAAC AACATCAAAC 120

AGCGCACCAA AAGCATGCTT GATTGCGGGC TTATTGAAGA AATCAAAGCC CTTTATATTA 180

AATACCCTAA AGATTCGCAG CCTTTTAAAG CCATAG 216

(2) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 654 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...654

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88 17

ATGCCTGTTA TAAGAGTTTT AGTAATGCTT GCAACAATGA TGATGAAATT AGTAAAAACG 60

GCAAAAGAAA AGAAAGTTTT TAAGAATGTG GGAATATCTA TAATGGGGAT TGCTTTTTGG 120

GAAGCGATAA AAGACTCGAT AAAAAAACAA ATTAAAAAAA GCGATTGGAT ATGCGGGAAT 180

GTTAAGACTG CGGATGATTA TTTAAAAACG CATCCTAACT CATGGTTTAA TTCAGCAATA 240

GGTGTAACAG CGATAACAGC CATGCTTATG AATGTGTGTT TTGCTGATGA CCAATCC AA 300

AAAGAAGTGG CTCAAGCTCA AAAGGAAGCT GAAAACGCTA GGGATAGAGC GAACAAGAGT 360

GGGATAGAAC TGGAACAAGA AGAGCAAAAG ACAGAACAAG AAAAACAAAA GACAGAACAA 420

GAAAAACAAA AGACAGAACA AGAAAAACAA AAGACAGAAC AAGAAAAACA AAAGACAGAA 480

CAAGAAAAAC AAAAGACAAG CAATATAGAG ACTAACAATC AAATAAAAGT AGAACAAGAA 540

CAACAAAAGA CAGAACAGGA AAAACAAAAG ACAAACAATA CGCAAAAAGA TTTGGTTAAC 600

AAAGCAGAAC AAAATTGCCA AGAAAATCAT AATCAATTCT TTATTAAAAA TTAA 654

(2) INFORMATION FOR SEQ ID NO: 89.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 228 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...228

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89

ATGGTTATTT CTGGGCATTT CACCACTTAT AGCTATATTG AGCCTTTTAT CATTCAAATC 60

AGCCAATTTT CTCCTGACAT TACAACGCTA ATGTTGTTTG TGTTTGGGTT AGCAGGCGTG 120

GTGGGGAGTT TTTTGTTCGG CCGTTTGTAT GCGAAAAATT CAAGAAAATT TATCGCTTTT 180

GCAATGGTTT TAGTCATTTG CCCGCAACCT CTTGCTTTTT GTGTTTAA 228

(2) INFORMATION FOR SEQ ID NO: 90:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 576 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...576

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90

ATGAAATCTA CAAGAATTGG TTCTAAAATT GTCATGATGG TGTGTGCGGT TGTTATTGTC 60 ATTAGCGCTG TTATGGGCGT TATTATCAGC TACAAGGTTG AAAGCGTGTT GCAAAGCCAA 120 GCCACAGAAT TGCTGCAAAA AAAAGCTCAG TTAGTCAGTT TTAAAATTCA AGGCATTATG 180 AAGCGCATTT TTATGGGCGC TAACACCCTT GAAAGGTTTT TAAGCGATGA AAATGGCGCT 240 ATTAATGACA CCCTAAAAAG ACGCATGCTC TCTGAGTTTT TGTTAGCAAA CCCTCATGTG 300 TTATTGGTTA GCGCGATTTA TACGAATAAT AATGAACGAA TGATCACTGC AATGAACATG 360 GATTCAAAAA TCGCCTACCC TAATACCGCA CTCAATGAAA ACATGACCMA CCCAATCCAT 420 TCGCTCAAAA GTATAACCCG TTCARATCCC TATTATAAAG AGGTTAATGM CRATAAAATC 480 TATRRCATRR ACATTACCCT CCCCCTAATR RRCAARAATY AAAATRTTAT ARRCRCWCTW 540 AATTTCKTTT TAAACATTGA CWGCTTTTTA TACTGM 576

(2) INFORMATION FOR SEQ ID NO: 91:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 762 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

In) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

( vi ) ORIGINAL SOURCE :

( A ) ORGANI SM : Hel icobac ter pylori

(ix) FEATURE-

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...762

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91

ATGGCATACA AATATGATAG AGACTTGGAA TTTTTAAAGC AACTGGAATC TAGTGATTTA 60

TTGGATTTGT TCGAGGTGCT TGTTTTTGGT AAAGACGGCG AAAAAAGACA CAATGAAAAA 120

CTCACAAGCT CCATAGAATA CAAAAGGCAT GGCGATGATT ACGCTAAATA CGCAGAAAGA 180

ATCGCTGAAG AGTTGCAATA CTATGGGAGC AATAGTTTTG CGAGTTTCAT TAAAGGTGAA 240

GGAGTCTTAT ACAAAGAGAT TTTATGCGAT GTGTGCGATA AATTAAAGGT CAATTACAAC 300

AAGAAAACTG AAACGACTTT AATTGAACAA AACATGCTTT CTAAAATCTT AGAAAGAAGC 360

CTAGAAGAAA TGGATGATGA AGAAGTGAAA GAAATGTGCG ATGAATTGTC CATAAAAAAC 420

ACGGACAATT TGAACAGACA AGCCTTAAGC GCGGCGACTT TAACGCTGTT TAAAATGGGA 480

GGCTTTAAAT CTTATCAATT AGCTGTCATT GTTGCGAATG CGGTTGCAAA AACCATTCTA 540

GGGCGTGGTT TATCGCTTGC GGGCAATCAA GTGCTTACAA GAACTCTGAG CTTTTTAACA 600

GGCCCTGTTG GCTGGATCAT TACAGGCGTA TGGACAGCGA TTGATATTGC AGGGCCGGCT 660

TATAGGGTAA CCATACCGGC ATGCATTGTG GTCGCCACTT TACGCCTAAA AACGCAACAA 720

GCCAATGAAG ATAAGAAGTC GTTGCAAATA GAATCCGTTT AA 762

(2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 882 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...882

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92

TTGTTGCTTT TTATCGTTGT GATCACCTCT TTGGTTAAAA ACACGATCCC AAATATTTGG 60 CTCACTAAAA TCCTTTATAT GGCTATCTTG CTTTGCGCGA TCGCTCATTC TGTGGGGCYA 120 ATCTTGCGYT GGTATGTGAG TGGGCATTCG CCTTGGAGTA ACGCTTATGA GTCCATGTTC 180 TATATCGCAT GGGCTTCTGT TATCGCAGGG TTTGTTTTAC GAMCTAAACT CGCGCTATCG 240 GCTTCTAGCT TTTTGGCCGG TATCGCGCTC TTTGTGGCTC ATTTAGGCTT TATGGACCCT 300 CAAATTGGCC CTTTAGTGCC GGTGTTAAAA TCCTATTGGC TCAATATCCA TGTCTCTGTC 360 ATCACCGCTA GTTATGGCTT TTTGGGCTTG TGTTTTGTGC TAGGGATTTT AAGTTTGGTT 420 TTGTTTATTT TGCGCAAACA AGGGCGTTTC AATTTAGACA AAACCATTCT TTCCATTAGC 480 GCTATCAATG AAATGAGCAT GATTTTAGGC CTGTTCATGC TCACAGCCGG GAATTTCTTA 540 GGTGGGGTGT GGGCGAATGA ATCTTGGGGG CGCTATTGGG GGTGGGACCC TAAAGAAACT 600 TGGGCGTTGA TTTCTATTTG CGTCTATGCC TTGATCTTGC ATTTGCGTTT TTTAGGCTCT 660 CAAAATTGGC CCTTTATTTT AGCGAGCAGC AGCGTGCTAG GGTTTTATTC GGTTTTAATG 720 ACTTTATTTT GGCGTGAATT ACTACCTTTC TGGCTTGCAC AGCTATGCCG CAGGKSATCS 780 TTTGCCGATC CCTACTTTTT TATACTTTTT GGTAGCGATA CCTTTCGCTC TCGTATCTTG 840 GCGTATTTCA AACGTCATTT GAGTTTGCCT AAATTGGTTT AA 882

(2) INFORMATION FOR SEQ ID NO: 3:

(l) SEQUENCE CHARACTERISTICS-

(A) LENGTH: 429 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(VI) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 ..429

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93

GTGGAAATGA TCCACACGCA AGATTACATT AAAATGGAAG AAGCCGCCAC TGAGGCGATT 60 AAGCGTAAGG AATCTTCCAT TTACTTGGGC ATGGATATTT TAAAAAATGG GGCTGACGCT 120 TTGATTTCAG CGGGGCATAG CGGGGCGACT ATGGGTTTAG CGACCTTGCG TTTAGGGCGT 180 ATCAAGGGGG TTGAAAGGCC TGCTATTTGC ACTTTAATGC CTAGCGTTGG CAAACGCCCT 240 AGCGTGCTAT TAGACGCAGG AGCGAACACG GATTGCAAGC CTGAATATTT GATTGATTTT 300 GCTCTCATGG GGTATGAATA CGCTAAAAGC GTGTTGCATT ATGACAGCCC TAAAGTGGGT 360 CTTTTGAGTA ATGGTGAAGA AGATATTAAG GGGGGAATAC GCTCGTTAAA GAAACGCATA 420 AAATGTTGA 429

(2) INFORMATION FOR SEQ ID NO: 4:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 433 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE. DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...433

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94 ATGCTAGAAA TCAAGAATTT AAACTGCGTT TTAAACTCTC ATTTTTCGCT CCAAAACATC 60 AATATTTCTT TAAGTTATAG TGAAAGGGTG GCGATCGTGG GCGAAAGCGG GAGCGGGAAA 120

AGCTCTATCG CTAATCTCGT CATGCGATTA AACCCTAGAT TCAAGTCCCA TAATGGCGAA 180

ATCCTGTTTG AAACAACCAA TCTTTTAAAG GAAAGCGAAG CGTTYMTGCA GCATTTAAGG 240

GGGAATATTA TCGCTTACAT CGCCCAAGAC CCCCTATCCA GCCTCAACCC CTTGCATAAA 300

ATCGGCAAGC AAATGAGTGA AGCCTATTTT TTACACCATA AAAACGCTTC TCAAGTGTCT 360

CTTAATGAAC AAGTTTTAAA CGTTATGAAA CAAGTTCAAT TGGATGAAAA TTTTTGGAAT 420

GTTTCTCTTA TGT 433

(2) INFORMATION FOR SEQ ID NO: 95-

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 252 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...252

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95

ATGAACTACA AAGTTGCATC TGCTAGAAAT ATCGCAACGC TTCTTTTCTT ATTCTTTTCT 60

CAAAGTGAAG CTTTTGATTT GGGTAAAATC GCTAAAATCA AAGCGGGTGC TGAAAGTTTC 120

TCTAAAGTCG GTTTCAATAA CAAACCTATC AACAMTAATA AAGGGATTTA CCCTACCGAA 180

ACCTTTATGA CGATTAATGG CTTACATGCA GGTGGATTTT ACGGAGCTCT TGCCCAAAAG 240

CGCTACGGCT AA 252

(2) INFORMATION FOR SEQ ID NO: 96:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 393 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...393

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96

ATGGACGCTT TAGAAATCAC CCAAAAACTC ATCAGTTACC CTACCATTAC GCCCAAAGAA 60

TGCGGTATTT TTGAATACAT TAAATCGCTT TTTCCTGCTT TTAAAACCCT AGAATGTGAA 120

AAAAATGGCG TGAAAAACCT TTTTTTATAC CGCATTTTTA ACCCCCTCAA AAAGCATGCA 180

GAAAAAGAAC ATGCAAAAGA AAAGCATGTR AAAGAAAATG TTAWGCCCTT GCATTTTTGC 240

TTKGCAGGGC ATATTGRTGT CGTGCCTCCT GGGRRCAWTK GGCRRRSKGA TTCCTTTWWA 300

YCCATCATTA AAGAGGGGTT TTTATACGGT CGTGGGGCGC AAGACATGAA GGGGGGCGTT 360

GGGSSGTTTT TKAGGTGCRR GTTWAAATTT TAA 393

(2) INFORMATION FOR SEQ ID NO: 97: (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1023 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...1023

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7

ATGATTTTAA GCATTGAAAG TTCTTGCGAT GACAGCTCTT TAGCCCTTAC AAGAATAGAG 60

GACGCCAAGC TCATCGCTCA TTTTAAAATC TCTCAAGAAA AGCACCACAG CTCTTATGGG 120

GGCGTTGTGC CTGAGATTGC ATCGCGCCTG CATGCTGAGA ATTTGCCGCT TTTATTAGAA 180

CGCGTTAAAA TAAGCTTGAA TAAGGATTTT TCCAAAATTA AAGCCATCGC TATCACTAAT 240

CAGCCAGGTT TGAGCGTTAC TTTAATAGAG GGTTTGATGA TGGCAAAAGC CTTGAGCTTG 300

TCTTTGAATT TACCCTTGAT TTTGGAAGAT CATTTGAGAG GGCATGTGTA TTCGCTCTTT 360

ATCAATGAAA AACAAACCCG CATGCCTTTA AGCGTGCTGC TAGTCTCTGG GGGGCATTCT 420

TTAATTTTAG AGGCTAGAGA TTATGAAGAC AT AAAATCG TTGCCACGAG TTTAGACGAT 480

AGCTTTGGGG AGAGTTTTGA TAAGGTTTCA AAAATGCTTG ATTTAGGCTA TCCAGGAGGC 540

CCCATAGTGG AAAAATTAGC CCTTGATTAT GCACACCCAA ACGAGCCTTT AATGTTCCCT 600

ATCCCTTTAA AAAACAGCCC GAATTTGGCT TTTAGTTTTT CAGGTTTAAA AAATGCGGTG 660

CGTTTGGAGG TTGAAAAAAA CGCCCATAAT TTGAACGATG AGGTAAAACA AAAGATTGGC 720

TATCATTTTC AAAGCGCGGC TATCGAGCAT TTAATCCAGC AGACTAAACG CTATTTTAAA 780

ATCAAACGCC CTAAAATTTT TGGCATTGTG GGGGGAGCGA GCCAAAATCT AGCCTTAAGA 840

AAGGCGTTTG AGGATTTGTG TGCTGAGTTT GATTGCGAGC TTGTTTTAGC CCCTTTAGAA 900

TTTTGCAGCG ACAATGCCGC CATGATAGGG CGATCAAGCC TAGAAGCTTA TCAAAAAAAG 960

CGCTTTATCC CTTTAGAAAA AGCCGATATT TCGCCAAGAA CGCTGTTAAA AAATTTTGAG 1020

TGA 1023

(2) INFORMATION FOR SEQ ID NO: 98:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 507 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...507

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8

ATGTTATCTT CTAATGATTT GTTTATGGTC GTTTTAGGGG CGATTTTATT GGTGTTGGTG 60

TGCTTGGTGG GGTATTTGTA TCTTAAAGAA AAAGAGTTTT ACCATAAAAT GAGGCGTTTA 120

GAAAAAACTT TAGATGAATC CTATCAAGAA AATTATCTCT ATTCTAAGCG TTTGAGAGAA 180

TTAGAGGGGC GTTTGGAAGG CCTTTCTTTA GAAAAAAGCG CTAAAGAGGA CAGCTCATTA 240

AAAACGACTC TTTCGCACCT TTATAACCAG TTGCAAGAAA TCCAAAAATC CATGGATAAA 300 GAGCGCGATT ACTTAGAAGA AAAAATCATT MYTTRGAAAA CAAWTTTWAA GACATGGGGC 360

ATTATGCCGC TAGCGATGAA GTCAACGGAA AAACAGGTTT TGAAAATGTA TCAAGAAGGC 420

TATAGCGTGG ATTCTATTTC TAAAGAATTT AAAGTGAGTA AGGGCGAGGT GGAATTTATA 480 TTGAACATGG CAGGGTTAAA ATGGTAG 507

(2) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERISTICS-

(A) LENGTH: 366 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

( i) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...366

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99

TTGGATCCCT TTAGCCATAA GGAGAATTTT TTAGCCGTTG AAACCTTTAA AATGCTAGGC 60 AAAACAGAAA GTAAAGACAA TCTTAATTGG ATGATCGCTT TGATCATTGA AAAAGACAAG 120 GTCTATGAGC AAGTGGGATC GGTGCGTTTT GTGGTGGTTG TAGCGAGTGC TATCATGGTG 180 TTAGCCTTAA TCATAGCGAT CACTCTTTTA ATGCGAGCGA TCGTGAGCAA TCGTTTGGAA 240 GTCGTTTCTA GCACCTTGTC TCATTTCTTT AAATTATTGA ACAATCAAKC CCATTCTAGC 300 RACAYTAAAT TGGTTRAAGC GCGATCTAAT GACGAATTAG GGCGCAYGCA AACASCTGAT 360 YAATAA 366

(2) INFORMATION FOR SEQ ID NO: 100:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 450 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...450

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100

ATGGAATTTT ATCAAGTCTA TGACCCATTA GGCCATATTT GGCTGAGCGC TTTAGTCGCA 60

CTTTCGCCTA TTGCGCTCTT TTTTATCTCT CTTATTGTCT TTAAACTTAA AGGGTATAGC 120

GCTGGGTTTT TAAGCTTAGC GCTTTCAATC CTTATTGCGT TATTTGTGTA TAAAATGCCT 180

GTTCAAATGG TGAGCGCGAG TTTTTTCTAT GGCTTTCTTT ATGGCTTGTG GCCGATCGCA 240

TGGATTGTGA TCGCTGCGAT TTTTCTTTAC AACCTTTCAG TGAAGTCCGG GTATTTTGAG 300

ATTTTAAAAG AAAGCATTTT AAGCTTGACG CCGGATCATC GCATTTTAGT GATTTTGATC 360

GGGTTTTGTT TTGGCTCGTT TTTAGMMGGC GCGRTTGGTT TTGGAGGCCC GGTAGCRATC 420 ACAGCGGCGA TTTTAGTGGC CTTGGGCTAA 450

(2) INFORMATION FOR SEQ ID NO: 101. (l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 978 base pairs

(B) TYPE- nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(πl MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...978

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101

ATGAAAAGAA TTTTAGTTTC TTTGGCTGTT TTGAGTCATA GCGCGCATGC TGTCAAAACT 60

CATAATTTGG AAAGGGTGGA AGCTTCAGGG GTGGCTAACG ATAAAGAAGC GCCTTTAAGC 120

TGGAGGAGCA AGGAAGTTAG AAATTATATG GGTTCTCGCA CGGTGATTTC TAACAAGCAA 180

CTCACTAAAA GCGCCAATCA AAGCATTGAA GAAGCTTTGC AAAATGTGCC AGGCGTGCAT 240

ATTAGAAACT CTACCGGTAT TGGAGCTGTG CCTAGCATTT CCATTAGGGG GTTTGGTGCT 300

GGAGGCCCAG GGCATTCTAA TACGGGAATG ATTCTAGTCA ATGGGATTCC TATTTATGTC 360

GCGCCCTATG TTGAAATTGG CACGGTTATT TTTCCTGTAA CCTTTCAGTC TGTGGATAGA 420

ATCAGCGTAA CTAAGGGTGG GGAGAGCGTG CGTTATGGCC CTAACGCTTT TGGCGGTGTG 480

ATCAACATCA TCACCAAAGG CATTCCTACC AATTGGGAAA GTCAGGTGAG CGAGAGGACC 540

ACTTTTTGGG GCAAGTCTGA AAACGGGGGC TTTTTCAATC AAAATTCTAA AAACATTGAT 600

AAAAGCTTAG TTAATAACAT GCTTTTTAAC ACCTATTTAA GAACGGGGGG TATGATGAAT 660

AAGCATTTTG GAATCCAAGC TCAAGTCAAT TGGCTCAAAG GGCAAGGGTT TAGATACAAC 720

AGCCCTACGG ATATTCAAAA TTACATGTTA GATTCATTGT ATCAAATCAA TGATAGCAAT 780

AAAATCACCG CTTTTTTTCA ATATTATAGT TATTTCTTGA CAGACCCTGG ATCTTTAGGC 840

ATAGCCGCTT ACAATCAAAA TCGTTTTCAA AACAACCGCC CCAATAACGA TAAAAGCGGG 900

AGAGCGAAGC GATGGGGAGC TGTGTATCAA AACTTTTTTG GGGACACGGA TAGGGTAGGG 960

GGGGGATTTC ACTTTTAG 978

(2) INFORMATION FOR SEQ ID NO: 102:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH. 759 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_ eature

(B) LOCATION 1...759

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102

TTGCGTTCAA TTTCAAGGAT AAAGATGCTT TCAGTGTATG AAAAAGGGAA TGCCCTAGAC 60 AAAAGGGTGC TTGAAGAATG GCTTTTAAGC GAAGACATTT TAATGGAAAA CGCCGCTATG 120 GCTTTAGAAA GGGCGGTTTT ACAAAACGCT TCTTTGGGCG CTAAGGTCAT TATTCTTTGT 180 GGGAGTGGGG ATAATGGAGG TGATGGCTAT ACTCTAGCCA GGCGTTTAGT GGGGCGTTTT 240 AAAACGCTGG TCTTTGAAAT GAAATTAGCA AAAAGCCCCA TGTGCCAATT GCAAAAAGAA 300 AGGGCTAAAA AAGTAGGGGT AGTCATCAAA GCATGGGAAG AAAAGAATGA AGATTTAGAA 360 TGCGATGTGT TAGTAGATTG CGTGGTAGGG AGCGCTTTTA AGGGCGGATT AGAGCCGTTT 420

TTAGATTTTG AAAGCCTTTC TCAAAAAGCA CGCTTTAAAA TCGCTTGCGA CATTCCTAGC 480

GGGATAGATT CTAAAGGCAG GGTGGATAAG AGGGCGTTTA ARGSCGGATA CCGACTATCA 540

GCATGGGCGC TATTCAAGTC ATGCTTACTA AGCRATAARR CTAAARACTA TATARRRRAA 600

TTGAAARTRR RRCATTTARR RGTTTTTAAT CAAATTTATG AGATCCCAAC ARACACTTTT 660

TTACTMGAAA AAARCGATTT GAARCTGCCC TTAAGGGATA GAAAGAAACG CTCACAAAGG 720 CGATTACGGG CATGCGCATG TGCTTTTGGG CAAGCATAG 759

(2) INFORMATION FOR SEQ ID NO: 103.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 417 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...417

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103

ATGGCATTAG ACAAAAGGAT TTGGATGCAY TTTGATCTTT TGCCTTTTGT GTTTATCATC 60 CCCTTGTTGG TGGTTTCTTT TTTGTTGATT TTTGAGAGTA GTGCGGTTTT GAGCTTGAAG 120 CAAGGGGTTT ATTATGCCAT AGGGTTTCTT CTCTTTTGGG TAGTGTTTTT TATCCCTTTC 180 AGGAAACTCG ATCGGTGGCT CTTTGCGCTT TATTGGGCGT GCGTTATTTT ATTAGCGTTA 240 GTGGATTTTA TGGGATCGAG CAAGCTTGGA GCGCAGCGAT GGCTAGTCAT TCCTTTCACT 300 TCTATCACCT TACAGCCTAG CGAGCCTGTG AAAAATCGCY ATTCYTTTAT TGTTGGCGCA 360 TTTGAKYAAA ATYAACCCGA CCYCCTTTTA AGGGCTATGA TTGGGGCATG TTTTTAA 417

(2) INFORMATION FOR SEQ ID NO: 104:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 981 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...981

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104

GTGTTAATGG CGTTGARCGA TAAACGCTAC GGCTTAGAAG CAGGGATCAA GTATTTCACC 60 ATGGGGGCGA TGGCGAGCGC GTTTTTTGCT ATGGGCGCGA TGGCTTTTTA CCTGCTTACA 120 GGGAGCTTGA ATCTTGAAGT CATTACCCTA TACTTACACA CTGAGGGCAT CACAAACCCC 180 ATGCTCTTTG CGATGGGCAC TATTTTTTTG ATTGGAGCGA TTGGCTTTAA GGTTTCTTTA 240 GTGCCTTTCC ATACCTGGAT GCCTGATGTG TATGAGGGYA ATAACCCAGT CTTTGCGAGC 300 TATATTTCCA TTGTGCCTAA AATCGCTGGC TTTGTGGTAG CGACTCGCCT TTTTGGGGCG 360 TTTATAGACA CTCATACCGC TTGGGTAGAA GACATTTTTT ATGTTTTGAT CCTTATGACT 420 ATCACCATCC CTAATTTCAT TGCTTTATGG CAAGAAGATG TCAAAAGGAT GCTCGCTTAT 480

AGTTCTATTT CGCATTCTGG GTTCGCTTTA GCGTGCGTGT TTATCCACAC TGAAGATAGC 540

CAACAAGCGA TGTTTGTTTA TTGGTTCATG TTTGCCTTCA CTTACATTGG GGCTTTTGGC 600

CTTTTATGGC TCTTAAAAAG CCGGGAAAAA ACATGGGATG AACGCTACGA TCACCCCTAT 660

TCTAAATTCA ACGGCCTTAT CAAAACCCAC CCCTTAGTGG CGATCTTGGG CGCTATTTTT 720

GTTTTTGGGC TTGCAGGGAT CCCGCCTTTT AGCGTGTTTT GGGGGAAATT TTTAGCCGTT 780

GAAAGCGCGT TAGAGAGCAA TCACATTCTT TTAGCGGTGG TGATGTTAGT TAATAGCGCG 840

GTGGCTGCGT TTTATTATTT CCGTTGGCTC GTGGCGATGT TTTTCAATAA GCCCTTACAA 900

ACCCAAAGCT ACGCCAAAAC GATATTTACA CCCAAAACGC CACCATGCCC ATTTATGCGG 960

TCATTATTGC CATGGCGTTA G 981

(2) INFORMATION FOR SEQ ID NO: 105:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 723 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE. DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE. NO

(vi) ORIGINAL SOURCE

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY- mιsc_feature

(B) LOCATION 1...723

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.105

ATGATAAACT CAAAGAAAAG CTTGAAAAAG GGCTTAAGGG GCTTTTTTAA AATTTTAAAG 60 GACAGAAATG GCGCACATTT TAGTTGCGGA GCGACTTCAG GGTTTGGGCT AGAAATCGCT 120 AAGGCGTTTT TACAAAAAAA CCATGTGGTT TTTGGCACAG GGAGGCGGCA AGAGAATTTA 180 CAAAAATTGC AGCTCGCTTA CCCTAAGCGT TTCATTCCCC TGTGTTTTGA TCTTCAAAAC 240 AAGCCTGAAA CTAAGCGAGC GATAGAAACT ATTTTTTCCA TGACGGATCG CATTGACGCT 300 TTAATCAATA ACGCCGGCTT AGCGCTAGGC TTGAACAAGG CTTATGAATG CGAGTTAGAC 360 GACTGGGAAG TCATGATAGA CACGAATATC AAGGGGTTGT TGCATCTCAC CCGCTTGATC 420 TTGCCCTCTA TGATAGAGCA TGACCAAGGG ACTATCATCA ATCTTGGTTC TATCGCTGGC 480 ACTTACGCCT ATCCTGGAGG GAAKGTCTAT GGAGCGAGCA AGGCGTTKGT GAAACAAYYY 540 TCTYYAAATT TGCGAGCGGA CGTGGCTGGC ACTAACACTA GAGGGAGAAG GTGGAACCCG 600 GGGTGTGTGG CGAAACCGAA AGTCAGCAGG GTGCGGGGTA AAGGCGATAA ACCAAAGCCC 660 AAATCCGGCT ATGAAAAACA CCCCTTACCC CAAACCACAA GACAAGGGCT AACATCGGGC 720 TAG 723

(2) INFORMATION FOR SEQ ID NO: 106:

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH. 615 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...615 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106

GTGAGCGGGG TGGTGTTAAG CAAATTTGAT AGCGATTCTA AAGGGGGTAT CGCCTTAGGC 60

ATCACTTATC AATTGGGCTT ACCCTTGCGT TTTATTGGGA GTGGGGAAAA AATCCCTGAT 120

TTAGACGTGT TTATGCCTGA AAGGATTGTG GGGCGTTTGA TGGGGGCTGG AGATATTATC 180

TCGCTCGCTG AAAAAACCGC CAGCGTTTTA AACCCTAATG AAGCCAAAGA TTTAAGCAAA 240

AAGCTCAAAA AAGGGCAATT CACTTTCAAC GATTTTTTAA ACCAAATTGA AAAAGTGAAA 300

AAATTAGGCT CTATGAGTTC TCTRATCTCT ATGATTCCAG GTTTAGGGAA TATGGCAAGC 360

GCGCTAAAAG ACACGGATTT AGAAAGTTCT TTAGAAGTGA AAAAAATCAA GGCCATGGTT 420

AATTCCATGA CGAAAAAAGA GCGAGAAAAC CCCGAGATTT TAAACGGCAG CCGAAGAAAA 480

AGGATCGCTT TAGGGARCGG CTTAGAAGYG YCTGAAATCA ATCGCATCAT CAAACGCTTT 540

GATCAGGCGA GCAAAATGGC GAAACGACTC ACGAATAAAA AGGGTATTAG CGATYTGATG 600

AATCTAWCGA KCTAG 615

(2) INFORMATION FOR SEQ ID NO: 107:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 279 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(IV) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...279

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107

GTGGAAAAAG CCCATCCGGA TGTGTTTAAC CTCTTGTTAC AGGTTTTAGA TGAGGGGCAT 60

TTAACCGATA GTAAGGGCGT GAGGGTGGAT TTCAAAAACA CGATTTTGAT TTTAACCAGC 120

AATGTGGCTA GCGGCGCGCT TTTAGAAGAG GATTTGAGTG AAGCCGATAA ACAAAAAGCG 180

ATCAAAGAGA GCCTGAGACA ATTCTTCAAG CCGGAATTTT TAAACCGCTT AGATGAAATC 240

ATCTCCTTTA ACGCCCTAGA TAGTCATGCT ATCATCTAA 279

(2) INFORMATION FOR SEQ ID NO: 108:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 246 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

111) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...246

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108

TTGGTGTTTT TAGACAGGCG TTTGATTGTG ATGGTTACGG ACTCTAAAGG GAGTCGTTAT 60 ATTAATGTGC ATATCTTATT CCGCCAAATC AGTTTGTATG CGCTGTTGAG CGTTGTGGGA 120 TCTTTATTGT TTTTAGGCGT TTCATTACTG GTTTTAAATA AAGAAATTAA AAACATTGAA 180 _AAACAGCATG CTTTAMTCAC TAAGGAATTT GAGAAAAAAA GAGAGACGAA TGAAMAGCTT 240 TCTTYG 246

(2) INFORMATION FOR SEQ ID NO:109.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH 702 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY, circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...702

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109

TTGAGTTTGA TGASTGTGTT AAATGCCAAA GAATGCGTTY CGCCCATAAC AAGAAGCGTT 60

AAGTATCATC AGCAAAGTGC SGAGATCAGA GCCTTGCAAT TACAAAGTTA CAAAATGGCG 120

AAAATGGCGC TAGACAATAA CCTTAAGCTC GTTAAAGACA AAAAGCCAGC CGTCATCTTG 180

GATTTAGATG AAACCGTTTT GAACACTTTT GATTATGCGG GCTATTTAGT CAAAAACTGC 240

ATTAAATACA CCCCAGAAAC TTGGGATAAA TTTGAAAAAG AAGGCTCTCT TACGCTCATT 300

CCTGGAGCGC TAGACTTTTT AGAATACGCT AATTCTAAGG GCGTTAAGAT TTTTTACATT 360

TCTAACCGCA CCCAAAAAAA TAAGGCATTC ACTTTAAAAA CGCTCAAAAG CTTTAAGCTC 420

CCCCAAGTGA GTGAAGAATC CGTTTTGTTA AAGGAAAAAG GCAAGCCTAA AGCCGTTAGG 480

CGGGAGTTAG TCGCTAAGGA TTATGCGATT GTTTTACAAG TGGGCGACAC TTTGCATGAT 540

TTTGACGCCA TTTTTGCTAA AGACGCTAAA AACAGCCAAG AACAACAAGC CAAAGTCTTG 600

CAAAACGCTC AAAAATTCGG CACAGAATGG ATCATTTTAC CCAACTCTCT TTATGGCACA 660

TGGGAAGATG GGCCTATAAA AGCATGGCAA AATAAAAAAT AA 702

(2) INFORMATION FOR SEQ ID NO:110:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 258 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...258

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110

ATGTTGGCGG CTGGTTTGAC TTTGCCTGAA TTTGGGTGTT ATTTAAGCCA TTATCTTTTA 60

TGGAAAGAAT GCGTCAAATT AGATCAACCG GTCGTTATTT TAGAAGATGA TGTAACGCTA 120

GARTCTCATT TCATGCAAGC CTTAGAAGAT TGTTTGAAAA GCCCTTTTGA TTTTGTGAGA 180

CTCTATGGGT GTTATTGGTA TTACCAACGA GACAAAATTC CATGTTTTGC CCAAAGAATT 240

TGTATTTCCT CCCTTTGA 258

(2) INFORMATION FOR SEQ ID NO: 111: (l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 348 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...348

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111

TTGATCGCTT TGAGAGTAAC GGCTTGGAAR GTGGYGGCCA TGAAACGCTT GCATTTGAGC 60 GTGAAAGACG CTGAAAACTT TGATGCGATC CTCAGAGAGA GACCCTTTTT TAAAGATTTG 120 ATAGAGTTTA TGGTGAGTGG TCCGGTGGTG GTTATGGTTT TAGAAGGCAA AGATGCGGTG 180 GCTAAAAACA GAGAGCTTAT GGGAGCGACT GATCCCAAAC TCGCCCAAAA AGGTACTATC 240 AGAGCGGATT TTGCTGAGAG CATTGACGCT AATGCGGTGC ATGGGAGCGA TAGCTTGGAA 300 AACGCGCACA ATGAAATCGC TTTCTTTTTT GCCGCTAGAG AGTTTTAA 348

(2) INFORMATION FOR SEQ ID NO: 112:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1185 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_f eature

(B) LOCATION 1...1185

(xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 112

TTGATGTGGC TCAAAACGCT TACACTTCAA ACGCTCAATA CCGACAAAGC CTTGCAAGAA 60

TTTTCTAAAA CGATGGAGGC GTTTAAAACC AAACTCATCC AATCCGCTAA CGATGTGCAT 120

TCAGAGACTT CTCGCGCCGC TATCGCTAAC GATTTAGAAC GCTTAAAAGA GCATATGATA 180

AATGTCGCTA ATACCTCCAT AGGGGGGGAA TTTTTATTTG GAGGCAGTAA GGTGGATAGA 240

CCCCCCATTG ATAGTAATGG GAAATACCAT GGCAATGGCG AAGATTTAAA CGCGCTTATT 300

AGCTCTGATA ACCTTGTGCC TTATAATATC AGCGGGCAAG ATTTGTTTTT AGGCACCGAT 360

AAAGACAAAC ACAAACTCAT TACCACCAAC ATTAAATTAC TCAATCAAAA CAAGCTCCAM 420

CCTGATGTGA TGGACGCTTT AGAGCATTCT TCATTGCCTG AAGAAGTTTT CATTAAACCC 480

AGCGATACCT TGCGAGAACT CATCGGCGAT AACGATAAAA ACCCCACCAA TGACCCTAAA 540

GAGTTTTTTT ATTTGCAAGG CATTAGGCCT GATGGCTCTA GTTTTAAAGA AAAATTCGCG 600

TTGGATAAAG CCTATCAAAA CCAAGAAAGC GCGACTAAAG TGAGCGATTT GTTGGATAAA 660

ATCGGGCATG CTTACGGGAA CACTTCGCAA AATAAAGTCG TGGATGTGAG TTTGAACAAT 720

TGGGGGCAAA TTGAGATTAA AAACCTAACC CCCGGCAGTG AAAATTTGGA TTTTCATTTG 780

ATTTCTAGCG ATGGGGATTT TGACGATTTA GACGCCTTGC GTTCGAGCGG TAAAAGGGTT 840

ACTGAATATG TCAAAAGCGC GTTTGTAACG GATAGGAGTT TGAGCCAAGT TAAAGCGGTG 900

CCTAACATGT ATAACCCTAA AGTGCTTGAA ATCCCTAGCG TGTTTGTGAC TAAAGACAAT 960

GTTTTAGCTA ACAAAAACAC CAAGTTGAGC GAGATTTTTG GMGATAAGGT GGAAACTTTA 1020 AAAATCAACG CCAGCCGTTT GGGCGATGAA AGCGCTATTA AAATCCCAAA CCTCCCTATT 1080 AATTTGGATA TTCCCATTCT TTTAGATGTG AAAAACTCTA CGATTAAAGA TTTGAAAGAC 1140 GCGATTAAAG AACGCTTCAA TAATGAAGGT GGATGTGGAA ATTGA 1185

(2) INFORMATION FOR SEQ ID NO: 113:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY circular

(ii) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(IV) ANTI-SENSE- NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 .309

(xi) SEQUENCE DESCRIPTION SEQ ID NO: 113

TTGAAGGCAT TAAACGACTG CATGGTATTT TTTCATAAGA AAATTATTTT AAATTTTATC 60

TATTCTTTAA TGGTTGCTTT TTTATTCCAT TTATCCTATG GGGTTCTTTT AAAAGCCGAT 120

GGAATGGCTA AAAAGCAAAC TCTTTTAGTG GGTGAAAGGC TTGTGTGGGA TAAGCTCACG 180

CTGTTAGGGT TTTTAGAAAA AAACCATATC CCCCAAAAAC TCTACTACAA TTTGAGCTCT 240

CAAGATAAAG AATTGAGTGC TGAAATCCAA AGCAATGTTA CCTACTACMA CTTTAAGAGA 300

TGCAAATAA 309

(2) INFORMATION FOR SEQ ID NO: 114:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1092 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE. DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...1092

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114

ATGAAATTTT TTCTTTTAAA GAAATTCAGC RAATTTTTAA ACACTCAAAC GCATTTTAAC 60

CTCAAACGCT TGAACGCGTC TAGTTTTTTA TTAGAGACTT TTTCTAAAGA AAAACACGCC 120

TTTGTTGTGG ATTTGAGCGC GCCTTATATT GGTTTGTCCA AAAAACCCCC AGAGAGCGTT 180

TTAAAAAACA CTTTAGCGTT AGATTTTTGT TTGAATAAAT TCACCAAAAA CGCCAAAATT 240

TTACAAGCAA ACGTCATTGA TAACGATCGG ATTTTAGAAA TCAAGGGCGC TAAAGATTTA 300

GCTTATAAGA GTGAAACTTT TATTTTGCGT TTAGAAATGA TCCCTAAAAA AGCCAATCTC 360

ATGATTTTAG ATCAAGAAAA ATGCGTGATA GAGGCTTTTC GTTTTAATGA CAGGGTGGCT 420

AAAAACGATA TTTTAGGGGC ATTGCCTCCT AATATTTACG AGCATCAAGA AGAGGATTTG 480

GATTTTAAGG GATTGTTGGA CATTTTAGAA AAAGATTTTT TATCCTATCA GCACAAAGAA 540

TTGGAACACA AAAAAAATCA AATCATCAAG CGATTAAACG CCCAAAAAGA ACGCTTGAAA 600

GAAAAATTAG AAAAACTAGA AGATCCTAAA ACTTTACAGC TGGAAGCGAA AGAATTGCAA 660

ACTCAAGCCT CATTGTTGCT CACTTACCAG CATTTAATCA ACAGGCGTGA AAATCGCGTG 720 ATTTTAAAGG ATTTTGAAGA TAAAGAATGC ATGATTGAAA TTGATAAGAG CATGCCCTTA 780

AACGCTTTTA TCAATAAAAA ATTCACTCTC AGCAAGAAAA AGAAACAAAA ATCGCAATTC 840

TTGTATTTAG AAGAAGAGAA TCTGAAAGAA AAAATCGCTT TTAAGGAAAA TCAAATCAAC 900

TATGTTAGAG ACGCTGCAGA AGAAAGCGTT TTAGAAATGT TTATGCCGGT AAAAAACTCT 960

AAAATCAAAC GCCCGATGAA CGGGTATGAA GTGCTGTATT ATAAGGATTT WAAAWCGGGT 1020

TTRGGAAAAA CCAAAAAGAG AATATCAAGC TTTTACAAGA CGCAARARCG AATGATTTKT 1080

GGATGCAYKT GA 1092

(2) INFORMATION FOR SEQ ID NO: 115:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 172 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...172

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115

Met Lys Gly Pro Ile Leu Trp Pro Ala Phe Ser Gin Phe Ser Asp Gin

1 5 10 15

Asp Leu Ser Asp Ile Val Ala Tyr Leu Thr Ser Ile Leu Pro Lys Asn

20 25 30

Leu Ser Asp Lys Glu Val Phe Ala Gin Ser Cys Gin Arg Cys His Ser

35 40 45

Leu Asp Tyr Ala Lys Asp Lys Ala Phe Ser Asp Pro Lys Asp Leu Ala

50 55 60

Asn Tyr Leu Gly Ser His Ala Pro Asp Leu Ser Met Met Ile Arg Ala 65 70 75 80

Lys Gly Glu His Gly Leu Asn Val Phe lie Asn Asp Pro Gin Lys Leu

85 90 95

Leu Pro Gly Thr Ala Met Pro Arg Val Gly Leu Asn Glu Lys Ala Gin

100 105 110

Lys Gin Val Ile Ser Tyr Leu Glu Lys Ala Gly Asp Arg Lys Lys His

115 120 125

Glu Arg Asn Thr Leu Gly Ile Lys Ile Met lie Phe Phe Ala Val Leu

130 135 140

Ser Phe Leu Ala Tyr Ala Gly Lys Glu Lys Phe Gly Ala Lys Cys Ile 145 150 155 160

Lys Phe Lys Lys Gly Gly Thr Trp Phe Tyr Asp Phe 165 170

(2) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 61 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(lil) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...61 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116

Met Gin Glu Phe Ser Leu Trp Cys Asp Phe Ile Glu Arg Asp Phe Leu

1 5 10 15

Glu Asn Asp Phe Leu Lys Leu Ile Asn Lys Gly Ala lie Cys Gly Xaa

20 25 30

Thr Ser Asn Pro Ser Leu Phe Cys Glu Ala Ile Thr Lys Ser Ala Phe

35 40 45

Tyr Gin Asp Glu Ile Ala Lys Xaa Gin Arg Gin Lys Ser 50 55 60

(2) INFORMATION FOR SEQ ID NO: 117:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 286 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ill) HYPOTHETICAL. YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...286

(XI) SEQUENCE DESCRIPTION: SEQ ID NO: 117

Leu Xaa Pro Met Lys Val Ile Gin Val Phe Leu Phe Ser Asn Pro Phe

1 5 10 15

Cys Ala Ile Val Pro Asn Thr Glu Pro Glu His Leu Glu His Tyr Asp

20 25 30

His Asp Leu Glu Arg Phe Phe Phe Ala Tyr Lys Tyr Phe Leu Asp His

35 40 45

Ala Gin Lys Arg Val Ile Tyr Lys Glu Asp Pro Phe Leu Lys Asn Tyr

50 55 60

Ser Lys Asp Ala lie Val Leu Glu Lys Lys Asp lie Tyr Asn Ile Gin 65 70 75 80

Tyr Ile Leu Lys Asp Gly Glu Pro Tyr Thr Ser Phe Glu Leu Lys Asn

85 90 95

Leu Gly Ala Phe Leu Val Trp Gly Leu Gly Glu His Asn Ala Thr Asn

100 105 110

Ala Ser Leu Ala Ile Leu Ser Ala Leu Asp Glu Leu Asn Leu Glu Glu

115 120 125

Ile Arg Asn Asn Xaa Leu Asn Phe Lys Gly Ile Lys Lys Arg Phe Asp

130 135 140

Ile Leu Gin Lys Asn Asn Leu lie Leu Ile Asp Asp Tyr Ala His His 145 150 155 160

Pro Thr Glu Ile Gly Xaa Thr Leu Lys Ser Ala Arg Ile Tyr Ala Asn

165 170 175

Leu Leu Asn Thr Gin Glu Lys Ile Ile Val Ile Trp Gin Ala His Lys

180 185 190

Tyr Ser Arg Leu Met Asp Asn Leu Glu Glu Phe Lys Lys Cys Phe Leu

195 200 205

Glu His Cys Asp Arg Leu lie Ile Leu Pro Val Tyr Ser Ala Ser Glu

210 215 220

Val Lys Arg Asp Ile Asp Leu Lys Ala His Phe Lys His Tyr Asn Pro 225 230 235 240

Thr Phe Ile Asp Arg Val Arg Lys Lys Gly Asp Phe Leu Glu Leu Leu

245 250 255

Val Asn Asp Asn Val Val Glu Thr Ile Glu Lys Gly Phe Val lie Gly

260 265 270

Phe Gly Ala Gly Asp Ile Thr Tyr Gin Leu Arg Gly Glu Met 275 280 285

(2) INFORMATION FOR SEQ ID NO: 118: (l) SEQUENCE CHARACTERISTICS

(A) LENGTH: 61 amino acids

(B) TYPE, ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...61

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118

Leu Leu Leu Phe Phe Leu Leu Lys Gly Val Val Phe Ser Leu Gly Phe

1 5 10 15

Phe Ser Phe Phe Glu Glu Val Ser Gly Ser Phe Xaa Ala Val Ser Leu

20 25 30

Xaa Val Leu Ala Leu Val Met Gly Ser Ser Xaa Gly Leu Glu Glu Phe

35 40 45

Cys Val Leu Glu Glu Leu lie Asn Ser Gly Leu Ser Val 50 55 60

(2) INFORMATION FOR SEQ ID NO: 119:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 122 amino acids

(B) TYPE: am o acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...122

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119

Met Gly Phe Leu Lys Val Leu Lys His Asp Ala Leu Gly Gin Val Gly

1 5 10 15

Asn Ile Val Ile Gly Asn Phe Leu Ile Thr Leu Thr Val Leu Ala Val

20 25 30

Cys Phe Ser Ser Gin Ser Ala Glu Glu Thr Thr Met Leu Thr Leu Ser

35 40 45

Tyr Thr Leu Phe Phe Ile Leu Gly Ala Phe Leu Leu Val Ala Ile Ser

50 55 60

Val Gly Ala Ile Lys Asn Leu Asn Ala Leu Phe Ser Lys Arg Gly Val 65 70 75 80

Leu Ser Phe Ser Leu Pro Ile Ser Leu Glu Ser Leu Leu Leu Pro Lys

85 90 95

Ile Leu Leu Pro Xaa Val Phe Phe Tyr Leu Gin Phe Val Leu Val Cys

100 105 110

Gly Glu Arg Ala Phe Gly Leu Leu Pro Phe 115 120

(2) INFORMATION FOR SEQ ID NO: 120:

(l) SEQUENCE CHARACTERISTICS-

(A) LENGTH: 187 ammo acids (B) TYPE: amino acid (D) TOPOLOGY: linear

In) MOLECULE TYPE: protein

(m) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM- Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 ..187

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120

Met Leu Lys Thr His Leu Ser Ser Ala Arg Gly Val Val Val Leu Ser

1 5 10 15

Lys Ile Leu Pro Val Asn Val Val Leu Met Val Ser Val Arg Leu Phe

20 25 30

Glu Lys Glu Leu Lys Arg Lys Pro Tyr Tyr Ile Ile Ala Ser Ala His

35 40 45

Ser Asp Glu Gly Leu Glu Lys Leu Lys Lys Xaa Gly Xaa Asp Met Val

50 55 60

Xaa Xaa Pro Thr Lys Leu Met Ala Gin Arg Val Ser Ala Asn Xaa Trp 65 70 75 80

Cys Xaa Leu Asp Met Glu Asn Ile Leu Glu Arg Phe Ile Asn Lys Lys

85 90 95

Asp Thr Leu Leu Asp Leu Glu Glu Val Ile Val Pro Lys Thr Ser Trp

100 105 110

Leu Val Leu Arg Lys Leu Lys Glu Ala His Phe Arg Glu Ile Ala Lys

115 120 125

Ala Phe Val Ile Gly Ile Thr Gin Lys Asp Gly Lys Tyr Ile Pro Met

130 135 140

Pro Asp Gly Glu Thr Ile Ile Ala Ser Glu Ser Lys Leu Leu Met Val 145 150 155 160

Gly Thr Ser Glu Gly Val Ala Thr Cys Lys Gin Leu Ile Thr Ser His

165 170 175

Gin Lys Pro Lys Glu Val Asp Tyr Ile Ser Leu 180 185

(2) INFORMATION FOR SEQ ID NO: 121:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 193 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...193

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121

Val Gly Ser Phe Leu Phe Val Gly Pro Ser Gly Val Gly Lys Thr Glu

1 5 10 15

Leu Ala Lys Glu Leu Ala Leu Asn Leu Xaa Leu His Phe Glu Arg Phe

20 25 30

Asp Met Ser Glu Tyr Lys Glu Ala His Ser Val Ala Lys Leu Ile Gly

35 40 45

Ser Pro Ser Gly Tyr Val Gly Phe Glu Gin Gly Gly Leu Leu Val Asn 50 55 60 Ala lie Lys Lys His Pro His Cys Leu Leu Leu Leu Asp Glu Ile Glu 65 70 75 80

Lys Ala His Pro Asn Val Tyr Asp Leu Leu Leu Gin Val Met Xaa Asn

85 90 95

Ala Thr Leu Ser Asp Asn Leu Gly Asn Lys Ala Ser Phe Lys His Val

100 105 110

Ile Leu lie Met Thr Xaa Xaa Val Gly Ser Lys Asp Lys Asp Thr Leu

115 120 125

Gly Phe Phe Ser Thr Lys Asn Ala Lys Tyr Asp Arg Ala Val Lys Glu

130 135 140

Leu Leu Thr Pro Glu Leu Arg Ser Arg Ile Asp Ala Ile Val Pro Phe 145 150 155 160

Asn Ala Leu Ser Leu Glu Asp Phe Glu Thr His Cys Phe Cys Gly Ile

165 170 175

Gly Arg Val Lys Ser Pro Ser Thr Arg Ala Arg Arg Asp Leu Lys lie

180 185 190

Pro

(2) INFORMATION FOR SEQ ID NO:122.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 303 ammo acids

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...303

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122

Met Ala Phe Gin Val Asn Thr Asn Ile Asn Ala Met Asn Ala His Val

1 5 10 15

Gin Ser Ala Leu Thr Gin Asn Ala Leu Lys Thr Ser Leu Glu Arg Leu

20 25 30

Ser Ser Gly Leu Arg Ile Asn Lys Ala Ala Asp Asp Ala Ser Gly Met

35 40 45

Thr Val Ala Asp Ser Leu Arg Ser Gin Ala Ser Ser Leu Gly Gin Ala

50 55 60

Ile Ala Asn Thr Asn Asp Gly Met Gly Ile Ile Gin Val Ala Asp Lys 65 70 75 80

Ala Met Asp Glu Gin Leu Lys Ile Leu Asp Thr Val Lys Val Lys Ala

85 90 95

Thr Gin Ala Ala Gin Asp Gly Gin Thr Thr Glu Ser Arg Lys Ala Ile

100 105 110

Gin Ser Asp Ile Val Arg Leu Ile Gin Gly Leu Asp Asn Ile Gly Asn

115 120 125

Thr Tnr Thr Tyr Asn Gly Gin Ala Leu Leu Ser Gly Gin Phe Thr Asn

130 135 140

Lys Glu Phe Gin Val Gly Ala Tyr Ser Asn Gin Ser Ile Lys Ala Ser 145 150 155 160

Ile Gly Ser Thr Thr Ser Asp Lys Ile Gly Gin Val Arg Ile Ala Thr

165 170 175

Gly Ala Leu Ile Thr Ala Ser Gly Asp Ile Ser Leu Thr Phe Lys Gin

180 185 190

Val ASD Gly Val Asn Asp Val Thr Leu Glu Ser Val Lys Val Ser Ser

195 200 205

Ser Ala Gly Thr Gly lie Gly Val Leu Ala Glu Val Ile Asn Lys Asn

210 215 220

Ser Asn Arg Thr Gly Val Lys Ala Tyr Ala Ser Val Ile Thr Thr Ser 225 230 235 240 Asp Val Ala Val Gin Ser Gly Ser Leu Ser Asn Leu Thr Leu Asn Gly

245 250 255 lie His Leu Gly Asn Ile Ala Asp Ile Lys Xaa Asn Asp Ser Asp Gly

260 265 270

Arg Leu Val Thr Ala lie Asn Ala Val Thr Ser Glu Thr Gly Val Xaa

275 280 285

Ala Tyr Thr Asp Gin Lys Gly Arg Leu Asn Leu Arg Ser Ile Gly 290 295 300

(2) INFORMATION FOR SEQ ID NO:123:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 161 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...161

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123

Met Phe Phe Lys Thr Tyr Gin Lys Leu Leu Gly Ala Ser Cys Leu Ala

1 5 10 15

Leu Tyr Leu Val Gly Cys Gly Asn Gly Gly Gly Gly Glu Ser Pro Val

20 25 30

Glu Met Ile Xaa Asn Ser Glu Gly Thr Phe Gin Ile Asp Ser Lys Ala

35 40 45

Asp Ser Ile Thr Ile Gin Gly Val Lys Leu Asn Arg Gly Asn Cys Ala

50 55 60

Val Asn Phe Val Pro Val Ser Glu Thr Phe Gin Met Gly Val Leu Ser 65 70 75 80

Gin Val Thr Pro Ile Ser Ile Gin Asp Phe Lys Asp Met Ala Ser Thr

85 90 95

Tyr Lys Ile Phe Asp Gin Lys Lys Gly Leu Ala Asn Ile Ala Asn Lys

100 105 110

Ile Ser Gin Leu Glu Gin Lys Gly Val Met Met Lys Pro Xaa Thr Leu

115 120 125

Asn Phe Gly Glu Ser Leu Lys Gly Ile Ser Gin Gly Cys Asn Ile Ile

130 135 140

Glu Ala Glu lie Gin Thr Asp Lys Gly Ala Trp Thr Phe Asn Phe Asp 145 150 155 160

Lys

(2) INFORMATION FOR SEQ ID NO:124:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 91 amino acids

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...91 (xi) SEQUENCE DESCRIPTION SEQ ID NO 124

Val Cys Leu Gly Leu Ala Asp Val Met Val Val Leu Ser Leu His Leu

1 5 10 15

Asn Leu Asn Pro Thr Asn Pro Lys Trp Leu Asn Arg Asp Arg Leu Val

20 25 30

Phe Ser Gly Gly His Ala Ser Ala Leu Val Tyr Ser Leu Leu His Leu

35 40 45

Trp Gly Phe Asp Leu Ser Leu Asp Asp Leu Lys Arg Phe Arg Gin Leu

50 55 60

His Ser Lys Thr Pro Gly His Pro Glu Leu His His Thr Glu Gly Ile 65 70 75 80

Glu Ile Thr Thr Xaa Phe Arg Ala Arg Phe Cys 85 90

(2) INFORMATION FOR SEQ ID NO 125

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH 187 amino acids

(D) TOPOLOGY linear

(n) MOLECULE TYPE prote

(ill) HYPOTHETICAL YES

(vi) ORIGINAL SOURCE

(A) ORGANISM Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY mιsc_feature

(B) LOCATION 1 187

(xi) SEQUENCE DESCRIPTION SEQ ID NO 125

Met Thr Thr Pro Met Ile Ile Ile Ser Leu Glu Met Gly Leu Ser Leu

1 5 10 15

Val Pro Met Arg Gin Cys Leu Val Cys Gin Ala Leu Ala Arg Ser Ile

20 25 30

Ser Trp Asn Gly Leu Gly Gly Asn Val Arg Asn Thr Lys Val Tyr Gly

35 40 45

Lys Phe Ala Ala Tyr His His Leu Gin Lys Tyr Leu Leu lie Asp Leu

50 55 60

Ile Ala Arg Phe Lys Thr Gin Gly Gly Tyr Ile Phe Arg Tyr Asn Thr 65 70 75 80

Asp Asp Tyr Leu Pro Leu Asn Ser Thr Phe Tyr Met Gly Gly Val Thr

85 90 95

Thr Val Arg Gly Phe Arg Asn Gly Ser Ile Thr Pro Lys Asp Glu Phe

100 105 110

Gly Leu Trp Leu Gly Gly Asp Gly Ile Phe Thr Xaa Ser Thr Glu Leu

115 120 125

Ser Tyr Gly Val Leu Lys Ala Ala Lys Met Arg Leu Ala Trp Phe Phe

130 135 140

Asp Phe Gly Phe Leu Thr Phe Xaa Thr Pro Thr Arg Gly Ser Phe Phe 145 150 155 160

Tyr Asn Ala Xaa Thr Thr Thr Ala Asn Phe Lys Asp Tyr Xaa Val Val

165 170 175

Gly Xaa Xaa Phe Glu Xaa Ala Thr Trp Arg Ala 180 185

(2) INFORMATION FOR SEQ ID NO 126

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH 104 am o acids

(B) TYPE amino acid (D) TOPOLOGY linear

(ii) MOLECULE TYPE protein (ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...104

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126

Met Gin Ala Leu Lys Ser Leu Leu Glu Val Ile Thr Lys Leu Gin Asn

1 5 10 15

Leu Gly Gly Tyr Leu Met His Ile Ala Ile Phe Ile lie Phe Ile Trp

20 25 30

Ile Gly Gly Leu Lys Phe Val Pro Tyr Glu Ala Glu Gly Ile Ala Pro

35 40 45

Phe Val Xaa Asn Ser Pro Phe Phe Ser Phe Met Tyr Lys Phe Glu Lys

50 55 60

Pro Ala Tyr Lys Gin His Lys Met Ser Glu Ser Gin Ser Met Gin Glu 65 70 75 80

Glu Met Gin Asp Asn Pro Lys Ile Val Glu Asn Lys Xaa Trp His Lys

85 90 95

Glu Asn Arg Thr Ser Phe Ser Gly 100

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 182 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...182

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127

Met Gin Phe Glu Glu Met Lys Glu Leu Ala His Gin Ile Gly Val Phe

1 5 10 15

Tyr His Val Gly Val Asp Gly lie Ala Leu Phe Leu Leu Leu Leu Asn

20 25 30

Ala Ile Val Val Leu Leu Ser Val Val Tyr Val Lys Glu Arg Arg Lys

35 40 45

Asp Phe Val Ile Cys Leu Leu Leu Leu Xaa Gly Ile Leu Met Gly Val

50 55 60

Phe Ser Ser Leu Asn Val Ile Phe Phe Tyr Ala Phe Trp Glu Ile Ser 65 70 75 80

Leu Leu Pro Val Leu Tyr Leu Ile Gly Arg Phe Gly Arg Asn Asn Lys

85 90 95

Ile Tyr Ser Gly Met Lys Phe Phe Leu Tyr Thr Phe Leu Ala Ser Leu

100 105 110

Cys Met Leu Leu Gly lie Leu Tyr Ile Gly Tyr Asp Tyr Ala Asn Asn

115 120 125

Tyr Gly Met Met Ser Phe Asp Ile Leu Asp Trp Tyr Gin Leu Asn Phe

130 135 140

Ser Ser Gly Ile Lys Thr Trp Leu Phe Val Ala Phe Leu Ile Gly lie 145 150 155 160

Ala Val Lys lie Pro Leu Phe Pro Phe Thr His Gly Cys Leu Met Arg 165 170 175 Ile Leu Thr Pro Pro Leu 180

(2) INFORMATION FOR SEQ ID NO: 128:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 116 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...116

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128

Val Lys Lvs Tyr Ala Glu ASD Phe Ile Thr Lys Asp Glu Val Lys Ser

1 5 10 15

Leu Leu Glu Arg Leu Ala Lys Asp Tyr Pro Thr Ile Val Glu Glu Ser

20 25 30

Lys Lys Ile Pro Thr Gly Ala Ile Arg Ser Val Leu Gin Ala Leu Leu

35 40 45

His Glu Lys Ile Pro Ile Lys Asp Met Leu Thr Ile Leu Glu Thr Ile

50 55 60

Thr Asp lie Ala Pro Leu Val Gin Asn Asp Val Asn Ile Leu Thr Glu 65 70 75 80

Gin Val Arg Ala Arg Leu Ser Arg Val Ile Thr Asn Ala Phe Lys Ser

85 90 95

Glu Asp Gly Arg Leu Lys Phe Leu Thr Phe Ser Thr Asp Xaa Glu Gin

100 105 110

Phe Xaa Ala Gin 115

(2) INFORMATION FOR SEQ ID NO: 129:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 240 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...240

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129

Met Met Lys Asn Lys Arg Ser Gin Asn Ser Pro Tyr Val Thr Pro Asp

1 5 10 15

Asn Pro Tyr Leu Thr Leu Glu Lys Ala Leu Gly Tyr Ser Phe Lys Asp

20 25 30

Lys Arg Leu Leu Glu Gin Ala Leu Thr His Lys Ser Cys Lys Leu Ala

35 40 45

Leu Asn Asn Glu Arg Leu Glu Phe Leu Gly Asp Ala Val Leu Gly Leu

50 55 60

Val lie Gly Glu Leu Leu Tyr His Lys Phe Xaa Xaa Xaa Asp Gly Gly 65 70 75 80

Lys Leu Ser Lys Leu Arg Ala Ser Ile Val Ser Ala His Gly Phe Thr

85 90 95

Lys Leu Ala Lys Ala lie Ala Leu Gin Asp Tyr Leu Arg Val Ser Ser

100 105 110

Ser Glu Glu Ile Ser Lys Gly Arg Glu Lys Pro Ser Ile Leu Ser Ser

115 120 125

Ala Phe Glu Ala Leu Met Ala Gly Val Tyr Leu Glu Ala Gly Leu Ala

130 135 140

Lys Val Arg Lys Ile Ile Gin Asn Leu Leu Asn Arg Ala Tyr Lys Arg 145 150 155 160

Leu Asp Leu Glu His Leu Phe Met Asp Tyr Lys Thr Ala Leu Gin Glu

165 170 175

Leu Thr Gin Xaa Gin Phe Cys Val Ile Pro Thr Tyr Gin Leu Leu Gin

180 185 190

Glu Lys Gly Pro Asp His His Lys Glu Phe Glu Met Ala Leu Tyr Ile

195 200 205

Gin Asp Lys Met Tyr Ala Thr Ala Lys Gly Lys Ser Lys Lys Glu Ala

210 215 220

Glu Gin Gin Cys Ala Tyr Gin Ala Leu Gin Asn Leu Arg Lys Pro Asn 225 230 235 240

(2) INFORMATION FOR SEQ ID NO: 130:

(1) SEQUENCE CHARACTERISTICS-

(A) LENGTH: 228 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

In) MOLECULE TYPE: protein

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...228

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:130

Leu Leu Val Leu Leu Asn Leu Lys Xaa Thr Pro Asn Leu Met Trp Pro

1 5 10 15

Leu Asp Ile lie Val Val Val Ala Trp Val Leu Trp Gly Val Asn Met

20 25 30

Phe Gly Ser Met Ser Val Arg Arg Glu Asn Thr Ile Tyr Val Ser Leu

35 40 45

Trp Tyr Tyr Ile Ala Thr Tyr Val Gly Ile Ala Val Met Tyr Ile Phe

50 55 60

Asn Asn Leu Ser Ile Pro Thr Tyr Phe Val Ala Asp Met Gly Ser Val 65 70 75 80

Trp His Xaa lie Ser Met Tyr Ser Gly Ser Asn Asp Ala Leu Ile Gin

85 90 95

Trp Trp Trp Gly H s Asn Ala Val Ala Phe Val Phe Thr Ser Gly Val

100 105 110 lie Gly Thr Ile Tyr Tyr Phe Leu Pro Lys Glu Ser Gly Gin Pro Ile

115 120 125

Phe Ser Tyr Lys Leu Thr Leu Phe Ser Phe Trp Ser Leu Met Phe Val

130 135 140

Tyr Ile Trp Ala Gly Gly His His Leu Ile Tyr Ser Thr Val Xaa Asp 145 150 155 160

Xaa Val Gin Thr Leu Ser Ser Xaa Phe Ser Val Val Leu Ile Leu Pro

165 170 175

Ser Xaa Gly Thr Ala lie Asn Met Leu Leu Xaa Met Arg Gly Gin Trp

180 185 190

His Gin Xaa Lys Glu Ser Pro Leu Ile Lys Phe Leu Val Leu Ala Ser

195 200 205

Thr Phe Tyr Met Leu Ser Thr Leu Glu Gly Ser Ile Gin Ala Ile Lys 210 215 220

Ser Val Asn Ala 225

(2) INFORMATION FOR SEQ ID NO: 131:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH- 162 amino acids

(B) TYPE ammo acid (D) TOPOLOGY linear

(n) MOLECULE TYPE: prote

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 ..162

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131

Met Lys Ala Pro Ser Gin Xaa Asp Leu Lys Lys Ile Leu Gly Ile Glu

1 5 10 15

Glu Val Ile Xaa Xaa Ser Thr Ser Pro Met Glu Leu Arg Leu Ala Asn

20 25 30

Gin Lys Leu Gly Asn Arg Phe Ile Lys Thr Leu Gin Ala Met Asn Glu

35 40 45

Leu Asp Met Gly Ala Phe Phe Asn Ala Tyr Ala Gin Thr Thr Lys Asp

50 55 60

Pro Thr His Ala Thr Ser Tyr Gly Val Phe Ala Ala Ser Leu Asn Met 65 70 75 80

Glu Leu Lys Lys Ala Leu Arg His Tyr Leu Tyr Ala Gin Thr Ser Asn

85 90 95

Met Val Ile Asn Cys Val Lys Ser Val Pro Leu Ser Gin Asn Asp Gly

100 105 110

Gin Lys Ile Leu Leu Ser Leu Gin Ser Pro Phe Asn Gin Leu Ile Glu

115 120 125

Lys Thr Leu Glu Leu Asp Glu Ser His Leu Cys Ala Ala Ser Val Gin

130 135 140

Asn Asp Ile Lys Ala Met Gin His Glu Ser Leu Tyr Ser Arg Leu Tyr 145 150 155 160

Met Ser

(2) INFORMATION FOR SEQ ID NO: 132:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(m) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE-

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...59

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 132

Met Ala Phe Ile Leu Thr Thr Asn Leu Phe Ile Lys Ser Phe Thr Asn

1 5 10 15 Ser Ile Arg Ile Thr Gly Cys Ile Ile Ser Pro Asn Val Phe Phe Ala

20 25 30

Tyr Glu Phe Cys Ala Leu Gly Phe Arg Lys Gly Gly Leu Ile Leu Asp

35 40 45

Asn Phe Ser Lys Phe Val Ser His Arg Leu Gin 50 55

(2) INFORMATION FOR SEQ ID NO: 133:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 248 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protem

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...248

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133

Val Arg Phe Phe Ile Phe Leu Ile Leu Ile Cys Pro Leu Ile Cys Pro

1 5 10 15

Leu Met Ser Ala Asp Ser Ala Leu Pro Ser Val Asn Leu Ser Leu Asn

20 25 30

Ala Pro Ser Asp Pro Lys Gin Leu Val Thr Thr Leu Asn Val Ile Ala

35 40 45

Leu Leu Thr Leu Leu Val Leu Ala Pro Ser Leu Ile Leu Val Met Thr

50 55 60

Ser Phe Thr Arg Leu lie Val Val Phe Ser Phe Leu Arg Thr Ala Leu 65 70 75 80

Gly Thr Gin Gin Thr Pro Pro Thr Gin Ile Leu Val Ser Leu Ser Leu

85 90 95

Ile Leu Thr Phe Phe Ile Met Glu Pro Ser Leu Lys Lys Ala Tyr Asp

100 105 110

Thr Gly Ile Lys Pro Tyr Met Asp Lys Lys lie Ser Tyr Thr Glu Ala

115 120 125

Phe Glu Lys Ser Thr Leu Pro Phe Lys Glu Phe Met Leu Lys Asn Thr

130 135 140

Arg Glu Lys Asp Leu Ala Leu Phe Phe Arg Ile Arg Asn Leu Pro Asn 145 150 155 160

Pro Lys Thr Pro Asp Asp Val Ser Leu Ser Val Leu Ile Pro Ala Phe

165 170 175

Met Ile Ser Glu Leu Lys Thr Ala Phe Gin Ile Gly Phe Leu Leu Tyr

180 185 190

Leu Pro Phe Leu Val Ile Asp Met Val Ile Ser Ser Ile Leu Met Ala

195 200 205

Met Gly Met Met Met Leu Pro Pro Val Met Ile Ser Leu Pro Phe Lys

210 215 220

Ile Leu Val Phe lie Leu Val Asp Gly Phe Asn Leu Leu Thr Glu Asn 225 230 235 240

Leu Val Ala Ser Phe Lys Met Val 245

(2) INFORMATION FOR SEQ ID NO: 134:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 166 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein ( i i i ) HYPOTHETICAL : YES

( vi ) ORIGINAL SOURCE :

(A ) ORGANI SM : Hel i cobac ter pylor i

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...166

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134

Leu Leu Val Thr Phe Leu Asn Gly Phe Asp Pro Lys Ile Ala Asn Leu

1 5 10 15

Arg Lys Ala Cys Asn Val Tyr Ser Val Gly Val Ile Tyr Ile Val Thr

20 25 30

Thr Asn Thr Leu Asn Ile Leu Ser Cys Glu Ser Phe Glu Ile Leu Glu

35 40 45

Lys Arg Glu Leu Asp Thr Ser Gly Val Thr Lys Thr Ser Thr Pro Phe

50 55 60

Phe Ser Arg Val Glu Gly Ile Asp Ala Gly Thr Leu Gly Lys Leu Phe 65 70 75 80

Ser Gly Ser Gin Ser Lys Asn Tyr Phe Ala Tyr Tyr Asp Ala Leu Val

85 90 95

Lys Lys Glu Lys Arg Lys Glu Val Arg Ile Glu Lys Lys Glu Glu Arg

100 105 110

Ile Asp Ala Arg Glu Asn Lys Arg Glu Ile Lys Gin Glu Ala Ile Lys

115 120 125

Glu Pro Lys Lys Ala Asn Gin Gly Thr Glu Asn Ala Pro Thr Leu Glu

130 135 140

Glu Lys Xaa Tyr Gin Lys Ala Glu Arg Lys Phe Asp Ala Lys Xaa Xaa 145 150 155 160

Arg Arg Ser Phe Lys Xaa 165

(2) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 127 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protem

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

( ix ) FEATURE :

( A) NAME/KEY : misc_f eature

( B ) LOCATION 1 . . . 127

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135

Met Glu Asn Ser Thr Leu Tyr Ile Val Ile Ala Gly Leu Trp Leu Ala

1 5 10 15

Val Gly Phe Gly Ile Phe Leu Lys Lys Leu Asp Met Pro Val Ile lie

20 25 30

Gly Tyr Ile Cys Thr Gly Thr Val Leu Ala Ala Phe Phe Lys Ile Asn

35 40 45

Asp Phe Asn Leu Leu Ser Asp Ile Gly Glu Phe Gly Ile Val Phe Leu

50 55 60

Met Phe Met Ile Gly Ile Glu Phe Asn Phe Asp Lys Leu Lys Ser Ile 65 70 75 80

Lys Gin Glu Val Leu Val Phe Gly Leu Leu Gin Val Val Leu Cys Ala

85 90 95

Leu Ile Ala Phe Leu Leu Gly Tyr Phe Val Leu Gly Leu Ser Pro Ile

100 105 110

Phe Ser Leu Val Leu Gly Met Gly Leu Ser Leu Ser Ser Thr Ala 115 120 125

(2) INFORMATION FOR SEQ ID NO: 136:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...16

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136

Leu Leu Leu Met Leu Asn Lys Pro Lys Pro Leu Phe Leu Xaa Leu Gly

1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 137:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 350 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...350

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137

Met Ala Leu Arg Val Leu Leu Phe Phe Cys Phe Leu Phe Leu Gin Ala

1 5 10 15

Glu Asp Lys Ser Gin Glu Leu Ser Ser Ile Gin Lys Gin Met Ala Leu

20 25 30

Val Asp Lys Lys Leu Ala Lys Asp Asp Asn Val Trp Leu Lys Lys Phe

35 40 45

Glu Asn Tyr Lys Ile Tyr Asn Gin Ile Tyr Thr Glu Lys Glu Ser Val

50 55 60

Arg Gin Glu Leu Arg Arg Leu Lys Asn Lys Lys Ser Lys Asp Leu Leu 65 70 75 80

Lys Ile Ser Thr Leu Glu His Thr Leu Lys Ala Leu Glu Ser Gin Gin

85 90 95

Lys Met Phe Glu Ser Tyr Gly Val Asn Pro Phe Lys Asp Leu Ile Glu

100 105 110

Arg Pro Asn Ile Pro Asn Ile Pro Asn Ile Ala Asn Pro Ile Ala Ile

115 120 125

Ile Asp Gly lie Ser Phe Ile Lys Ser Met Arg Leu Lys His Glu Asn

130 135 140

Leu Lys Asn Asn Gin Thr Ser Leu Gly Glu Val Leu Lys Leu Leu Asp 145 150 155 160

Gin Lys His Gin Leu Leu Asn Gin Trp His Ala Leu Asp Lys Ser Ala

165 170 175

Lys Leu Ser Asp Glu Ile Tyr Gin Thr Gin Ala Lys Arg Leu Glu Leu 180 185 190 Gin Gly Ala Gin Asn Ile Leu Lys Thr Thr Ile Gly lie Phe Gin Lys

195 200 205

Asp Ser Asp Glu Ala Ile Ser lie Val Lys Ser Gin Val Lys Asn Gin

210 215 220

Leu Phe Lys Leu Val Tyr Val Phe Leu Ala Ala Leu Leu Ser Val Val 225 230 235 240

Phe Ala Trp Ile Leu Lys Ile Ile Ser Ser Lys Tyr Ile Glu Asn Asn

245 250 255

Glu Arg Val Tyr Thr Val Asn Lys Ala Ile Asn Phe Val Asn Val Ser

260 265 270

Val Ile Xaa Xaa Ile Xaa Leu Phe Ser Tyr Leu Glu Asn Val Thr Tyr

275 280 285

Leu Val Thr Val Leu Gly Phe Ala Ser Ala Gly Leu Ala Ile Xaa Met

290 295 300

Lys Asp Leu Phe Met Ser Leu Leu Gly Trp Phe Ile Ile Leu Ile Gly 305 310 315 320

Gly Ser Val His Val Gly Asp Arg Val Arg Ile Ala Lys Gly Thr Asp

325 330 335

Ile Phe Ile Gly Asp Val Leu Asp Thr Ser Asn Val Val His 340 345 350

(2) INFORMATION FOR SEQ ID NO: 138

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 99 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY, linear

(ii) MOLECULE TYPE: prote

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE-

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 ..99

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138

Met Lys Glu Gin Glu Trp Asp Leu Ser Ala Leu Phe Glu Asn Lys Glu

1 5 10 15

Ser Ala Glu Glu Phe Leu Lys Thr Leu Gin Thr Glu Val Gin Glu Phe

20 25 30

Glu Asn Ala Tyr Gin Asn Asn Leu Lys Asn Leu Asp Ala Ala Lys Phe

35 40 45

Ala Asn Thr Leu Lys His Tyr Glu Asn Leu Ser Glu Lys Ile Ser Arg

50 55 60

Ala Met Ala Tyr Ala Asn Tyr Phe Leu Pro Arg Thr Leu Lys Lys Arg 65 70 75 80

Ser Phe Ile Arg Asn Ala Asn Gly Leu Cys Lys Tyr Pro Thr Thr Pro

85 90 95

Phe Ile Leu

(2) INFORMATION FOR SEQ ID NO: 139:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 78 ammo acids

(B) TYPE: am o acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori ( ix ) FEATURE :

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1.. 78

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139

Leu Arg Val Gly Met Tyr Glu Val Cys Asn His Lys Asp Gly Thr Ala

1 5 10 15

Tyr His Ser Thr Arg Gly Ser Lys Val Thr Leu Ala Cys Lys Thr Gly

20 25 30

Thr Ala Gin Val Val Glu Ile Ala Gin Asn Ile Val Asn Arg Met Lys

35 40 45

Glu Lys Asp Met Glu Tyr Phe His Xaa Ser His Xaa Trp Ile Thr Xaa

50 55 60

Tyr Leu Xaa Pro Met Lys Asn Pro Asn Thr Leu Ser Leu Phe 65 70 75

(2) INFORMATION FOR SEQ ID NO: 140:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 52 ammo acids

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: prote

(111) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...52

( i) SEQUENCE DESCRIPTION: SEQ ID NO:140

Leu Gly Leu Val Xaa Gly Ile Ser Leu Leu His Leu Ser Leu Glu Gin

1 5 10 15

Lys Ile Ser Val Phe Leu Gly Xaa Asn Leu Met Leu Tyr Pro Val Xaa

20 25 30

Glu Val Leu Phe Ser Ile Leu Arg Arg Lys Ile Lys Arg Gin Lys Ala

35 40 45

Thr His Ala Gly 50

(2) INFORMATION FOR SEQ ID NO: 141:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 377 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...377

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141

Leu Ala Gin Pro Val Gin Val Arg Thr Val Phe Met Ser Met Thr Leu 1 5 10 15 Asn Ala Met Gly Gin Phe Ala Tyr Asn Phe Pro Ala Asn Ile Ser Lys

20 25 30

Asp Lys Gin Lys Leu Thr Met Val Tyr Met Asp Lys Asp Tyr Gly Ala

35 40 45

Tyr Gly Asn Ile Val Ala Met Gly Gly Glu Tyr Val Lys Ile Glu Leu

50 55 60

Gly Thr Asp Thr Gly Leu Asn Pro Phe Ala Trp Ala Ala Cys Val Gin 65 70 75 80

Lys Thr Asn Ala Thr Met Glu Gin Lys Gin Thr Ala Ile Ser Val Val

85 90 95

Lys Glu Leu Val Lys Asn Leu Ala Thr Lys Ser Asp Glu Lys Asp Glu

100 105 110

Asn Gly Asn Ser Ile Ser Phe Ser Leu Ala Asp Ser Asn Thr Leu Ala

115 120 125

Ala Ala Val Thr Asn Leu Ile Thr Gly Asp Met Asn Leu Asp Tyr Pro

130 135 140

Ile Thr Gin Leu Ile Asn Ala Phe Gly Lys Asp His Asn Asp Pro Asn 145 150 155 160

Gly Leu Val Ala Arg Leu Ala Pro Phe Cys Lys Ser Thr Asn Gly Glu

165 170 175

Phe Gin Trp Leu Phe Asp Asn Lys Ala Thr Asp Arg Leu Asp Phe Ser

180 185 190

Lys Thr Ile Ile Gly Val Asp Gly Ser Ser Phe Leu Asp Asn Asn Asp

195 200 205

Val Ser Pro Phe Ile Cys Phe Tyr Leu Phe Ala Arg lie Gin Glu Ala

210 215 220

Met Asp Gly Arg Arg Phe Val Leu Asp Ile Asp Glu Ala Trp Lys Tyr 225 230 235 240

Leu Gly Asp Pro Lys Val Ala Tyr Phe Val Arg Asp Met Leu Lys Thr

245 250 255

Ala Arg Lys Arg Asn Ala Ile Val Arg Leu Ala Thr Gin Ser Ile Thr

260 265 270

Asp Leu Leu Ala Cys Pro Ile Ala Asp Thr Ile Arg Glu Gin Cys Pro

275 280 285

Thr Lys Ile Phe Leu Arg Asn Asp Gly Gly Asn Leu Ser Asp Tyr Gin

290 295 300

Arg Leu Ala Asn Val Thr Glu Lys Glu Phe Glu Ile Ile Thr Lys Gly 305 310 315 320

Leu Asp Arg Lys Ile Leu Tyr Lys Gin Asp Gly Ser Pro Ser Val Ile

325 330 335

Ala Ser Phe Asn Leu Arg Gly Ile Pro Lys Glu Tyr Leu Lys Ile Leu

340 345 350

Ser Thr Asp Thr Val Phe Val Lys Glu Ile Asp Lys Ile Ile Gin Asn

355 360 365

His Ser Ile Ile Asp Lys Tyr Gin Pro 370 375

(2) INFORMATION FOR SEQ ID NO: 142.

(l) SEQUENCE CHARACTERISTICS-

(A) LENGTH: 154 ammo acids

(B) TYPE amino acid (D) TOPOLOGY linear

(ii) MOLECULE TYPE- protem

(ill) HYPOTHETICAL YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM- Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1...154

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142

Met Lys Leu Val Ser Leu Ile Val Ala Leu Val Phe Cys Cys Phe Leu 1 5 10 15 Gly Ala Val Glu Leu Pro Gly Val Tyr Gin Thr Gin Glu Phe Leu Tyr

20 25 30

Met Lys Ser Ser Phe Val Glu Phe Phe Glu His Asn Gly Lys Phe Tyr

35 40 45

Ala Tyr Gly Ile Ser Asp Val Xaa Xaa Ser Lys Ala Lys Lys Asp Lys

50 55 60

Leu Asn Pro Asn Pro Lys Leu Arg Asn Arg Ser Asp Lys Gly Val Val 65 70 75 80

Phe Leu Ser Asp Leu Ile Lys Val Gly Glu Gin Ser Tyr Lys Gly Gly

85 90 95

Lys Ala Xaa Asn Phe Xaa Asp Gly Lys Thr Xaa His Val Arg Val Thr

100 105 110

Gin Xaa Ser Asn Gly Asp Leu Xaa Phe Thr Ser Ser Tyr Xaa Lys Trp

115 120 125

Gly Tyr Val Gly Lys Thr Phe Thr Trp Lys Arg Leu Ser Asp Glu Glu

130 135 140

Ile Lys Asn Leu Lys Leu Lys Arg Phe Asn 145 150

(2) INFORMATION FOR SEQ ID NO:143.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH- 7 amino acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(ill) HYPOTHETICAL. YES

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1...7

(xi) SEQUENCE DESCRIPTION. SEQ ID NO:143

Leu Glu Thr Leu Phe Leu Val

1 5

(2) INFORMATION FOR SEQ ID NO:144

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH- 114 amino acids

(B) TYPE, amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE, prote

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...114

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144

Met Xaa Thr His Asp Arg Arg Lys Leu Arg lie Xaa Leu Thr Gin Thr

1 5 10 15

Thr Thr Leu Val Ala Thr Ile Gly Ser Asn Ala Pro Tyr Ile Gly Leu

20 25 30

Leu Gly Thr Val Met Gly Ile Met Leu Thr Phe Met Asp Leu Gly Ser

35 40 45

Ala Ser Gly Ile Asp Thr Lys Ala Ile Met Thr Asn Leu Ala Leu Ala 50 55 60

Leu Lys Ala Thr Gly Met Gly Leu Leu Val Ala Ile Pro Ala Ile Val 65 70 75 80

Ile Tyr Asn Leu Leu Val Arg Lys Ser Glu Ile Leu Val Thr Lys Trp

85 90 95

Asp Ile Phe His His Pro Val Asp Thr Gin Ser H s Glu Val Tyr Ser

100 105 110

Lys Ala

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 67 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...67

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145

Met Gin Asp Leu Asp Asn Asn Met Ser Leu Asp Thr Ala His Asn Thr

1 5 10 15

Leu Ser Ser Asn Gly Lys Asn Ile Thr Ile Ala Gly Val Val Lys Ala

20 25 30

Leu Gin Lys Ile Gly Val Ser Ala Lys Gly Met Val Ser Ile Leu Gin

35 40 45

Ala Leu Lys Lys Ser Gly Ala Ile Ser Ala Lys Trp Arg Tyr Tyr Asp

50 55 60

Lys Gin Gin 65

(2) INFORMATION FOR SEQ ID NO: 146:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 88 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...88

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146

Leu His Pro Leu Ala Asp Val Phe Val Val Asn Asp Lys Arg Xaa Val

1 5 10 15

Leu Ala Met Val Xaa Met Leu Ile Xaa Ser Leu Ala Asn Ile Phe Phe

20 25 30

Asn Tyr Leu Phe Ile Phe Xaa Leu Glu Val Gly Val Gin Gly Xaa Ala

35 40 45

Ile Val Thr Val Ile Gly His Ala lie Gly Gly Leu Val Leu Met Gin 50 55 60 His Phe Trp Arg Lys Lys Gly Glu Leu Tyr Phe lie Lys Leu Ile Phe

65 70 75 80

Phe Ile Phe Ser His Phe Phe Ser 85

(2) INFORMATION FOR SEQ ID NO: 147:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 276 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: prote

(iii) HYPOTHETICAL: YES

(v ) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...276

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147

Met Leu Arg Lys Asn Ile Leu Ala Tyr Tyr Gly Ala Asn Phe Leu Leu

1 5 10 15

Ile Ile Ala Gin Ser Leu Pro His Ala Ile Leu Thr Pro Leu Leu Leu

20 25 30

Ser Lys Gly Leu Ser Leu Ser Glu Ile Leu Leu Val Gin Thr Phe Phe

35 40 45

Ser Phe Cys Val Leu Val Ala Glu Tyr Pro Ser Gly Val Leu Ala Asp

50 55 60

Leu Met Ser Arg Lys Asn Leu Phe Leu Val Ser Asn Val Phe Leu Ile 65 70 75 80

Ala Ser Phe Ser Leu Val Leu Phe Phe Asp Ser Phe Ile Leu Met Leu

85 90 95

Leu Ala Trp Gly Leu Tyr Gly Leu Tyr Ser Ala Cys Ser Ser Gly Thr

100 105 110

Ile Glu Ala Ser Leu Ile Thr Asp Ile Lys Glu Asn Lys Lys Asp Leu

115 120 125

Ser Lys Phe Leu Ala Lys Asn Asn Gin Ile Thr Tyr Leu Gly Met Ile

130 135 140

Ile Gly Ser Ser Leu Gly Ser Phe Leu Tyr Leu Lys Val His Ala Met 145 150 155 160

Leu Tyr Val Val Gly Ile Phe Leu Ile Met Leu Cys Ala Leu Thr Ile

165 170 175

Ile Ile Tyr Phe Lys Glu Lys Glu Gly Asp Phe Lys Ser Gin Lys Asn

180 185 190

Leu Lys Leu Leu Lys Glu Gin Val Lys Gly Ser Leu Lys Glu Leu Lys

195 200 205

Asp Asn Pro Lys Leu Lys lie Leu Leu Val Gly His Leu Ile Thr Pro

210 215 220

Val Phe Phe Met Ser His Phe Gin Met Trp Gin Ala Tyr Phe Leu Lys 225 230 235 240

Gin Gly Val Lys Glu Gin Tyr Leu Phe Val Phe Tyr Ile Ala Phe Gin

245 250 255

Val lie Ser Ile Pro His Ser Phe Phe Lys Ser Gin Lys Leu Xaa Ala

260 265 270

Lys Lys Ser Pro 275

(2) INFORMATION FOR SEQ ID NO:148:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 ammo acids

(D) TOPOLOGY: linear (ii) MOLECULE TYPE, protein

(ill) HYPOTHETICAL. YES

(vi) ORIGINAL SOURCE

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 ..93

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.148

Leu Tyr Pro Pro Gly Ser Val Val Lys Met Gly Val Gly Leu Ser Phe

1 5 10 15

Leu Glu Asn Leu His Ile Thr Glu Asn Thr Thr Ile Pro Thr Pro Pro

20 25 30

Phe Ile Glu Val Gly Lys Arg Lys Phe Arg Asp Trp Lys Lys Thr Gly

35 40 45

His Gly Asn Ser Asn Leu Tyr Lys Ala Ile Arg Glu Ser Val Asp Val

50 55 60

Tyr Phe Tyr Lys Phe Gly Leu Glu Ile Ser Ile Glu Xaa Leu Ser Lys 65 70 75 80

Xaa Pne Lys Xaa Ser Gly Leu Trp Gly Lys Asn Gly Arg 85 90

(2) INFORMATION FOR SEQ ID NO: 149:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY, linear

(n) MOLECULE TYPE: prote

(ill) HYPOTHETICAL. YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149

Met Ala His His Xaa Glu Gin His Gly Gly His His His His His His

1 5 10 15

His Thr His His His His Tyr His Gly Gly Glu His His His His His

20 25 30

His Ser Ser His His Glu Glu Gly Cys Cys Ser Thr Ser Asp Ser His

35 40 45

His Gin Glu Glu Gly Cys Cys His Gly Xaa His Glu 50 55 60

(2) INFORMATION FOR SEQ ID NO: 150-

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 297 am o acids

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protem

(m) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori ( ix ) FEATURE -

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1...297

(xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 150

Leu Val Lys Ile Arg Leu Phe Asp Phe Thr Ile Arg Leu Phe Lys Pro

1 5 10 15

Glu Phe His Ile Phe Asp Phe Leu Lys Gly Ile Arg Val Leu Met Ile

20 25 30

Glu Trp Met Gin Asn His Arg Lys Tyr Leu Val Val Thr Ile Trp Ile

35 40 45

Ser Thr Ile Ala Phe Ile Ala Ala Gly Met Ile Gly Trp Gly Gin Tyr

50 55 60

Ser Phe Ser Leu Asp Ser Asp Ser Ala Ala Lys Val Gly Gin Ile Lys 65 70 75 80

Ile Ser Gin Glu Glu Leu Ala Gin Glu Tyr Arg Arg Leu Lys Asp Ala

85 90 95

Tyr Ala Glu Ser lie Pro Asp Phe Lys Glu Leu Thr Glu Asp Gin Ile

100 105 110

Lys Ala Met His Leu Glu Lys Ser Ala Leu Asp Ser Leu Ile Asn Gin

115 120 125

Ala Leu Leu Arg Asn Phe Ala Leu Asp Leu Gly Leu Gly Ala Thr Lys

130 135 140

Gin Glu Val Ala Lys Glu Ile Arg Lys Thr Asn Val Phe Gin Lys Asp 145 150 155 160

Gly Val Phe Asp Glu Glu Leu Tyr Lys Asn lie Leu Lys Gin Ser His

165 170 175

Tyr Arg Pro Lys His Phe Glu Glu Ser Val Glu Arg Leu Leu Ile Leu

180 185 190

Gin Lys Ile Ser Ala Leu Phe Pro Lys Thr Thr Thr Pro Leu Glu Gin

195 200 205

Ser Ser Leu Ser Leu Trp Ala Lys Leu Gin Asp Lys Leu Asp lie Leu

210 215 220

Ile Leu Asn Pro Asn Asp Val Lys Ile Ser Leu Asn Glu Glu Glu Met 225 230 235 240

Lys Lys Tyr Tyr Glu Asn His Arg Lys Asp Phe Lys Lys Pro Thr Ser

245 250 255

Phe Lys Thr Arg Ser Leu Tyr Phe Asp Ala Ser Leu Glu Lys Thr Asp

260 265 270

Leu Lys Glu Leu Glu Glu Tyr Tyr His Lys Asn Lys Val Ser Tyr Leu

275 280 285

Asp Xaa Xaa Gly Glu Ile Thr Gly Phe 290 295

(2) INFORMATION FOR SEQ ID NO: 151:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 90 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...90

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151

Met Val Lys His Tyr Leu Phe Met Ala Val Ser Gin Val Phe Phe Ser 1 5 10 15

Phe Phe Leu Val Leu Phe Phe Ile Ser Ser Ile Val Leu Leu Ile Ser 20 25 30 Ile Ala Ser Val Thr Leu Val Ile Lys Val Ser Phe Leu Asp Leu Val

35 40 45

Gin Leu Phe Leu Tyr Ser Leu Pro Gly Thr Ile Phe Phe Ile Leu Pro

50 55 60

Ile Thr Phe Phe Ala Ala Xaa Arg Leu Gly Xaa Ser Arg Leu Ser Tyr 65 70 75 80

Asp His Glu Leu Leu Val Phe Phe Leu Xaa 85 90

(2) INFORMATION FOR SEQ ID NO: 152

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH 86 am o acids

(B) TYPE, ammo acid (D) TOPOLOGY- linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...86

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152

Met Ser Lys Arg Ala lie Arg Phe Pro Asn Lys Leu Phe Ser Tyr Pro

1 5 10 15

Lys Pro Lys Ile Lys Ala Thr Asn Thr Ser His Thr Val Leu Phe Ala

20 25 30

Tyr Pro Leu Lys Pro His Glu Met Ala Leu Leu Ala Leu Ala Thr Ser

35 40 45

Leu Leu Ala Pro Ile Phe Asn Ala Ile His Ser Thr Asn Ala Leu Asn

50 55 60

Ala Ile Lys Pro Asp Gly Thr Gly Ser Lys Ile Asn Pro Ile lie Met 65 70 75 80

Pro Met Lys Ile Gin Lys 85

(2) INFORMATION FOR SEQ ID NO: 153:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH- 141 amino acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...141

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153

Val Tyr Ser Arg Phe Phe Ala Asn Gin His Glu Phe Asp Phe Glu Ala

1 5 10 15

Gin Gly Ala Leu Gly Ser Asp Gin Ser Ser Leu Asn Phe Lys Ser Thr

20 25 30

Leu Leu Gin Asp Leu Asn Gin Ser Tyr Asn Tyr Leu Ala Tyr Ser Ala

35 40 45

Thr Ala Arg Ala Ser Tyr Gly Tyr Asp Phe Ala Phe Phe Arg Asn Ala 50 55 60

Leu Val Leu Lys Pro Ser Val Gly Val Ser Tyr Asn His Leu Gly Ser 65 70 75 80

Thr Asn Phe Lys Ser Asn Ser Gin Ser Gin Val Ala Leu Lys Asn Gly

85 90 95

Ala Ser Ser Gin His Leu Phe Asn Ala Asn Ala Thr Trp Lys Arg Val

100 105 110

Ile Ile Met Gly Thr Leu His Thr Phe Ile Cys Met Trp Glu Phe Tyr

115 120 125

Lys Ser Ser Leu Thr Leu Asp Arg Met Met Trp Arg Leu 130 135 140

(2) INFORMATION FOR SEQ ID NO: 154:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 185 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(lli) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

( ix ) FEATURE :

(A) NAME/KEY : raιsc_f eature

( B ) LOCATION 1 . . . 185

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 154

Met Xaa Glu Asn Gly Arg Gly Val Pro Lys Asp Tyr Lys Lys Ala Val

1 5 10 15

Glu Tyr Phe Gin Lys Ala Val Asp Asn Asp Ile Pro Arg Gly Tyr Asn

20 25 30

Asn Leu Gly Val Met Tyr Lys Glu Gly Lys Gly Val Pro Lys Asp Glu

35 40 45

Lys Lys Ala Val Glu Tyr Phe Arg Ile Ala Thr Glu Lys Gly Tyr Thr

50 55 60

Asn Ala Tyr Ile Asn Leu Gly Ile Met Tyr Met Glu Gly Arg Gly Val 65 70 75 80

Pro Ser Asn Tyr Ala Lys Ala Thr Glu Cys Phe Arg Lys Ala Met His

85 90 95

Lys Gly Asn Val Xaa Ala Tyr Ile Leu Leu Gly Asp Ile Tyr Tyr Ser

100 105 110

Gly Met Ile Asn Trp Val Leu Ser Arg Thr Lys Ile Arg Leu Val His

115 120 125

Tyr Lys Met Ala Ala Asp Val Ser Ser Ser Arg Ala Tyr Xaa Gly Leu

130 135 140

Ser Glu Ser Tyr Xaa Tyr Gly Leu Gly Val Glu Lys Xaa Xaa Lys Lys 145 150 155 160

Ala Glu Glu Tyr Met Gin Lys Ala Cys Asp Phe Asp Ile Asp Lys Asn

165 170 175

Cys Lys Lys Lys Asn Thr Ser Ser Arg 180 185

(2) INFORMATION FOR SEQ ID NO: 155:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 139 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(iii) HYPOTHETICAL YES

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...139

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155

Leu Leu Asn Met Trp Asp Glu Ala Lys Lys Glu Gly Ile Asn lie Asn

1 5 10 15

Thr Glu Lys Leu Ser Gin Glu Leu Gly Val Val Cys Val Pro Thr Ser

20 25 30

Ala Arg Xaa Lys Glu Asp Arg Leu Asn Thr Glu Leu Leu Leu Asp Glu

35 40 45

Ile Val Arg Leu Tyr Ser Gin Asn Thr Thr Asn Asn Glu Asn Ile Lys

50 55 60

Val Pro Ser Gin Ser Phe Lys Glu Ser Leu Lys Tyr Ser Gin Ser Ala 65 70 75 80

Gin Arg Ile Ala Lys Ser Val Ile Ser Glu Asn Lys Gin Asn Ala Ser

85 90 95

Phe Glu His Thr Tyr Lys Ile Asp Lys Ile Phe Asn Ala Pro Ala Leu

100 105 110

Trp Asp Phe His Phe Phe Xaa Val Tyr Val Tyr His Leu Phe Phe Glu

115 120 125

Leu Phe Asn Arg Arg Gly Ser Ala Lys Ser Pro 130 135

(2) INFORMATION FOR SEQ ID NO: 156:

<l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 193 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...193

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156

Met Gin Glu Ala Leu Leu Arg Phe Gin Glu Gly Phe Lys Glu Trp Gly

1 5 10 15

Tyr Leu Ile Leu Phe Leu Tyr Ser Leu Gly Gly Gly Tyr Val Gly Ile

20 25 30

Val Ile Ala Ser Ile Leu Ser Ala Thr Thr His Ala Leu Asp Ile Lys

35 40 45

Ile Thr Ile Leu Val Ala Phe Leu Gly Asn Leu Ile Gly Ser Gly Ala

50 55 60

Leu Val Ile Phe Ala Arg Tyr Gin Lys Arg Glu Phe Leu Lys Tyr Phe 65 70 75 80

Gin Lys His Arg Arg Lys Leu Ala Leu Ala Ser Leu Trp Val Lys Arg

85 90 95

Tyr Ala Leu Leu Met Ile Phe Val Asn Lys Tyr Leu Tyr Gly Ile Lys

100 105 110

Ser Val Val Pro Leu Ala Ile Gly Phe Ser Lys Tyr Pro Leu Lys Lys

115 120 125

Phe Leu Trp Leu Asn Val Phe Ser Ser Phe Leu Trp Ala Leu Ile Val

130 135 140

Gly Ser Val Ser Phe Gin Ala Ser Asp Trp Val Lys Thr Leu Tyr Glu 145 150 155 160

Arg Leu Ser His Tyr Thr Ser Phe Phe Val lie Ser Phe Val Leu Ile 165 170 175 Ala Leu Leu Ile Tro Phe Leu Leu Lys Arg Tyr Ser Arg Lys Met Gly

180 185 190

Phe

(2) INFORMATION FOR SEQ ID NO:157:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH. 129 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY- linear

(n) MOLECULE TYPE, protein

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...129

(xi) SEQUENCE DESCRIPTION: SEQ ID NO-157

Met Arg Lys Gly Arg Val Met Leu Cys Val Phe Asp Ile Glu Thr Ile

1 5 10 15

Pro Asn Ile Ser Leu Cys Lys Glu His Phe Gin Leu Lys Glu Asp Asp

20 25 30

Ala Leu Lys lie Cys Glu Trp Ser Phe Glu Lys Gin Lys Glu Lys Ser

35 40 45

Gly Ser Glu Phe Leu Pro Leu Tyr Leu His Glu Ile Ile Ser Ile Ala

50 55 60

Ala Val Ile Gly Asp Asp Tyr Gly Gin Phe Ile Lys Val Gly Asn Phe 65 70 75 80

Gly Gin Lys His Glu Asn Lys Glu Asp Phe Ala Ser Glu Lys Glu Leu

85 90 95

Leu Glu Asp Phe Phe Lys Tyr Phe Asn Glu Lys Gin Pro Arg Leu Ile

100 105 110

Ser Phe Xaa Gly Arg Gly Phe Gly Tyr Ser Pro Thr His Ala Gin Ser

115 120 125

Pro

(2) INFORMATION FOR SEQ ID NO: 158:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...307

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158

Met Ala Lys Lys Lys Ile Ala Ile Ser Cys Gly Asp Ile Gin Gly Val

1 5 10 15

Gly Leu Glu Leu Ile Leu Lys Ser His Lys Glu Val Ser Ala Leu Cys

20 25 30

Glu Pro Leu Tyr Leu Val His Ser Glu Leu Leu Glu Arg Ala Asn Gin 35 40 45

Leu Leu Asp Asn Ala Tyr Glu Thr Lys Thr Leu Asn Ala Ile Ala Ile

50 55 60

Asp Ala Pro Leu Pro Leu Leu Asn Ser Ser Thr Ile Gly Lys Val Ser 65 70 75 80

Thr Gin Ser Gly Ala Tyr Ser Phe Glu Ser Phe Lys Lys Ala Cys Glu

85 90 95

Leu Ala Asp Ser Lys Glu Val Asp Gly Ile Cys Thr Leu Pro Ile Asn

100 105 110

Lys Leu Ala Trp Gin Gin Ala Gin Ile Pro Phe Val Gly His Thr Asp

115 120 125

Phe Leu Lys Gin Arg Tyr Lys Asp His Gin Ile lie Met Met Leu Gly

130 135 140

Cys Ser Lys Leu Phe Val Gly Leu Phe Ser Asp His Val Pro Leu Ser 145 150 155 160

Ala Val Ser Gin Leu Ile Gin Val Lys Ala Leu Val Lys Phe Leu Leu

165 170 175

Ala Phe Gin Lys Ser Thr Gin Ala Lys Ile Val Gin Val Cys Gly Phe

180 185 190

Asn Pro His Ala Gly Glu Glu Gly Leu Phe Gly Glu Glu Asp Glu Lys

195 200 205

Ile Leu Lys Ala Ile Gin Glu Ser Asn Gin Thr Leu Gly Phe Glu Cys

210 215 220

Phe Leu Gly Pro Leu Pro Ala Asp Ser Ala Phe Ala Pro Asn Lys Arg 225 230 235 240

Lys Ile Thr Pro Phe Tyr Val Ser Met Ser His Asp Val Gly Leu Ala

245 250 255

Pro Leu Lys Ala Leu Tyr Phe Asp Glu Ser Ile Asn Val Ser Leu Asn

260 265 270

Ala Pro Ile Leu Arg Ala Ser Thr Asp His Gly Thr Ala Phe Asp Ile

275 280 285

Ala Tyr Gin Asn Lys Ala Asn His Lys Ser Tyr Leu Asn Ala lie Lys

290 295 300

Tyr Leu Ala 305

(2) INFORMATION FOR SEQ ID NO:159:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 146 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...146

(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:159

Met Ser Ser Gly Leu Ile Tyr Ile Ser Leu Glu Val Leu Val Xaa Cys

1 5 10 15

Leu Ile Thr Ala Leu Ile Met Tyr Tyr Val Met Lys Lys Ile Tyr Tyr

20 25 30

Ala Arg Gly Gin Ala Ile Leu Lys Gly Ala Ser Ala Lys Ala Lys Leu

35 40 45

Met Glu Phe Gin Ala Lys Ser Phe Val Glu Ala Glu Glu Met Arg Met

50 55 60

Lys Ser Gin Glu Cys Lys Leu Gin Gin Gin Tyr Glu Asn Lys Asn Leu

65 70 75 80

Gin Leu Gin Thr His Phe Asp Lys Lys Glu Ala His Leu Lys His Leu

85 90 95

Glu Ala Gin His Lys Glu Phe Val Arg Asp Glu Lys Arg Tyr Leu Glu 100 105 110

Lys Glu Lvs Lys Glu Leu Glu Lys Glu Arg Gin Ile Leu Glu Xaa Glu

115 120 125

Arg Glu Asn Phe Xaa Xaa Gin Arg Ala Phe Val Xaa Xaa Xaa Xaa Ala

130 135 140

Lys Ala 145

(2) INFORMATION FOR SEQ ID NO: 160:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 127 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY, linear

(n) MOLECULE TYPE: prote

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...127

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160

Met Asn Ile Lys Ile Leu Lys Ile Leu Val Gly Gly Leu Phe Phe Leu

1 5 10 15

Ser Leu Asn Ala His Leu Trp Gly Lys Gin Asp Asn Ser Phe Leu Gly

20 25 30

Ile Gly Glu Arg Ala Tyr Lys Ser Gly Asn Tyr Ser Lys Ala Ala Ser

35 40 45

Tyr Phe Lys Lys Ala Cys Asn Asp Gly Val Ser Glu Gly Cys Thr Gin

50 55 60

Leu Gly Ile Ile Tyr Glu Asn Gly Gin Gly Thr Arg Ile Asp Tyr Lys 65 70 75 80

Lys Ala Leu Glu Tyr Tyr Lys Thr Ala Cys Gin Ala Asp Asp Arg Glu

85 90 95

Gly Cys Phe Gly Leu Gly Gly Leu Tyr Asp Glu Gly Leu Gly Thr Ala

100 105 110

Gin Asn Tyr Gin Glu Ala Xaa Asp Ala Tyr Ala Arg His Ala Phe 115 120 125

(2) INFORMATION FOR SEQ ID NO: 161:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 116 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

( lil) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...116

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161

Met Ala Ile Ala Ile Lys Asp Leu Leu Ser Ala Tyr Lys Val Val Leu 1 5 10 15

Pro Leu Asp Lys Ile Ser Met Pro Ser Ser Ala Asp Leu Lys Leu Thr 20 25 30 Leu Gin Phe Leu Lys Asn Thr Ala Pro Leu Phe Ser Val Gin Gly Ser

35 40 45

Val Asn Leu Gin Glu Gly Thr Phe Ser Leu Tyr Asn Ile Pro Leu Tyr

50 55 60

Thr Gin Ser Ala Gin Ile Asn Leu Asp Ile Ala Gin Glu Tyr Gin Tyr 65 70 75 80

Ile Tyr lie Asp Thr lie His Thr Arg Tyr Ala Asn Met Xaa Asp Leu

85 90 95

Asp Ala Lys Ile Ala Leu Asp Leu Gly Gin Lys Asn Leu Ser Xaa Xaa

100 105 110

Xaa Leu Gly Pro 115

(2) INFORMATION FOR SEQ ID NO: 162:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 82 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...82

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162

Met Pro Asp Asn Leu His Leu His Thr Leu Leu Xaa Lys Phe Leu Gin

1 5 10 15

Gin Arg Ser Phe Asn Tyr Pro Asn Pro Leu Cys Ala Phe lie Leu Ile

20 25 30

Leu Cys Asn Leu Pro Phe Ile Leu Ile Ser Val Leu Phe Arg Leu Asp

35 40 45

Ala Tyr Ala Leu Ile Val Ile Ser Leu Val Phe Ile Xaa Cys Tyr Leu

50 55 60

Ile Gly Xaa Ala Tyr Leu Asn Arg Gin Val Cys Ala Leu Glu Lys Arg 65 70 75 80

Ala Phe

(2) INFORMATION FOR SEQ ID NO: 163:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 116 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(u) MOLECULE TYPE: protem

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...116

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163

Leu Lvs Val Thr Asn Pro His Leu Leu Val Val Ile Gin Asp Leu Asn

1 5 10 15

Ala Arg Ile Ala Leu Met Lys Leu Leu Phe Gin Asn Val Lys Ser Ala 20 25 30

Asn Lys Glu Leu Val Phe Cys Asn Lys Glu Lys Arg Leu Ile Arg Ser

35 40 45

Phe Asp Ala Gin Lys Glu Tyr Gly lie Thr Pro Val Glu Asn Ile Leu

50 55 60

Ser Val Leu Asp Thr Ala Met Asn Pro Asn Ser Ala Leu Val Ile Asp 65 70 75 80

Asn Leu Asn Glu Ala Lys Glu Leu His Asp Lys Val Gly Ala Glu Lys

85 90 95

Leu Lys Ser Phe Leu Glu Lys Ala Xaa Arg Gin Arg Ala Val Leu Arg

100 105 110

His Phe Cys Ala 115

(2) INFORMATION FOR SEQ ID NO: 164:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 198 amino acids

(B) TYPE: amino acid (D) TOPOLOGY, linear

(n) MOLECULE TYPE: protem

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...198

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164

Met Lys Glu Ser Phe Tyr Ile Glu Gly Met Thr Cys Thr Ala Cys Ser

1 5 10 15

Ser Gly lie Glu Arg Ser Leu Gly Arg Lys Ser Phe Val Lys Lys Ile

20 25 30

Glu Val Ser Leu Leu Asn Lys Ser Ala Asn Ile Glu Phe Asn Glu Asn

35 40 45

Glu Thr Asn Leu Asp Glu lie Phe Lys Leu Ile Glu Lys Leu Gly Tyr

50 55 60

Ser Pro Lys Lys Thr Leu Ala Glu Glu Lys Lys Glu Phe Phe Ser Pro 65 70 75 80

Asn Val Lys Leu Ala Leu Ala Val Ile Phe Thr Leu Phe Val Val Tyr

85 90 95

Leu Ser Met Gly Ala Met Leu Ser Pro Ser Leu Leu Pro Glu Ser Leu

100 105 110

Leu Thr Ile Asn His His Ser Asn Phe Leu Asn Ala Cys Leu Gin Leu

115 120 125

Ile Gly Ala Leu Ile Val Met His Leu Gly Arg Asp Phe Tyr Ile Gin

130 135 140

Gly Phe Lys Ala Leu Trp His Arg Gin Pro Asn Met Ser Ser Leu Ile 145 150 155 160

Ala Ile Gly Thr Ser Ala Ala Leu Ile Ser Ala Cys Gly Asn Cys Ile

165 170 175

Trp Phe Ile Pro Ile Ile Ile Pro Ile Ser Gly Leu Met Gly Ile Ile

180 185 190

Ile Leu Lys Ala Cys Ala 195

(2) INFORMATION FOR SEQ ID NO: 165:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 85 ammo acids

(D) TOPOLOGY, linear

(n) MOLECULE TYPE: protem (m) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...85

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165

Val Gly lie Val Pro Asp Asn Leu Trp Lys Leu Lys Arg Phe Asn Gin

1 5 10 15

Asp Trp Arg Val Gly Asp Thr Leu Ile Thr Ala lie Gly Gin Gly Ser

20 25 30

Phe Leu Ala Thr Pro Leu Gin Val Leu Ala Tyr Thr Gly Leu lie Ala

35 40 45

Thr Gly Lys Leu Ala Thr Pro His Phe Ala Ile His Asn Gin Gin Pro

50 55 60

Leu Lys Asp Pro Leu Asn Arg Phe Ser Lys Lys Glu Ala Pro Ser Leu 65 70 75 80

Ala Arg Gly His Val 85

(2) INFORMATION FOR SEQ ID NO: 166:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 343 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(lil) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...343

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166

Met Gin Asn Leu Leu Ile Gin Ala Glu Asn Ala lie Ala Leu Leu Phe

1 5 10 15

Leu Leu Asn Asp Lys Asn Leu Lys Gly Lys lie Asp Leu Ile Tyr Ile

20 25 30

Asp Pro Pro Phe Ala Thr Asn Asn His Phe Thr Ile Thr Asn Gly Arg

35 40 45

Ala Thr Thr Ile Ser Asn Ser Lys Asn Gly Asp Ile Ala Tyr Ser Asp

50 55 60

Lys Val Val Gly Met Asp Phe Met Glu Phe Leu Lys Gin Arg Leu Val 65 70 75 80

Leu Leu Lys Glu Leu Leu Ser Glu Gin Gly Ser Ile Tyr Val His Thr

85 90 95

Asp Tyr Lys Ile Gly His Tyr Val Lys Val Met Leu Asp Glu Ile Phe

100 105 110

Gly Ile Gin Asn Phe Arg Asn Glu Ile Thr Arg Ile Lys Cys Asn Pro

115 120 125

Lys Asn Phe Lys Arg Ile Gly Tyr Gly Asn lie Lys Asp Met Ile Leu

130 135 140

Phe Tyr Ser Lys Gly Lys Asn Pro lie Phe Asn Glu Pro Lys Ile Pro 145 150 155 160

Tyr Thr Pro Gin ASD Leu Glu Lys Arg Phe Pro Lys lie Asp Lys Asp

165 170 175

Lys Arg Arg Tvr Thr Thr Val Pro Ile His Ala Pro Gly Glu Val Glu 180 185 190 Ser Glv Glu Cys Ser Lys Ala Phe Lys Gly Met Leu Pro Pro Lys Gly

195 200 205

Arg His Trp Arg Thr Asp Ile Ala Thr Leu Glu Arg Trp Asp Lys Glu

210 215 220

Gly Leu lie Glu Tyr Ser Asn Asn Asn Asn Pro Arg Lys Lys Ile Tyr 225 230 235 240

Ala Leu Glu Gin Val Gly Lys Arg Val Gin Asp Ile Trp Glu Phe Lys

245 250 255

Asp Pro Gin Tyr Pro Ser Tyr Pro Thr Glu Lys Asn Ala Gin Leu Leu

260 265 270

Asp Leu Ile Ile Lys Thr Ser Ser Asn Lys Asp Ser Ile Val Leu Asp

275 280 285

Cys Phe Cys Gly Ser Gly Thr Thr Leu Lys Ser Ala Phe Leu Leu Gin

290 295 300

Arg Lys Phe Ile Gly Ile Asp Asn Ser Asp Leu Ala Ile Gin Ala Cys 305 310 315 320

Lys Asn Lys Leu Glu Thr Ile Thr Lys Asp Leu Phe Val Ser Gin Asn

325 330 335

Phe Tyr Asp Phe Leu Val Phe 340

(2) INFORMATION FOR SEQ ID NO: 167:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 176 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: prote

(ni) HYPOTHETICAL. YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...176

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167

Met Thr Ser Val Val Ile Lys Pro His Ala Tyr Gly Glu Gin Val Gin

1 5 10 15

Glu Ile Glu Glu Glu Ser Asp Ser Asp Tyr Glu Lys Asn Asn Asp Gin

20 25 30

Glu Ala Ile Asn Phe Gly Ile Ala Leu His Lys Gly Leu Glu Tyr Gin

35 40 45

Tyr Ala Tyr Asn Ile Pro Lys Gin Ser Val Leu Glu Tyr Leu Asn Tyr

50 55 60

His Tyr Gly Phe Tyr Gly Leu Asp Tyr Gin Ala Leu Glu Glu Ser Leu 65 70 75 80

Glu Leu Phe Glu Asn Asp Ala Gly Ile Gin Ala Leu Phe Lys Asn His

85 90 95

Ala Leu Lys Gly Glu Ala Ala Phe Leu Phe Gin Gly Val Val Ser Arg

100 105 110

Ile Asp Val Leu Leu Trp Asp Arg Gly Gin Asn Leu Tyr Val Leu Asp

115 120 125

Tyr Lys Ser Ser Gin Asn Tyr Gin Gin Ser His Lys Ala Gin Val Ser

130 135 140

His Tyr Ala Glu Phe Leu Arg Thr Gin Xaa Pro His Phe Lys lie Gin 145 150 155 160

Ala Gly Ile lie Tyr Ala His Lys Arg Leu Leu Glu Lys Xaa Trp Xaa 165 170 175

(2) INFORMATION FOR SEQ ID NO: 168:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 260 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...260

( i) SEQUENCE DESCRIPTION: SEQ ID NO:168

Met Ser Glu Asp Leu Pro Phe Ala Ser Asp Ser Gin Phe Thr Tyr Asn

1 5 10 15

Gly Val Ser Ile Thr Arg Pro Thr Asn Glu Val Asn Asp Val Ile Ser

20 25 30

Gly Val Asn Ile Thr Leu Glu Gin Thr Thr Glu Pro Asn Lys Pro Ala

35 40 45

Ile Ile Ser Val Ser Arg Asp Asn Gin Ala Ile Ile Asp Ser Leu Lys

50 55 60

Glu Phe Val Lys Ala Tyr Asn Glu Leu Ile Pro Lys Leu Asp Glu Asp 65 70 75 80

Thr Arg Tyr Asp Ala Asp Thr Lys Ile Ala Gly Ile Phe Asn Gly Val

85 90 95

Gly Asp Ile Arg Ala Ile Arg Ser Ser Leu Asn Asn Val Phe Ser Tyr

100 105 110

Ser Val His Thr Asp Asn Gly Val Glu Ser Leu Met Lys Tyr Gly Leu

115 120 125

Ser Leu Asp Asp Lys Gly Val Met Ser Leu Asp Glu Ala Lys Leu Ser

130 135 140

Ser Ala Leu Asn Ser Asn Pro Lys Ala Thr Gin Asp Phe Phe Tyr Gly 145 150 155 160

Ser Asp Ser Lys Asp Met Gly Gly Arg Glu Ile His Gin Glu Gly Ile

165 170 175

Phe Ser Lys Phe Asn Gin Val Ile Ala Asn Leu Ile Asp Gly Gly Asn

180 185 190

Ala Lys Leu Lys lie Tyr Glu Asp Ser Leu Asp Arg Asp Ala Lys Ser

195 200 205

Leu Thr Lys Asp Lys Glu Asn Ala Gin Glu Leu Leu Lys Thr Arg Tyr

210 215 220

Asn Ile Met Ala Glu Arg Phe Ala Ala Tyr Asp Ser Gin Ile Ser Lys 225 230 235 240

Ala Asn Gin Lys Phe Asn Ser Val Gin Met Met Ile Asp Gin Ala Ala

245 250 255

Ala Lys Lys Asn 260

(2) INFORMATION FOR SEQ ID NO: 169:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 145 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...145

( i) SEQUENCE DESCRIPTION: SEQ ID NO: 169 Met Arg Ile Val Phe Met Gly Thr Pro Ser Phe Ala Glu Val Ile Leu

1 5 10 15

Arg Ala Leu Val Glu Asn Glu Asp Lys Lys Ile Glu Val Val Gly Leu

20 25 30

Phe Thr Gin Arg Asp Lys Pro Phe Gly Arg Lys Lys Glu Leu Lys Ala

35 40 45

Pro Glu Thr Lys Thr Tyr Ile Leu Glu Asn His Leu Asn Ile Pro Ile

50 55 60

Phe Gin Pro Gin Ser Leu Lys Glu Pro Glu Val Gin Ile Leu Lys Gly 65 70 75 80

Leu Lys Pro Asp Phe Ile Val Val Val Ala Tyr Gly Lys Ile Leu Pro

85 90 95

Lys Glu Val Leu Thr Ile Ala Pro Cys Ile Asn Leu His Ala Ser Leu

100 105 110

Leu Pro Lys Tyr Arg Gly Ala Ser Pro Ile His Glu Met lie Leu Asn

115 120 125

Asp Asp Arg lie Tyr Gly Ile Ser Thr Met Leu Met Xaa Phe Gly Ile

130 135 140

Gly 145

(2) INFORMATION FOR SEQ ID NO: 170.

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 248 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(il) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιεc_feature

(B) LOCATION 1...248

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170

Met Arq Phe Tyr Phe Lys Phe Leu Trp Leu Leu Gly Ile Phe Leu Ile

1 5 10 15

Phe Tyr Phe Leu Asp Ile Lys Gly Ser Ser Ser Tyr Ile Ser Asp Arg

20 25 30

Val Lys Ser Ala Leu Met Ser Ala Lys Asn Ser Leu Leu Asp Asn Val

35 40 45

Gin Ala Tyr Phe Phe Gin Ala Gin Asn Ile Lys Glu Phe Gin Lys Glu

50 55 60

Arg Leu Ile Leu Glu Ala Leu Lys Leu Glu Asn Ala Asp Leu Lys Glu 65 70 75 80

Arg Leu Asn Ser Ile Tyr Pro Leu Glu Asn Pro Lys Met Thr Tyr Thr

85 90 95

Pro Thr Phe Met Thr Ser Phe Ile Asn Leu Glu Asp Thr His Ser Val

100 105 110

Ser Leu Asn Pro Ile Val Asn Leu Glu Glu Asn Lys Ile Tyr Gly Leu

115 120 125

Val Ser His Asn Gin Ala Ile Gly Ile Ala Val Leu Glu Lys Gly Arg

130 135 140

Leu Asn Gly Phe Leu Asn Ala His Lys Arg Cys Ala Tyr Ser Val Met 145 150 155 160 lie Gly Gin Asn Gin Val Leu Gly Phe Ile Gly Thr Asn Phe Lys Gin

165 170 175

Glu Leu Val Val Asp Phe Ile Val Pro Ser Ala Glu Ile Asn Ile Gly

180 185 190

Asp Gin Val Leu Thr Ser Gly Leu Asp Gly Ile Phe Gly Ala Gly Val

195 200 205

Phe Val Gly Glu Val Ser Ser Val Glu Asp His Tyr Thr Tyr Lys Ser 210 215 220

Ala Val Leu Lys Asn Ala Phe Leu Ser Glu Ala Lys Leu Leu Arg His 225 230 235 240

Val Phe Leu Ser Gly Val Lys Asn 245

(2) INFORMATION FOR SEQ ID NO: 171:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 119 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...119

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171

Leu Ala Leu Arg Leu Pro Phe Leu Ile Ala His Val Ile Asn Met Phe

1 5 10 15

Leu Phe Tyr Leu Ile Gly Arg Lys Ile Leu Lys Lys Pro Lys Asp Ala

20 25 30

Leu Tyr Val Val Leu Thr Tyr Ala Leu Leu Pro Gly Val Asn Leu Phe

35 40 45

Ala Ile Leu Leu Ala Lys Ser Val Leu Val Leu Ser Leu Gly Leu Leu

50 55 60

Ile Ser Tyr Leu Tyr Ile Lys Thr Gin Lys Ile Pro Tyr Leu Thr Leu 65 70 75 80

Ser Ala Cys Ala Phe Leu Asp Gly Ala Phe Ile Pro Leu Leu Leu Gly

85 90 95

Val Phe Ala Tyr Ala Leu Arg Lys Thr Ala Ile Leu Arg Ala Arg Ser

100 105 110

Leu Leu Trp Trp Phe Xaa Leu 115

(2) INFORMATION FOR SEQ ID NO: 172:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...108

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 172

Val Asn Leu Met Asp Tyr Phe Ser Lys Ser Leu Phe Leu Asn Ser Leu

1 5 10 15

Asn Thr Gin Arg Leu Ile Val Ser Asn Lys Leu Ala Ile Asp Val Gin

20 25 30

Tyr Gly Met Leu Gin Ser Val Arg Lys Asn Tyr Pro Asp Val Val Asp 35 40 45 Gly Glv Val Arg Glu Gly Pro Phe Trp Val Leu Ala Gly Ala Leu Met

5θ^" 55 60

Pro Ser lie Leu Ile Glu Ile Gly Tyr Asn Ser His Ala Ile Glu Ser 65 70 75 80

Lys Arg lie Gin Ser Lys Pro Tyr Gin Lys Ile Leu Ala Lys Gly lie

85 90 95

Ala Asp Gly Ile Asp Ser Phe Phe Ser Lys Asn Asp 100 105

(2) INFORMATION FOR SEQ ID NO.173:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 157 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY, linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE-

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE-

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1...157

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173

Leu Ala Ser Arg Tyr Ser Val Ala Val Gly Asn Leu Phe Ser Glu His

1 5 10 15

Leu Tyr Asp Leu Arg Asn Glu Thr Met Thr Asn Leu Ile Gly Phe Leu

20 25 30

Leu Val Leu Ala Ser Ile Trp Val Phe Phe Leu Ala Leu Gly Val Leu

35 40 45

Leu Gly Lys Met Leu Val Phe Ser Gly Leu Gly Ile Ile Asp Lys Ala

50 55 60

Leu Gly Phe Ile Phe Ser Cys Leu Lys Thr Phe Leu Val Leu Ser Phe 65 70 75 80

Ile Leu Tyr Ala Leu Ser Lys Met Asp Leu Met Lys Asp Ala Asn Ala

85 90 95

Tyr Leu Gin Glu Lys Xaa Xaa Ile Phe Pro Thr Xaa Lys Xaa Xaa Xaa

100 105 110

Ser Lys lie Met Arg Leu Asp Gly Val Lys His Val Glu Lys Asn Leu

115 120 125

Lys Asp Asn Leu Glu Glu Met Ser Asp Glu Val Lys Asn Lys Gly Ser

130 135 140

Ile Asp Asn Ala Lys Glu Ser Phe Asn Lys Gly Tyr Gly 145 150 155

(2) INFORMATION FOR SEQ ID NO: 174:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 81 ammo acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

( n) HYPOTHETICAL: YES

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY. nusc_feature

(B) LOCATION 1...81

( i) SEQUENCE DESCRIPTION: SEQ ID NO.174 Leu Ser Lys Gin Ser Ala Asp Ile Val Ile Thr Asn Asp Ser Leu Ser

1 5 10 15

Ser Leu Val Lys Val Leu Ala lie Ala Lys Lys Thr Lys Ser Ile Thr

20 25 30

Trp Gin Asn Ile Leu Phe Ala Leu Gly lie Lys Ala Val Phe Ile Val

35 40 45

Leu Gly Leu Met Gly Val Ala Ser Leu Trp Glu Ala Val Phe Gly Asp

50 55 60

Val Gly Val Thr Leu Leu Ala Leu Ala Asn Ser Xaa Arg Thr Met Arg 65 70 75 80

Ala

(2) INFORMATION FOR SEQ ID NO:175:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 80 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...80

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175

Met Lys Asn Leu Arg His Phe Arg Lys Leu Ile Ala Phe Leu Gly Phe

1 5 10 15

Ser Pro Leu Leu Leu Gin Ala Asp Met Thr Thr Phe Phe Asn Ser Ile

20 25 30

Glu Gin Gin Leu Thr Ser Pro Thr Ala Lys Gly Ile Leu Met Val Ile

35 40 45

Phe Leu Gly Leu Ala Ile Phe Ile Trp Lys Asn Leu Asp Arg Trp Lys

50 55 60

Glu Ile Leu Met Thr Val Leu Ala Leu Lys Xaa Val Pro Met Gin Xaa 65 70 75 80

(2) INFORMATION FOR SEQ ID NO: 176:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 325 am o acids

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...325

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:176

Leu Ala Gly Leu Xaa Val Gly Cys Xaa Arg Met Lys Gin Thr Phe Trp 1 5 10 15

Xaa Leu Ser Trp Gly Glu Lys Ser Gin Lys Val Cys Val His Arg Pro 20 25 30 Trp Tyr Ala Ile Trp Ser Cys Asp Lys Trp Glu Glu Lys Thr Gin Gin

35 40 45

Phe Thr Gly Asn Gin Leu Ile Thr Lys Thr Trp Ala Gly Gly Asn Ala

50 55 60

Ala Asn Tyr Tyr His Ser Gin Asn Asn Gin Asp Ile Thr Ala Asn Leu 65 70 75 80

Lys Asn Asp Asn Gly Thr Tyr Phe Leu Ser Gly Leu Tyr Asn Tyr Thr

85 90 95

Gly Gly Glu Tyr Asn Gly Gly Asn Leu Asp Ile Glu Leu Gly Ser Asn

100 105 110

Ala Thr Phe Asn Leu Gly Ala Ser Ser Gly Asn Ser Phe Thr Ser Trp

115 120 125

Tyr Pro Asn Gly His Thr Asp Val Thr Phe Ser Ala Gly Thr Ile Asn

130 135 140

Val Asn Asn Ser Val Glu Val Gly Asn Arg Val Gly Ser Gly Ala Gly 145 150 155 160

Thr His Thr Gly Thr Ala Thr Leu Asn Leu Asn Ala Asn Lys Val Thr

165 170 175 lie Asn Ser Asn Ile Ser Ala Tyr Lys Thr Ser Gin Val Asn Val Gly

180 185 190

Asn Ala Asn Ser Val Ile Thr lie Asn Ser Val Ser Leu Asn Gly Glu

195 200 205

Thr Cys Xaa Ser Leu Ala Arg Val Gly Val Gly Ala Asn Cys Ser Thr

210 215 220

Ser Gly Pro Ser Tyr Ser Phe Lys Gly Thr Thr Asn Ala Thr Asn Thr 225 230 235 240

Thr Phe Ser Xaa Ser Ser Gly Ser Phe Thr Phe Glu Glu Asn Ala Thr

245 250 255

Phe Ser Gly Ala Lys Leu Asn Gly Gly Ala Phe Thr Phe Asn Lys Lys

260 265 270

Phe Asn Ala Thr Asn Asn Thr Ala Phe Asn Ser Gly Ser Phe Thr Phe

275 280 285

Lys Gly Thr Ser Ser Phe Asn Gly Ala Asn Phe Ser Asn Ala Ser Tyr

290 295 300

Thr Phe Asn Asn Gin Ala Thr Phe Gin Asn Ser Ser Phe Asn Gly Gly 305 310 315 320

Thr Phe Thr Phe Asn 325

(2) INFORMATION FOR SEQ ID NO:177-

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 271 ammo acids

(D) TOPOLOGY linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 ..271

(Xi) SEQUENCE DESCRIPTION: SEQ ID NO.177

Leu Leu Ser Leu Val Lys Gly Lys Thr Met Leu Arg Ser Leu Tyr Ser

1 5 10 15

Ala Thr Ser Gly Met Leu Ala Gin Gin Thr His Ile Asp Thr Thr Ser

20 25 30

Asn Asn Ile Ala Asn Val Asn Thr Thr Gly Phe Lys Lys Ser Arg Ala

35 40 45

Asp Phe Asn Asp Leu Phe Tyr Gin Ala Met Gin Tyr Ala Gly Thr Asn

50 55 60

Thr Ser Asn Thr Thr Leu Ser Pro Asp Gly Met Glu Val Gly Leu Gly 65 70 75 80 Val Arg Pro Ser Ala lie Thr Lys Met Phe Ser Gin Gly Ser Pro Lys

85 90 95

Glu Thr Glu Asn Asn Leu Asp Ile Ala Ile Thr Gly Lys Gly Pne Phe

100 105 110

Gin Val Gin Leu Pro Asp Gly Thr Thr Ala Tyr Thr Arg Ser Gly Asn

115 120 125

Phe Lys Leu Asp Glu Gin Gly Asn Leu Val Thr Ser Glu Gly Tyr Leu

130 135 140

Leu Ile Pro Gin Ile Thr Leu Pro Glu Asp Thr Thr Gin Val Asn Ile 145 150 155 160

Gly Val Asp Gly Thr Val Ser Val Thr Gin Gly Leu Gin Thr Thr Ser

165 170 175

Asn Val Ile Gly Gin Ile Thr Leu Ala Asn Phe Val Asn Pro Ala Gly

180 185 190

Leu His Ser Met Gly Asp Asn Leu Phe Ser Ile Thr Asn Ala Ser Gly

195 200 205

Asp Ala Ile Val Gly Asn Pro Asp Ser Gin Gly Leu Gly Lys Leu Arg

210 215 220

Gin Gly Phe Leu Glu Leu Ser Asn Val Arg Leu Val Glu Glu Met Thr 225 230 235 240

Asp Leu Ile Thr Ala Gin Arg Ala Tyr Glu Ala Asn Ser Lys Ser lie

245 250 255

Gin Thr Ala Asp Ala Met Leu Gin Thr Val Asn Ser Leu Lys Arg 260 265 270

(2) INFORMATION FOR SEQ ID NO:178:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 90 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM. Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...90

(xi) SEQUENCE DESCRIPTION. SEQ ID NO 178

Met Gin Asn Gly Tyr Tyr Ala Ala Thr Gly Ala Met Ala Thr Gin Phe

1 5 10 15

Asn Arg Leu Asp Leu Thr Ser Asn Asn Leu Ala Asn Leu Asn Thr Asn

20 25 30

Gly Phe Lys Arg Asp Asp Ala Ile Thr Gly Asp Phe Leu Arg Leu Tyr

35 40 45

Gin Glu Tyr Arg Glu Gin Leu Pro Leu Glu Asp Gin Thr Lys Ala Ser

50 55 60

Ala Lys Tyr Leu Asn Arg Xaa Leu Asn Arg Val Pro Ile Leu Ser Xaa 65 70 75 80

Ile Tyr Thr Xaa Arg Xaa Leu Gly Xaa Val 85 90

(2) INFORMATION FOR SEQ ID NO: 179:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 195 ammo acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(in) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE-

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...195

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 179

Val Gly Ala Met Pro Thr Ile Gin Ile Arg Xaa Phe Gly Ala Gly Gly

1 5 10 15

Ser Gly His Ser Asp Ala Thr Leu Met Leu Val Asn Gly Ile Pro Val

20 25 30

Tyr Met Ala Pro Tyr Ala His lie Glu Leu Asp Ile Phe Pro Val Thr

35 40 45

Phe Gin Ala Ile Asp Arg Ile Asp Val Ile Lys Gly Gly Gly Ser Val

50 55 60

Gin Tyr Gly Pro Asn Thr Tyr Gly Gly Ile Val Asn Ile lie Thr Lys 65 70 75 80

Pro Ile Pro Asn Gin Trp Glu Asn Gin Ala Ala Glu Arg Xaa Thr Tyr

85 90 95

Trp Ala Lys Ala Arg Asn Ala Gly Phe Ala Ala Pro Xaa Asp Lys Thr

100 105 110

Gly Asp Pro Ser Phe Ile Lys Ser Leu Gly Asn Asn Leu Leu Tyr Asn

115 120 125

Thr Tyr Val Arg Ser Gly Gly Met Ile Asn Lys His Val Gly Ile Gin

130 135 140

Arg Lys Leu Thr Gly Leu Glu Ala Lys Ala Leu Gly Thr Ile Ala Pro 145 150 155 160

Leu Val Phe Gin Thr Ile Gly Trp Met Gly Ser Met Thr Ser Met Lys

165 170 175

Ala Met Gly Leu Lys Pro lie Thr Asn Thr Thr Ile Leu Ala Ile Xaa

180 185 190

Gin Pro Gly 195

(2) INFORMATION FOR SEQ ID NO: 180:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 84 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(lil) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...84

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 180

Met Arg Xaa Glu Lys Ile Met Thr Asn Phe Glu Lys Xaa Ile Ala Gin

1 5 10 15

Asn Arg Leu Lys Thr Asn Ala Val Leu Thr Thr Tyr Cys Ala Ile Phe

20 25 30

Ala Phe Ile Gly Leu Leu Val Asp Ala lie Arg Ile Asn Ala Asn Asp

35 40 45

Leu Gly Ile Ala Leu Phe Lys Leu Met Thr Phe Gin Ile Phe Pro Thr

50 55 60

Xaa Thr Ile Val Met Phe Val Val Ala Phe Val Ile Xaa Xaa Ser Leu 65 70 75 80

Tyr Pro Lys Phe (2) INFORMATION FOR SEQ ID NO: 181:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH. 76 amino acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE, protem

(in) HYPOTHETICAL. YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE-

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...76

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 181

Met Xaa Met Ser His lie Ile Lys Ser Ile Glu Ala Leu Asp Asp Tyr

1 5 10 15

Thr Ile Arg Phe Thr Leu Asn Gly Pro Glu Ala Pro Phe Leu Ala Asn

20 25 30

Leu Gly Met Asp Phe Leu Ser Ile Leu Ser Lys Asp Tyr Ala Asp Tyr

35 40 45

Leu Ala Gin Asn Asn Lys Lys Asp Glu Leu Ala Lys Xaa Pro Val Gly

50 55 60

Thr Gly Pro Phe Lys Phe Phe Leu Trp Asn Lys Arg 65 70 75

(2) INFORMATION FOR SEQ ID NO: 182:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 196 ammo acids

(B) TYPE- amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE, protem

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...196

(xi) SEQUENCE DESCRIPTION- SEQ ID NO: 182

Leu Met Arg Lys Ile Phe Ser Tyr Ile Ser Lys Val Leu Leu Phe Ile

1 5 10 15

Gly Val Val Tyr Ala Glu Pro Asp Ser Lys Val Glu Ala Leu Glu Gly

20 25 30

Arg Lys Gin Glu Ser Ser Leu Asp Lys Lys Ile Arg Gin Glu Leu Lys

35 40 45

Ser Lys Glu Leu Lys Asn Lys Glu Leu Lys Asn Lys Asp Leu Lys Asn

50 55 60

Lys Glu Glu Lys Lys Glu Thr Lys Ala Lys Arg Lys Pro Arg Ala Glu 65 70 75 80

Val His His Gly Asp Ala Lys Asn Pro Thr Pro Lys Ile Thr Pro Pro

85 90 95

Lys Ile Lys Gly Ser Ser Lys Gly Val Gin Asn Gin Gly Val Gin Asn

100 105 110

Asn Ala Pro Lys Pro Glu Glu Lys Asp Thr Thr Pro Gin Ala Thr Glu

115 120 125

Lys Asn Lys Glu Thr Ser Pro Ser Ser Gin Phe Asn Ser Ile Phe Gly 130 135 140 Asn Pro Asn Asn Ala Thr Asn Asn Thr Leu Glu Asp Lys Val Val Gly 145 150 155 160

Gly Ile Ser Leu Leu Val Asn Gly Ser Pro Ile Thr Leu Tyr Gin lie

165 170 175

Gin Glu Glu Gin Glu Lys Ser Lys Val Ser Xaa Ala Xaa Ala Arg Asp

180 185 190

Arg Leu Xaa Xaa 195

(2) INFORMATION FOR SEQ ID NO: 183:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 179 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_ eature

(B) LOCATION 1...179

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183

Met Lys Arg Ser Ser Val Phe Ser Phe Leu Val Ala Phe Leu Leu Val

1 5 10 15

Val Gly Cys Ser His Lys Met Asp Asn Lys Thr Val Ala Gly Asp Val

20 25 30

Ser Thr Lys Ala Val Gin Thr Ala Pro Val Thr Thr Glu Pro Ala Pro

35 40 45

Glu Lys Glu Glu Pro Lys Gin Glu Pro Ala Pro Val Val Glu Glu Lys

50 55 60

Pro Ala Ile Glu Ser Gly Thr Ile Ile Ala Ser Ile Tyr Phe Asp Phe 65 70 75 80

Asp Lys Tyr Glu Ile Lys Glu Ser Asp Gin Glu Thr Leu Asp Glu Ile

85 90 95

Val Gin Lys Ala Lys Glu Asn His Met Gin Val Leu Leu Glu Gly Asn

100 105 110

Thr Asp Glu Phe Gly Ser Ser Glu Tyr Asn Gin Ala Leu Gly Val Lys

115 120 125

Arg Thr Leu Ser Val Lys Asn Ala Leu Val Ile Lys Gly Val Glu Lys

130 135 140

Asp Met Ile Lys Thr Ile Ser Phe Gly Glu Ser Lys Pro Lys Cys Val 145 150 155 160

Gin Lys Thr Arg Glu Cys Tyr Arg Glu Asn Arg Arg Val Asp Val Lys

165 170 175

Leu Val Lys

(2) INFORMATION FOR SEQ ID NO:184:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 286 am o acids

(B) TYPE: amino acid <D) TOPOLOGY: linear

(n) MOLECULE TYPE: prote

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE: (A) NAME/KEY. mιsc_feature

(B) LOCATION 1. .286

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 184

Met Gly Thr Leu Ile Glu Lys Trp Phe Gly Phe Ser Gin Ile Arg Glu

1 5 10 15

Glu Leu Glu Ala Arg lie Ser Glu Leu Glu Asp Glu Asn Thr Glu Leu

20 25 30

Leu Arg Glu Arg Glu Tyr Leu Ala Ala Glu Thr Ser Glu Leu Lys Asp

35 40 45

Ala Asn Asp Gin Leu Arg Gin Lys Asn Asp Lys Leu Phe Ile Thr Lys

50 55 60

Asp Lys Leu Thr Lys Glu Asn Thr Glu Leu Phe Ala Glu Asn Glu Ser 65 70 75 80

Leu Ser Val Lys Ile Ser Gly Leu Glu H s Ser Asn Asp Gin Leu Trp

85 90 95

Gin Asn Asn Asn Lys Leu Thr Lys Glu Lys Ala Glu Leu Lys Thr Glu

100 105 110

Lys Asp Ile Leu Ala Lys Glu Asn Thr Arg Leu Leu Ala Ala Arg Asp

115 120 125

Arg Leu Thr Glu Glu Lys Arg Glu Leu Thr Thr Glu Lys Glu Arg Leu

130 135 140

Lys Arg Glu Asn Thr Glu Leu Thr His Lys Ile Thr Glu Leu Thr Lys 145 150 155 160

Glu Asn Lys Ala Leu Thr Thr Glu Asn Asp Lys Leu Asn His Gin Val

165 170 175

Thr Ala Leu Thr Asn Glu Arg Asp Ser Leu Glu Gin Glu Arg Ala Arg

180 185 190

Leu Gin Asp Ala His Gly Phe Leu Glu Lys Arg Cys Thr Asn Leu Glu

195 200 205

Lys Glu Asn Gin Arg Leu Thr Asp Lys Leu Lys Gin Leu Glu Ser Ala

210 215 220

Gin Lys Ser Leu Glu Asn Thr Asn Asn Gin Leu Arg Gin Ala Leu Glu 225 230 235 240

Asn Ser Asn Val Gin Leu Ala Gin Ala Lys Glu Xaa Ile Ala Ile Glu

245 250 255

Xaa Ser Glu Leu Xaa Arg Arg Asn Arg Thr Leu Glu Glu Leu Arg Gly

260 265 270

Tyr Gly Ser Gin Lys Xaa Ile Trp Thr Tyr Thr Xaa Gly Val 275 280 285

(2) INFORMATION FOR SEQ ID NO: 185-

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 110 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...110

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 185

Val Leu Arg Lys Leu Leu Gly Lys Asn Cys Ile Glu Thr His Lys Gly

1 5 10 15

Val Gly Tyr Arg Leu Thr His Tyr Glu Lys Lys Ser Leu Lys Leu Phe

20 25 30

Leu Gly Thr Tyr Leu Gly Ser Ser Phe Val Leu Met Leu Val Ile Ser

35 40 45

Val Leu Ala Phe Asn Tyr Glu Lys Asn Glu Lys Ile Lys Xaa Ile Arg 50 55 60

Met Asp Met Asp Lys Met Ala Ser Lys Ile Ala Ser Glu Ile Ile Gin 65 70 75 80

Leu His Met Gin Thr His Ala Asp Tyr His Asn Ala Leu Asn Ma. Leu

85 90 95

Ile Ser Arg Tyr Lys Asp Val Ser Ile Xaa Leu Xaa Asp Thr 100 105 110

(2) INFORMATION FOR SEQ ID NO 186:

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH: 124 ammo acids

(D) TOPOLOGY- linear

(n) MOLECULE TYPE, protein

(ill) HYPOTHETICAL. YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY mιsc_feature

(B) LOCATION 1...124

( i) SEQUENCE DESCRIPTION: SEQ ID NO: 186

Leu Met Thr Lys Ser Leu Lys Leu Ile Gin Lys Gly Val Lys Asn Leu

1 5 10 15

Tyr Glu Thr Leu Lys Asn Arg Ala Leu Glu His Gin Asp Thr Leu Met

20 25 30

Val Gly Arg Ser His Gly Val Phe Gly Glu Pro Ile Thr Phe Gly Leu

35 40 45

Val Leu Ala Leu Phe Ala Asp Glu Ile Lys Arg His Leu Lys Ala Leu

50 55 60

Asp Leu Thr Met Glu Phe Ile Xaa Val Gly Ala Ile Ser Gly Ala Met 65 70 75 80

Gly Asn Phe Ala His Ala Pro Leu Glu Leu Glu Glu Leu Ala Cys Gly

85 90 95

Phe Leu Gly Leu Lys Thr Ala Asn Ile Ser Asn Gin Val Ile Gin Arg

100 105 110

Asp Arg Tyr Ala Gly Leu His Ala Ile Trp Leu Phe 115 120

(2) INFORMATION FOR SEQ ID NO: 187:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 95 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...95

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 187

Leu Ser Asp Ala Ser Lys Arg Ser Leu Asn Pro Thr Leu Met Met Asn

1 5 10 15

Asn Asn Asn Thr Leu Pro Lys Pro Leu Glu Glu Ser Leu AΞD Leu Lys 20 25 30 Glu Phe Ile Ala Leu Phe Lys Thr Phe Phe Ala Lys Glu Arg Gly Ser

35 40 45 lie Ala Leu Glu Asn Asp Leu Lys Gin Ala Phe Thr Tyr Leu Asn Glu

50 55 60

Val Asp Ala Ile Gly Leu Pro Ala Pro Xaa Lys Arg Glu Arg Lys Arg 65 70 75 80

Ser Tyr Cys Cys Gin Thr His Gin lie Arg Asp Ala Pro Phe Arg 85 90 95

(2) INFORMATION FOR SEQ ID NO.188:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH- 80 ammo acids

(B) TYPE, ammo acid (D) TOPOLOGY linear

(n) MOLECULE TYPE: protem

(m) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...80

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188

Leu Pro lie Ile Leu Xaa Val Ile Val Met Met Phe Phe Ser Lys Ile

1 5 10 15

Val Gly Asp Phe Ile Glu Lys His Tyr Arg Val Lys Thr Leu Ala Phe

20 25 30

Val Phe Leu Leu Val Val Gly Val Phe Leu Phe Leu Glu Gly Leu His

35 40 45

Leu His Ile Asn Lys Asn Tyr Leu Tyr Ala Gly Ile Gly Phe Ala Leu

50 55 60

Leu Ile Glu Cys Leu Xaa Ile Phe Ile Glu Lys Lys Met Lys Lys Ser 65 70 75 80

(2) INFORMATION FOR SEQ ID NO: 189:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 265 ammo acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(in) HYPOTHETICAL. YES

( i) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...265

(xi) SEQUENCE DESCRIPTION- SEQ ID NO: 189

Met Ile Lys Ala Arg Phe Lys Lys Arg Leu Leu Gly Ser Arg Gly Ala

1 5 10 15

Phe Asp Leu Asn Ile Asp Leu Glu lie Lys Glu Ala Glu Val Val Ala

20 25 30

Leu Leu Gly Glu Ser Gly Ala Gly Lys Ser Thr Ile Leu Arg Ile Leu

35 40 45

Ala Gly Leu Glu Ala Val Ser Ser Gly Tyr Ile Glu Ala Asn His Ser

50 55 60

Val Trp Leu Asp Thr Gin Lys Lys Ile Phe Leu Lys Pro Gin Gin Arg 65 70 75 80

Lys Ile Gly Phe Val Phe Gin Asp Tyr Ala Leu Phe Pro His Leu Asn

85 90 95

Val Tyr Gin Asn Ile Ala Phe Ala His Pro Lys Asp Lys Asn Lys Ile

100 105 110

His Glu Val Leu Arg Leu Met Arg Leu Glu Asn Leu Ser Gin Gin Lys

115 120 125

Ile Pro Lys Leu Ser Gly Gly Gin Ala Gin Arg Val Ala Leu Ala Arg

130 135 140

Ala Leu Ile Ala Ala Lys Asn Leu Leu Leu Leu Asp Glu Pro Leu Asn 145 150 155 160

Ala Leu Asp Asn Ala Leu Lys Asn Glu Val Gin Gin Gly Leu Leu Asp

165 170 175

Phe Ile Lys Arg Glu Asn Leu Ser Val Leu Leu Val Ser His Asp Pro

180 185 190

Asn Glu Ile Thr Lys Leu Ala Arg Thr Phe Leu Phe Leu Asn Asn Gly

195 200 205

Val Ile Asp Pro Asn Gin Glu Asn Arg Leu Phe Ser Asn Arg Leu Leu

210 215 220

Val Lys Pro Leu Phe Glu Asp Glu Asn Tyr Cys His Tyr Glu Val Ile 225 230 235 240

Pro Gin Thr Ile Ser Leu Pro Lys Asp Cys Leu Asn Pro Thr Phe Lys

245 250 255

Leu Asp Phe Ile Gin Asn Lys Lys Phe 260 265

(2) INFORMATION FOR SEQ ID NO: 190:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...64

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 190

Val Lys Phe Ser Val Leu Thr Leu Phe Pro Gin Leu Ile Leu Pro Tyr

1 5 10 15

Phe Glu Asp Ser Ile Leu Lys Arg Ala Leu Glu Lys Asn Leu Phe Glu

20 25 30

Leu Glu Val Leu Asn Leu Arg Asp Phe Ser Ala Asn Lys Tyr Gin Lys

35 40 45

Ala Xaa Ser His Ala His Trp Trp Gly Cys Gly Ala Asn Phe Arg Pro 50 55 60

(2) INFORMATION FOR SEQ ID NO: 191:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 138 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori ( ix ) FEATURE :

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...138

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 191

Leu Trp Arg Thr Pro Lys Thr Pro Leu Val Ile Lys Pro Tyr Leu Lys

1 5 10 15

Ser Met Ser Asp Ser Glu Ile Phe Ala Xaa Xaa Cys Val Gly Met Ala

20 25 30

Ser Val Xaa Gly Pro Val Leu Ala Gly Tyr Ala Ser Met Gly Ile Pro

35 40 45

Leu Pro Tyr Leu Ile Ala Ala Ser Phe Met Ser Ala Pro Gly Gly Leu

50 55 60

Leu Phe Ala Lys Thr Ile Tyr Pro Gin Asn Glu Thr Ile Ser Ser His 65 70 75 80

Ala Asp Val Ser Ala Glu Glu His Val Asn Ile Ile Glu Ala Xaa Ala

85 90 95

Xaa Gly Ala Ser Thr Gly Xaa His Leu Ala Leu His Val Gly Ala Met

100 105 110

Leu Leu Ala Phe Val Gly Met Val Ala Leu Val Asn Gly Leu Leu Gly

115 120 125

Val Val Gly Gly Phe Leu Gly Met Glu His 130 135

(2) INFORMATION FOR SEQ ID NO: 192:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 116 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_ eature

(B) LOCATION 1...116

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 192

Val Met Asn Phe Phe Val Gly Gly Leu Ser Ile Val Cys Asn Val Val

1 5 10 15

Val Ile Thr Tyr Ser Ala Leu His Pro Thr Ala Pro Val Glu Gly Ala

20 25 30

Glu Asp lie Val Gin Val Ser His His Leu Thr Ser Phe Tyr Gly Pro

35 40 45

Ala Thr Gly Leu Leu Phe Gly Phe Thr Tyr Leu Tyr Ala Ala Ile Asn

50 55 60

His Thr Phe Gly Leu Asp Trp Arg Pro Tyr Ser Trp Tyr Ser Leu Phe 65 70 75 80

Val Ala lie Asn Thr Val Pro Ala Ala Ile Leu Ser His Tyr Ser Asp

85 90 95

Met Leu Asp Asp His Lys Val Leu Gly Ile Thr Glu Gly Asp Trp Trp

100 105 110

Ala Ile Ile Xaa 115

(2) INFORMATION FOR SEQ ID NO: 193:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 227 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear (n) MOLECULE TYPE: protem

(in) HYPOTHETICAL. YES

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY mιsc_feature

(B) LOCATION 1 227

(xi) SEQUENCE DESCRIPTION. SEQ ID NO:193

Val Leu Leu Gly Lys His Ser Gly Ala Gly Leu Leu Ser Ala Leu Xaa

1 5 10 15

Ala Leu Ser Phe Gly Ser Gly Val Val Ser Ile Gin Ala Leu Glu Cys

20 25 30

Glu Ile Thr Ser Asn Asn Lys Pro Leu Glu Leu Val Phe Cys Glu Asn

35 40 45

Phe Pro Lys Lys Leu Ser Ala Phe Ala Leu Gly Met Gly Leu Glu Asn

50 55 60

Ile Pro Lys Asp Phe Lys Lys Trp Leu Glu Leu Ala Pro Cys Val Leu 65 70 75 80

Asp Ala Gly Val Phe Tyr His Lys Glu Val Leu Gin Ala Leu Glu Lys

85 90 95

Glu Val Ile Leu Thr Pro His Pro Lys Glu Phe Leu Ser Leu Leu Lys

100 105 110

Ser Val Gly Ile Asn Ile Ser Met Leu Glu Leu Leu Asp Asn Lys Leu

115 120 125

Glu Ile Ala Arg Asp Phe Ser Gin Lys Tyr Pro Lys Val Val Leu Leu

130 135 140

Leu Lys Gly Ala Asn Thr Leu Ile Ala His Gin Gly Arg Val Phe Ile 145 150 155 160

Asn Asn Leu Gly Ser Val Ala Leu Ala Lys Ala Gly Ser Gly Asp Val

165 170 175

Leu Ala Gly Leu Ile Val Ser Leu Leu Ser Gin Asn Tyr Thr Pro Leu

180 185 190

Xaa Ala Ala Ile Asn Ala Ser Leu Ala His Ala Leu Ala Gly Leu Xaa

195 200 205

Phe Lys Asn Xaa Xaa Ala Leu Thr Pro Xaa Asp Leu Ile Glu Lys Xaa

210 215 220

Lys Arg Leu 225

(2) INFORMATION FOR SEQ ID NO: 194:

(l) SEQUENCE CHARACTERISTICS-

(A) LENGTH: 109 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(in) HYPOTHETICAL- YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...109

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194

Val Xaa Leu Tyr Leu Ala Leu Thr Leu Ser Leu Gly Ile Ala Met Leu

1 5 10 15

Leu Val Glu Met Leu Ile Gly Asn Leu Gly Lys Lys Asp Val Val Ser

20 25 30

Asn Tyr Gin Ile Leu Asp Pro Lys Arg Lys Lys Tyr Tyr Pro Phe Thr 35 40 45

Ser Phe Phe Ile Leu Gly Gly Pro Leu Ile Leu Ser Phe Tyr Ala Val

50 55 60

Val Leu Gly Trp Val Leu Tyr Tyr Leu Phe Val Val Thr Phe Asp Leu 65 70 75 80

Pro Lys Asp Leu Xaa Gin Ala Lys Met Gin Phe Xaa Met Leu Gin Asn

85 90 95

Gly Ser Leu Ile Trp Pro Val Ile Asp Phe Ser Ala Cys 100 105

(2) INFORMATION FOR SEQ ID NO: 195.

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 97 ammo acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

( i) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...97

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 195

Leu Thr Thr Lys Ala Cys Trp Leu Leu Arg Val Cys Cys Tyr Arg Ser

1 5 10 15

Leu Asn Ile Thr Ile Lys Asp Arg Thr Met Lys Thr Asn Gly His Phe

20 25 30

Lys Asp Phe Ala Trp Lys Lys Cys Phe Leu Gly Ala Ser Val Val Ala

35 40 45

Leu Leu Val Gly Cys Ser Pro His Ile Ile Glu Thr Asn Glu Val Ala

50 55 60

Leu Lys Leu Asn Tyr His Pro Ala Ser Glu Lys Val Gin Ala Leu Asp 65 70 75 80

Glu Lys Ile Leu Leu Leu Arg Pro Ala Phe Gin Tyr Ser Xaa Asn Ile

85 90 95

Cys

(2) INFORMATION FOR SEQ ID NO: 196:

(l) SEQUENCE CHARACTERISTICS :

(A) LENGTH: 145 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...145

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 196

Leu Ser Glu Trp Gin Thr Phe Cys Leu Lys Asp Leu Gly Lys Ile Val 1 5 10 15

Gly Gly Ala Thr Pro Pro Thr Asn Asn Pro Lys Asn Tyr Gly Asn Lys 20 25 30 Ile Ala Trp Ile Thr Pro Lys Asp Leu Ser Thr Leu Gin Gly Arg Tyr

35 40 45

Ile Lys Lys Gly Ser Arg Ser Ile Ser Arg Leu Gly Phe Lys Ser Cys

50 55 60

Ser Cys Val Leu Leu Pro Lys His Ala Ile Leu Phe Ser Ser Arg Ala 65 70 75 80

Pro Ile Gly Tyr Val Ala Ile Ala Glu Lys Arg Leu Cys Thr Asn Gin

85 90 95

Gly Phe Lys Ser lie Ile Pro Asn Lys Lys Ile Tyr Phe Glu Phe Leu

100 105 110

Tyr Tyr Leu Leu Lys Tyr Tyr Lys Asp Asn Ile Ser Asn Ile Gly Gly

115 120 125

Gly Thr Thr Phe Lys Glu Val Ser Gly Ala Thr Leu Gly Ser Ile Pro

130 135 140

Ser 145

(2) INFORMATION FOR SEQ ID NO:197:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 273 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: prote

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...273

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197

Met Glu Phe Met Lys Lys Phe Val Ala Leu Gly Leu Leu Ser Ala Val

1 5 10 15

Leu Ser Ser Ser Leu Leu Ala Glu Gly Asp Gly Val Tyr Ile Gly Thr

20 25 30

Asn Tyr Gin Leu Gly Gin Ala Arg Leu Asn Ser Asn Ile Tyr Asn Thr

35 40 45

Gly Asp Cys Thr Gly Ser Val Val Gly Cys Pro Pro Gly Leu Thr Ala

50 55 60

Asn Lys His Asn Pro Gly Gly Thr Asn Ile Asn Trp His Ser Lys Tyr 65 70 75 80

Ala Asn Gly Ala Leu Asn Gly Phe Gly Leu Asn Val Gly Tyr Lys Lys

85 90 95

Phe Phe Gin Phe Lys Ser Leu Asp Met Thr Ser Lys Trp Phe Gly Phe

100 105 110

Arg Val Tyr Gly Leu Phe Asp Tyr Gly His Ala Asp Leu Gly Lys Gin

115 120 125

Val Tyr Ala Pro Asn Lys Ile Gin Leu Asp Met Val Ser Trp Gly Val

130 135 140

Gly Ser Asp Leu Leu Ala Asp Ile Ile Asp Lys Asp Asn Ala Ser Phe 145 150 155 160

Gly Ile Phe Gly Gly Val Ala lie Gly Gly Asn Thr Trp Lys Ser Ser

165 170 175

Ala Ala Asn Tyr Trp Lys Glu Gin lie Ile Glu Ala Lys Gly Pro Asp

180 185 190

Val Cys Thr Pro Thr Tyr Cys Asn Pro Asn Ala Pro Tyr Ser Thr Asn

195 200 205

Thr Ser Thr Val Ala Phe Gin Val Trp Leu Asn Phe Gly Val Arg Ala

210 215 220

Asn Ile Tyr Lys His Asn Gly Val Glu Phe Gly Val Arg Val Pro Leu 225 230 235 240

Leu Ile Asn Lys Phe Leu Ser Ala Gly Pro Asn Ala Thr Asn Leu Tyr 245 250 255 Tyr His Leu Lys Arg Asp Tyr Ser Leu Tyr Leu Gly Tyr Asn Tyr Thr

260 265 270

Phe

(2) INFORMATION FOR SEQ ID NO: 198:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH. 148 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL- YES

(vi) ORIGINAL SOURCE-

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...148

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 198

Leu Val Gin Ile Val Val Val Phe Tyr Gly Leu Pro Ala Leu Gly Val

1 5 10 15

Tyr Met Asp Pro Ile Pro Ala Gly Ile Ile Ala Phe Ser Phe Asn Val

20 25 30

Gly Ala Tyr Ala Ser Glu Thr Leu Arg Ala Ser Phe Leu Ser Val Pro

35 40 45

Lys Asp Gin Trp Asp Ser Ser Leu Ser Leu Gly Leu Asn Tyr Leu Gin

50 55 60

Thr Phe Trp His Val Ile Phe Phe Gin Ala Leu Lys Val Ala Thr Pro 65 70 75 80

Ser Leu Ser Asn Thr Phe Ile Ser Leu Phe Lys Glu Thr Ser Leu Ala

85 90 95

Ser Val Val Thr Ile Ala Glu Xaa Phe Arg Ile Ala Gin Gin Lys Xaa

100 105 110

Asn Val Ser Tyr Asp Phe Xaa Pro Ile Tyr Leu Glu Xaa Ala Leu Ile

115 120 125

Tyr Trp Leu Phe Cys Leu Val Leu Glu Val Ile Gin Lys Arg Val Glu

130 135 140

Lys Ile Leu Asn 145

(2) INFORMATION FOR SEQ ID NO: 199:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 134 amino acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...134

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199

Val Val Ala Asp Glu Val Arg Asn Leu Ala Gly Arg Thr Gin Lys Ser

1 5 10 15

Leu Ala Glu Ile Asn Ser Thr lie Met Val Ile Val Gin Glu lie Asn 20 25 30

Asp Val Ser Ser Gin Met Asn Leu Asn Ser Gin Lys Met Glu Arg Leu

35 40 45

Ser Asp Met Ser Lys Ser Val Gin Glu Thr Tyr Glu Lys Met Ser Ser

50 55 60

Asn Leu Ser Ser Val Val Leu Asp Ser Asn Gin Ser Met Asp Asp Tyr 65 70 75 80

Ala Lys Ser Gly His Gin Ile Glu Ala Met Val Ser Asp Phe Ala Glu

85 90 95

Val Glu Lys Val Ala Ser Lys Thr Leu Ala Asp Ser Ser Asp lie Leu

100 105 110

Asn Ile Ala Thr His Val Ser Gly Thr Thr Met Asn Leu Xaa Lys Gin

115 120 125

Val Asn Leu Phe Lys Thr 130

(2) INFORMATION FOR SEQ ID NO: 200:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 133 amino acids

(B) TYPE: amino acid (D) TOPOLOGY linear

(n) MOLECULE TYPE: protem

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...133

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200

Met Asn Tyr Asp Asn Tyr Trp Asp Glu Asp Lys Pro Glu Leu Asn Ile

1 5 10 15

Thr Pro Leu Val Asp Val Met Leu Val Leu Leu Ala Ile Leu Met Val

20 25 30

Thr Thr Pro Thr Leu Thr Tyr Lys Glu Glu Ile Ala Leu Pro Ser Gly

35 40 45

Ser Lys Thr Ala Arg Ala Thr Gin Asp Lys Val lie Glu Ile Arg Met

50 55 60

Asp Lys Asp Ala Lys Ile Tyr Ile Asp Ser Gin Thr Tyr Glu Tyr Xaa 65 70 75 80

Ser Phe Pro Asp Thr Phe Asn Leu Leu Ser Lys Lys Tyr Asp Lys Asp

85 90 95

Thr Arg Val Ser Ile Arg Ala Asp Lys Arg Leu Thr Tyr Asp Lys Val

100 105 110

Ile Tyr Leu Leu Lys Thr Ile Lys Glu Ala Gly Phe Leu Lys Val Ser

115 120 125

Leu Ile Thr Ser Pro 130

(2) INFORMATION FOR SEQ ID NO: 201:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 71 ammo acids

(D) TOPOLOGY, linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori (ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...71

(xi) SEQUENCE DESCRIPTION SEQ ID NO:201

Met Pro Pro Thr Xaa Pro Gin Ala Ser Ile Leu Arg Leu Thr Leu Lys

1 5 10 15

Asn Pro Leu Xaa Xaa Leu Ser Arg Tyr Ser Leu Cys Leu Leu Lys Lys

20 25 30

Thr Arg Leu Gin Thr Thr Ser Asn Ser Ala Pro Lys Ala Cys Leu Ile

35 40 45

Ala Gly Leu Leu Lys Lys Ser Lys Pro Phe Ile Leu Asn Thr Leu Lys

50 55 60

Ile Arg Ser Leu Leu Lys Pro 65 70

(2) INFORMATION FOR SEQ ID NO:202:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 217 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...217

(XI) SEQUENCE DESCRIPTION: SEQ ID NO:202

Met Pro Val Ile Arg Val Leu Val Met Leu Ala Thr Met Met Met Lys

1 5 10 15

Leu Val Lys Thr Ala Lys Glu Lys Lys Val Phe Lys Asn Val Gly Ile

20 25 30

Ser Ile Met Gly Ile Ala Phe Trp Glu Ala Ile Lys Asp Ser lie Lys

35 40 45

Lys Gin Ile Lys Lys Ser Asp Trp lie Cys Gly Asn Val Lys Thr Ala

50 55 60

Asp Asp Tyr Leu Lys Thr His Pro Asn Ser Trp Phe Asn Ser Ala Ile 65 70 75 80

Gly Val Thr Ala Ile Thr Ala Met Leu Met Asn Val Cys Phe Ala Asp

85 90 95

Asp Gin Ser Lys Lys Glu Val Ala Gin Ala Gin Lys Glu Ala Glu Asn

100 105 110

Ala Arg Asp Arg Ala Asn Lys Ser Gly Ile Glu Leu Glu Gin Glu Glu

115 120 125

Gin Lys Thr Glu Gin Glu Lys Gin Lys Thr Glu Gin Glu Lys Gin Lys

130 135 140

Thr Glu Gin Glu Lys Gin Lys Thr Glu Gin Glu Lys Gin Lys Thr Glu 145 150 155 160

Gin Glu Lys Gin Lys Thr Ser Asn Ile Glu Thr Asn Asn Gin Ile Lys

165 170 175

Val Glu Gin Glu Gin Gin Lys Thr Glu Gin Glu Lys Gin Lys Thr Asn

180 185 190

Asn Thr Gin Lys Asp Leu Val Asn Lys Ala Glu Gin Asn Cys Gin Glu

195 200 205

Asn His Asn Gin Phe Phe Ile Lys Asn 210 215

(2) INFORMATION FOR SEQ ID NO: 203:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 75 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: prote

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...75

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203

Met Val Ile Ser Gly His Phe Thr Thr Tyr Ser Tyr Ile Glu Pro Phe

1 5 10 15

Ile Ile Gin Ile Ser Gin Phe Ser Pro Asp Ile Thr Thr Leu Met Leu

20 25 30

Phe Val Phe Gly Leu Ala Gly Val Val Gly Ser Phe Leu Phe Gly Arg

35 40 45

Leu Tvr Ala Lys Asn Ser Arg Lys Phe Ile Ala Phe Ala Met Val Leu

50 55 60

Val Ile Cys Pro Gin Pro Leu Ala Phe Cys Val 65 70 75

(2) INFORMATION FOR SEQ ID NO: 204:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 192 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...192

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204

Met Lys Ser Thr Arg Ile Gly Ser Lys Ile Val Met Met Val Cys Ala

1 5 10 15

Val Val Ile Val Ile Ser Ala Val Met Gly Val Ile Ile Ser Tyr Lys

20 25 30

Val Glu Ser Val Leu Gin Ser Gin Ala Thr Glu Leu Leu Gin Lys Lys

35 40 45

Ala Gin Leu Val Ser Phe Lys Ile Gin Gly Ile Met Lys Arg lie Phe

50 55 60

Met Gly Ala Asn Thr Leu Glu Arg Phe Leu Ser Asp Glu Asn Gly Ala 65 70 75 80

Ile Asn Asp Thr Leu Lys Arg Arg Met Leu Ser Glu Phe Leu Leu Ala

85 90 95

Asn Pro His Val Leu Leu Val Ser Ala lie Tyr Thr Asn Asn Asn Glu

100 105 110

Arg Met Ile Thr Ala Met Asn Met Asp Ser Lys Ile Ala Tyr Pro Asn

115 120 125

Thr Ala Leu Asn Glu Asn Met Thr Xaa Pro Ile His Ser Leu Lys Ser

130 135 140

Ile Thr Arg Ser Xaa Pro Tyr Tyr Lys Glu Val Asn Xaa Xaa Lys Ile 145 150 155 160

Tyr Xaa Xaa Xaa Ile Thr Leu Pro Leu Xaa Xaa Lys Asn Xaa Asn Xaa 165 170 175

Ile Xaa Xaa Leu Asn Phe Xaa Leu Asn lie Asp Xaa Phe Leu Tyr Xaa 180 185 190

(2) INFORMATION FOR SEQ ID NO: 205.

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH- 253 amino acids

(B) TYPE, amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...253

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.205

Met Ala Tyr Lys Tyr Asp Arg Asp Leu Glu Phe Leu Lys Gin Leu Glu

1 5 10 15

Ser Ser Asp Leu Leu Asp Leu Phe Glu Val Leu Val Phe Gly Lys Asp

20 25 30

Gly Glu Lys Arg His Asn Glu Lys Leu Thr Ser Ser Ile Glu Tyr Lys

35 40 45

Arg His Gly Asp Asp Tyr Ala Lys Tyr Ala Glu Arg Ile Ala Glu Glu

50 55 60

Leu Gin Tyr Tyr Gly Ser Asn Ser Phe Ala Ser Phe Ile Lys Gly Glu 65 70 75 80

Gly Val Leu Tyr Lys Glu Ile Leu Cys Asp Val Cys Asp Lys Leu Lys

85 90 95

Val Asn Tyr Asn Lys Lys Thr Glu Thr Thr Leu Ile Glu Gin Asn Met

100 105 110

Leu Ser Lys Ile Leu Glu Arg Ser Leu Glu Glu Met Asp Asp Glu Glu

115 120 125

Val Lys Glu Met Cys Asp Glu Leu Ser Ile Lys Asn Thr Asp Asn Leu

130 135 140

Asn Arg Gin Ala Leu Ser Ala Ala Thr Leu Thr Leu Phe Lys Met Gly 145 150 155 160

Gly Phe Lys Ser Tyr Gin Leu Ala Val Ile Val Ala Asn Ala Val Ala

165 170 175

Lys Thr Ile Leu Gly Arg Gly Leu Ser Leu Ala Gly Asn Gin Val Leu

180 185 190

Thr Arg Thr Leu Ser Phe Leu Thr Gly Pro Val Gly Trp Ile Ile Thr

195 200 205

Gly Val Trp Thr Ala Ile Asp Ile Ala Gly Pro Ala Tyr Arg Val Thr

210 215 220

Ile Pro Ala Cys Ile Val Val Ala Thr Leu Arg Leu Lys Thr Gin Gin 225 230 235 240

Ala Asn Glu Asp Lys Lys Ser Leu Gin Ile Glu Ser Val 245 250

(2) INFORMATION FOR SEQ ID NO: 206:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 293 ammo acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(m) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 ..293

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206

Leu Leu Leu Phe Ile Val Val Ile Thr Ser Leu Val Lys Asn Thr Ile

1 5 10 15

Pro Asn Ile Trp Leu Thr Lys Ile Leu Tyr Met Ala Ile Leu Leu Cys

20 25 30

Ala Ile Ala His Ser Val Gly Xaa Ile Leu Arg Trp Tyr Val Ser Gly

35 40 45

His Ser Pro Trp Ser Asn Ala Tyr Glu Ser Met Phe Tyr lie Ala Trp

50 55 60

Ala Ser Val Ile Ala Gly Phe Val Leu Arg Xaa Lys Leu Ala Leu Ser 65 70 75 80

Ala Ser Ser Phe Leu Ala Gly Ile Ala Leu Phe Val Ala His Leu Gly

85 90 95

Phe Met Asp Pro Gin Ile Gly Pro Leu Val Pro Val Leu Lys Ser Tyr

100 105 110

Trp Leu Asn lie His Val Ser Val Ile Thr Ala Ser Tyr Gly Phe Leu

115 120 125

Gly Leu Cys Phe Val Leu Gly Ile Leu Ser Leu Val Leu Phe Ile Leu

130 135 140

Arg Lys Gin Gly Arg Phe Asn Leu Asp Lys Thr Ile Leu Ser Ile Ser 145 150 155 160

Ala Ile Asn Glu Met Ser Met lie Leu Gly Leu Phe Met Leu Thr Ala

165 170 175

Gly Asn Phe Leu Gly Gly Val Trp Ala Asn Glu Ser Trp Gly Arg Tyr

180 185 190

Trp Gly Trp Asp Pro Lys Glu Thr Trp Ala Leu Ile Ser Ile Cys Val

195 200 205

Tyr Ala Leu Ile Leu His Leu Arg Phe Leu Gly Ser Gin Asn Trp Pro

210 215 220

Phe Ile Leu Ala Ser Ser Ser Val Leu Gly Phe Tyr Ser Val Leu Met 225 230 235 240

Thr Leu Phe Trp Arg Glu Leu Leu Pro Phe Trp Leu Ala Gin Leu Cys

245 250 255

Arg Arg Xaa Ser Phe Ala Asp Pro Tyr Phe Phe Ile Leu Phe Gly Ser

260 265 270

Asp Thr Phe Arg Ser Arg Ile Leu Ala Tyr Phe Lys Arg His Leu Ser

275 280 285

Leu Pro Lys Leu Val 290

(2) INFORMATION FOR SEQ ID NO- 207:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 142 ammo acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...142

(Xl) SEQUENCE DESCRIPTION. SEQ ID NO:207

Val Glu Met Ile His Thr Gin Asp Tyr Ile Lys Met Glu Glu Ala Ala 1 5 10 15 Thr Glu Ala Ile Lys Arg Lys Glu Ser Ser Ile Tyr Leu Gly Met Asp

20 25 30

Ile Leu Lys Asn Gly Ala Asp Ala Leu Ile Ser Ala Gly His Ser Gly

35 40 45

Ala Thr Met Gly Leu Ala Thr Leu Arg Leu Gly Arg Ile Lys Gly Val

50 55 60

Glu Arg Pro Ala lie Cys Thr Leu Met Pro Ser Val Gly Lys Arg Pro 65 70 75 80

Ser Val Leu Leu Asp Ala Gly Ala Asn Thr Asp Cys Lys Pro Glu Tyr

85 90 95

Leu Ile Asp Phe Ala Leu Met Gly Tyr Glu Tyr Ala Lys Ser Val Leu

100 105 110

His Tyr Asp Ser Pro Lys Val Gly Leu Leu Ser Asn Gly Glu Glu Asp

115 120 125 lie Lys Gly Gly Ile Arg Ser Leu Lys Lys Arg Ile Lys Cys 130 135 140

(2) INFORMATION FOR SEQ ID NO: 208:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 144 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protem

(ill) HYPOTHETICAL. YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

( x) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...144

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 208

Met Leu Glu Ile Lys Asn Leu Asn Cys Val Leu Asn Ser His Phe Ser

1 5 10 15

Leu Gin Asn Ile Asn Ile Ser Leu Ser Tyr Ser Glu Arg Val Ala Ile

20 25 30

Val Gly Glu Ser Gly Ser Gly Lys Ser Ser Ile Ala Asn Leu Val Met

35 40 45

Arg Leu Asn Pro Arg Phe Lys Ser His Asn Gly Glu lie Leu Phe Glu

50 55 60

Thr Thr Asn Leu Leu Lys Glu Ser Glu Ala Phe Xaa Gin His Leu Arg 65 70 75 80

Gly Asn Ile Ile Ala Tyr Ile Ala Gin Asp Pro Leu Ser Ser Leu Asn

85 90 95

Pro Leu His Lys Ile Gly Lys Gin Met Ser Glu Ala Tyr Phe Leu His

100 105 110

His Lys Asn Ala Ser Gin Val Ser Leu Asn Glu Gin Val Leu Asn Val

115 120 125

Met Lys Gin Val Gin Leu Asp Glu Asn Phe Trp Asn Val Ser Leu Met 130 135 140

(2) INFORMATION FOR SEQ ID NO: 209:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 83 amino acids

(B) TYPE, ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE- protein

(m) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori ( ix ) FEATURE

(A) NAME/KEY mιsc_feature

(B) LOCATION 1...83

(xi) SEQUENCE DESCRIPTION SEQ ID NO.209

Met Asn Tyr Lys Val Ala Ser Ala Arg Asn Ile Ala Thr Leu Leu Phe

1 5 10 15

Leu Phe Phe Ser Gin Ser Glu Ala Phe Asp Leu Gly Lys Ile Ala Lys

20 25 30

Ile Lys Ala Gly Ala Glu Ser Phe Ser Lys Val Gly Phe Asn Asn Lys

35 40 45

Pro Ile Asn Xaa Asn Lys Gly Ile Tyr Pro Thr Glu Thr Phe Met Thr

50 55 60

Ile Asn Gly Leu His Ala Gly Gly Phe Tyr Gly Ala Leu Ala Gin Lys 65 70 75 80

Arg Tyr Gly

(2) INFORMATION FOR SEQ ID NO: 210:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH. 130 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY- linear

(n) MOLECULE TYPE: protem

(ill) HYPOTHETICAL: YES

(Vl) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1...130

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 210

Met Asp Ala Leu Glu Ile Thr Gin Lys Leu Ile Ser Tyr Pro Thr Ile

1 5 10 15

Thr Pro Lys Glu Cys Gly Ile Phe Glu Tyr Ile Lys Ser Leu Phe Pro

20 25 30

Ala Phe Lys Thr Leu Glu Cys Glu Lys Asn Gly Val Lys Asn Leu Phe

35 40 45

Leu Tyr Arg Ile Phe Asn Pro Leu Lys Lys His Ala Glu Lys Glu His

50 55 60

Ala Lys Glu Lys His Val Lys Glu Asn Val Xaa Pro Leu His Phe Cys 65 70 75 80

Xaa Ala Gly His Ile Xaa Val Val Pro Pro Gly Xaa Xaa Xaa Xaa Xaa

85 90 95

Asp Ser Phe Xaa Xaa Ile Ile Lys Glu Gly Phe Leu Tyr Gly Arg Gly

100 105 110

Ala Gin Asp Met Lys Gly Gly Val Gly Xaa Phe Xaa Arg Cys Xaa Xaa

115 120 125

Lys Phe 130

(2) INFORMATION FOR SEQ ID NO-211.

(l) SEQUENCE CHARACTERISTICS-

(A) LENGTH: 340 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY linear

(n) MOLECULE TYPE: prote

(ill) HYPOTHETICAL YES (vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1 ..340

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211

Met Ile Leu Ser Ile Glu Ser Ser Cys Asp Asp Ser Ser Leu Ala Leu

1 5 10 15

Thr Arg He Glu Asp Ala Lys Leu Ile Ala His Phe Lys Ile Ser Gin

20 25 30

Glu Lys His His Ser Ser Tyr Gly Gly Val Val Pro Glu lie Ala Ser

35 40 45

Arg Leu His Ala Glu Asn Leu Pro Leu Leu Leu Glu Arg Val Lys Ile

50 55 60

Ser Leu Asn Lys Asp Phe Ser Lys Ile Lys Ala Ile Ala Ile Thr Asn 65 70 75 80

Gin Pro Gly Leu Ser Val Thr Leu Ile Glu Gly Leu Met Met Ala Lys

85 90 95

Ala Leu Ser Leu Ser Leu Asn Leu Pro Leu Ile Leu Glu Asp His Leu

100 105 110

Arg Gly His Val Tyr Ser Leu Phe Ile Asn Glu Lys Gin Thr Arg Met

115 120 125

Pro Leu Ser Val Leu Leu Val Ser Gly Gly His Ser Leu Ile Leu Glu

130 135 140

Ala Arg Asp Tyr Glu Asp Ile Lys Ile Val Ala Thr Ser Leu Asp Asp 145 150 155 160

Ser Phe Gly Glu Ser Phe Asp Lys Val Ser Lys Met Leu Asp Leu Gly

165 170 175

Tyr Pro Gly Gly Pro Ile Val Glu Lys Leu Ala Leu Asp Tyr Ala His

180 185 190

Pro Asn Glu Pro Leu Met Phe Pro Ile Pro Leu Lys Asn Ser Pro Asn

195 200 205

Leu Ala Phe Ser Phe Ser Gly Leu Lys Asn Ala Val Arg Leu Glu Val

210 215 220

Glu Lys Asn Ala His Asn Leu Asn Asp Glu Val Lys Gin Lys Ile Gly 225 230 235 240

Tyr His Phe Gin Ser Ala Ala lie Glu His Leu Ile Gin Gin Thr Lys

245 250 255

Arg Tyr Phe Lys Ile Lys Arg Pro Lys Ile Phe Gly Ile Val Gly Gly

260 265 270

Ala Ser Gin Asn Leu Ala Leu Arg Lys Ala Phe Glu Asp Leu Cys Ala

275 280 285

Glu Phe Asp Cys Glu Leu Val Leu Ala Pro Leu Glu Phe Cys Ser Asp

290 295 300

Asn Ala Ala Met Ile Gly Arg Ser Ser Leu Glu Ala Tyr Gin Lys Lys 305 310 315 320

Arg Phe Ile Pro Leu Glu Lys Ala Asp Ile Ser Pro Arg Thr Leu Leu

325 330 335

Lys Asn Phe Glu 340

(2) INFORMATION FOR SEQ ID NO: 212:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 168 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori ( ix ) FEATURE

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1 ..168

(xi) SEQUENCE DESCRIPTION SEQ ID NO:212

Met Leu Ser Ser Asn Asp Leu Phe Met Val Val Leu Gly Ala Ile Leu

1 5 10 15

Leu Val Leu Val Cys Leu Val Gly Tyr Leu Tyr Leu Lys Glu Lys Glu

20 25 30

Phe Tyr His Lys Met Arg Arg Leu Glu Lys Thr Leu Asp Glu Ser Tyr

35 40 45

Gin Glu Asn Tyr Leu Tyr Ser Lys Arg Leu Arg Glu Leu Glu Gly Arg

50 55 60

Leu Glu Gly Leu Ser Leu Glu Lys Ser Ala Lys Glu Asp Ser Ser Leu 65 70 75 80

Lys Thr Thr Leu Ser His Leu Tyr Asn Gin Leu Gin Glu Ile Gin Lys

85 90 95

Ser Met Asp Lys Glu Arg Asp Tyr Leu Glu Glu Lys Ile Ile Xaa Xaa

100 105 110

Lys Thr Xaa Xaa Lys Thr Trp Gly Ile Met Pro Leu Ala Met Lys Ser

115 120 125

Thr Glu Lys Gin Val Leu Lys Met Tyr Gin Glu Gly Tyr Ser Val Asp

130 135 140

Ser Ile Ser Lys Glu Phe Lys Val Ser Lys Gly Glu Val Glu Phe Ile 145 150 155 160

Leu Asn Met Ala Gly Leu Lys Trp 165

(2) INFORMATION FOR SEQ ID NO:213:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 121 ammo acids

(B) TYPE, amino acid (D) TOPOLOGY, linear

(n) MOLECULE TYPE: protem

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM. Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...121

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO.213

Leu Asp Pro Phe Ser His Lys Glu Asn Phe Leu Ala Val Glu Thr Phe

1 5 10 15

Lys Met Leu Gly Lys Thr Glu Ser Lys Asp Asn Leu Asn Trp Met Ile

20 25 30

Ala Leu Ile Ile Glu Lys Asp Lys Val Tyr Glu Gin Val Gly Ser Val

35 40 45

Arg Phe Val Val Val Val Ala Ser Ala lie Met Val Leu Ala Leu Ile

50 55 60

Ile Ala lie Thr Leu Leu Met Arg Ala Ile Val Ser Asn Arg Leu Glu 65 70 75 80

Val Val Ser Ser Thr Leu Ser His Phe Phe Lys Leu Leu Asn Asn Gin

85 90 95

Xaa His Ser Ser Xaa Xaa Lys Leu Val Xaa Ala Arg Ser Asn Asp Glu

100 105 110

Leu Gly Arg Xaa Gin Thr Xaa Asp Xaa 115 120

(2) INFORMATION FOR SEQ ID NO: 214:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH. 149 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY- linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL. YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM. Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...149

(xi) SEQUENCE DESCRIPTION: SEQ ID NO -214

Met Glu Phe Tyr Gin Val Tyr Asp Pro Leu Gly His Ile Trp Leu Ser

1 5 10 15

Ala Leu Val Ala Leu Ser Pro Ile Ala Leu Phe Phe Ile Ser Leu Ile

20 25 30

Val Phe Lys Leu Lys Gly Tyr Ser Ala Gly Phe Leu Ser Leu Ala Leu

35 40 45

Ser Ile Leu Ile Ala Leu Phe Val Tyr Lys Met Pro Val Gin Met Val

50 55 60

Ser Ala Ser Phe Phe Tyr Gly Phe Leu Tyr Gly Leu Trp Pro Ile Ala 65 70 75 80

Trp Ile Val Ile Ala Ala Ile Phe Leu Tyr Asn Leu Ser Val Lys Ser

85 90 95

Gly Tyr Phe Glu Ile Leu Lys Glu Ser Ile Leu Ser Leu Thr Pro Asp

100 105 110

His Arg Ile Leu Val Ile Leu Ile Gly Phe Cys Phe Gly Ser Phe Leu

115 120 125

Xaa Gly Ala Xaa Gly Phe Gly Gly Pro Val Ala Ile Thr Ala Ala Ile

130 135 140

Leu Val Ala Leu Gly 145

(2) INFORMATION FOR SEQ ID NO: 215:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 325 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(ill) HYPOTHETICAL YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...325

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215

Met Lys Arg Ile Leu Val Ser Leu Ala Val Leu Ser His Ser Ala His

1 5 10 15

Ala Val Lys Thr His Asn Leu Glu Arg Val Glu Ala Ser Gly Val Ala

20 25 30

Asn Asp Lys Glu Ala Pro Leu Ser Trp Arg Ser Lys Glu Val Arg Asn

35 40 45

Tyr Met Gly Ser Arg Thr Val Ile Ser Asn Lys Gin Leu Thr Lys Ser

50 55 60

Ala Asn Gin Ser Ile Glu Glu Ala Leu Gin Asn Val Pro Gly Val His 65 70 75 80

Ile Arg Asn Ser Thr Gly Ile Gly Ala Val Pro Ser Ile Ser Ile Arg 85 90 95

Gly Phe Gly Ala Gly Gly Pro Gly His Ser Asn Thr Gly Met lie Leu

100 105 110

Val Asn Gly Ile Pro Ile Tyr Val Ala Pro Tyr Val Glu Ile Gly Thr

115 120 125

Val Ile Phe Pro Val Thr Phe Gin Ser Val Asp Arg Ile Ser Val Thr

130 135 140

Lys Gly Gly Glu Ser Val Arg Tyr Gly Pro Asn Ala Phe Gly Gly Val 145 150 155 160

Ile Asn Ile Ile Thr Lys Gly Ile Pro Thr Asn Trp Glu Ser Gin Val

165 170 175

Ser Glu Arg Thr Thr Phe Trp Gly Lys Ser Glu Asn Gly Gly Phe Phe

180 185 190

Asn Gin Asn Ser Lys Asn Ile Asp Lys Ser Leu Val Asn Asn Met Leu

195 200 205

Phe Asn Thr Tyr Leu Arg Thr Gly Gly Met Met Asn Lys His Phe Gly

210 215 220

Ile Gin Ala Gin Val Asn Trp Leu Lys Gly Gin Gly Phe Arg Tyr Asn 225 230 235 240

Ser Pro Thr Asp Ile Gin Asn Tyr Met Leu Asp Ser Leu Tyr Gin Ile

245 250 255

Asn Asp Ser Asn Lys lie Thr Ala Phe Phe Gin Tyr Tyr Ser Tyr Phe

260 265 270

Leu Thr Asp Pro Gly Ser Leu Gly Ile Ala Ala Tyr Asn Gin Asn Arg

275 280 285

Phe Gin Asn Asn Arg Pro Asn Asn Asp Lys Ser Gly Arg Ala Lys Arg

290 295 300

Trp Gly Ala Val Tyr Gin Asn Phe Phe Gly Asp Thr Asp Arg Val Gly 305 310 315 320

Gly Gly Phe His Phe 325

(2) INFORMATION FOR SEQ ID NO.216:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 252 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(il) MOLECULE TYPE: protem

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...252

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216

Leu Arg Ser Ile Ser Arg Ile Lys Met Leu Ser Val Tyr Glu Lys Gly

1 5 10 15

Asn Ala Leu Asp Lys Arg Val Leu Glu Glu Trp Leu Leu Ser Glu Asp

20 25 30

Ile Leu Met Glu Asn Ala Ala Met Ala Leu Glu Arg Ala Val Leu Gin

35 40 45

Asn Ala Ser Leu Gly Ala Lys Val lie Ile Leu Cys Gly Ser Gly Asp

50 55 60

Asn Gly Gly Asp Gly Tyr Thr Leu Ala Arg Arg Leu Val Gly Arg Phe 65 70 75 80

Lys Thr Leu Val Phe Glu Met Lys Leu Ala Lys Ser Pro Met Cys Gin

85 90 95

Leu Gin Lys Glu Arg Ala Lys Lys Val Gly Val Val lie Lys Ala Trp

100 105 110

Glu Glu Lys Asn Glu Asp Leu Glu Cys Asp Val Leu Val Asp Cys Val

115 120 125

Val Gly Ser Ala Phe Lys Gly Gly Leu Glu Pro Phe Leu Asp Phe Glu 130 135 140

Ser Leu Ser Gin Lys Ala Arg Phe Lys Ile Ala Cys Asp lie Pro Ser 145 150 155 160

Gly Ile Asp Ser Lys Gly Arg Val Asp Lys Arg Ala Phe Lys Xaa Gly

165 170 175

Tyr Arg Leu Ser Ala Trp Ala Leu Phe Lys Ser Cys Leu Leu Ser Xaa

180 185 190

Lys Xaa Lys Xaa Tyr Ile Xaa Xaa Leu Lys Xaa Xaa His Leu Xaa Val

195 200 205

Phe Asn Gin Ile Tyr Glu Ile Pro Thr Xaa Thr Phe Leu Leu Glu Lys

210 ^" 215 220

Xaa Asp Leu Lys Leu Pro Leu Arg Asp Arg Lys Lys Arg Ser Gin Arg 225 230 235 240

Arg Leu Arg Ala Cys Ala Cys Ala Phe Gly Gin Ala 245 250

(2) INFORMATION FOR SEQ ID NO: 217:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 138 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protem

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...138

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217

Met Ala Leu Asp Lys Arg Ile Trp Met His Phe Asp Leu Leu Pro Phe

1 5 10 15

Val Phe Ile lie Pro Leu Leu Val Val Ser Phe Leu Leu Ile Phe Glu

20 25 30

Ser Ser Ala Val Leu Ser Leu Lys Gin Gly Val Tyr Tyr Ala Ile Gly

35 40 45

Phe Leu Leu Phe TrD Val Val Phe Phe lie Pro Phe Arg Lys Leu Asp

50 ^* 55 60

Arg Trp Leu Phe Ala Leu Tyr Trp Ala Cys Val Ile Leu Leu Ala Leu 65 70 75 80

Val Asp Phe Met Gly Ser Ser Lys Leu Gly Ala Gin Arg Trp Leu Val

85 90 95

Ile Pro Phe Thr Ser lie Thr Leu Gin Pro Ser Glu Pro Val Lys Asn

100 105 110

Arg Xaa Ser Phe Ile Val Gly Ala Phe Xaa Xaa Asn Xaa Pro Asp Xaa

115 120 125

Leu Leu Arg Ala Met Ile Gly Ala Cys Phe 130 135

(2) INFORMATION FOR SEQ ID NO: 218:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 326 ammo acids

(B) TYPE: ammo acid <D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori ( ix ) FEATURE :

(A) NAME/KEY: misc_feature

(B) LOCATION 1...326

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218

Val Leu Met Ala Leu Xaa Asp Lys Arg Tyr Gly Leu Glu Ala Gly Ile

1 5 10 15

Lys Tyr Phe Thr Met Gly Ala Met Ala Ser Ala Phe Phe Ala Met Gly

20 25 30

Ala Met Ala Phe Tyr Leu Leu Thr Gly Ser Leu Asn Leu Glu Val Ile

35 40 45

Thr Leu Tyr Leu His Thr Glu Gly Ile Thr Asn Pro Met Leu Phe Ala

50 55 60

Met Gly Thr Ile Phe Leu Ile Gly Ala Ile Gly Phe Lys Val Ser Leu 65 70 75 80

Val Pro Phe His Thr Trp Met Pro Asp Val Tyr Glu Gly Asn Asn Pro

85 90 95

Val Phe Ala Ser Tyr Ile Ser Ile Val Pro Lys Ile Ala Gly Phe Val

100 105 110

Val Ala Thr Arg Leu Phe Gly Ala Phe Ile Asp Thr His Thr Ala Trp

115 120 125

Val Glu Asp lie Phe Tyr Val Leu Ile Leu Met Thr Ile Thr Ile Pro

130 135 140

Asn Phe lie Ala Leu Trp Gin Glu Asp Val Lys Arg Met Leu Ala Tyr 145 150 155 160

Ser Ser Ile Ser His Ser Gly Phe Ala Leu Ala Cys Val Phe Ile His

165 170 175

Thr Glu Asp Ser Gin Gin Ala Met Phe Val Tyr Trp Phe Met Phe Ala

180 185 190

Phe Thr Tyr Ile Gly Ala Phe Gly Leu Leu Trp Leu Leu Lys Ser Arg

195 200 205

Glu Lys Thr Trp Asp Glu Arg Tyr Asp His Pro Tyr Ser Lys Phe Asn

210 215 220

Gly Leu Ile Lys Thr His Pro Leu Val Ala Ile Leu Gly Ala lie Phe 225 230 235 240

Val Phe Gly Leu Ala Gly Ile Pro Pro Phe Ser Val Phe Trp Gly Lys

245 250 255

Phe Leu Ala Val Glu Ser Ala Leu Glu Ser Asn His Ile Leu Leu Ala

260 265 270

Val Val Met Leu Val Asn Ser Ala Val Ala Ala Phe Tyr Tyr Phe Arg

275 280 285

Trp Leu Val Ala Met Phe Phe Asn Lys Pro Leu Gin Thr Gin Ser Tyr

290 295 300

Ala Lys Thr Ile Phe Thr Pro Lys Thr Pro Pro Cys Pro Phe Met Arg 305 310 315 320

Ser Leu Leu Pro Trp Arg 325

(2) INFORMATION FOR SEQ ID NO:219:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 240 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(lil) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...240

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219 Met lie Asn Ser Lys Lys Ser Leu Lys Lys Gly Leu Arg Gly Phe Phe

1 5 10 15

Lys Ile Leu Lys Asp Arg Asn Gly Ala His Phe Ser Cys Gly Ala Thr

20 25 30

Ser Gly Phe Gly Leu Glu Ile Ala Lys Ala Phe Leu Gin Lys Asn His

35 40 45

Val Val Phe Gly Thr Gly Arg Arg Gin Glu Asn Leu Gin Lys Leu Gin

50 55 60

Leu Ala Tyr Pro Lys Arg Phe Ile Pro Leu Cys Phe Asp Leu Gin Asn 65 70 75 80

Lys Pro Glu Thr Lys Arg Ala Ile Glu Thr lie Phe Ser Met Thr Asp

85 90 95

Arg Ile Asp Ala Leu Ile Asn Asn Ala Gly Leu Ala Leu Gly Leu Asn

100 105 110

Lys Ala Tyr Glu Cys Glu Leu Asp Asp Trp Glu Val Met Ile Asp Thr

115 120 125

Asn Ile Lys Gly Leu Leu His Leu Thr Arg Leu Ile Leu Pro Ser Met

130 135 140

Ile Glu His Asp Gin Gly Thr Ile Ile Asn Leu Gly Ser Ile Ala Gly 145 150 155 160

Thr Tyr Ala Tyr Pro Gly Gly Xaa Val Tyr Gly Ala Ser Lys Ala Xaa

165 170 175

Val Lys Gin Xaa Ser Xaa Asn Leu Arg Ala Asp Val Ala Gly Thr Asn

180 185 190

Thr Arg Gly Arg Arg Trp Asn Pro Gly Cys Val Ala Lys Pro Lys Val

195 200 205

Ser Arg Val Arg Gly Lys Gly Asp Lys Pro Lys Pro Lys Ser Gly Tyr

210 215 220

Glu Lys His Pro Leu Pro Gin Thr Thr Arg Gin Gly Leu Thr Ser Gly 225 230 235 240

(2) INFORMATION FOR SEQ ID NO:220:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 204 amino acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(ill) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE-

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY- mιsc_feature

(B) LOCATION 1...204

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220

Val Ser Gly Val Val Leu Ser Lys Phe Asp Ser Asp Ser Lys Gly Gly

1 5 10 15

Ile Ala Leu Gly Ile Thr Tyr Gin Leu Gly Leu Pro Leu Arg Phe Ile

20 25 30

Gly Ser Gly Glu Lys Ile Pro Asp Leu Asp Val Phe Met Pro Glu Arg

35 40 45 lie Val Gly Arg Leu Met Gly Ala Gly Asp Ile Ile Ser Leu Ala Glu

50 55 60

Lys Thr Ala Ser Val Leu Asn Pro Asn Glu Ala Lys Asp Leu Ser Lys 65 70 75 80

Lys Leu Lys Lys Gly Gin Phe Thr Phe Asn Asp Phe Leu Asn Gin Ile

85 90 95

Glu Lys Val Lys Lys Leu Gly Ser Met Ser Ser Leu Ile Ser Met Ile

100 105 110

Pro Gly Leu Gly Asn Met Ala Ser Ala Leu Lys Asp Thr Asp Leu Glu

115 120 125

Ser Ser Leu Glu Val Lys Lys lie Lys Ala Met Val Asn Ser Met Thr 130 135 140 Lys Lys Glu Arg Glu Asn Pro Glu Ile Leu Asn Gly Ser Arg Arg Lys 145 150 155 160

Arg Ile Ala Leu Gly Xaa Gly Leu Glu Xaa Xaa Glu Ile Asn Arg Ile

165 170 175

Ile Lys Arg Phe Asp Gin Ala Ser Lys Met Ala Lys Arg Leu Thr Asn

180 185 190

Lys Lys Gly Ile Ser Asp Leu Met Asn Leu Xaa Xaa 195 200

(2) INFORMATION FOR SEQ ID NO: 221:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 92 ammo acids

(B) TYPE: ammo acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...92

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221

Val Glu Lys Ala His Pro Asp Val Phe Asn Leu Leu Leu Gin Val Leu

1 5 10 15

Asp Glu Gly His Leu Thr Asp Ser Lys Gly Val Arg Val Asp Phe Lys

20 25 30

Asn Thr Ile Leu Ile Leu Thr Ser Asn Val Ala Ser Gly Ala Leu Leu

35 40 45

Glu Glu Asp Leu Ser Glu Ala Asp Lys Gin Lys Ala lie Lys Glu Ser

50 55 60

Leu Arg Gin Phe Phe Lys Pro Glu Phe Leu Asn Arg Leu Asp Glu Ile

65 70 75 80

Ile Ser Phe Asn Ala Leu Asp Ser His Ala Ile Ile 85 90

(2) INFORMATION FOR SEQ ID NO:222:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 82 ammo acids

(B) TYPE: am o acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: protem

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...82

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:222

Leu Val Phe Leu Asp Arg Arg Leu Ile Val Met Val Thr Asp Ser Lys

1 5 10 15

Gly Ser Arg Tyr Ile Asn Val His Ile Leu Phe Arg Gin Ile Ser Leu

20 25 30

Tyr Ala Leu Leu Ser Val Val Gly Ser Leu Leu Phe Leu Gly Val Ser

35 40 45

Leu Leu Val Leu Asn Lys Glu Ile Lys Asn Ile Glu Lys Gin His Ala 50 55 60

Leu Xaa Thr Lys Glu Phe Glu Lys Lys Arg Glu Thr Asn Glu Xaa Leu 65 70 75 80

Ser Xaa

(2) INFORMATION FOR SEQ ID NO: 223:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 233 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: prote

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_£eature

(B) LOCATION 1...233

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:223

Leu Ser Leu Met Xaa Val Leu Asn Ala Lys Glu Cys Val Xaa Pro Ile

1 5 10 15

Thr Arg Ser Val Lys Tyr His Gin Gin Ser Ala Glu Ile Arg Ala Leu

20 25 30

Gin Leu Gin Ser Tyr Lys Met Ala Lys Met Ala Leu Asp Asn Asn Leu

35 40 45

Lys Leu Val Lys Asp Lys Lys Pro Ala Val lie Leu Asp Leu Asp Glu

50 55 60

Thr Val Leu Asn Thr Phe Asp Tyr Ala Gly Tyr Leu Val Lys Asn Cys 65 70 75 80

Ile Lys Tyr Thr Pro Glu Thr Trp Asp Lys Phe Glu Lys Glu Gly Ser

85 90 95

Leu Thr Leu Ile Pro Gly Ala Leu Asp Phe Leu Glu Tyr Ala Asn Ser

100 105 110

Lys Gly Val Lys Ile Phe Tyr Ile Ser Asn Arg Thr Gin Lys Asn Lys

115 120 125

Ala Phe Thr Leu Lys Thr Leu Lys Ser Phe Lys Leu Pro Gin Val Ser

130 135 140

Glu Glu Ser Val Leu Leu Lys Glu Lys Gly Lys Pro Lys Ala Val Arg 145 150 155 160

Arg Glu Leu Val Ala Lys Asp Tyr Ala lie Val Leu Gin Val Gly Asp

165 170 175

Thr Leu His Asp Phe Asp Ala Ile Phe Ala Lys Asp Ala Lys Asn Ser

180 185 190

Gin Glu Gin Gin Ala Lys Val Leu Gin Asn Ala Gin Lys Phe Gly Thr

195 200 205

Glu Tro Ile Ile Leu Pro Asn Ser Leu Tyr Gly Thr Trp Glu Asp Gly

210 215 220

Pro lie Lys Ala Trp Gin Asn Lys Lys 225 230

(2) INFORMATION FOR SEQ ID NO: 224:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 85 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protem

(m) HYPOTHETICAL YES

(vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori

(ix) FEATURE-

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...85

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:224

Met Leu Ala Ala Gly Leu Thr Leu Pro Glu Phe Gly Cys Tyr Leu Ser

1 5 10 15

His Tyr Leu Leu Trp Lys Glu Cys Val Lys Leu Asp Gin Pro Val Val

20 25 30

Ile Leu Glu Asp Asp Val Thr Leu Glu Ser His Phe Met Gin Ala Leu

35 40 45

Glu Asp Cys Leu Lys Ser Pro Phe Asp Phe Val Arg Leu Tyr Gly Cys

50 55 60

Tyr Trp Tyr Tyr Gin Arg Asp Lys Ile Pro Cys Phe Ala Gin Arg Ile 65 70 75 80

Cys Ile Ser Ser Leu 85

(2) INFORMATION FOR SEQ ID NO: 225:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 115 ammo acids

(D) TOPOLOGY, linear

(n) MOLECULE TYPE, prote

(in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE.

(A) ORGANISM. Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY- mιsc_feature

(B) LOCATION 1...115

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.225

Leu lie Ala Leu Arg Val Thr Ala Trp Lys Val Xaa Ala Met Lys Arg

1 5 10 15

Leu His Leu Ser Val Lys Asp Ala Glu Asn Phe Asp Ala lie Leu Arg

20 25 30

Glu Arg Pro Phe Phe Lys Asp Leu lie Glu Phe Met Val Ser Gly Pro

35 40 45

Val Val Val Met Val Leu Glu Gly Lys Asp Ala Val Ala Lys Asn Arg

50 55 60

Glu Leu Met Gly Ala Thr Asp Pro Lys Leu Ala Gin Lys Gly Thr Ile 65 70 75 80

Arg Ala Asp Phe Ala Glu Ser Ile Asp Ala Asn Ala Val His Gly Ser

85 90 95

Asp Ser Leu Glu Asn Ala His Asn Glu Ile Ala Phe Phe Phe Ala Ala

100 105 110

Arg Glu Phe 115

(2) INFORMATION FOR SEQ ID NO: 226:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 394 am o acids

(D) TOPOLOGY: linear

(n) MOLECULE TYPE: protein

(in) HYPOTHETICAL YES (vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...394

( i) SEQUENCE DESCRIPTION: SEQ ID NO: 226

Leu Met Trp Leu Lys Thr Leu Thr Leu Gin Thr Leu Asn Thr Asp Lys

1 5 10 15

Ala Leu Gin Glu Phe Ser Lys Thr Met Glu Ala Phe Lys Thr Lys Leu

20 25 30

Ile Gin Ser Ala Asn Asp Val His Ser Glu Thr Ser Arg Ala Ala lie

35 40 45

Ala Asn Asp Leu Glu Arg Leu Lys Glu His Met Ile Asn Val Ala Asn

50 55 60

Thr Ser Ile Gly Gly Glu Phe Leu Phe Gly Gly Ser Lys Val Asp Arg 65 70 75 80

Pro Pro Ile Asp Ser Asn Gly Lys Tyr His Gly Asn Gly Glu Asp Leu

85 90 95

Asn Ala Leu Ile Ser Ser Asp Asn Leu Val Pro Tyr Asn Ile Ser Gly

100 105 110

Gin Asp Leu Phe Leu Gly Thr Asp Lys Asp Lys His Lys Leu Ile Thr

115 120 125

Thr Asn Ile Lys Leu Leu Asn Gin Asn Lys Leu Xaa Pro Asp Val Met

130 135 140

Asp Ala Leu Glu His Ser Ser Leu Pro Glu Glu Val Phe Ile Lys Pro 145 150 155 160

Ser Asp Thr Leu Arg Glu Leu Ile Gly Asp Asn Asp Lys Asn Pro Thr

165 170 175

Asn Asp Pro Lys Glu Phe Phe Tyr Leu Gin Gly lie Arg Pro Asp Gly

180 185 190

Ser Ser Phe Lys Glu Lys Phe Ala Leu Asp Lys Ala Tyr Gin Asn Gin

195 200 205

Glu Ser Ala Thr Lys Val Ser Asp Leu Leu Asp Lys Ile Gly His Ala

210 215 220

Tyr Gly Asn Thr Ser Gin Asn Lys Val Val Asp Val Ser Leu Asn Asn 225 230 235 240

Trp Gly Gin Ile Glu Ile Lys Asn Leu Thr Pro Gly Ser Glu Asn Leu

245 250 255

Asp Phe His Leu Ile Ser Ser Asp Gly Asp Phe Asp Asp Leu Asp Ala

260 265 270

Leu Arg Ser Ser Gly Lys Arg Val Thr Glu Tyr Val Lys Ser Ala Phe

275 280 285

Val Thr Asp Arg Ser Leu Ser Gin Val Lys Ala Val Pro Asn Met Tyr

290 295 300

Asn Pro Lys Val Leu Glu Ile Pro Ser Val Phe Val Thr Lys Asp Asn 305 310 315 320

Val Leu Ala Asn Lys Asn Thr Lys Leu Ser Glu Ile Phe Gly Asp Lys

325 330 335

Val Glu Thr Leu Lys Ile Asn Ala Ser Arg Leu Gly Asp Glu Ser Ala

340 345 350

Ile Lys Ile Pro Asn Leu Pro lie Asn Leu Asp Ile Pro lie Leu Leu

355 360 365

Asp Val Lys Asn Ser Thr Ile Lys Asp Leu Lys Asp Ala lie Lys Glu

370 375 380

Arg Phe Asn Asn Glu Gly Gly Cys Gly Asn 385 390

(2) INFORMATION FOR SEQ ID NO: 227:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(n) MOLECULE TYPE: prote (in) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...102

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227

Leu Lys Ala Leu Asn Asp Cys Met Val Phe Phe His Lys Lys Ile Ile

1 5 10 15

Leu Asn Phe Ile Tyr Ser Leu Met Val Ala Phe Leu Phe His Leu Ser

20 25 30

Tyr Gly Val Leu Leu Lvs Ala Asp Gly Met Ala Lys Lys Gin Thr Leu

35 40 45

Leu Val Gly Glu Arg Leu Val Trp Asp Lys Leu Thr Leu Leu Gly Phe

50 55 60

Leu Glu Lys Asn His Ile Pro Gin Lys Leu Tyr Tyr Asn Leu Ser Ser 65 70 75 80

Gin Aso Lys Glu Leu Ser Ala Glu Ile Gin Ser Asn Val Thr Tyr Tyr

85 90 95

Xaa Phe Lys Arg Cys Lys 100

(2) INFORMATION FOR SEQ ID NO:228:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 363 ammo acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: prote

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...363

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228

Met Lys Phe Phe Leu Leu Lys Lys Phe Ser Xaa Phe Leu Asn Thr Gin

1 5 10 15

Thr His Phe Asn Leu Lys Arg Leu Asn Ala Ser Ser Phe Leu Leu Glu

20 25 30

Thr Phe Ser Lys Glu Lys His Ala Phe Val Val Asp Leu Ser Ala Pro

35 40 45

Tyr Ile Gly Leu Ser Lys Lys Pro Pro Glu Ser Val Leu Lys Asn Thr

50 55 60

Leu Ala Leu Asp Phe Cys Leu Asn Lys Phe Thr Lys Asn Ala Lys Ile 65 70 75 80

Leu Gin Ala Asn Val Ile Asp Asn Asp Arg Ile Leu Glu lie Lys Gly

85 90 95

Ala Lys Asp Leu Ala Tyr Lys Ser Glu Thr Phe Ile Leu Arg Leu Glu

100 105 110

Met Ile Pro Lys Lys Ala Asn Leu Met Ile Leu Asp Gin Glu Lys Cys

115 120 125

Val Ile Glu Ala Phe Arg Phe Asn Asp Arg Val Ala Lys Asn Asp Ile

130 135 140

Leu Gly Ala Leu Pro Pro Asn Ile Tyr Glu His Gin Glu Glu Asp Leu 145 150 155 160

Asp Phe Lys Gly Leu Leu Asp Ile Leu Glu Lys Asp Phe Leu Ser Tyr

165 170 175

Gin His Lys Glu Leu Glu His Lys Lys Asn Gin Ile Ile Lys Arg Leu 180 185 190

Asn Ala Gin Lys Glu Arg Leu Lys Glu Lys Leu Glu Lys Leu Glu Asp

195 200 205

Pro Lys Thr Leu Gin Leu Glu Ala Lys Glu Leu Gin Thr Gin Ala Ser

210 215 220

Leu Leu Leu Thr Tyr Gin His Leu Ile Asn Arg Arg Glu Asn Arg Val 225 230 235 240

Ile Leu Lys Asp Phe Glu Asp Lys Glu Cys Met Ile Glu Ile Asp Lys

245 250 255

Ser Met Pro Leu Asn Ala Phe Ile Asn Lys Lys Phe Thr Leu Ser Lys

260 265 270

Lys Lys Lys Gin Lys Ser Gin Phe Leu Tyr Leu Glu Glu Glu Asn Leu

275 280 285

Lys Glu Lys Ile Ala Phe Lys Glu Asn Gin Ile Asn Tyr Val Arg Asp

290 295 300

Ala Ala Glu Glu Ser Val Leu Glu Met Phe Met Pro Val Lys Asn Ser 305 310 315 320

Lys Ile Lys Arg Pro Met Asn Gly Tyr Glu Val Leu Tyr Tyr Lys Asp

325 330 335

Xaa Lys Xaa Gly Leu Gly Lys Thr Lys Lys Arg Ile Ser Ser Phe Tyr

340 345 350

Lys Thr Gin Xaa Arg Met Ile Xaa Gly Cys Xaa 355 360

(2) INFORMATION FOR SEQ ID NO 229

(1) SEQUENCE CHARACTERISTICS

(A) LENGTH 22 base pairs

(B) TYPE nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY circular

(n) MOLECULE TYPE DNA (genomic)

(in) HYPOTHETICAL NO

(iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE

(A) ORGANISM Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY mιsc_teature

(B) LOCATION 1 22

(Xl) SEQUENCE DESCRIPTION SEQ ID NO 229 ATATCCATGG TGAGTTTGAT GA 22

(2) INFORMATION FOR SEQ ID NO 230

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH 25 base pairs

(B) TYPE nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY circular

(li) MOLECULE TYPE DNA (genomic)

(111) HYPOTHETICAL NO

(iv) ANTI-SENSE NO

(Vl) ORIGINAL SOURCE

(A) ORGANISM Helicobacter pylori

(ix) ΓEATURE

(A) NAME/KEY mιsc_feature

(B) LOCATION 1 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:230 ATGAATTCAA TTTTTTATTT TGCCA 25

(2) INFORMATION FOR SEQ ID NO:231:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:231 AATTCCATGG TGGGGGCTAT G 21

(2) INFORMATION FOR SEQ ID NO:232:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION 1...23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:232 ATGAATTCTC GATAGCCAAA ATC 23

(2) INFORMATION FOR SEQ ID NO:233:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (in) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:233 ATTTCCATGG TCATGTCTCA TATT 24

(2) INFORMATION FOR SEQ ID NO:234:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:234 ATGAATTCCA TCTTTTATTC CAC 23

(2) INFORMATION FOR SEQ ID NO:235:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...27

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:235 AACCATGGTG ATTTTAAGCA TTGAAAG 27

(2) INFORMATION FOR SEQ ID NO: 236:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular (n) MOLECULE TYPE DNA (genomic)

(in) HYPOTHETICAL- NO

(iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...28

(xi) SEQUENCE DESCRIPTION. SEQ ID NO:236 AAGAATTCCA CTCAAAATTT TTTAACAG 28

(2) INFORMATION FOR SEQ ID NO- 237-

(l) SEQUENCE CHARACTERISTICS-

(A) LENGTH- 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...25

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:237 GATCATCCAT ATGTTATCTT CTAAT 25

(2) INFORMATION FOR SEQ ID NO:238

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:238 TGAATTCAAC CATTTTAACC CTG 23

(2) INFORMATION FOR SEQ ID NO.239: (l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...27

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:239 TATACCATGG TGAAATTTTT TCTTTTA 27

(2) INFORMATION FOR SEQ ID NO: 240:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:240 AGAATTCAAT TGCGTCTTGT AAAAG 25

(2) INFORMATION FOR SEQ ID NO:241:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

( x) FEATURE:

(A) NAME/KEY. mιsc_feature

(B) LOCATION 1...25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:241 TTATGGATCC AAACCAATTA AAACT 25

(2) INFORMATION FOR SEQ ID NO: 242.

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. αouble

(D) TOPOLOGY: circular

In) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM- Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...23

( i) SEQUENCE DESCRIPTION. SEQ ID NO:242 TATCTCGAGT TATAGAGAAG GGC 23

(2) INFORMATION FOR SEQ ID NO:243:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:243 ATATCCATGG TGAGTTTGAT GA 22

(2) INFORMATION FOR SEQ ID NO:244:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

( vi ) ORIGINAL SOURCE - (A) ORGANISM Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:244 ATGAATTCAA TTTTTTATTT TGCCA 25

(2) INFORMATION FOR SEQ ID NO:245:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

( ) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:245 AATTCCATGG CTATCCAAAT CCG 23

(2) INFORMATION FOR SEQ ID NO: 246:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...25

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:246 ATGAATTCGC CAAAATCGTA GTATT 25

(2) INFORMATION FOR SEQ ID NO: 247:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic) (in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE-

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE.

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:247 GATACCATGG AATTTATGAA AAAG 24

(2) INFORMATION FOR SEQ ID NO:248:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...25

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:248 TGAATTCGAA AAAGTGTAGT TATAC 25

(2) INFORMATION FOR SEQ ID NO:249:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH- 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 249 TTGAACACTT TTGATTATGC GG 22

(2) INFORMATION FOR SEQ ID NO:250: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH 23 base pairs

(B) TYPE nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY circular

(i ) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL- NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:250 GGATTATGCG ATTGTTTTAC AAG 23

(2) INFORMATION FOR SEQ ID NO:251.

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL. NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:251 GTCTTTAGCA AAAATGGCGT C 21

(2) INFORMATION FOR SEQ ID NO:252:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE. NO

( i) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:252 AATGAGCGTA AGAGAGCCTT C 21

(2) INFORMATION FOR SEQ ID NO: 253:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY- circular

In) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_ eature

(B) LOCATION 1...18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:253 CTTATGGGGG TATTGTCA 18

(2) INFORMATION FOR SEQ ID NO: 254:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:254 AGCATGTGGG TATCCAGC 18

(2) INFORMATION FOR SEQ ID NO:255:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori (ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...19

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:255 AGGTTGTTGC CTAAAGACT 19

(2) INFORMATION FOR SEQ ID NO.256:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v ) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 256 CTGCCTCCAC CTTTGATC 18

(2) INFORMATION FOR SEQ ID NO:257:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...19

(Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 257 ACCAATATCA ATTGGCACT 19

(2) INFORMATION FOR SEQ ID NO:258:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY- circular

(n) MOLECULE TYPE: DNA (genomic) (m) -^HYPOTHETICAL: NO

(iv) ANTI-SENSE- NO

(vi) ORIGINAL SOURCE

(A) ORGANISM- Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...18

(xi) SEQUENCE DESCRIPTION. SEQ ID NO:258 ACTTGGAAAA GCTCTGCA 18

(2) INFORMATION FOR SEQ ID NO: 259.

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH: 19 base pairs

(B) TYPE- nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY, circular

(ii) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE- NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE-

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...19

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:259 CTTGCTTGTC ATATCTAGC 19

(2) INFORMATION FOR SEQ ID NO: 260-

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS. double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: mιsc_feature

(B) LOCATION 1...18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:260

GTTGAAGTGT TGGTGCTA 18

(2) INFORMATION FOR SEQ ID NO: 261:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 22 base pairs (B) TYPE nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(in) HYPOTHETICAL: NO

(iv) ANTI-SENSE. NO

(vi) ORIGINAL SOURCE

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: misc eature

(B) LOCATION 1...22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 261 CAAGCAAGTG GTTTGGTTTT AG 22

(2) INFORMATION FOR SEQ ID NO: 262:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi ) ORIGINAL SOURCE.

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: miscjeature

(B) LOCATION 1...22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:262 TGGAAAGAGC AAATCATTGA AG 22

(2) INFORMATION FOR SEQ ID NO: 263:

(l) SEQUENCE CHARACTERISTICS.

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(IX) FEATURE:

(A) NAME/KEY: miscjeature

(B) LOCATION 1...21

(xi) SEQUENCE DESCRIPTION. SEQ ID NO:263 GCCCATAATC AAAAAGCCCA T 21 (2) INFORMATION FOR SEQ ID NO 264

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH 24 base pairs

(B) TYPE nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY circular

(u) MOLECULE TYPE DNA (genomic)

(111) HYPOTHETICAL NO

(iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE

(A) ORGANISM Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY miscjeature

(B) LOCATION 1 24

(xi) SEQUENCE DESCRIPTION SEQ ID NO 264 CTAAAACCAA ACCACTTGCT TGTC 24

(2) INFORMATION FOR SEQ ID NO 265

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH 16 base pairs

(B) TYPE nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY circular

(n) MOLECULE TYPE DNA (genomic)

(ill) HYPOTHETICAL NO

(iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE

(A) ORGANISM Helicobacter pylori

(ix) FEATURE

(A) NAME/KEY miscjeature

(B) LOCATION 1 16

(xi) SEQUENCE DESCRIPTION SEQ ID NO 265 GTAAAACGAC GGCCAG 16

(2) INFORMATION FOR SEQ ID NO 266

(l) SEQUENCE CHARACTERISTICS

(A) LENGTH 17 base pairs

(B) TYPE nucleic acid

(C) STRANDEDNESS double

(D) TOPOLOGY circular

(n) MOLECULE TYPE DNA (genomic)

(m) HYPOTHETICAL NO

(iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE

(A) ORGANISM Helicobacter pylori ( ix ) FEATURE :

(A) NAME/KEY: miscjeature

(B) LOCATION 1...17

(xi) SEQUENCE DESCRIPTION SEQ ID NO.266 CAGGAAACAG CTATGAC 17

(2) INFORMATION FOR SEQ ID NO: 267:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS- double

(D) TOPOLOGY, circular

(n) MOLECULE TYPE: DNA (genomic)

(ill) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY. miscjeature

(B) LOCATION 1...21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:267 ATCTTACCTA TCACCTCAAA T 21

(2) INFORMATION FOR SEQ ID NO:268:

(l) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(n) MOLECULE TYPE: DNA (genomic)

(m) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(VI) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME/KEY: miscjeature

(B) LOCATION 1...21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:268 AGACAGCAAC ATCTTTGTGA A 21

Claims

1. A substantially pure nucleic acid encoding an H. pylori polypeptide, said nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.1-114.

2. A substantially pure nucleic acid from naturally occurring H. pylori which hybridizes under stringent conditions to a nucleic acid which encodes an H. pylori polypeptide, said nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:l-l 14.

3. A method of evaluating a compound for the ability to bind an H pylori nucleic acid comprising: contacting said compound with an H. pylori nucleic acid selected from the group consisting of SEQ ID NO:l-l 14 and determining if said compound binds said H. pylori nucleic acid.

4. The method of claim 3, wherein said compound is an activator of the bacterial life cycle.

5. The method of claim 3, wherein said compound is an inhibitor of the bacterial life cycle.

6. The method of claim 3, wherein said method is performed in vitro.

7. The method of claim 3, wherein said method is performed in vivo.

8. A method of generating a vaccine for immunizing a subject against H. pylori infection comprising: immunizing said subject with a nucleic acid encoding an H. pylori polypeptide or a fragment thereof, said nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-114, and a therapeutically acceptable carrier.

9. A method of detecting the presence oi & Helicobacter species in a sample comprising: contacting said sample with a nucleic acid encoding an H. pylori polypeptide, said nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:l-1 14; hybridizing said sample to said nucleic acid; said hybridization being indicative of the presence of said Helicobacter species in said sample.

10. The method of claim 9, wherein said Helicobacter species is H. pylori.

11. The method of claim 9, wherein said nucleic acid is 20 or more nucleotides in length.

12. A method of inhibiting expression of a gene from a Helicobacter species comprising: administering to said species an H. pylori antisense nucleic acid selected from the group consisting of SEQ ID NO:l-114.

13. The method of claim 12, wherein said Helicobacter species is H. pylori.

14. The method of claim 12, wherein said antisense nucleic acid is administered in a carrier.

15. The method of claim 12, wherein said carrier is a liposome or a bacteriophage.

16. The method of claim 12, wherein said antisense nucleic acid is 20 or more nucleotides in length.

17. The method of claim 12, wherein said antisense nucleic acid is capable of binding to Helicobacter nucleic acid or mRNA.

18. A method of generating a vaccine for immunizing a subject against H. pylori infection comprising: immunizing said subject with a nucleic acid encoding an H. pylori polypeptide or a fragment thereof, said polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 115-228, and a therapeutically acceptable carrier.